Neurosteroids: endogenous analgesics? by Humble, Stephen R.
University of Dundee
DOCTOR OF SCIENCE
Neurosteroids
 endogenous analgesics?
Humble, Stephen R.
Award date:
2013
Awarding institution:
University of Dundee
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 17. Feb. 2017
DOCTOR OF SCIENCE
Neurosteroids
 endogenous analgesics?
Stephen R. Humble
2013
University of Dundee
Conditions for Use and Duplication
Copyright of this work belongs to the author unless otherwise identified in the body of the thesis. It is permitted
to use and duplicate this work only for personal and non-commercial research, study or criticism/review. You
must obtain prior written consent from the author for any other use. Any quotation from this thesis must be
acknowledged using the normal academic conventions. It is not permitted to supply the whole or part of this
thesis to any other person or to post the same on any website or other online location without the prior written
consent of the author. Contact the Discovery team (discovery@dundee.ac.uk) with any queries about the use
or acknowledgement of this work.
 
 
 
 
NEUROSTEROIDS; ENDOGENOUS 
ANALGESICS? 
 
 
 
 
 
 
 
STEPHEN R. HUMBLE 
 
MBChB, MSc, FRCA, FCARCSI 
 
 
 
 
A thesis submitted in candidature for 
the degree of Doctor of Philosophy, 
University of Dundee, December 2012. 
i 
 
Table of Contents 
List of Tables ................................................................................................................................... vii 
List of Figures .................................................................................................................................... x 
Abbreviations ................................................................................................................................ xiv 
Acknowledgements .................................................................................................................... xvii 
Candidate’s declaration ............................................................................................................. xix 
Supervisor’s declaration ............................................................................................................ xx 
Abstract............................................................................................................................................ xxi 
Chapter 1. Introduction ................................................................................................................. 1 
Part 1. Pain ........................................................................................................................................ 2 
1.1.1 Physiological pain ........................................................................................................... 2 
1.1.2 Nociception ........................................................................................................................ 4 
1.1.3 Spinal cord ......................................................................................................................... 4 
1.1.4 Descending modulation ................................................................................................ 9 
1.1.5 Ascending tracts ............................................................................................................ 11 
1.1.6 Thalamus .......................................................................................................................... 11 
1.1.7 nRT ...................................................................................................................................... 12 
1.1.8 Cerebral cortex ............................................................................................................... 13 
1.1.9 Inflammatory pain ........................................................................................................ 15 
1.1.10 Neuropathic pain ........................................................................................................ 16 
1.1.11 Diabetes .......................................................................................................................... 17 
1.1.12 Diabetic mouse models ............................................................................................ 18 
Part 2. The GABAAR ...................................................................................................................... 21 
1.2.1 History of GABA & the GABAAR ............................................................................... 21 
1.2.2 GABA Synthesis .............................................................................................................. 23 
1.2.3 Metabolism ...................................................................................................................... 24 
1.2.4 Release .............................................................................................................................. 24 
1.2.5 Re-uptake ......................................................................................................................... 24 
1.2.6 Developmental role of GABA .................................................................................... 25 
1.2.7 GABAA receptors ............................................................................................................ 26 
1.2.8 Receptor subunits ......................................................................................................... 27 
1.2.9 Phasic inhibition ............................................................................................................ 29 
ii 
 
1.2.10 Tonic inhibition ........................................................................................................... 30 
1.2.11 Pharmacology .............................................................................................................. 31 
1.2.12 Benzodiazepines ......................................................................................................... 32 
1.2.13 The Glycine receptor ................................................................................................. 34 
Part 3. Neurosteroids .................................................................................................................. 35 
1.3.1 Overview ........................................................................................................................... 35 
1.3.2 Neurosteroid binding site .......................................................................................... 36 
1.3.3 Synthesis and metabolism ......................................................................................... 36 
1.3.4 Localisation and distribution ................................................................................... 43 
1.3.5 Modulation of the GABAAR ........................................................................................ 44 
1.3.6 Neurodevelopment ....................................................................................................... 46 
1.3.7 Neurosteroids, pain and the GABAAR .................................................................... 48 
Hypotheses ...................................................................................................................................... 50 
Chapter 2. Methods ........................................................................................................................ 51 
2.1 Electrophysiology .................................................................................................................. 52 
2.2 Breeding and housing of mice .......................................................................................... 54 
2.3 Spinal cord dissection technique ..................................................................................... 54 
Hydraulic extrusion ................................................................................................................. 55 
Anterior Laminectomy ........................................................................................................... 55 
2.4 Spinal cord slice preparation ............................................................................................ 56 
Initial technique: No supporting block ............................................................................ 56 
Definitive technique: Agar block ........................................................................................ 57 
Brain slicing technique .......................................................................................................... 57 
Electrophysiology .................................................................................................................... 58 
2.5 Data analysis ............................................................................................................................ 60 
2.6 Drug and solution preparation and administration ................................................. 64 
2.7 Behavioural experiments ................................................................................................... 64 
Drug adminstration ................................................................................................................. 64 
Rotarod test ................................................................................................................................ 65 
Thermal nociception ............................................................................................................... 65 
Mechanical nociception ......................................................................................................... 66 
Cold allodynia test ................................................................................................................... 67 
2.8 Statistical analysis ................................................................................................................. 68 
iii 
 
Chapter 3: A characterisation of GABA-ergic synaptic events with 
development at three levels of the pain pathway in WT mice. ............................... 69 
3.1 The decay time of GABAAR mIPSCs of LII spinal neurones decreases with 
development. ............................................................................................................................. 70 
3.2 Glycinergic mIPSCs of lamina II neurones of the dorsal horn of the spinal 
cord. ............................................................................................................................................... 75 
3.3 The decay time of synaptic GABAARs of nucleus reticularis (nRT) neurones 
decreases with development. .............................................................................................. 78 
3.4 The decay time of synaptic GABAARs of cortical layer 2/3 neurones 
decreases with development. .............................................................................................. 80 
3.5 The acute application of allopregnanolone prolongs the decay time of 
GABAAR mIPSCs more effectively in spinal LII neurones from older mice. ...... 81 
3.6 The acute application of ganaxolone prolongs the decay time of GABAAR 
mIPSCs in nRT neurones (P17-25).................................................................................... 84 
3.7 The acute application of allopregnanolone and its synthetic analogue 
ganaxolone prolongs the decay time of GABAAR mIPSCs of layer 2/3 neurones 
in mature WT mice (P60-75). .............................................................................................. 87 
3.8 The effect of γ-cyclodextrin (γ-CD) applied by three different methods on 
nRT GABAAR mIPSCs (P6-7). ............................................................................................... 89 
3.9 The effect of γ-CD 0.5mM in the recording pipette on nRT GABAAR-
mediated mIPSCs at three stages of development. ..................................................... 92 
3.10 Pipette-applied γ-CD reduces decay time of GABAAR mIPSCs of layer 2/3 
cortical neurones at two stages of development. ........................................................ 95 
Chapter 4: The role of neurosteroids on mature layer 2/3 neurones from the 
cerebral cortex of WT mice........................................................................................................ 97 
4.1 The effect of the acute application of allopregnanolone or ganaxolone on 
GABAAR mIPSCs in mature WT mice (P60-75). ............................................................ 99 
4.2 The effect of prolonged incubation of allopregnanolone (100 - 300 nM), or 
ganaxolone (30 nM - 3 μM), on cortical GABAAR-mediated mIPSCs of adult WT 
mice. ........................................................................................................................................... 104 
4.3 The effect of intracellular allopregnanolone or ganaxolone (3-10 M) on 
layer 2/3 cortical GABAA mIPSCs in mature WT mice (P60-75) ........................ 109 
4.4 The effect of cyclodextrins on layer 2/3 cortical GABAA mIPSCs in mature 
WT mice. ................................................................................................................................... 115 
4.5 Is the effect of prolonged ganaxolone incubation on cortical GABAAR-
mediated mIPSCs influenced by intracellular -CD? ............................................... 118 
4.6 Can mature layer 2/3 cortical neurones synthesise neurosteroids? ......... 119 
iv 
 
4.7 The effect of prolonged progesterone incubation (1-50μM) on cortical 
GABAAR-mediated mIPSCs of mature WT mice. ....................................................... 121 
4.8 Does the 5α-reductase inhibitor finasteride block the effect of 
progesterone on the cortical mIPSCs of WT mice? .................................................. 121 
4.9 The effect of acute DHP & prolonged DHP incubation on cortical GABAAR 
mIPSCs of mature WT mice. .............................................................................................. 125 
4.10 Does intracellular cyclodextrin influence the effect of pre-incubated DHP 
on cortical mIPSCs of WT mice? ...................................................................................... 130 
4.11 The effect of intracellular DHP on layer 2/3 cortical GABAA-mediated 
mIPSCs of mature WT mice. .............................................................................................. 132 
4.12 Provera, an inhibitor of 3α-HSD, prevents the effects of DHP but not 
ganaxolone on cortical mIPSCs of mature WT mice. ............................................... 132 
4.13 The 3α-HSD inhibitor indometacin prevents the effect of DHP but not 
allopregnanolone on cortical mIPSCs of mature WT mice.................................... 135 
4.14 The effect of pipette-applied ganaxolone and indometacin on layer 2/3 
cortical GABAA mIPSCs in mature WT mice (P60-75). ........................................... 141 
Chapter 5: The role of neurosteroids on mature layer 2/3 neurones from the 
cerebral cortex of ob/ob and db/db mice. ....................................................................... 144 
5.1 A comparison of synaptic GABAAR mIPSCs of cortical layer 2/3 neurones in 
adult WT, ob/ob and db/db mice. .................................................................................... 146 
5.2 The effect of cyclodextrin on layer 2/3 cortical GABAA mIPSCs in mature 
ob/ob mice (P60-75). ........................................................................................................... 150 
5.3 A comparison of the effects of γ-cyclodextrin on cortical mIPSCs of adult 
WT, ob/ob and db/db mice. ............................................................................................... 153 
5.4 The effect of the acute application of allopregnanolone, or ganaxolone, on 
GABAAR mIPSCs of mature ob/ob mice. ....................................................................... 154 
5.5 The effect of prolonged incubation of allopregnanolone, on GABAAR-
mediated mIPSCs of mature ob/ob and db/db mice. ............................................... 157 
5.6 The effect of ganaxolone incubation on GABAAR mIPSCs in mature ob/ob 
and db/db mice. ..................................................................................................................... 162 
5.7 The effect of intracellular allopregnanolone, or ganaxolone, on layer 2/3 
cortical GABAAR mIPSCs of mature ob/ob mice. ....................................................... 166 
5.8 The effect of pipette-applied ganaxolone and indometacin on layer 2/3 
cortical GABAA mIPSCs in mature ob/ob and WT mice (P60-75). ..................... 172 
5.9 The effect of prolonged pre-incubation with indometacin on GABAAR 
mIPSCs of mature ob/ob mice. ......................................................................................... 176 
v 
 
5.10 Can mature layer 2/3 cortical neurones from diabetic mice synthesise 
neurosteroids? ....................................................................................................................... 176 
5.11 The effect of progesterone pre-incubation on cortical mIPSCs of mature 
ob/ob mice. .............................................................................................................................. 177 
5.12 The influence of finasteride on the effects of progesterone on cortical 
mIPSCs of mature ob/ob mice. ......................................................................................... 179 
5.13 The effect of DHP on GABAAR mIPSCs of mature ob/ob and db/db mice.
 ...................................................................................................................................................... 179 
Chapter 6: Behavioural work ................................................................................................ 188 
6.1 ob/ob mice have impaired sensorimotor coordination in comparison to 
WT mice. ................................................................................................................................... 190 
6.2 ob/ob mice exhibit prolonged tail withdrawal from noxious heat in 
comparison to WT mice. ..................................................................................................... 191 
6.3 Ganaxolone increases tail withdrawal latency in WT mice. .......................... 193 
6.4 High doses of ganaxolone impair rotarod performance of WT mice. ........ 194 
6.5 ob/ob mice exhibit cold allodynia in comparison to WT mice. .................... 197 
6.6 ob/ob mice exhibit mechanical hypersensitivity in comparison to WT mice.
 ...................................................................................................................................................... 199 
6.7 Ganaxolone reduces mechanical hypersensitivity in ob/ob mice and 
reduces mechanical nociceptive pain in both WT and ob/ob mice. .................. 201 
Chapter 7: Discussion ................................................................................................................ 207 
7.1 The decay time of GABAAR mIPSCs decreases with development at three 
levels of the pain pathway. ................................................................................................ 208 
7.2 Region specific properties of pain pathway neurones. ................................... 211 
7.3 GABAARs from pain pathway neurones are sensitive to modulation by 
neurosteroids. ........................................................................................................................ 212 
7.4 The role of neurosteroids on mature layer 2/3 neurones from the cerebral 
cortex of WT mice. ................................................................................................................ 214 
7.5 Intracellularly applied γ-CD reduces the decay time of GABAAR mIPSCs of 
layer 2/3 cortical neurones in mature WT mice. ...................................................... 217 
7.6 Can mature layer 2/3 cortical neurones synthesise neurosteroids? ......... 219 
7.7 The role of neurosteroids on mature layer 2/3 neurones from the cerebral 
cortex of ob/ob and db/db mice. ..................................................................................... 224 
7.8 The effect of neurosteroids on the decay time of GABAAR mIPSCs from 
mature layer 2/3 cortical neurones of ob/ob mice. ................................................. 227 
vi 
 
7.9 Can mature layer 2/3 cortical neurones from diabetic mice synthesise 
neurosteroids? ....................................................................................................................... 228 
7.10 Overview of electrophysiological data. ............................................................... 230 
7.11 The impact of neuropathy on behavioural measures of hypersensitivity 
and the response to neuroactive steroids. .................................................................. 231 
7.12 Ganaxolone impairs thermal nociception in WT mice.................................. 234 
7.13 ob/ob mice exhibit cold allodynia. ........................................................................ 235 
7.14 ob/ob mice exhibit mechanical hypersensitivity in comparison to WT 
mice. ........................................................................................................................................... 236 
7.15 Ganaxolone reduces mechanical hypersensitivity in ob/ob mice and 
reduces mechanical nociceptive pain in both WT and ob/ob mice. .................. 237 
Chapter 8: Conclusions.............................................................................................................. 244 
Reference List ................................................................................................................................ 248 
  
vii 
 
List of Tables 
 
Table 1  The decay time of GABAAR mIPSCs of LII spinal neurones decreases with 
development ........................................................................................................................................ 72 
Table 2 The properties of GABAAR-mediated mIPSCs in mice (P17-25) versus data 
recorded by a former laboratory colleague in rats (P15-21; Mitchell et al., 2007). 74 
Table 3 The properties of glycine receptor mediated mIPSCs in LII spinal neurones 
of mice (P17-25) versus data recorded by a former laboratory colleague in rats 
(P15-21; Mitchell et al., 2007). ..................................................................................................... 75 
Table 4 The decay time of GABAAR mIPSCs of nRT neurones decreases with 
development ........................................................................................................................................ 79 
Table 5 The decay time of GABAAR mIPSCs of layer 2/3 cortical neurones 
decreases with development ........................................................................................................ 80 
Table 6 The acute application of allopregnanolone (Allo) prolongs the decay time 
of GABAAR mIPSCs more effectively in spinal LII neurones from older mice. ........... 84 
Table 7 The acute application of ganaxolone (Ganax) prolongs the decay time of 
GABAAR mIPSCs in nRT neurones (P17-25). .......................................................................... 86 
Table 8 The acute application of allopregnanolone (Allo) and its synthetic 
analogue ganaxolone (Ganax) prolongs the decay time of GABAAR mIPSCs of layer 
2/3 cortical neurones from mature WT mice (P60-75). .................................................... 86 
Table 9 The effect of bath applied γ-cyclodextrin (CD) on nRT GABAAR mIPSCs 
(P6-7). .................................................................................................................................................... 90 
Table 10 The effect of γ-cyclodextrin (CD) applied by three different methods on 
nRT GABAAR mIPSCs (P6-7). ......................................................................................................... 90 
Table 11 The effect of γ-cyclodextrin (CD) 0.5mM in the recording pipette on nRT 
GABAAR-mediated mIPSCs at three stages of development. ............................................ 93 
Table 12 Pipette-applied γ-cyclodextrin (CD) reduces decay time of GABAA mIPSCs 
of layer 2/3 cortical neurones at two stages of development (P9-10 and P60-75).93 
Table 13 The acute application of allopregnanolone (Allo) or ganaxolone (Ganax) 
prolongs the decay time of GABAAR mIPSCs of L2/3 cortical neurones (P60-75) of 
WT mice. ............................................................................................................................................. 100 
Table 14 The effect of prolonged incubation of allopregnanolone (Allo) or 
ganaxolone (Ganax) on GABAAR  mIPSCs of L2/3 cortical neurones (P60-75) of WT 
mice ...................................................................................................................................................... 101 
Table 15 The effect of intracellular allopregnanolone (Allo) or ganaxolone (Ganax) 
on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT mice ............... 110 
Table 16 The effect of intracellular /β/γ – cyclodextrin (CD) 0.5mM on GABAAR 
mIPSCs of layer 2/3 cortical neurones (P60-75) of WT mice. ...................................... 116 
Table 17 The effect of ganaxolone (Ganax) incubation treatment with -CD 
presented intracellularly, on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-
75) of WT mice. ............................................................................................................................... 119 
viii 
 
Table 18 The effect of progesterone (Prog) incubation treatment on GABAAR 
mIPSCs of layer 2/3 cortical neurones (P60-75) of WT mice. ...................................... 122 
Table 19 The effect of DHP applied acutely via the intracellular or extracellular 
routes on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT mice. 127 
Table 20 The effect of DHP incubation treatment (with -CD presented 
intracellularly), on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT 
mice. ..................................................................................................................................................... 128 
Table 21 The 3 -HSD inhibitor provera reduces the effect of DHP but not 
ganaxolone (Ganax) incubation treatment on GABAAR mIPSCs of layer 2/3 cortical 
neurones (P60-75) of WT mice. ................................................................................................ 134 
Table 22 The 3 -HSD inhibitor indometacin (indo) reduces the effect of DHP 
incubation treatment on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) 
of WT mice......................................................................................................................................... 137 
Table 23 The 3 -HSD inhibitor indometacin (indo) reduces the effect of 
ganaxolone (Ganax) but not allopregnanolone (Allo) incubation treatment on 
GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT mice. .................... 140 
Table 24 The effect of pipette-applied ganaxolone and indometacin on layer 2/3 
cortical GABAAR mIPSCs in mature WT mice (P60-75). .................................................. 142 
Table 25 A comparison of synaptic GABAAR mIPSCs of cortical layer 2/3 neurones 
in adult WT, ob/ob and db/db mice. ........................................................................................ 148 
Table 26 The effect of intracellular /β/γ – cyclodextrin (CD) 0.5mM on GABAAR 
mIPSCs of layer 2/3 cortical neurones (P60-75) of WT and ob/ob  mice. ............... 151 
Table 27 A comparison of the effects of 0.5mM γ-cyclodextrin (γ-CD) on cortical 
GABAAR mIPSCs of adult WT, ob/ob and db/db mice (P60-75). .................................. 153 
Table 28 The acute application of allopregnanolone (Allo) or ganaxolone (Ganax) 
prolongs the decay time of GABAAR mIPSCs of L2/3 cortical neurones (P60-75) of 
WT and ob/ob mice. ....................................................................................................................... 156 
Table 29 The effect of allopregnanolone (Allo) incubation treatment on GABAAR 
mIPSCs of L2/3 cortical neurones (P60-75) of WT, ob/ob and db/db mice. ........... 159 
Table 30 The effect of ganaxolone (Ganax) incubation treatment (30-100nM) on 
GABAAR mIPSCs of L2/3 cortical neurones (P60-75) of WT, ob/ob and db/db mice
................................................................................................................................................................ 163 
Table 31 The effect of ganaxolone (Ganax) incubation treatment (300nM, 1μM or 
3μM) on GABAAR mIPSCs of L2/3 cortical neurones (P60-75) of WT, ob/ob and 
db/db mice ......................................................................................................................................... 164 
Table 32 The effect of intracellular allopregnanolone (Allo) on GABAAR mIPSCs of 
layer 2/3 cortical neurones (P60-75) of WT or ob/ob mice. ......................................... 168 
Table 33 The effect of intracellular ganaxolone (Ganax) on GABAAR mIPSCs of 
layer 2/3 cortical neurones (P60-75) of WT or ob/ob mice. ......................................... 169 
Table 34 The effect of pipette-applied ganaxolone and indometacin on GABAAR 
mIPSCs of layer 2/3 cortical neurones (P60-75) of WT or ob/ob mice. .................... 173 
Table 35 The effect of progesterone (Prog) incubation treatment on GABAAR 
mIPSCs of layer 2/3 cortical neurones (P60-75) of WT, ob/ob or db/db mice. ..... 174 
ix 
 
Table 36 Finasteride (Finast) prevents the effect of progesterone (Prog) 
incubation treatment on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) 
of WT, ob/ob or db/db mice. ....................................................................................................... 181 
Table 37 The effect of DHP incubation treatment on GABAAR mIPSCs of layer 2/3 
cortical neurones (P60-75) of WT, ob/ob and db/db mice. ............................................ 182 
  
x 
 
List of Figures 
 
Figure 1 Pain pathway schematic. ............................................................................................... 3 
Figure 2 Modulation of the GABAAR by endogenous neurosteroids. ........................... 38 
Figure 3 Neurosteroid synthesis pathway ............................................................................. 39 
Figure 4 Cyclodextrins sequester neurosteroids. ................................................................ 42 
Figure 5 Simplified schematic illustrating the approach to obtaining 
electrophysiological recordings from pain pathway neurones. ...................................... 53 
Figure 6 Superimposed individual mIPSCs from spinal & cortical neurones. .......... 61 
Figure 7 Determination of GABAAR mIPSC decay time constant. .................................. 62 
Figure 8 Representative current traces from neurones aged P17-25 exhibiting 
GABAAR mIPSCs from three levels of the pain pathway illustrating the regional 
variations. ............................................................................................................................................. 71 
Figure 9 The decay time of GABAAR mIPSCs of neurones from three levels of the 
pain pathway decreases with development. ........................................................................... 73 
Figure 10 Representative current traces from LII spinal neurones aged P17-25 
exhibiting GABAAR & GlyR mIPSCs. ............................................................................................ 76 
Figure 11 The distribution pattern of T70 values of GABAAR mIPSCs varies in 
neurones from three different levels of the pain pathway. ............................................... 77 
Figure 12 Acute exposure (10-20mins) to allopregnanolone (1 M) has a greater 
effect on the function of synaptic GABAARs from mature spinal LII neurones 
compared to immature neurones................................................................................................ 83 
Figure 13 Acute exposure (10-20mins) of nRT neurones to ganaxolone (1 M) 
modestly enhances the function of synaptic GABAARs. ...................................................... 85 
Figure 14 The acute exposure (10-20mins) of mature cortical neurones to 
allopregnanolone (1 M), or ganaxolone (1-3 M) modestly enhances the function 
of synaptic GABAARs. ........................................................................................................................ 88 
Figure 15 The effect of -CD on P6-7 nRT neurones varies according to the method 
of administration. .............................................................................................................................. 91 
Figure 16 Effect of -CD applied intracellularly on nRT neurones varies depending 
on stage of development. ................................................................................................................ 94 
Figure 17 -CD applied intracellularly shortens the duration of GABAAR mIPSCs in 
L2/3 cortical neurones at age P9-10 & P60-75. .................................................................... 96 
Figure 18 The acute exposure (10-20mins) of mature cortical neurones to 
allopregnanolone (1 M), or ganaxolone (1-3 M) modestly enhances the function 
of synaptic GABAARs. ..................................................................................................................... 103 
Figure 19 The prolonged exposure (~2 hrs) of mature cortical neurones to 
relatively low concentrations of allopregnanolone (100-300 nM) greatly enhances 
the function of synaptic GABAARs. ........................................................................................... 105 
Figure 20 The prolonged exposure (~2 hrs) of mature cortical neurones to 
ganaxolone (30 nM- 3 M) greatly enhances the function of synaptic GABAARs in a 
concentration-dependent manner. .......................................................................................... 107 
xi 
 
Figure 21 A comparison of the effects of prolonged exposure (~2 hrs) of mature 
cortical neurones to allopregnanolone (100-300 nM) and ganaxolone (100-300 
nM) on synaptic GABAAR function. .......................................................................................... 108 
Figure 22 Intracellular allopregnanolone enhances synaptic GABAAR function of 
mature cortical neurones. ........................................................................................................... 111 
Figure 23 Intracellular ganaxolone enhances the synaptic GABAAR function of 
mature cortical neurones. ........................................................................................................... 112 
Figure 24 A comparison of the effects of extracellular acute, or prolonged and 
intracellular allopregnanolone on the function of synaptic GABAARs of mature 
cortical neurones. ........................................................................................................................... 113 
Figure 25 Comparison of the effects of intracellular allopregnanolone & 
ganaxolone on the function of synaptic GABAARs of mature cortical neurones. ... 114 
Figure 26 Intracellular -CD reduces the duration of GABAAR-mediated mIPSCs of 
mature cortical neurones: evidence for an endogenous neurosteroid tone. .......... 117 
Figure 27 Intracellular -CD reduces the effect of extracellular ganaxolone on 
GABAAR-mediated mIPSCs of mature cortical neurones. ............................................... 120 
Figure 28 Prolonged exposure (~2 hrs) of mature cortical neurones to 
progesterone (1-50 M) enhances the function of synaptic GABAARs, suggesting 
that these neurones can synthesise allopregnanolone. ................................................... 123 
Figure 29 The 5 -reductase inhibitor finasteride prevents the effects of 
progesterone incubation on synaptic GABAARs of mature cortical neurones. ....... 124 
Figure 30 Prolonged exposure (~2 hrs) of mature cortical neurones to DHP 
greatly enhances the function of synaptic GABAARs, but acute extracellular or 
intracellular DHP is inert. ............................................................................................................ 129 
Figure 31 Intracellular -CD reduces the effect of DHP incubation on GABAAR 
mIPSCs of mature cortical neurones. ...................................................................................... 131 
Figure 32 By contrast to allopregnanolone and ganaxolone, intracellular DHP has 
no effect on the function of synaptic GABAARs of mature cortical neurones. ......... 133 
Figure 33 The 3 -HSD enzyme inhibitor provera suppresses the effects of DHP, 
but not ganaxolone on GABAAR-mediated mIPSCs of mature cortical neurones. . 136 
Figure 34 The 3 -HSD enzyme inhibitor indometacin suppresses the effects of 
DHP and ganaxolone, but not those of allopregnanolone on GABAAR-mediated 
mIPSCs of mature cortical neurones. ...................................................................................... 139 
Figure 35 The 3 -HSD enzyme inhibitor indometacin does not suppress the acute 
effects of intracellularly applied ganaxolone on GABAAR mIPSCs of mature cortical 
neurones (in contrast to its inhibitory effect on ganaxolone incubation treatment).
................................................................................................................................................................ 143 
Figure 36 Ob/ob & db/db mice exhibit a morbid obesity phenotype on a normal 
diet, consistent with reports in the literature. .................................................................... 147 
Figure 37 Mature cortical neurones of ob/ob & db/db mice exhibit shorter GABAAR 
mIPSCs compared to those from three different WT strains. ....................................... 149 
Figure 38 Intracellular -CD (but not -CD or β-CD) reduces the duration of 
GABAAR mIPSCs of mature cortical neurones from WT and ob/ob mice. ................ 152 
xii 
 
Figure 39 Intracellular -CD reduces the duration of GABAAR mIPSCs of mature 
cortical neurones from five different types of mice to a similar baseline level...... 155 
Figure 40 Acute exposure (10-20mins) of WT & ob/ob mature cortical neurones 
to allopregnanolone (1 M) or ganaxolone (1 M) modestly enhances the function of 
synaptic GABAARs by a similar margin. ................................................................................. 158 
Figure 41 Prolonged exposure (~2 hrs) of WT & ob/ob mature cortical neurones 
to allopregnanolone (100-300 nM) greatly enhances the function of synaptic 
GABAARs by a similar margin. ................................................................................................... 161 
Figure 42 Prolonged exposure (~2 hrs) of mature cortical neurones to ganaxolone 
(30 nM- 1 M) greatly enhances the function of synaptic GABAARs in a 
concentration-dependent manner and has an exaggerated effect in ob/ob mice 
compared to WT mice. .................................................................................................................. 165 
Figure 43 The intracellular application of allopregnanolone to mature cortical 
neurones enhances synaptic GABAAR function by a similar margin in WT and ob/ob 
mice. ..................................................................................................................................................... 170 
Figure 44 The intracellular application of ganaxolone to mature cortical neurones 
enhances synaptic GABAAR function by a similar margin in WT and ob/ob mice. 171 
Figure 45 The 3 -HSD enzyme inhibitor indometacin does not suppress the acute 
effects of intracellularly applied ganaxolone on GABAAR mIPSCs of mature cortical 
neurones of WT or ob/ob mice (in contrast to its inhibitory effect on ganaxolone 
incubation treatment)................................................................................................................... 175 
Figure 46 Prolonged exposure (~2 hrs) of mature cortical neurones to 
progesterone (1-50 μM) enhances the function of synaptic GABAARs, suggesting 
that both WT & ob/ob neurones can synthesise allopregnanolone. ........................... 178 
Figure 47 The 5 -reductase enzyme inhibitor finasteride prevents the effects of 
progesterone incubation treatment on synaptic GABAARs of mature cortical 
neurones of WT & ob/ob mice. .................................................................................................. 180 
Figure 48 Prolonged exposure (~2 hrs) of mature cortical neurones to DHP (1-3 
M) greatly enhances the function of synaptic GABAARs and has an exaggerated 
effect on the cortical neurones of ob/ob mice in comparison to WT mice. .............. 184 
Figure 49 Intracellular DHP has no effect on the function of synaptic GABAARs of 
mature cortical neurones of WT or ob/ob mice (in contrast to allopregnanolone & 
ganaxolone). ..................................................................................................................................... 186 
Figure 50 Comparison of the effect of prolonged exposure to several neuroactive 
steroids on mature cortical neurones of three strains of mice: WT, ob/ob and 
db/db. .................................................................................................................................................. 187 
Figure 51 Ob/ob mice have impaired sensorimotor coordination and exhibit 
prolonged tail withdrawal from noxious heat in comparison to WT mice. ............. 192 
Figure 52 Ganaxolone increases the latency for tail withdrawal from noxious heat 
in WT mice. ........................................................................................................................................ 195 
Figure 53 The highest dose of ganaxolone impairs the rotarod performance of WT 
mice. ..................................................................................................................................................... 196 
Figure 54 Ob/ob mice exhibit cold allodynia in comparison to WT mice. .............. 198 
xiii 
 
Figure 55 Ob/ob mice exhibit mechanical hypersensitivity in comparison to WT 
mice. ..................................................................................................................................................... 200 
Figure 56 Vehicle has no significant effect in ob/ob mice or WT mice. .................... 202 
Figure 57 Ganaxolone reduces mechanical hypersensitivity in ob/ob mice and 
reduces mechanical nociceptive pain in both WT and ob/ob mice. ............................ 203 
Figure 58 DHP reduces mechanical allodynia in ob/ob mice but has no significant 
effect in WT mice. ........................................................................................................................... 205 
  
xiv 
 
Abbreviations 
 
3 -HSD  3 -Hydroxysteroid dehydrogenase  
5 -R   5 -Reductase  
5 -THDOC  Tetrahydrodeoxycorticosterone 
Allo   Allopregnanolone 
AMPA -amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid  
ANOVA  Analysis of variance  
ASIC   Acid-sensing ion channel 
ATP   Adenosine triphosphate 
BDNF   Brain derived neurotrophic factor 
BDZs   Benzodiazepines 
Cl-   Chloride ion 
CD   Cyclodextrin 
CGRP   Calcitonin gene related peptide 
CNS   Central nervous system 
COX   Cyclo-oxygenase  
Ctrl   Control 
CYP450scc  Cytochrome P450 side-chain cleavage  
DH   Dorsal horn 
DHP   Dihydroxyprogesterone 
DMSO   Dimethylsulfoxide 
ECS   Extracellular solution 
Finast   Finasteride 
fMRI   Functional magnetic resonance imaging 
GABAAR  Gamma aminobutyric acid type A receptor 
Ganax   Ganaxolone 
xv 
 
GAT   GABA transporter 
GlyR   Glycine receptor 
HEK293  Human embryonic kidney (293) cells 
ICS   Intracellular solution 
Indo   Indometacin 
IPSC   Inhibitory postsynaptic current 
KCC2   Potassium-chloride co-transporter 2 
L2/3   Neurones from layer 2/3 of the cerebral cortex 
LGIC   Ligand gated ion channel 
LII   Lamina II neurones of the spinal cord 
mGluR   Metabotropic glutamate receptor 
mIPSC   Miniature inhibitory postsynaptic current 
NMDA   N-methyl-D-aspartate receptor 
NSAIDs  Non-steroidal anti-inflammatory drugs 
nRT   Nucleus reticularis neurones of the prethalamus 
P60-75  Mice that have a (postnatal) age of 60-75 days 
PAG   Periaqueductal grey 
PET   Positron emission tomography 
PB   Parabrachial area 
SD   Standard deviation 
SSI Somatosensory cortex I 
StAR Steroidogenic acute regulatory protein (mitochondrial 
membrane) 
T70   Time taken for synaptic event to decay by 70% 
τW   Weighted tau (exponential decay time constant) 
T1DM   Type-1 diabetes mellitus 
T2DM   Type-2 diabetes mellitus 
xvi 
 
TLA   Three letter abbreviaton 
TM1   Transmembrane domain 1 (GABAAR) 
TNF-    Tumour necrosis factor alpha 
TRPM8  Transient receptor potential subfamily M8  
TRPV1 Transient receptor potential subfamily V1 (vanilloid 
receptor) 
TSPO   Translocator protein (mitochondrial membrane) 
TTX   Tetrodotoxin 
VB   Ventrobasal thalamus 
Veh   Vehicle 
vF   von Frey filament 
WDR   Wide dynamic range  
WT   Wild type mouse 
  
xvii 
 
Acknowledgements 
 
I would like to acknowledge the generous support that the Wellcome Trust has 
provided for me to undertake a PhD looking at the underlying mechanisms 
responsible for neuropathy and neuropathic pain.  I have taken the responsibility 
of my project very seriously and worked extremely hard to attempt to create a 
body of work that is in some way worthy of the amount of resources made 
available for my personal project.  Over the last three years I have seen success and 
failure and have learned a lot about scientific research and also about human 
nature through my choices and mistakes.  First impressions can be deceptive and 
the technical parts of my project that should have been the hardest challenges 
were all relatively straightforward.  In contrast, the non-technical issues were the 
biggest obstacles to overcome and were typically kafkaesque in nature.   
I would specifically like to thank my girlfriend Emma for her staunch support 
throughout the entire duration of my project and beyond and also my family for 
their strong encouragement and wise advice on how to deal with moral dilemmas.  
It is also important to acknowledge the roles played by my supervisors (Prof 
Lambert, Prof Hales and Dr Belelli) with regards to the project and also to 
acknowledge the University of Dundee, where the experiments took place.  I am 
very grateful to Miss Linda Gallacher and Miss Lisa Wright for the help they 
provided with the behavioural experiments.  Dr Graeme McLeod was also very 
generous in giving me the von Frey filaments numerous times on loan.  I would 
also like to acknowledge the support that I received from other clinical colleagues 
including Drs: Allison, Bhagya, Bannister, Barker, Barraclough, Bathgate, Beecroft, 
Beveridge, Checketts, Cole, Colvin, Connolly, Coventry, Christie, Clarke, Crawley, 
Crichton, Crofts, Cumming, Dalton, Duncan, Fell, Fernandes, Fettes, Forster, 
Gillespie, Goldmann, Grant, Gray, Hardy, Hartmann, Hay, Hayes, Hennessey, 
Holliday, Howell, Howes, Hunter, Hutchison, Johnston, Jollands, Joss, King, Lacoux, 
Lawes, Lee, Levack, Li, Macmillan, Mackenzie, Macrae, Manthri, McClymont, 
Mcleod, McGuire, McNulty, Mellor, Munnoch, Nanson, Neil, Purdie, Raghavan, Raju, 
Richie, Rodney, Salisbury, Sim, Srivastava, Thompson, Ulyatt, Wallace, Weir, 
Whiteside, Whyte, Williams, Willis, Wilson, Younger. 
xviii 
 
 
Throughout the PhD, a considerable number of people offered me help and 
encouragement, which took numerous forms including advice, practical assistance 
and moral support.  I would therefore like to thank the following (in alphabetical 
order): Miss Amy Alexander, Prof David Balfour, Mr Jean-Dominique Bauby, Mrs 
Karen Bolan, Mr Jorge Borges, Dr Adam Brown, Mr Mikhail Bulgakov, Miss Leonora 
Carrington, Ms Catherine Cavanagh, Dr Chris Connolly, Dr Michelle Cooper, Dr 
Shuaibu Dambatta, Dr John Dempster (Strathclyde), Mr Philip Dick, Prof Anthony 
Dickenson, Miss Ashley Dorning, Dr Catherine Dunford, Mrs Lynn Dyer, Dr B Ebert, 
Dr Lori-An Etherington, Dr Lindsay Graham, Mr Scott Grieg, Dr Benjamin Gunn, Dr 
Murray Herd, Dr Laura James, Mr Franz Kafka, Dr Matthew Livesey, Dr Edward 
Maguire, Dr Rory McCrimmon, Mr John McLeod (and everyone else in the Animal 
Resource Unit), Dr Alison McNeilly, Prof Guy Mensah-Nyagan, Dr Laurence Meyer, 
Dr Gareth Miles, Dr Elizabeth Mitchell, Dr Chris Moffat, Mr Haruki Murakami, Dr 
Luke Newman, Miss Kara Panetta, Dr Kashyap Patel, Dr Dianne Peden, Prof 
Pierrick Poisbeau, Ms Nastja Saranzewa, Dr Samuel Shem, Dr Ross Simmons, Mr H 
Thompson, Mrs Victoria Thomson, Mr Kurt Vonnegut, Miss Nicola Walker, Dr 
Joanne Wallace. Finally I would also like to thank my examiners Prof John Peters 
and Prof Keith Sillar and my examination convener Prof Keith Matthews.  
 
  
xix 
 
Candidate’s declaration 
 
I declare that I am the author of this thesis, and that it is a true record of the work 
performed by me.  This thesis has not been previously submitted for application 
for a higher degree. All references used in the preparation of this thesis have been 
consulted and are cited correctly. This work was carried out in the Centre for 
Neuroscience and the Institute of Academic Anaesthesia, University of Dundee, 
under the combined supervision of Prof Jeremy Lambert, Dr Delia Belelli and Prof 
Timothy Hales. 
 
 
 
 
Stephen Humble 
 
  
xx 
 
Supervisor’s declaration 
 
I certify that Stephen R. Humble has completed nine terms of experimental 
research and he has fulfilled the conditions of Ordinance 39, University of Dundee, 
such that he is eligible to submit the following thesis in application for the degree 
of Doctor of Philosophy. 
 
 
 
 
 
 
Prof Jeremy Lambert, Dr Delia Belelli and Prof Timothy Hales. 
 
 
  
xxi 
 
Abstract 
 
Peripheral sensitisation and central sensitisation are implicated in the 
development of neuropathic pain with neuroplasticity occurring at multiple levels 
of the pain pathway. Hypersensitivity of the spinothalamic tract has been 
described in neuropathic animal models of diabetes. Spinal dorsal horn neurones 
of diabetic rats exhibit abnormally high spontaneous firing, suggesting an 
imbalance between excitatory and inhibitory signals converging within this 
structure. GABAergic neurones within the spinal cord and thalamus are crucial for 
the transmission of painful stimuli to higher centres of the brain that are involved 
in pain perception. GABAA receptors (GABAARs) are an important target for many 
clinical drugs, and certain endogenous neurosteroids act as potent allosteric 
modulators of these receptors. A developmental change in the rate of exponential 
decay of GABAergic synaptic events has been observed in other types of neurones 
and this may be related in part to fluctuations in endogenous neurosteroid tone. 
The objective of this study was to investigate changes to inhibitory 
neurotransmission with development in three levels of the pain pathway and to 
explore potential mechanisms underlying diabetic neuropathy. 
The whole-cell patch-clamp technique was used on slices of neural tissue. 
Electrophysiological recordings were obtained from wild type mice between the 
ages of 6 and 80 days in lamina II of the spinal cord, the nucleus reticularis (nRT) 
of the thalamus and the cerebral cortex. Recordings were also obtained from mice 
with diabetic neuropathy (ob/ob and db/db) between the ages of 60 and 80 days.  
Neurosteroids and their precursors were employed along with compounds that 
xxii 
 
prevented their activity at the GABAAR such as γ-cyclodextrin, which is a barrel-
shaped cyclic oligosaccharide with a lipophilic interior that sequesters 
neurosteroids. Behavioural experiments were also performed using von Frey 
filaments and the tail flick test to examine mechanical and thermal nociception. 
Recordings from the spinal cord, the thalamus and the cerebral cortex revealed 
that the decay time of miniature inhibitory postsynaptic currents are significantly 
reduced with development. The neurosteroids allopregnanolone and ganaxolone 
were significantly more effective in neurones from the older mice. In contrast, γ-
cyclodextrin had significantly less effect in neurones from the older mice. In 
mature diabetic mice (ob/ob mice), the endogenous neurosteroid tone is reduced 
compared to control mice, but certain neurosteroid compounds have a greater 
effect on the GABAARs of these diabetic mice. In addition, the diabetic mice exhibit 
mechanical allodynia and hyperalgesia, which is responsive to exogenously applied 
neurosteroids. 
These results are consistent with the hypothesis that a dramatic reduction in 
endogenous neurosteroid tone occurs as development progresses and that this 
impacts on the exponential decay time of GABAergic mIPSCs within neurones of 
the pain pathway. The higher neurosteroid tone in the youngest mice may confer a 
degree of neural protection over the nervous system as it develops. The reduction 
of endogenous neurosteroid tone in diabetic mice may be associated with their 
hypersensitivity. It is possible that pregnane-derived neurosteroids may exert 
analgesic effects in pathological pain states by attempting to restore the 
physiological GABAergic inhibitory tone that is observed in immature animals.  
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Chapter 1. Introduction 
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Part 1. Pain 
1.1.1 Physiological pain  
 
Pain is ‘an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage’ (Merskey & 
Bogduk, 1994). Nociceptive (or physiological) pain refers to pain due to the 
stimulation of specialised peripheral nerve endings by mechanical pressure, high 
or low temperatures, chemical irritation or other forms of tissue damage. It has a 
protective role, alerting the individual to the presence of a harmful situation from 
which they may withdraw (Caterina et al., 2005; Costigan et al., 2009; Woolf & 
Salter, 2000). Everyone knows instinctively what pain is, but the underlying 
mechanisms for this highly complex phenomenon are not fully understood. The 
‘pain pathway’ may be considered as a rational construct (based on current 
scientific knowledge) to explain the anatomical structures and physiological 
processes involved in the generation of the experience of pain.  
 
First order neurones transmit neural impulses from the periphery to the spinal 
cord, where they make synaptic connections with second order neurones within 
the dorsal horn, which relay the signal to the thalamus via the spinothalamic tract 
as depicted in Figure 1 (Costigan et al., 2009; D’Mello & Dickenson, 2008). The 
thalamus relays the impulses onto higher centres, which constitute the so-called 
pain matrix e.g. pre-frontal cortex, limbic system, somatosensory cortex, insula and 
anterior cingulate cortex (D’Mello & Dickenson, 2008).  The pain pathway is 
subject to descending modulation principally within lamina II (LII) of the dorsal 
horn of the spinal cord (Knabl et al., 2008; Munro et al., 2009; Takazawa & 
MacDermott, 2010). In pathological states, such as neuropathy, this descending 
modulation may be impaired (Knabl et al., 2008, Munro et al., 2009; Takazawa & 
MacDermott, 2010). 
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L6
(A) First order neurones (Aβ, Aδ and C fibres) transmit an action potential from the periphery to the 
dorsal horn of the spinal cord.  Nociception specific neurones are principally located in laminae I and 
II, while wide dynamic range neurones are typically found in deeper layers such as lamina V.  Second 
order projection neurones in the dorsal horn innervate regions such as the thalamus, the 
periaqueductal grey and parabrachial area.  These regions relay the signals onto higher centres, 
which constitute the so-called pain matrix (e.g. pre frontal cortex, limbic system, somatosensory 
cortex, insula and anterior cingulate cortex). The pain pathway is subject to descending modulation 
by areas located within the brainstem over the superficial layers of the dorsal horn.  GABAARs and 
GlyRs are expressed by inhibitory neurones within the dorsal horn of the spinal cord and these 
mediate descending inhibitory tone over spinal second order projection neurones (Adapted from 
D'Mello & Dickenson, 2008). (B) The reciprocal inter-relationship between the VB and nRT creates a 
fine balance of excitation and inhibition of nociceptive transmission to the cortex. The cortex itself is 
organised in parallel columns (Layers 1-6) that function in modules with vertical excitatory and 
inhibitory loops. 
Figure 1 Pain pathway schematic. 
Superficial 
dorsal horn  
 
VB Thalamus & 
nRT 
Cortex  
A  B  
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1.1.2 Nociception 
 
Specialised sensory neurones known as primary afferent nerves have peripheral 
cutaneous and visceral nociceptive terminals that are activated by a range of 
stimuli, including mechanical, thermal and chemical insults (Caterina et al., 2005; 
Costigan et al., 2009; Woolf & Salter, 2000). Direct activation of ion channel 
proteins such as transient receptor potential (TRP) channels on the nociceptive 
terminal, or stimulation of neurotrophin, or G protein-coupled receptors initiates 
the depolarisation of the sensory nerve fibre (Caterina et al., 2005; Costigan et al., 
2009; Woolf & Salter, 2000). Depolarisation results in the initiation of an action 
potential, which is transmitted from the periphery to the spinal cord. The principle 
types of sensory neurones in the mammalian nervous system are A , A  and C 
fibres. The A  fibres typically have a larger diameter and are more highly 
myelinated than A  fibres, which enables them to conduct neural impulses at a 
great velocity (Caterina et al., 2005; D’Mello & Dickenson, 2008; Millan, 1999). C 
fibres lack myelin and are of even smaller diameter than A  fibres (0.4-1.2μM and 
2-6μM respectively), thus making them the slowest conductors. Additionally, A  
fibres have low activation thresholds, which means that they respond rapidly to 
innocuous stimuli such as light touch (Caterina et al., 2005; D’Mello & Dickenson, 
2008; Millan, 1999).  In contrast, A  and C fibres have higher activation thresholds 
and respond to painful, or noxious mechanical, or thermal stimuli (Caterina et al., 
2005; D’Mello & Dickenson, 2008; Millan, 1999). The different properties of these 
first order afferent neurones facilitate the processes of sensory discrimination and 
the monitoring of the physical environment, which confer survival advantages for 
the individual. Conversely, the loss of nociception as a result of a loss of function 
mutation of the gene encoding for the sodium channel Nav1.7 is associated with 
repeated and disabling self-injury (Costigan et al., 2009; Cregg et al., 2010).   
 
1.1.3 Spinal cord 
 
The mammalian spinal cord is a highly complex neurological structure that 
conducts, integrates and modulates neural signals between the brain and the 
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peripheral nervous system. A cross section through the spinal cord reveals a 
circumferential outer layer known as white matter, which contains sensory and 
motor nerve tracts (Hunt & Bester, 2005). Located within the white matter is the 
butterfly-shaped grey matter, which consists of nerve cell bodies. The grey matter 
is divided into ten layers (or Rexed’s laminae I-X) according to differences in cell 
structure. Laminae I-VI are located within the dorsum of the spinal cord and 
comprise the dorsal horn. First order afferent neurones terminate within the 
dorsal horn, where they synapse with second order projection neurones. The 
superficial laminae I and II (LI & LII; also known as substantia gelatinosa) are 
integral to spinal nociceptive processing, while the deeper laminae V, VI and X also 
play a role (Chery & De Koninck 1999; D’Mello & Dickenson, 2008; Millan, 1999). 
Cutaneous afferent C fibres project primarily to LII while A  fibres more commonly 
project to LI. Unmyelinated afferent fibres from muscles, joints and organs 
typically project to LI, LV, LVI and LX. There is a substantial degree of convergence 
of afferent fibres from different locations onto individual spinal neurones. For 
example, somatosensory afferents from the left upper arm frequently share spinal 
pathways with visceral afferents from the heart. This organisation means that 
myocardial infarction may present with ‘referred’ left arm pain. Wide-dynamic 
range (WDR) neurones in particular receive multiple convergent afferent fibres 
from a range of tissue (D’Mello & Dickenson, 2008; Millan, 1999). WDRs are found 
predominantly in LIV-LVI, but also in LI, LII and LX. Their name refers to their 
ability to produce a variable stimulus-dependent response over a wide range of 
afferent input and they also mediate the ‘wind-up’ phenomenon (D’Mello & 
Dickenson, 2008; Mendell & Wall, 1965; Millan, 1999). 
 
LI has the highest concentration of projection neurones within the dorsal horn, 
these neurones project to areas such as the thalamus, hypothalamus, nucleus of the 
tractus soliarius, periaqueductal grey (PAG) and parabrachial (PB) areas (D’Mello 
& Dickenson, 2008; Millan, 1999; Todd & Ribeiro da Silva, 2005). The axons of the 
projection neurones typically cross the midline of the spinal cord and ascend 
within the anterolateral region of the white matter (Todd & Ribeiro da Silva, 
2005). Animal models have been used to provide important insights into the 
molecular mechanisms that occur in the mammalian nervous system.  In rats, LI 
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neurones of the spinal cord are subject to fast synaptic inhibition mediated by 
strychnine-sensitive glycine receptors (GlyRs), while gamma-aminobutyric acid 
type A receptors (GABAARs) mediate extra synaptic tonic inhibition (Chery & De 
Koninck, 1999; Lynch, 2009; Mitchell et al., 2007).  
 
In contrast, LII neurones receive fast synaptic inhibition mediated by GlyRs and 
GABAARs (Chery & De Koninck, 1999; Keller et al., 2001). Pharmacological 
blockade of either the GABAAR or the GlyR results in hyperexcitability of dorsal 
horn neurones, which is associated with neuropathic pain symptoms (Charlet et al., 
2008; Yaksh, 1989). The organisation of LII is complex, however, there are 
considered to be four main cell-types, including: islet, vertical, radial and central 
cells (Yasaka et al., 2010). Islet cells function as inhibitory interneurones, which 
may have projections to LI. Vertical and radial cells are usually (but not always) 
glutamatergic and therefore excitatory. Central cells may also be glutamatergic or 
GABAergic (Yasaka et al., 2010). LII may also be subdivided into the inner and 
outer layers: LIII and LIIO respectively. The different cell types within LII enable 
this layer to have a critical role in the transmission, integration and modulation of 
nociceptive signals within the dorsal horn (Poisbeau et al., 2005). For these 
reasons, LII has been the focus of research seeking to examine the implications of 
the loss of inhibitory tone that may be associated with pathological 
hypersensitivity (Chen & Pan, 2002; Keller et al., 2001; Millan, 1999; Poisbeau et 
al., 2005; Todd & Ribeiro da Silva, 2005; Yaksh, 1989).  
 
The majority of A  and C nerve fibres terminate centrally in the superficial layers 
of the dorsal horn of the spinal cord: laminae I-II, while most A  fibres terminate in 
the deeper layers: laminae III-VI (D’Mello & Dickenson, 2008; Todd & Ribeiro da 
Silva, 2005). Second order spinal neurones, which receive synaptic projections 
from the afferent first order neurones, may be classified into three principle 
categories: 1) Nociception specific neurones located superficially; 2) 
Proprioception specific neurones located in the deeper laminae and; 3) WDR 
neurones which receive synaptic projections from A , A  and C fibres and are able 
to relay a graded response to higher centres via LIII-VI (D’Mello & Dickenson, 
2008, Hunt & Bester, 2005; Millan, 1999).  
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The principle excitatory neurotransmitter in the spinal cord and the entire central 
nervous system (CNS) is the amino acidglutamate (Rousseaux, 2008a). Glutamate, 
which is released from the presynaptic nerve terminal, activates the postsynaptic 
receptor and thus initiates depolarisation. The major classes of ionotropic 
glutamate receptors are the NMDA, AMPA, and kainate receptors, and a family of 
G-protein coupled receptors (metabotropic glutamate receptors mGluRs; 
Bleakman et al., 2006; Dickenson, 2011; D’Mello & Dickenson, 2008; Petrenko et 
al., 2003; Rousseaux, 2008a; Traynelis et al., 2010). Acute, or low frequency, 
noxious impulses to the spinal cord activate the AMPA receptors via the release of 
glutamate, while repetitive, or high frequency, impulses from C fibres activate the 
NMDA receptors.  NMDA receptors do not conduct until the cell depolarises via 
AMPA receptor activation and the magnesium ion block is removed by prolonged 
depolarisation associated with substance P and other peptides (Dickenson, 2011; 
D’Mello & Dickenson, 2008). NMDA receptors are implicated in the induction and 
maintenance of central sensitisation (Bleakman et al., 2006; Petrenko et al., 2003; 
Rousseaux, 2008a; Traynelis et al., 2010).  
 
The NMDA receptor (NMDAR) is comprised of four (variable) subunits that may be 
assembled in different configurations (GluN1, GluN2A-D, GluN3A & GluN3B) to 
produce the individual NMDAR isoforms (Bleakman et al., 2006; Petrenko et al., 
2003; Rousseaux, 2008a; Traynelis et al., 2010). These isoforms are differentially 
distributed within the CNS (Millan, 1999; Rousseaux, 2008a). Each NMDA receptor 
isoform has individual pharmacological properties, but they all exhibit relatively 
slow channel kinetics, a variable degree of magnesium ion block and are 
permeable to calcium ions (Bleakman et al., 2006; Millan, 1999; Petrenko et al., 
2003; Rousseaux, 2008a; Traynelis et al., 2010). NMDA receptors also have a 
recognition site for glycine (or D-serine), the occupation of which is necessary for 
the function of the associated ion channel (Bleakman et al., 2006; Millan, 1999; 
Rousseaux, 2008a; Traynelis et al., 2010). The voltage-dependent magnesium ion 
‘plug’ remains within the channel and inhibits receptor activation until it is 
removed by prolonged depolarisation of the postsynaptic membrane, aided by co-
transmitters such as substance P and CGRP (Dickenson, 2011; D’Mello & 
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Dickenson, 2008; Rousseaux, 2008a; Traynelis et al., 2010). Thus the NMDA 
receptor requires more noxious and prolonged stimuli for activation and results in 
a more amplified and sustained response of the second order neurones. This 
phenomenon is referred to as ‘wind-up.’ Indeed, the NMDA receptor is implicated 
in the development of hypersensitivity to pain that is observed in inflammation or 
neuropathy (Dickenson, 2011; D’Mello & Dickenson, 2008; Petrenko et al., 2003). 
Activation of the NMDA receptor results in a large influx of calcium, which 
depolarises the membrane and triggers a cascade of secondary messengers that 
activate enzymes such as protein kinase C, calcium-calmodulin dependent protein 
kinase II and phospholipase A and C (D’Mello & Dickenson, 2008; Rousseaux, 
2008a).  An excitatory post synaptic potential induces sodium ion flux via voltage-
gated sodium channels, which generates an action potential. The action potential is 
transmitted by the second order spinal projection neurones of the dorsal horn via 
the ascending tracts to higher areas such as the thalamus (D’Mello & Dickenson, 
2008; Rousseaux, 2008a; Traynelis et al., 2010).  
 
The AMPA receptor (AMPAR) is comprised of four subunits and may be assembled 
as a homomeric, or heteromeric, configuration (GluA1-4; Bleakman et al., 2006; 
Rousseaux, 2008a; Traynelis et al., 2010). Calcium permeable AMPARs are located 
within the superficial laminae of the dorsal horn of the spinal cord and can act 
presynaptically to enhance the spontaneous release of GABA from GABAergic 
inhibitory neurones (Bleakman et al., 2006; Rousseaux, 2008a; Traynelis et al., 
2010).  AMPARs are also expressed ubiquitously in brain regions associated with 
nociception, including the brainstem, thalamus and sensory cortices (Bleakman et 
al., 2006; Rousseaux, 2008a; Traynelis et al., 2010). Selective AMPAR antagonists 
are able to suppress the firing of WDR neurones of the dorsal horn in response to 
both noxious and mild stimuli, suggesting that AMPARs are involved in nociceptive 
and sensory transmission (Bleakman et al., 2006; Rousseaux, 2008a). Indeed, 
AMPARs may also be involved in the phenomenon of ‘wind-up’ (Bleakman et al., 
2006; Mendell & Wall, 1965; Traynelis et al., 2010). 
 
The kainate receptor has a similar tetrameric structure to the AMPAR and may be 
expressed in either homomeric, or heteromeric, configurations of the various 
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subunits (GluK1-5; Bleakman et al., 2006; Rousseaux, 2008a; Traynelis et al., 
2010).  These receptors are distributed within areas of the nociceptive pathway 
and have a similar role to AMPARs (Bleakman et al., 2006; Rousseaux, 2008a; 
Traynelis et al., 2010).  
 
The metabotropic glutamate receptors (mGluR) are a family of G-protein coupled 
receptors that modulate the presynaptic release of glutamate and the postsynaptic 
sensitivity to glutamate (Rousseaux, 2008a). Multiple mGluR receptor subtypes 
(mGluR1-8) are expressed on pre- and post-synaptic neurones of both the 
ascending and descending nociceptive tracts of the spinal cord (Bleakman et al., 
2006; Rousseaux, 2008b). mGluR subtypes 1,5 and 6 stimulate inositol phosphate 
metabolism and calcium mobilisation, mGluR subtypes 2-4 and 6-8 are linked to 
adenylcyclase (Rousseaux, 2008a). Increases in mGluR activity within the spinal 
cord have been observed in inflammatory and neuropathic pain, coinciding with 
the manifestation of hypersensitivity (Bleakman et al., 2006, Rousseaux, 2008b). 
mGluRs expression at higher levels of the nociceptive pathway may also be 
increased in neuropathic pain states (Bleakman et al., 2006; Rousseaux, 2008b). 
 
1.1.4 Descending modulation 
 
Historically, pain pathway neurones as described above were considered to remain 
inert until a noxious event occurred to activate them. However, it is now 
understood that the nervous system is continually active in its physiological role as 
a monitoring system of the external environment. Graded ascending impulses are 
constantly being sent from the periphery, even in resting conditions and 
descending pathways from higher centres influence these impulses (Gebhart & 
Proudfit, 2005). Neurones in the ventrolateral periaqueductal grey (PAG) region of 
the midbrain regulate the activation of neurones in the rostroventral medulla 
(RVM) region and the dorsolateral pontine tegmentum (DLPT) (Gebhart & 
Proudfit, 2005). The RVM and DLPT both have separate descending neural 
pathways that project to the spinal cord. These brainstem pathways can mediate 
an inhibitory, or an excitatory influence over nociceptive transmission in the 
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dorsal horn (Gebhart & Proudfit, 2005). Thus this system can act as a regulatory 
mechanism for the transmission of sensory information from the peripheral 
nervous system to higher centres. Interestingly, electrical or pharmacological 
stimulation of the PAG has been shown to have an analgesic effect, while loss of 
physiological inhibitory tone is associated with hypersensitivity to pain (D’Mello & 
Dickenson, 2008; Gebhart & Proudfit, 2005). The underlying mechanisms 
responsible for mediating descending modulation are complex and not fully 
understood, but this system has been a target for analgesic or pain-relieving drugs. 
Opioid receptors and endogenous opioid compounds have been discovered in the 
brainstem and neurones descending from the RVM mediate their actions via 
serotonin receptors and adrenoceptors (Gebhart & Proudfit, 2005). These findings 
provided a rationale for the effectiveness of opioid drugs and tricyclic 
antidepressants for the management of pain and/or hypersensitivity respectively 
(D’Mello & Dickenson, 2008; Gebhart & Proudfit, 2005). In clinical practice, opioid 
drugs are very effective for acute nociceptive and inflammatory pain (Macintyre & 
Schug, 2007). However, both opioids and tricyclic antidepressants have limited 
effectiveness in chronic neuropathic pain and hypersensitivity (Dworkin et al., 
2007; 2010; Macintyre & Schug, 2007). Despite increasing knowledge of the 
underlying pathophysiology of neuropathic pain there has been relatively little 
change in clinical management over recent years (Dworkin et al., 2007; 2010; 
Macintyre & Schug, 2007). Indeed, neuropathic symptoms are untreatable in many 
people with conditions such as diabetic neuropathy or phantom limb pain, which 
places a large burden on society and provides an incentive for further, detailed 
research of this field (Bouhassira et al., 2008).  
 
GABAARs are the major inhibitory receptors in the mammalian nervous system 
(Reviewed in: Belelli & Lambert, 2005; D’Hulst et al., 2009). GABAARs and GlyRs 
are expressed by inhibitory neurones within the dorsal horn of the spinal cord 
(Chery & De Koninck, 1999; Keller et al., 2001; Mitchell et al., 2007).  Activation of 
GABAARs is allows a chloride ion flux which usually causes hyperpolarisation of the 
postsynaptic membrane, a reduction of the potential for depolarisation and also 
shunting of membrane resistance (see Part 2 of the Introduction for a detailed 
description of the GABAAR). Hence, GABAARs may mediate descending inhibitory 
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tone over spinal second order projection neurones and loss of GABAergic function 
is associated with hypersensitivity manifested as allodynia, or hyperalgesia 
(Munro et al., 2009; von Hehn et al., 2012; Yaksh, 1989; Zeilhofer, 2008).   
 1.1.5 Ascending tracts 
 
Neurones from the dorsal horn of the spinal cord project rostrally to higher centres 
such as: the periaqueductal grey, the parabrachial area and the dorsal reticular 
nucleus within the brainstem, the thalamus, the limbic system and the cerebral 
cortex (Hunt & Bester, 2005). Signals travel via multiple and complex ascending 
nociceptive pathways that reach the supraspinal structures by direct and indirect 
routes (Hunt & Bester, 2005; Millan, 1999). For instance, the parabrachial nucleus 
is the target for several ascending pathways, however, it also sends neuronal 
projections up to the thalamus and back down to the spinal cord (Hunt & Bester, 
2005; Millan, 1999). The parabrachial nucleus is a region of the pons involved the 
integration of the autonomic and motivational response to pain (Hunt & Bester, 
2005; Millan, 1999). The classic three monosynaptic pathways are the 
spinothalamic, spinoreticular and spinomesencephalic tracts (Millan, 1999). The 
neurones within these tracts cross the midline to ascend on the contralateral side, 
while neurones belonging to polysynaptic tracts typically remain on the ipsilateral 
side (Hunt & Bester, 2005; Millan, 1999). 
 
1.1.6 Thalamus 
 
The thalamus is considered to be the key region for the relay and modulation of 
sensory transmission from the periphery to higher centres. It integrates 
discriminative information concerning the location, intensity, type and temporal 
pattern of the nociceptive stimulus (Clasca et al., 2012; Millan, 1999). The thalamus 
may be divided into multiple substructures with different structural and functional 
characteristics that act in concert. In rodents, the ventrobasal (VB) complex is 
comprised of three components: ventroposteriolateral (VPL), 
ventroposteriomedial (VPM) and ventroposterioinferior (Clasca et al., 2012; 
Millan, 1999). The VPL and VPM are important for the integration of sensory 
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information related to the sensory-discriminative components of pain such as 
intensity and location. In contrast, the VPI and the posteriolateral region of the 
thalamus are involved in the affective-cognitive components of pain such as 
emotional distress and escape/avoidance behaviour. The distinct areas of the 
thalamus tend to innervate separate regions of the cortex according to their 
specialist functions (Clasca et al., 2012; Millan, 1999). For instance, the VPL and 
VPM have strong connections with the somatosensory cortex I (SSI) which is 
involved in the sensory-discriminative component of pain. Other parts of the 
thalamus such as the VPI and the posteriolateral region that are concerned with 
the affective-cognitive components of pain primarily innervate relevant cortical 
areas such as the SSII and the insula, pre-frontal, parietal and cingulated cortices 
(Millan, 1999). Thalamic somatosensory projection neurones from areas such as 
the VB arborise, or branch out principally to layers III-IV of the cerebral cortex. 
Other layers of the cortex also receive axonal projections from those areas of the 
thalamus, but to a lesser degree (Clasca et al., 2012; DeFelipe & Farinas, 1992; 
Lubke et al., 2000; Lubke & Feldmeyer, 2007; Mountcastle, 1997; Treede et al., 
1999).   
 
1.1.7 nRT 
 
In rodents, the nucleus reticularis (nRT) consists of a crescent of neural tissue that 
encircles the ventral surface of the oval-shaped thalamus. The nRT is part of the 
pre-thalamus and it is an important regulator of somatosensory transmission via 
the relay neurones of other parts of the thalamus such as the VB (Arcelli et al., 
1997; Cox et al., 1997; Gentet & Ulrich, 2003; Guillery & Harting, 2003; Huh et al., 
2012). The nRT is comprised of GABAergic inhibitory neurones that receive input 
from pyramidal neurones of the cerebral cortex, but do not project back to the 
cortex directly themselves (Gentet & Ulrich, 2003; Guillery & Harting, 2003). nRT 
neurones are the main source of GABAergic regulation of VB neurones via closed 
disynaptic loops, which mediate reciprocal and lateral inhibition (Arcelli et al., 
1997; Cox et al., 1997; Gentet & Ulrich, 2003; Guillery & Harting, 2003; Huh et al., 
2012; Figure 1). The inter-relationship between the nRT and VB creates a fine 
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balance of excitation and inhibition, which modulates nociceptive transmission 
and can therefore ultimately influence nociceptive behaviour in live animals 
(Guillery & Harting, 2003; Huh et al., 2012). VB neurones that project to the 
cerebral cortex exhibit both tonic and burst firing patterns (Cheong et al., 2008; 
2011). The tonic and burst firing patterns are regulated by the phospholipase C 4-
protein kinase C cellular transduction pathway, which modulates both T- and L-
type calcium channel activity (Cheong et al., 2008; 2011). The nRT regulates the 
predominant pattern within an individual VB neurone and can therefore increase, 
or decrease, sensitivity to a painful stimulus such as inflammation (Cheong et al., 
2008; 2011; Huh et al., 2012). Specifically, PLC 4-deficient mice have a diminished 
visceral pain response, which is related to an increase in burst firing with a 
decrease in tonic firing of thalamocortical neurones (Cheong et al., 2008). 
 
1.1.8 Cerebral cortex 
 
Historically it was believed that there was a single pain centre somewhere within 
the brain that would be activated in response to a peripheral noxious stimulus 
(Wall et al., 2006). However, pain has sensory, emotional and cognitive 
components and therefore multiple areas within the cerebral cortex (or neocortex) 
are involved in generating the experience of pain (Flor & Bushnell 2005; Treede et 
al., 1999; Wall et al., 2006). These areas may be considered as the ‘pain matrix.’ 
There have been numerous neuroimaging studies to attempt to identify the 
implicated regions however the results obtained have often been inconsistent. 
Despite the uncertainty, a number of key cortical areas have been identified: the 
somatosensory cortices I-II and the insula, pre-frontal, parietal and cingulated 
cortices (Flor & Bushnell, 2005; Millan, 1999; Moisset & Bouhassira, 2007; Treede 
et al., 1999; Treede & Apkarian, 2007; Wall et al., 2006). Other regions of the brain 
such as the cerebellum and the basal ganglia are also thought to play minor roles in 
the phenomenon of pain (Flor & Bushnell, 2005; Treede & Apkarian, 2007).  
 
In rodents the cerebral cortex is a thin layer with a large area that overlies the rest 
of the brain. There are billions of cortical neurones that exist in the form of a 
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complex integrated network with trillions of synaptic connections to facilitate the 
rapid transfer of neural impulses between cells (Ben Ari & Spitzer, 2010; 
Mountcastle, 1997). The cerebral cortex is organised into parallel mini-columns of 
synaptically linked neurones that span part, or all of the six horizontal cortical 
layers. Multiple mini-columns may also be clustered together to constitute 
functional modules (Lubke et al., 2003; Lubke & Feldmeyer, 2007; Meyer et al., 
2011; Mountcastle, 1997).  
 
Within the cerebral cortex there are two types of neurones: spiny and aspiny. The 
spiny neurones may be further subdivided into pyramidal and non-pyramidal cells. 
Pyramidal neurones account for around 80 percent of cortical neurones and 
consist of a pyramid-shaped body with long axons that project into the white 
matter. They are the major output fibres and found in all layers except for layer 1 
(DeFelipe & Farinas, 1992). Spiny non-pyramidal cells have short axons and 
function as interneurones within the cortical network.  Cortical interneurones have 
heterogenous properties and have been described and classified according to their 
variable morphological, physiological and molecular characteristics (Ascoli et al., 
2008).  There is a degree of heterogeneity in the electrophysiological properties of 
cortical neurones, but there appears to be little difference between different 
regions of the cerebral cortex such as the sensorimotor and the cingulate cortices 
(Brown, 2012; Lubke & Feldmeyer, 2007; McCormick et al., 1985; Viaene et al., 
2011). 
 
All cortical regions receive communications from the thalamus and other cortical 
areas via corticothalamocortical and corticocortical pathways organised in parallel 
(Sherman & Guillery, 2011; Viaene et al., 2011). These pathways may be 
considered as ‘drivers’ and ‘modulators’ respectively (Sherman & Guillery, 2011; 
Viaene et al., 2011). Trans-thalamic pathways incorporate the thalamus as a 
GABAergic gating system, which can be opened, or closed (Sherman & Guillery, 
2011; Viaene et al., 2011). Layer 4 neurones are the principle target for 
thalamocortical ‘driver’ (or afferent) inputs and they relay the neural signal to 
layer 2/3 via strong excitatory connections (Viaene et al., 2011; 2011b).  Layer 2/3 
neurones mostly receive ‘modulatory’ thalamic inputs and have a more complex 
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involvement in neural processing and the generation of cortical output signals 
(Bannister, 2005; Eto et al., 2011; Lubke et al., 2000; Lubke & Feldmeyer, 2007; 
Sherman & Guillery, 2011; Viaene et al., 2011; 2011b).  
 
GABAergic inhibitory interneurones are present in all layers of the cortex but are 
most abundant in layers 2/3 and lower in layer 4 (Meyer et al., 2011). They project 
vertically down to the lower layers, exerting GABAergic inhibitory tone on 
pyramidal cells within the column (Helmstaedter et al., 2009; Mountcastle, 1997).  
These connections create, in effect, narrow vertical loops of excitation and 
inhibition, but there are also horizontal connections between neurones within 
layer 2/3 (Helmstaedter et al., 2009). Despite the large amount of work that has 
focused on this area, understanding of these complex processes and their 
functional significance remains relatively limited (Lubke & Feldmeyer, 2007; 
Treede & Apkarian, 2007).  
 
1.1.9 Inflammatory pain 
 
Tissue damage results in the release of chemical substances referred to as 
inflammatory mediators. There are numerous inflammatory mediators which act 
via different mechanisms to lower the activation thresholds of peripheral 
nociceptors, thereby promoting peripheral sensitisation (Caterina et al., 2005; 
Costigan et al., 2009). The exact mechanisms responsible for this inflammatory 
sensitisation process have not yet been fully elucidated, but substances such as 
protons, prostaglandins, ATP, serotonin, bradykinin, BDNF, TNF-  and arachidonic 
acid are able to directly, or indirectly, temporarily enhance the sensitivity of 
receptors such TRPV1, ASIC and TRPM8  (Costigan et al., 2009; Harvey & 
Dickenson, 2008).  The consequence of sensitisation of TRPV1 is that these 
channels, which are normally activated by noxious, or harmful, temperatures, may 
be activated at body temperature and therefore result in spontaneous pain 
(Caterina et al., 2005; Woolf & Salter, 2000). The physiological benefit of this 
process is the enforced resting of the injured area of the body in order to optimise 
tissue healing, however chronic inflammation such as osteoarthritis, or 
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rheumatoid arthritis, can be disabling diseases associated with perpetual 
hypersensitivity (Costigan et al., 2009; Harvey & Dickenson, 2008). 
 
1.1.10 Neuropathic pain 
 
Neuropathic pain results from a dysfunctional, or damaged, nervous system and 
may be associated with pathological neuroplasticity within the peripheral, or 
central, nervous system (Harvey & Dickenson, 2008; Merskey & Bogduk, 1994, 
Woolf & Salter, 2000).  The underlying pathophysiological processes are highly 
complex and not fully understood, but involve the interaction of the immune and 
nervous systems (Costigan et al., 2009; Scholz & Woolf, 2007).  Neuropathic pain 
may be characterized by spontaneous sharp, shooting, or burning sensations 
associated with sensory loss and paradoxical hypersensitivity (Costigan et al., 
2009; Kehlet et al., 2006). Hyperalgesia describes an exaggerated response to a 
painful stimulus, while allodynia describes an unpleasant, or painful, response 
associated with an innocuous stimulus (Merskey & Bogduk, 1994). 
 
A number of disorders are associated with neuropathic pain, including diabetes 
mellitus, post-herpetic neuralgia, phantom limb pain, complex regional pain 
syndrome and cancer (Freynhagen & Bennett, 2009). Intractable neuropathy and 
neuropathic pain have a large impact on society (Bouhassira et al., 2008; Harstall & 
Ospina, 2003) and the treatment options available such as opioids often have very 
limited efficacy and significant side effects (Dworkin et al., 2007; 2010). By 
improving the understanding of these conditions at the molecular level it may be 
possible to identify novel therapeutic targets. 
 
Both peripheral and central sensitisation are implicated in the development of 
painful diabetic neuropathy (Fischer & Waxman, 2010). Hypersensitivity of the 
spinothalamic tract has been described in neuropathic animal models of type I 
diabetes (Chen et al., 2001, Pertovaara et al., 2001). In particular, the spinal dorsal 
horn neurones of diabetic rats exhibit abnormally high rates of spontaneous action 
potential discharge, suggesting an imbalance between excitatory and inhibitory 
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signals converging within this structure (Chen & Pan 2002).  These neurones are 
crucial to the transmission of painful stimuli to the higher centres of the brain 
involved in pain perception (Hunt & Bester, 2005; D’Mello & Dickenson, 2008). 
 
1.1.11 Diabetes 
 
Diabetes mellitus is a very common and devastating disease, which has a large 
socioeconomic cost (Davies et al., 2006; Edwards et al., 2008; Kaplan & Wagner, 
2006). In type-1 diabetes mellitus (T1DM) there is a lack of insulin due to 
autoimmune destruction of the  cells of the islets of Langerhans in the pancreas 
(Mathis et al., 2001). Type-2 diabetes mellitus (T2DM) is more common and is 
characterised by a loss of sensitivity to insulin and the eventual inability of the 
islets of Langerhans to compensate (Buchanan, 2003; De Fronzo, 2004). These 
pathological processes result in the development of hyperglycaemia and current 
management is focused primarily on the optimisation of blood glucose levels in 
order to reduce the severity of neuropathy (Edwards et al., 2008). The underlying 
mechanisms for the development of diabetic neuropathy are not well understood 
but appear to involve oxidative stress and protein kinase signalling pathways in 
response to hyperglycaemia (Edwards et al., 2008). 
 
Individuals with diabetes typically suffer from significant macrovascular and 
microvascular complications including neuropathy (Boulton, 2004; Cefalu, 2006; 
Davies et al., 2006). This condition can manifest itself in ischaemic heart disease 
and peripheral vascular disease, which often leads to chronic pain, or even lower 
limb amputation (Boulton, 2004; Davies et al., 2006; Edwards et al., 2008). 
However, these complications usually take many years to develop, which makes it 
challenging to assess the impact of therapeutic interventions. Therefore it is 
important to utilise animal models to facilitate the development of effective clinical 
management (Cefalu, 2006; Kaplan & Wagner, 2006; Rees & Alcolado, 2005). 
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1.1.12 Diabetic mouse models 
 
In mice, diabetic neuropathy develops over weeks, which allows disease 
progression and the efficacy of interventions to be studied within a relatively a 
short timeframe (Cefalu, 2006; Kaplan & Wagner, 2006; Neubauer & Kulkarni, 
2006; Rees & Alcolado, 2005). T2DM is the more common type seen in humans (90 
percent of diabetics) and with the burgeoning obesity epidemic in the developed 
world the incidence is likely to become even greater (Buchanan 2003; Cefalu 2006; 
Davies et al., 2006; Edwards et al., 2008; Kaplan & Wagner 2006). Taking these 
factors into consideration, it was decided to focus on T2DM for the purposes of this 
project. A complete discussion of the complex pathophysiological mechanisms 
implicated in the development of diabetes mellitus and diabetic neuropathy is 
beyond the scope of this thesis, but the matter has been the subject of several in-
depth reviews (Buchanan 2003; Cefalu 2006; Dobretsov et al., 2007; Edwards et 
al., 2008; Mathis et al., 2001). There are multiple established mouse and rat models 
of diabetes, but no single animal model fully replicates the condition in humans 
ergo, all models have pros and cons (Cefalu, 2006; Kaplan & Wagner, 2006; Mathis 
et al., 2001; Sullivan et al., 2007).  
 
For the purposes of this study the most important issue was to identify a model 
which exhibited consistent features of neuropathy and neuropathic 
hypersensitivity. Mouse models of diabetes are useful because they have a short 
life cycle, with a relatively rapid development of disease symptoms and are readily 
available from commercial sources (Kaplan & Wagner, 2006). In addition, with 
specific reference to the GABAAR, there are multiple transgenic mouse models with 
GABAAR subunits either genetically deleted, or mutated, which has led to a better 
understanding of the physiological role of GABAAR isoforms (Neubauer & Kulkarni, 
2006; Rudolph & Mohler, 2004). Transgenic models could facilitate a greater 
understanding of how a given drug may exert its effect on the GABAAR should the 
drug be proven to be advantageous in diabetic neuropathy. 
 
One of the most common models of T1DM is generated by the injection of 
streptozotocin to destroy the β cells of the Islets of Langerhans (Agarwal, 1980; 
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Cefalu, 2006; Kaplan & Wagner, 2006; Ozcan et al., 2008). However, streptozotocin 
is not always completely effective and therefore the development of consistent 
neuropathy cannot be guaranteed (Sullivan et al., 2007). In contrast, the type-2 
diabetic ob/ob mouse, which has an autosomal recessive nonsense mutation on 
chromosome 6 develops morbid obesity due to its rapacious appetite and exhibits 
a predictable and spontaneous neuropathic phenotype (Cefalu, 2006; Drel et al., 
2006; Latham et al., 2009; Lindström 2009; Vareniuk et al., 2007).  In the ob/ob 
mouse hyper-insulinaemia develops around 3-4 weeks of age, but diabetes 
develops as a result of failure to increase  cell mass in response to insulin 
resistance induced by profound obesity (Cefalu, 2006; Lindström, 2007). It 
subsequently exhibits both large motor fibre and smaller sensory fibre neuropathy 
(Drel et al., 2006; Latham et al., 2009). The ob/ob is particularly useful for the 
study of neuropathic pain because it has a less severe hyperglycaemia (19mmol/l 
of blood) and therefore arguably provides a more clinically relevant form of 
diabetes than other models (Cefalu, 2006; Drel et al., 2006; Latham et al., 2009; 
Lindström, 2009; Neubauer & Kulkarni, 2006; Sullivan et al., 2007). The ob/ob 
mouse develops mechanical hypersensitivity consistently by the age of 8 weeks in 
contrast to some of the other models, which exhibit a more severe (and less 
predictable) neuropathy associated with earlier sensory and motor deficits that is 
less clinically relevant (Drel et al., 2006; Latham et al., 2009; Lindström, 2009; 
Vareniuk et al., 2007). There are conflicting reports from two different research 
centres stating on the one side that the ob/ob mouse develops thermal 
hypersensitivity but on the other that it develops hyposensitivity (Drel et al., 2006; 
Latham et al., 2009). This issue will be explored further in the Discussion: section 
7.11. 
  
The ob/ob mouse was discovered in 1949 and found to have a nonsense mutation 
in the gene responsible for the synthesis of leptin, thereby making the mouse 
totally deficient of leptin (Lindström 2007; Zhang et al., 1994). Leptin is a 16kDa 
protein hormone that is engaged in the regulation of metabolism and appetite. 
Specifically, leptin is involved in the process of satiety after eating and deficiency of 
the hormone is associated with hyperphagia, morbid obesity and T2DM (Ahima et 
al., 1996; Frühbeck 2006; Lindström 2009). 
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In contrast, the db/db mouse has an autosomal recessive mutation of the leptin 
receptor gene, which prevents leptin from activating its receptor (Chen et al., 1996; 
Chung et al., 1996). In this mouse, hyperinsulinaemia develops around 2 weeks, 
obesity by ~3-4 weeks and severe hyperglycaemia (>30mmol/l) around 4-8 weeks 
of age following -cell failure (Bates et al., 2005; Cefalu, 2006; Neubauer & 
Kulkarni, 2006). In common with the ob/ob mouse, the db/db mouse develops 
neuropathy consistently by the age of 8 weeks (Sullivan et al., 2007). This 
condition is characterised by a significant loss of thermal sensation and profound 
reductions of motor and sensory nerve conduction velocity (Sullivan et al., 2007). 
Indeed, the db/db mouse model appears to provide a relatively more rapid and 
extreme form of diabetes and neuropathy that is associated with a much-reduced 
lifespan (Bates et al., 2005; Sullivan et al., 2007).   
 
The ob/ob model appears to reflect more closely the paradoxical combination of 
sensory thresholds observed in humans with diabetic neuropathy. The degree of 
neuropathy can be objectively determined using electrophysiologal studies and the 
microscopic examination of nerve fibres. Nevertheless, the actual levels of 
discomfort experienced cannot be quantified within an animal model and this is 
perhaps the greatest limitation of this type of experiment. Equally, it is worth 
noting that human experiments also struggle with this issue to an extent because 
of the potential difficulties inherent in the description of a subjective experience. A 
dimensionless visual analogue score (i.e. subjective severity score of pain out of 
ten) is frequently used but its value is limited and questionable. More recently, 
clinical studies of pain have started to incorporate multidimensional tools such as 
the McGill Pain Questionnaire, which includes emotional descriptors (Melzack, 
1987). 
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Part 2. The GABAAR 
1.2.1 History of GABA & the GABAAR 
 
Gamma-aminobutyric acid (GABA) is the principle inhibitory neurotransmitter 
within the mammalian central nervous system (Reviewed in: Belelli & Lambert, 
2005; D’Hulst et al., 2009). However, the key role of GABA was not established 
until the second half of the twentieth century. The role of GABA in 
neurotransmission was investigated first in crustaceans in the 1950s and then in 
the mammalian nervous system in the 1960s (Bazemore et al., 1956; Curtis et al., 
1959; Florey & McLennon, 1955; Krnjevic & Schwartz, 1967; Obata et al., 1967). 
Technological advances such as intracellular recording microelectrodes, 
stimulating electrodes and multi-barrel pyrex microiontophoretic pipettes 
facilitated greater understanding of the significance of GABA (Curtis et al., 1959). 
Subsequently, in the 1970s the role of GABA as a major inhibitory 
neurotransmitter was confirmed using bicuculline to selectively antagonise the 
inhibitory effects of GABA (Bennett & Balcar, 1999; Bowery et al., 2004; Curtis et 
al., 1970; Krnjevic 2004; 2010). In the same decade, intracellular recording 
techniques were performed on mouse spinal neurones maintained in cell culture 
to investigate which pharmacological agents could replicate, modulate, or 
antagonise, the response to GABA (MacDonald & Barker, 1977; 1978a; 1978b; See 
section 1.2.11 for further details about GABA pharmacology). In their landmark 
paper, Hamill et al., (1983), used the pioneering patch-clamp technique (Neher & 
Sakmann, 1976) to demonstrate the presence of chloride ion channel currents that 
were activated by GABA and blocked by bicuculline.  
 
Subsequent advances in cloning techniques led to the discovery that GABAARs are 
comprised of distinct subunits such as ,  and  (Pritchett et al., 1989; Schofield et 
al., 1987; See section 1.2.8 for further details on subunits).  During the years that 
followed, the number of subunits identified by cloning grew and led to the 
understanding that multiple heterogenous GABAARs existed in the mammalian 
nervous system (McKernan & Whiting, 1996; Olsen & Sieghart, 2008). The 
expression of these individual, structurally distinct GABAARs with specialised 
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physiological and pharmacological functions was found to vary in different regions 
of the brain (Olsen & Sieghart, 2008). GABAARs belong to the Cys loop ligand gated 
ion channel (LGIC) family, which includes nicotinic acetylcholine receptors, 
strychnine sensitive glycine receptors (see section 1.2.13) and a subtype of 
serotonin receptors (5-HT3; Olsen & Sieghart, 2008).  
 
GABAARs are the target of many drugs used clinically including benzodiazepines 
(BDZs; see section 1.2.12), barbiturates and general anaesthetics, which all act to 
enhance receptor function (Belelli & Lambert, 2005; D’Hulst et al., 2009). In 
addition, endogenous neurosteroids such as allopregnanolone have a high affinity 
for GABAARs and are involved in the maintenance of physiological neural 
inhibitory tone (Belelli & Lambert, 2005; D’Hulst et al., 2009). Pharmacological 
agents that antagonise the GABAAR such as bicuculline and picrotoxin are pro-
convulsant (D’Hulst et al., 2009; Hevers & Luddens, 1998; see section 1.2.11 for 
further details on the pharmacology of the GABAAR).   
 
In the early 1980s it became evident that there were two main classes of GABA 
receptor; those that were sensitive to bicuculline (GABAARs) and those that were 
insensitive (GABABRs; Bowery et al., 1980; Hill & Bowery 1981). Despite both 
receptors being activated by GABA, the two receptors have entirely different 
structures and functional mechanisms (Bormann 2000; Ulrich & Bettler 2007).  
GABAARs are LGICs, GABABRs are G-protein coupled receptors whose structure 
includes seven transmembrane spanning loops (Ulrich & Bettler, 2007). GABABR 
activation induces G-protein subunit dissociation, which in turn can mediate a 
chain of events such as the inhibition of adenylate cyclase, leading to a decrease in 
the levels of cyclic AMP and a subsequent decrease in activation of protein kinase A 
(Bowery & Enna, 2000; Ulrich & Bettler, 2007). In the postsynaptic neurone, 
GABABRs mediate slow inhibitory postsynaptic potentials via the activation of 
potassium ion channels, which hyperpolarise the postsynaptic membrane (Ulrich 
& Bettler, 2007). The GABABR agonist baclofen is a clinically useful anti-spasmodic 
agent, which decreases the probability that depolarisation will activate voltage-
gated calcium channels, leading to a decrease in neurotransmitter release. The 
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hyperpolarisation thus reduces the generation of action potentials and therefore 
reducing muscular contraction (Bowery & Enna, 2000).   
 
In 1984, another type of GABA receptor was discovered and given the name 
‘GABACR’ (Drew et al., 1984). ‘GABACRs’ are functionally distinct from GABAARs but 
due to structural similarities are now predominantly considered to be a subclass of 
GABAARs known as GABAA- Rs (Alexander et al., 2011; Bormann, 2000.  GABAA-
Rs are composed of -subunits and insensitive to both bicuculline and baclofen, 
but they have greater affinity for GABA and can mediate strong neural inhibition. 
(See section 1.2.8 for further details on subunits).  The GABAA- Rs are expressed 
much less densely than the other types of GABAA receptors and are present 
predominantly in the retina, cerebellum and spinal cord (Cutting et al., 1991; Park 
et al., 1999; Rozzo et al., 2002).  
 
1.2.2 GABA Synthesis 
 
In the nervous system, glutamate is decarboxylated to GABA by glutamic acid 
decarboxylase (GAD; Awapara et al., 1950; D’Hulst et al., 2009; Madsen et al., 2008; 
Roberts & Frankel, 1950). There are two different isoforms of GAD, with differing 
molecular weights: GAD 65 and GAD 67 (Conti et al., 2011; Wei & Wu, 2008). The 
two forms of GAD have very similar molecular structures, but mediate different 
physiological processes.  GAD 67 is widely distributed throughout the brain with 
its cofactor pyridoxal phosphate, while GAD 65 is localised to axonal terminals 
(Kaufman et al., 1991). These distribution patterns suggest that the former may 
generate GABA to be involved in trophic or metabolic processes, while the latter 
may play a role in GABAergic neurotransmission (Kaufman et al., 1991; Owens & 
Kriegstein, 2002). 
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1.2.3 Metabolism 
 
The enzyme GABA -oxoglutarate transaminase metabolises GABA to succinate 
semialdehyde, which is subsequently converted to succinic acid in order to enter 
the tricarboxylic acid cycle for oxidative metabolism (Madsen et al., 2008).  
However, a substantial amount of GABA is repackaged into synaptic vesicles within 
the nerve terminal and thus recycled as a neurotransmitter (Madsen et al., 2008). 
The transporter protein VGAT mediates the vesicular uptake of GABA by a co-
transport process linked to proton exchange (McIntire et al., 1997). 
 
1.2.4 Release 
 
GABA is released from presynaptic intracellular vesicles by the process of 
exocytosis. This is a rapid but highly complex process that is mediated by a 
superfamily of specialised proteins that are described as SNAREs (Gerst, 1999; 
Jahn & Scheller, 2006; Martens & McMahon, 2008). Exocytosis is initiated by 
calcium ion influx via voltage-gated calcium channels into the presynaptic nerve 
terminal ~1ms following an action potential. Calcium binds to synaptobrevin, 
which is located on the vesicular membrane and to SNAP25 and syntaxin-1, which 
are located on the plasma membrane (Gerst, 1999; Martens & McMahon, 2008). 
The binding of calcium brings the vesicle into close proximity with the plasma 
membrane of the presynaptic bouton, thus facilitating vesicular fusion and the 
neurotransmitter release (Martens & McMahon, 2008). 
 
1.2.5 Re-uptake 
 
Synaptic GABAergic transmission is typically rapid, but relatively short-lived. Two 
processes terminate these synaptic (or phasic) events: GABA diffuses away from 
the synaptic cleft and/or GABA transporters (GATs) mediate re-uptake. GATs differ 
from the other GABA transporters and consist of a 12-transmembrane spanning 
protein that incorporates the electrogenic process of sodium flux into its 
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mechanism of action. The Na+K+ATPase pump generates an electrochemical 
sodium gradient across the plasma membrane, which provides the energy for GAT 
to transport GABA into neurones and glia (Kanner, 2006). In mice, four different 
subtypes of GAT have been identified and each of these has a unique molecular 
structure and subsequently a different affinity for GABA (Conti et al., 2011; Liu et 
al., 1993). The GAT subtypes have varying distribution patterns within the brain 
and there may also be interspecies differences in subtype profiles. For instance, 
GAT1 is particularly localised to presynaptic nerve terminals where it is thought to 
contribute to the regulation of synaptic inhibition (Conti et al., 2011; Durkin et al., 
1995). GABA transporters have an indirect but important role in neuronal 
inhibition and are targets for therapeutic interventions, such as anti-epileptic 
drugs (Madsen et al., 2010). 
 
1.2.6 Developmental role of GABA 
 
In addition to its major role of inhibitory neurotransmitter in the adult mammalian 
nervous system, GABA also has a separate complex role in neurodevelopment. 
During development, GABA influences neuronal proliferation, migration, 
differentiation, synapse maturation and signalling (Ben Ari et al., 2007; Di Cristo, 
2007; Owens & Kriegstein, 2002). GABA is present in evolutionarily primitive 
organisms and may have a trophic role in that setting (Owens & Kriegstein, 2002). 
In early mammalian development, GABAAR activation may result in depolarisation 
rather than the hyperpolarisation observed in mature neurones. This situation is a 
consequence of a relatively high intracellular chloride concentration resulting from 
the delayed expression of the chloride ion transporter KCC2 (Ben Ari et al., 2007; 
Di Cristo, 2007; Owens & Kriegstein, 2002). GABAAR-mediated depolarisation in 
turn may be sufficient to activate voltage-gated calcium channels, which results in 
a rise in the concentration of calcium ions, which are integral for multiple 
developmental processes (Ben Ari et al., 2007; Di Cristo, 2007; Owens & Kriegstein, 
2002). In this way, GABA may exert apparently paradoxical but vital effects in the 
development of neuronal networks (Ben Ari et al., 2007; Owens & Kriegstein, 
2002). Indeed, in very early development GABA can mediate primary afferent 
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depolarisation and thus provide the earliest functional excitatory synapses prior to 
the establishment of glutamate synapses (Ben Ari et al., 2007).  In certain 
pathological states such as epilepsy and neuropathic pain, GABAAR activation may 
also result in depolarisation of spinal neurones and hippocampal neurones 
respectively (Coull et al., 2003; Huberfeld et al., 2007). 
 
1.2.7 GABAA receptors 
 
The GABAAR is a member of the Cys-loop superfamily of LGICs (D’Hulst et al., 2009; 
Miller & Smart, 2010; Olsen & Sieghart, 2008). Other members of this superfamily 
include the serotonin (5-HT3), the glycine (GlyR) and the nicotinic acetylcholine 
receptor (D’Hulst et al., 2009; Olsen & Sieghart, 2008; Peters et al., 2005). Cys-loop 
LGICs are pentameric structures made up of five parallel subunits that have an 
extracellular domain that binds the ligand and a membrane-spanning domain that 
forms the ion-channel (D’Hulst et al., 2009; Olsen & Sieghart, 2008; Peters et al., 
2005). The extracellular, hydrophilic N-terminal domain contains the GABA 
binding site, in addition to the characteristic eponymous loop formed by a disulfide 
bond between two cysteine residues (Miller & Smart, 2010; Olsen & Sieghart, 
2008). The membranal component comprises four -helix transmembrane 
domains (M1-4), with a short extracellular C-terminus (D’Hulst et al., 2009; Olsen 
& Sieghart, 2008; Peters et al., 2005). The lining of the ion channel is formed by M2, 
with a potential contribution from M1 (Olsen & Sieghart, 2008). There is a 
relatively large loop between M3 and M4, which contributes to the ion 
conductance pathway and phosphorylation of this loop may be involved in the 
regulation of ion-channel function (Hinkle & Macdonald, 2003; Peters et al., 2005). 
 
When a ligand such as GABA binds to the interface between the extracellular 
domains of two adjacent subunits of the relevant Cys-loop receptor it initiates a 
conformational change in the receptor (Hansen et al., 2005; Miller & Smart 2010).  
The C-loop moves inwards, trapping the agonist molecule and also induces a tilting 
motion of the intracellular M2 and M3 domains, which causes a widening of the 
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pore diameter and thus opens the ion-channel (Bocquet et al., 2009; Hibbs & 
Gouaux, 2001; Miller & Smart, 2010). 
 
1.2.8 Receptor subunits 
 
Each GABAAR is composed of 5 subunits, but these subunits are drawn from a 
selection of 19 different types (Belelli & Lambert, 2005; Olsen & Sieghart, 2008; 
Simon et al., 2004). Different subunit configurations permit the expression of ~20 
distinct GABAAR subtypes in the mammalian CNS that exhibit unique expression 
patterns, have diverse physiological/pharmacological properties and mediate 
distinct behaviours (Belelli & Lambert, 2005; D'Hulst et al., 2009). In humans and 
rodents, the 19 identified GABAAR subunits are: 1-6, 1-3, 1-3, , , , , 1-3 
(Belelli & Lambert, 2005; Möhler, 2006; Olsen & Sieghart, 2008; Simon et al., 
2004). The majority of native GABAARs are composed of one , two  and two  
subunits in a quasi-symmetrical arrangement (Belelli & Lambert, 2005; Möhler, 
2006; Olsen & Sieghart, 2008; Peters et al., 2005). Approximately 60% of GABAARs 
in vivo have the configuration 1 2 2, while the majority of the remainder are 
either 2 3 2, or 3 x 2 (Belelli & Lambert, 2005; Möhler, 2006). The other 
subunits such as the , or the  are only present in a minority of GABAARs, but they 
may have greater affinity for certain endogenous ligands, thus providing 
specialised physiological roles in certain brain regions (Belelli & Lambert, 2005; 
Möhler, 2006; Olsen & Sieghart, 2008). 
 
Immunocytochemical and in situ hybridisation studies in rodents have revealed 
that individual GABAAR subunits have distinctive patterns of distribution within 
the CNS (Bohlhalter et al., 1996; D’Hulst et al., 2009; Frischy et al., 1992; Pirker et 
al., 2000; Rudolph et al., 2001; Wisden et al., 1992). This phenomenon enables 
diverse physiological and pharmacological properties of different regions of the 
CNS and may mediate distinct patterns of behaviour (D’Hulst et al., 2009; Siegert & 
Sperk, 2002). The subunits 1, 1-3 and 2 are the most widely distributed, but are 
still subject to regional variation. Other subunits such as 2-6, 1 and  appear to 
be confined to specific brain regions, for instance, the 2 subunit is predominantly 
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localised to the cerebellum and forebrain, while 3 is preferentially expressed in 
the nRT and dorsal horn neurones of the spinal cord and the 6 is limited to the 
cerebellar granule cells (Bohlhalter et al., 1996; D’Hulst et al., 2009; Knabl et al., 
2008; Pirker et al., 2000; Rudolph et al., 2001; Siegert & Sperk, 2002). In 
comparison, the cerebral cortex and ventrobasal thalamus predominantly express 
1, 4, 2 and  subunits (Pirker et al., 2000; Siegert & Sperk, 2002). The 
distribution and function of subunits has been studied using gene ‘knock-in’ and 
‘knock-out’ strategies that involve the respective substitution, or ablation, of a 
specific GABAAR subunit (Luscher et al., 2012; Rudolph et al., 2001; see section 
1.3.5 for further details). 
 
Each GABAAR subunit has a molecular mass of 40-60 kDa, which means that each 
complete GABAAR typically has a mass in the region of 240-290 kDa (Hevers & 
Luddens, 1998). Subunits are comprised of a large extracellular hydrophilic N-
terminal domain that contains the GABA binding site, four hydrophobic 
transmembrane -helix domains (TM1-4) and a relatively small extracellular C-
terminus (Carland et al., 2009; Hevers & Luddens, 1998, Olsen & Sieghert, 2008; 
Peters et al., 2005). Chloride ions entering the external ‘vestibule’ of the receptor 
are funnelled through the narrow transmembrane pore lined by the TM2 domain, 
with a potential contribution from TM1 (Carland et al., 2009; Olsen & Sieghert, 
2008). The TM2 pore extends into an intracellular ‘vestibule,’ which is perforated 
by five narrow openings that allow the chloride ions to pass into the cytoplasm 
(Carland et al., 2009; Olsen & Sieghert, 2008; Peters et al., 2005).  These openings, 
which constitute the only pathway for ions into the cytoplasm, are lined by the 
long intracellular TM3-TM4 loop (Carland et al., 2009; Peters et al., 2005). The 
TM3-TM4 loop mediates interactions with signalling factors and trafficking such as 
the polysynaptic clustering of GABAARs (Luscher et al., 2011; Vithlani et al., 2011).  
Phosphorylation of key residues within the intracellular loops of 1-3 subunits and 
2 subunits may also provide a diverse and ubiquitous mechanism for the 
regulation of receptor activity (Jacob et al., 2008; Kittler & Moss, 2003).  
Specifically, the TM3-TM4 loop of  subunits contains a phosphorylation site for 
multiple kinases, which may have an important role in ion channel regulation 
(Hinkle & Macdonald, 2003).  
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Subunit composition is of critical importance to the deactivation kinetics of 
GABAergic currents (Eyre et al., 2012). For instance, the decay time constant W of 
miniature inhibitory synaptic currents (mIPSCs) from GABAARs containing the 1 
subunit and 3 subunits is around 4-6ms and ~28ms respectively (Eyre et al., 
2012). Interestingly, the subunit expression observed in mature animals may be 
different from that of developing animals (Bosman et al., 2002; Chudomel et al., 
2009; Fritschy et al., 1994; Laurie et al., 1992; Okada et al., 2000).  In the immature 
thalamus and cerebral cortex GABAergic synaptic events have longer decay times 
than those recorded in developed neurones (Bosman et al., 2002; Okada et al., 
2000). These differential kinetics appear to be due to the delayed replacement of 
2/ 3 subunits by the 1 subunit in these neurones (Bosman et al., 2005; Fritschy 
et al., 1994; Okada et al., 2000; Peden et al., 2008).  However, in 1 ‘knock-out’ 
mice (i.e. genetically engineered to lack the 1 subunit) there is also a change in 
decay kinetics with development (Bosman et al., 2005; Peden et al., 2008).  This 
developmental change will be explored further in the Results Chapter 3.  
1.2.9 Phasic inhibition 
 
GABAAR-mediated synaptic transmission facilitates the rapid and precise transfer 
of a presynaptic signal into a postsynaptic response (Farrant & Nusser, 2005, Mody 
et al., 1994).  A presynaptic action potential triggers a local calcium influx, which 
facilitates the simultaneous release of thousands of GABA molecules from multiple 
vesicles in the presynaptic membrane. The GABA molecules bind rapidly to 
GABAARs that are clustered opposite in postsynaptic groups that range in number 
from ten to several hundred receptors (Farrant & Nusser, 2005).  This results in 
the near-synchronous opening of a proportion of the GABAARs, which are usually 
comprised of  subunits (Farrant & Nusser, 2005; Mody et al., 1994). Under 
whole-cell voltage-clamp recording conditions a miniature inhibitory postsynaptic 
current (mIPSC) occurs when a single vesicle releases GABA molecules, which bind 
to postsynaptic GABAARs almost simultaneously.  However, an action potential 
may also trigger the release of multiple GABA-containing vesicles simultaneously, 
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which may activate GABAARs at adjacent postsynaptic densities or neighbouring 
synapses giving rise to an IPSC (Farrant & Nusser, 2005).  An important feature of 
synaptic inhibition is its transient nature, which is due to the rapid diffusion of 
GABA away from the synaptic cleft (Farrant & Nusser, 2005). The efficient gating of 
the postsynaptic GABAAR requires two GABA molecules (Hevers & Lüddens, 1998) 
and this process is relatively slow in comparison to the rate of diffusion of GABA 
away from the area (Farrant & Nusser, 2005). Therefore, although the peak 
synaptic GABA concentration may be potentially saturating, not all postsynaptic 
GABAARs will be occupied. This means that there is scope for other factors such as 
allosteric modulators of the GABAAR to have a significant impact on synaptic 
transmission (Barberis et al., 2011; Farrant & Nusser, 2005; Mody et al., 1994). 
Although synaptic GABAARs open near-simultaneously (resulting in a relatively 
rapid rising phase), they remain open for different lengths of time, which means 
that a typical mIPSC has an initial rapid rising phase, followed by a relatively slow 
‘decay’ phase back to the baseline. The rate of receptor deactivation (and 
desensitisation) may be influenced by differences in subunit composition, or even 
the presence of endogenous allosteric modulators of the GABAAR, which can 
prolong the duration of decay time and therefore prolong the duration of phasic 
inhibition (Barberis et al., 2011; Farrant & Nusser, 2005; Mody et al., 1994; Peden 
et al., 2008). 
 
1.2.10 Tonic inhibition 
 
When GABA diffuses away from the synaptic cleft it may ‘spillover’ to activate 
neighbouring synapses, or even the synapses of adjacent neurones (Farrant & 
Nusser, 2005; Kullmann et al., 2005; Mody, 2001). In addition to synaptic spillover, 
low ambient concentrations of GABA may exert a persistent, or ‘tonic,’ effect on 
extrasynaptic GABAARs that is distinct from phasic activation (Farrant & Nusser, 
2005; Kullmann et al., 2005; Mody, 2001).  Extrasynaptic GABAARs often contain 
subunits such as the 6 or  subunits that are less commonly observed in the 
synaptic setting. These subunits have greater affinity for GABA, or lower rates of 
desensitisation (Brickley et al., 1999; Kullmann et al., 2005; Mody, 2001). While 
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phasic activation has a crucial role in the transfer of inter-neuronal signals, tonic 
activation is less well understood, but appears to be important for preventing 
neuronal over-activation (Farrant & Nusser, 2005; Kullmann et al., 2005; Mody, 
2001). The presence of an endogenous extrasynaptic outward tonic current may 
be revealed by the application of the GABAARs antagonist bicuculline, which under 
conditions of equal intra- and extra-cellular chloride concentration and a negative 
holding potential, produces an outward current and an associated decrease in 
membrane noise as the tonically active GABAARs shut (Herd et al., 2007). 
 
1.2.11 Pharmacology 
 
Therapeutic agents that target GABAAR function are used in a variety of clinical 
settings including: anticonvulsants (lorazepam and phenobarbital); general 
anaesthetics (etomidate and propofol); anxiolytics and sedatives (diazepam and 
temazepam); and also to treat acute alcohol withdrawal syndrome 
(chlordiazepoxide; D’Hulst et al., 2009; Johnston, 2005; Korpi et al., 2002; Möhler, 
2011).  Drugs that activate the GABAAR directly are termed agonists, while 
compounds that enhance the receptor’s response to GABA, such as the 
benzodiazepines (BDZs) are referred to as positive allosteric modulators (D’Hulst 
et al., 2009; Johnston, 2005).  Some of these drugs such as the general anaesthetics, 
barbiturates and neurosteroids act as positive allosteric modulators at low 
concentrations to enhance the effect of GABA, but at higher concentrations activate 
the GABAAR directly (Belelli et al., 1996; Hales & Lambert, 1991; Johnston, 2005). 
In contrast, compounds that exert negative efficacy at the GABAAR are termed 
allosteric inverse agonists, such as bicuculline (D’Hulst et al., 2009; Johnston, 
2005).  Compounds that bind allosterically but are without efficacy are termed 
allosteric antagonists, for example, flumazenil which reverses the allosteric 
modulation of the GABAAR by BDZs (D’Hulst et al., 2009; Johnston, 2005; Möhler, 
2011).  Flumazenil is used clinically for the reversal of sedation associated with 
BDZ overdose (Veiraiah et al., 2012). 
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The diverse array of GABAAR modulators and the distinctive effects that different 
compounds exert is due to the existence of multiple binding sites on the GABAAR, 
which are influenced by subunit composition (Belelli & Lambert, 2005; Hevers & 
Lüddens, 1998; Siegert & Sperk, 2002). For example, the -  interface is crucial for 
GABA binding, the -  interface is required for BDZ binding and the -  interface 
appears to mediate high affinity to GABA and certain neurosteroids (Brown et al., 
2002; Cromer et al., 2002; D’Hulst et al., 2009).  The relevance of these distinct 
binding sites may be illustrated using examples of drugs with specific binding 
properties, such as etomidate, 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-3-ol 
hydrochloride (THIP) and BDZs.   
 
The anaesthetic agent etomidate has greater efficacy for GABAARs containing the 
2 or 3 subunits than 1 subunit (Belelli et al., 1997).  Indeed, the hypnotic effects 
of etomidate are inhibited in ‘knock-in mice’ that have point mutations in the 2, or 
3, subunits, 2N265S and 3N265M respectively (Jurd et al., 2003; Reynolds et 
al., 2003).  THIP is a low affinity partial agonist at receptors expressing the  
subunit (i.e. most GABAARs), but has high affinity for GABAARs that express the 
4 3  subunits where it behaves as a ‘superagonist’ compared to GABA (Brown et 
al., 2002; Farrant & Nusser, 2005; Krogsgaard-Larsen et al., 2004). -GABAARs are 
predominantly located at extrasynaptic locations; therefore THIP is a useful 
pharmacological agent for the selective activation of tonic currents (Belelli et al., 
2005; Farrant & Nusser, 2005).  
 
1.2.12 Benzodiazepines 
 
BDZs such as diazepam and chlordiazepoxide induce a conformational change in 
the GABAAR, which favours the open state of the channel, thus increasing the 
efficacy of GABA, but they cannot induce chloride currents themselves (D’Hulst et 
al., 2009; Hevers & Lüddens, 1998; Lüscher et al., 2012; Macdonald & Olsen, 1994; 
Study & Barker, 1981).  This allosteric modulation of the GABAAR mediates their 
sedative, anxiolytic, anticonvulsant and muscle relaxant effects (Luscher et al., 
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2012).  BDZs merit further discussion due to the important role that they have 
played in exploring the functional properties of the GABAAR. 
 
Classical BDZs exhibit greater activity for GABAARs expressing the 2 subunit, 
rather than the 1, or 3 subunits (Pritchett et al., 1989) and they do not modulate 
GABAARs that lack the -subunit, i.e. those that alternatively express the , ,  or  
subunits (Rudolph & Knoflach, 2011).  The , but not the , subunit is also 
important for BDZ binding to the GABAAR (Korpi et al., 2002; Rudolph & Knoflach, 
2011). For instance, GABAARs expressing the 1, 2, 3 or 5 subunits are highly 
sensitive to diazepam, while GABAARs expressing the 4 or 6 subunits are 
insensitive to diazepam (Rudolph & Knoflach, 2011). A single histidine residue of 
the 1 subunit (H101; Wieland et al., 1992) and phenylalanine and methionine 
residues at positions 77 and 130 respectively of the 2 subunit (Buhr & Sigel, 1997; 
Sigel & Lüscher, 2011) have been identified as being key to GABAAR sensitivity to 
BDZs.  Thus, the BDZ binding site is at the interface between 1 and 2 subunits, in 
the large extracellular domain of the GABAAR and is homologous to the binding site 
for GABA at the -  interface (Lüscher et al., 2012). 
 
The histidine residue H101 within the 1 subunit and the homologous residues 
2H101, 3H126 and 5H105 are essential for GABAAR modulation by diazepam 
(Lüscher et al., 2012; Mohler, 2011). Behavioural and pharmacological 
investigations of ‘knock-in’ mice, where an arginine residue replaced the relevant 
histidine residue, enabled the study of the properties of individual  subunits 
(Luscher et al., 2012; Mohler, 2011).  The 1 subunit mediates the sedative and 
amnesic effects of diazepam, while the 2 and 3 subunits mediate the anxiolytic 
effect of the drug (Luscher et al., 2012). In addition, the 1, 2, 3 and 5 subunits 
mediate the myorelaxant effects of diazepam (Luscher et al., 2012).  2 and 3 
‘knock-in’ mice have been used to demonstrate that the 2 and 3 subunits of 
GABAARs mediate the analgesic effect of BDZs (Knabl et al., 2008). Indeed, the ‘ 1-
sparing’ BDZ-site ligand L-838,417 was highly effective against both inflammatory 
and neuropathic pain, without the usual BDZ side effects of sedation, ataxia and 
34 
 
tolerance by targeting neurones expressing the 2 and 3 subunits, but was 
ineffective in the  ‘knock-in’ mice (Knabl et al., 2008). 
 
1.2.13 The Glycine receptor 
 
As mentioned above, the glycine receptor (GlyR) is also a member of the Cys-loop 
superfamily of ligand-gated ion-channels (LGICs; Connolly & Wafford, 2004; Lynch, 
2009; Miller & Smart, 2010).  The GlyR is an important mediator of neural 
inhibition within the spinal cord, brainstem and retina, but the receptor is also 
expressed at relatively low levels in other regions (Baer et al., 2009; Lynch, 2009). 
Functional GlyRs are comprised of five membrane-spanning subunits ( 1- 4 and 
) that form a central chloride ion-channel (Baer et al., 2009; Lynch, 2009). The 
receptor may be constructed solely from a single isoform of  subunits 
(homomeric), as is the case early in development, or it may contain  and  
subunits (heteromeric; Baer et al., 2009; Lynch, 2009). GlyRs may be distinguished 
from GABAARs pharmacologically, because the former is sensitive to strychnine, 
while the latter is sensitive to bicuculline (Callister & Graham, 2010; Inquimbert et 
al., 2007; Keller et al., 2001; Mitchell et al., 2007). Indeed, these agents may be used 
to distinguish between the two receptors in electrophysiological studies of the 
dorsal horn neurones of the pain pathway (Inquimbert et al., 2007; Keller et al., 
2001; Mitchell et al., 2007). In parallel with the GABAAR, the GlyR plays an 
important inhibitory role in the dorsal horn of the spinal cord and potentially may 
be modulated by specific neuroactive steroids such as minaxolone (Mitchell et al., 
2007). Indeed, the GlyR may also prove to be a therapeutic target for diseases 
associated with the lack of neural inhibition such as neuropathic pain syndromes 
(Inquimbert et al., 2007; Keller et al., 2001; Lynch, 2009). 
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Part 3. Neurosteroids 
 
1.3.1 Overview 
 
Steroid hormones are synthesised in peripheral endocrine glands such as the 
ovaries and the adrenal glands and regulate protein transcription at the level of the 
cellular nucleus (Reviewed in: Belelli & Lambert, 2005; Paul & Purdy, 1992; Picard 
& Yamamoto, 1987). They exert important long-term reproductive and 
neuroendocrine effects that may take hours, or days, to manifest (McEwen, 1991; 
Paul & Purdy, 1992; Sierra, 2004). However, metabolites of the steroid hormone 
progesterone have been shown to have rapid anaesthetic effects that are 
inconsistent with a genomic mechanism of action (Belelli & Lambert, 2005; 
McEwen, 1991; Paul & Purdy, 1992; Selye, 1941).  Alphaxalone, a synthetic steroid 
structurally related to these progesterone metabolites was subsequently found to 
be an allosteric modulator of the GABAAR (Barker et al., 1987; Belelli & Lambert, 
2005; Cottrell et al., 1987; Harrison & Simmonds, 1984). At low concentrations the 
progesterone-related neuroactive steroids typically exert their effects by 
increasing the sensitivity of the GABAAR to GABA, but at high concentrations may 
activate the GABAAR directly (Callachan et al., 1987; Peters et al., 1988; Shu et al., 
2004).  
 
Traditionally it was believed that neuroactive steroids were synthesised only in 
peripheral endocrine glands in response to physiological stimuli such as 
pregnancy, or emotional stress, and subsequently crossed the blood-brain barrier 
(Baulieu et al., 2001; Paul & Purdy, 1992; Purdy et al., 1991). However, it was 
discovered that neurones and glial cells within the CNS (including the cortex and 
thalamus) were able to synthesise neuroactive steroids, which were able to 
influence neuronal function in a paracrine, or autocrine, manner (Agis-Balboa et 
al., 2006; Baulieu et al., 2001; Do Rego et al., 2009; Lambert et al., 2003). 
Neurosteroids play a crucial role in the development and function of the CNS and 
they are implicated in the proliferation, differentiation, activity and survival of 
neurones (Belelli & Lambert, 2005; Do Rego et al., 2009; Mellon, 2007; Mellon et 
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al., 2001). In addition, changes in neurosteroid levels occur with certain forms of 
depression, epilepsy, schizophrenia, pregnancy, acute stress and Alzheimer’s 
disease (Belelli et al., 2006; Gunn et al., 2011; Luchetti et al., 2011; Reddy, 2010).   
 
1.3.2 Neurosteroid binding site 
 
Radioligand binding and functional studies have demonstrated that neurosteroids 
enhance GABAAR function by binding to a site(s) that is distinct from the BDZ and 
barbiturate binding sites (Callachan et al., 1987; Gee et al., 1988; Peters et al., 
1988). Hosie et al., (2006) used molecular biology techniques in insects to 
indentify two discrete putative binding sites for neurosteroids in the 
transmembrane domain of the GABAAR that mediate their potentiating effects and 
direct activation. Specifically, neurosteroids potentiate GABA from a cavity within 
the  subunit domain, while direct activation is via the -  interface (Hosie et al., 
2006). Using tight-seal cell attached electrophysiological recordings in which 
direct drug access to the membrane was prevented Akk et al., (2005) 
demonstrated that steroids can reach the GABAAR either through plasma 
membrane lateral diffusion or via intracellular routes. In addition, a membrane-
impermeable neuroactive steroid was only able to activate the GABAAR when 
applied intracellularly (Akk et al., 2005). However, only the bath application of a 
membrane permeable neurosteroid potentiated the GABAAR, suggesting that the 
neurosteroid either partitioned into the membrane, or diffused into the cell (Akk et 
al., 2005). The demonstration that intracellular neurosteroid is effective in 
modulating the GABAAR is consistent with the hypothesis that neurosteroids may 
act in an autocrine fashion (Akk et al., 2009; Chisari et al., 2009). 
 
1.3.3 Synthesis and metabolism 
 
The initial rate-limiting step in the synthesis of neurosteroids is the translocation 
of cholesterol across the mitochondrial membrane by the 18 kDa translocator 
protein (TSPO; Rupprecht et al., 2010; Sierra, 2004; see Figure 2). TSPO functions 
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in a coordinated manner with the steroidogenic acute regulatory (StAR) protein to 
shuttle the hydrophobic cholesterol molecule across the aqueous intermembrane 
space of the mitochondrial membrane (Do Rego et al., 2009; Sierra, 2004).  
Cholesterol is then converted to pregnenolone by the cholesterol side-chain 
cleavage enzyme P450scc, which is located in the inner mitochondrial membrane 
(Do Rego et al., 2009; Mellon et al., 2001; Rupprecht et al., 2010; Sierra, 2004). 
Pregnenolone is the precursor for numerous synthesis pathways that result in the 
production of a wide range of neurosteroids, each with differing functions, and 
including: oestradiol, testosterone and progesterone (Baulieu et al., 2001; Do Rego 
et al., 2009; Mellon et al., 2001).  Pregnenolone exits the mitochondria and 
undergoes a stepwise series of specific enzymatic conversions to produce 
allopregnanolone. The pathway is as follows: Pregnenolone is converted to 
progesterone by 3 -hydroxysteroid dehydrogenase (3 -HSD); Progesterone is 
converted to 5 -dihydroxyprogesterone (DHP) by 5 -reductase (5 -R); DHP is 
converted to allopregnanolone (5 3 ) by 3 -hydroxysteroid dehydrogenase (3 -
HSD).  
 
In addition, the active compound allopregnanolone may be converted back to DHP, 
or to the inactive epiallopregnanolone (3 5 ) (Belelli & Lambert, 2005; Mellon et 
al., 2001; Rupprecht et al., 2010; Schumacher et al., 2012; Stoffel-Wagner, 2003; 
see Figure 3).  The neurosteroid synthesis pathways are complex, not fully 
understood and the expression of different subtypes of the relevant enzymes 
appears to be species-specific. For example, two types of 5 -R and four types of 
3 -HSD have been identified and each of these isoforms has a different capacity to 
modulate the levels of active steroid hormones (Agis-Balboa et al., 2006, Li et al., 
1997; Pelletier et al., 2004; Penning et al., 2000; Stoffel-Wagner, 2003; Tsuruo, 
2005).  
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Figure 2 Modulation of the GABAAR by endogenous neurosteroids. 
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Cholesterol is taken through the mitochondrial membrane by the translocator protein (TSPO) 
where it is converted to pregnenolone by the cytochrome P450 side chain cleavage enzyme. 
Pregnenolone undergoes stepwise enzymatic conversion to other neurosteroid compounds and 
ultimately allopregnanolone which modulates GABAAR function. Neurosteroids may act via 
paracrine, or autocrine, mechanisms. Postsynaptic GABAARs are activated by GABA that has been 
released from vesicles in the presynaptic nerve terminal.  GABA induces a conformational change in 
the GABAAR, which ‘opens’ its central pore, allowing the passage of chloride ions and the generation 
of mIPSCs. The negatively charged chloride ions typically induce hyperpolarisation of the neuronal 
membrane, which is associated with neuronal inhibition.  Neurosteroids such as allopregnanolone 
enhance GABAAR function and therefore facilitate neural inhibition. 
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Figure 3 Neurosteroid synthesis pathway 
  
Cholesterol Pregnenolone
ProgesteroneDHP
Allopregnanolone
(5 -pregnan-3 -ol-20-one)
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(5 -pregnan-3β-ol-20-one)
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5 -R
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Allopregnanolone is synthesised from neurosteroid precursors by a sequence of enzymatic 
conversions. These neurosteroids have a characteristic steroidal structure composed of three 6-
member and one 5-member carbon rings.  Hydroxyl- and methyl- groups attached to specific 
locations are responsible for selective activity at receptors. Cholesterol is cleaved by the enzyme 
cytochrome P450scc within the mitochondria to form pregnenolone, which diffuses into the 
cytoplasm.  Cytoplasmic pregnenolone is converted to progesterone by 3β-hydroxysteroid 
dehydrogenase (HSD), which is in turn reduced to DHP by 5 -reductase (5 -R).  DHP is converted 
to allopregnanolone by 3 -HSD, which also catalyses the back-conversion reaction.  The GABAAR-
modulatory compound allopregnanolone may be metabolised by 3( →β) hydroxysteroid 
epimerase to the inactive compound epiallopregnanolone (Adapted from Schumacher et al., 2012). 
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The heterogeneous nature of enzyme expression can lead to regional (and species) 
variation in the levels of a given neurosteroid and may therefore affect its 
availability to modulate the GABAAR. For this reason, neurosteroid mediated 
GABAergic inhibitory tone may be relatively high in one region of the CNS, but less 
so in another (Belelli & Lambert, 2005; see section 1.3.4 for further details).  In 
addition, pharmacological agents may be used to target different stages of the 
neurosteroid synthesis pathway to facilitate the study of neurosteroids and their 
precursors in the physiological setting as well as in pathological states and in 
neurodevelopment. The perturbation of neurosteroid levels is associated with 
numerous neuropathologies, therefore manipulation of their synthesis and 
metabolism could potentially be of therapeutic benefit (Gunn et al., 2011; Luchetti 
et al., 2011; Reddy, 2010; Rupprecht et al., 2010).  
 
Numerous synthetic ligands exist for mitochondrial TSPO, including emapunil 
(XBD173), etifoxine, diazepam and 1-(2-chlorophenyl)-N-methyl-N-(1-methyl-
propyl)-3-isoquinoline carboxamide (PK-11195; Giatti et al., 2009; Papadopoulos 
& Lecanu, 2009; Rupprecht et al., 2010). The TSPO is considered to be a promising 
therapeutic target for the treatment of nerve injury and anxiety disorders via the 
enhancement of neurosteroidogenesis (Girard et al., 2008; Rupprecht et al., 2009, 
2010). However, a TSPO ligand still requires the presence of all the key enzymes 
downstream in order for active neurosteroids such as allopregnanolone to be 
produced. The function of these enzymes has been the subject of numerous 
investigations: Finasteride inhibits the enzyme 5 -reductase (5 -R), which 
converts progesterone to DHP (which is subsequently converted to 
allopregnanolone; Aggarwal et al., 2010). Finasteride does not have a direct effect 
on synaptic GABAARs, but pre-treatment of the brain slice with finasteride can 
prevent the conversion of progesterone into the GABA-active neurosteroid 
metabolites in the hippocampal CA1 neurones of mature mice (Sanna et al., 2004). 
Interestingly, finasteride spinal slice treatment has been shown to reduce the 
duration of synaptic GABAergic events in the spinal LII neurones of immature rats, 
but had no effect on mature rats (Inquimbert et al., 2007; Keller et al., 2004). A 
similar phenomenon was observed in the cortical neurones of immature mice that 
were treated with another 5 -R inhibitor, 17β-17-[bis (1methylethyl) amino 
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carbonyl] androstane-3,5-diene-3-carboxylic acid (SKF 105111; Puia et al., 2003).  
Interestingly, when SKF 105111 was given by an in vivo intraperitoneal injection it 
reduced the endogenous concentration of allopregnanolone to a greater extent 
than when the brain slice tissue was incubated with the drug; 80 percent and 30 
percent reductions respectively (Puia et al., 2003).  These findings are consistent 
with the hypothesis that there is an endogenous neurosteroid tone in immature 
animals that has a significant modulatory effect on the GABAAR (Keller et al., 2004).  
 
Medroxyprogesterone acetate (provera) and indometacin have been used as 
inhibitors of 3 -HSD, the enzyme that converts DHP into the active compound 
allopregnanolone (Askonas et al., 1991; Belelli & Herd, 2003; Belelli & Lambert, 
2005; Duax et al., 1978; Hori et al., 2006; Sunde et al., 1982). 3 -HSD also inhibits 
the back reaction of allopregnanolone to DHP, thus inhibition of this enzyme has 
been shown to enhance the effect of exogenously applied allopregnanolone in 
dentate gyrus neurones of rats (Belelli & Herd, 2003).  Interestingly, in the same 
dentate gyrus neurones, the synthetic neurosteroid ganaxolone had a greater effect 
on GABAergic synaptic events than allopregnanolone (Belelli & Herd, 2003).  
Ganaxolone is a metabolically stable synthetic analogue of allopregnanolone, the 
molecular structure of which differs only by having an extra methyl group i.e. 3β 
(adjacent to the hydroxyl group) that prevents oxidation to an inactive form 
(Carter et al., 1997; see Figure 3).     
 
 
The cyclodextrins (CDs) have been used as pharmacological tools to study 
neurosteroids. The CDs are relatively large cyclic oligomers of glucose, which are 
barrel-shaped molecules with a hydrophilic exterior and a hollow lipophylic 
interior (Davis & Brewster, 2004; Adam et al., 2002; see Figure 4). These 
characteristics mean that CDs are water soluble, but are able to sequester smaller 
lipophilic molecules including certain neurosteroids (Shu et al., 2004, 2007).  As a 
result of being trapped inside the CD molecule the neurosteroid agent is unable to 
exert an effect at the plasma membrane, such as the modulation of the GABAAR. 
CDs may be characterised by the size of the hydrophobic pore, which is determined 
by the number of glucose residues it contains.  
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Figure 4 Cyclodextrins sequester neurosteroids. 
  
cyclodextrin
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β-CD 0.78 nm
-CD 0.95 nm
d
The cyclodextrins (CDs) are relatively large cyclic oligomers of glucose, barrel-shaped molecules 
with a hydrophilic exterior and a hollow lipophilic interior. CDs are water soluble, but are able to 
sequester smaller lipophilic molecules including certain neurosteroids such as allopregnanolone. 
As a result of being trapped inside the CD molecule the neurosteroid compound is unable to exert 
an effect at the plasma membrane, such as the modulation of the GABAAR. The three principal types 
of CD that have been described in the literature are the -CD hexamer, the -CD heptamer and the 
-CD octomer, these are characterised by the size of their hydrophobic pore, which is determined 
by the number of glucose residues present. 
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The three principal types of CD that have been described in the literature are the 
-CD hexamer, the -CD heptamer and the -CD octomer (Cooper et al., 2005; 
Davis & Brewster, 2004). However, there are numerous possible CD configurations 
based on variation in ring-size and composition. -CD does not appear to modulate 
the GABAAR directly (Shu et al., 2004, 2007). Paradoxically, in addition to removing 
endogenous lipophilic compounds from their potential target, the CDs may be used 
as complexing agents to solubilise lipophilic agents in aqueous solution (Brewster 
& Loftsson, 2007). Neuroactive steroids may be sequestered inside the lipophilic 
interior of CDs, thus allowing for injection in vivo (Davis & Brewster, 2004). Once 
injected, the neurosteroids are able to leave the CD molecule due to the favourable 
concentration gradient, or be displaced by an endogenous lipid (Brewster & 
Loftsson, 2007). This property is useful because oil-based vehicles may cause 
localised inflammation and irritation at the injection site. CDs have various current 
applications, including the sequestration of the muscle relaxant agent rocuronium 
from the circulation in order to reverse muscle relaxation rapidly (Adam et al., 
2002; Cooper et al., 2005). 
 
1.3.4 Localisation and distribution 
 
Immunohistochemical studies have investigated the cellular distribution patterns 
of the enzymes involved in the neurosteroid synthesis pathway, however, a 
somewhat inconsistent picture has emerged.  Melcangi et al., (1990) found that 5 -
R activity was preserved in neurones, oligodendrocytes and astrocytes isolated 
from rat brains by density ultracentrifugation and also in neurones and glial cells 
grown in cultures. Subsequent immunohistochemical studies on the rat brain 
revealed 5 -R to be expressed in glial cells, while studies on the mouse brain found 
that 5 -R only appeared to be present in neurones (Agis-Balboa et al., 2006; 
Pelletier et al., 1994; Tsuruo, 2005). The reason for this discrepancy is uncertain 
but may be due to species-specific isoforms. A study using antibody-
immunolabelling of allopregnanolone in rats found the neurosteroid had a wide 
distribution pattern, but that it only appeared to be present in neurones and not 
glial cells (Saalmann et al., 2007). Mass spectrometry and liquid, or gas 
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chromatography, have identified several free neuroactive steroids in the rat brain 
including allopregnanolone, along with their respective precursors (Caruso et al., 
2008; Ebner et al., 2006).  Separately, the GABAergic Purkinje cells of the 
cerebellum have been shown to synthesise progesterone de novo from cholesterol 
and to convert progesterone to allopregnanolone (Tsutsui, 2008). The 
neurosteroid-binding site appears to be within the transmembrane component of 
the GABAAR and therefore accessible from within the cell or via external lateral 
diffusion (Akk et al., 2005). The high lipophilicity of neurosteroids is consistent 
with a proposed autocrine mechanism of GABAAR activation (Akk et al., 2009; 
Chisari et al., 2009).   
 
1.3.5 Modulation of the GABAAR 
 
Neurosteroids may modulate the GABAAR at presynaptic, postsynaptic and 
extrasynaptic locations (Kullmann et al., 2005). The principle effect of 
neurosteroids on synaptic GABAARs is to increase the duration of inhibitory 
postsynaptic currents (IPSCs) by prolonging the channel opening time (Herd et al., 
2007; Mitchell et al., 2008; Zhu & Vicini, 1997). Interestingly, the magnitude of 
neurosteroid effect on synaptic GABAARs is neurone specific (Cooper et al., 1999; 
Harney et al., 2003; Koksma et al., 2003; Vicini et al., 2002). Certain cerebellar and 
hippocampal neurones are sensitive to nanomolar concentrations of neurosteroids 
such as allopregnanolone, while hypothalamic magnocellular neurones may 
require micromolar concentrations of such steroids for modulation of GABAARs 
(Cooper et al., 1999; Harney et al., 2003; Koksma et al., 2003; Vicini et al., 2002). 
These differences in sensitivity may be related to the interaction of numerous 
factors including subunit composition, phosphorylation and metabolism (Belelli & 
Lambert, 2005).   
 
Subunit composition appears to have a modest but potentially physiologically 
significant effect on the sensitivity of the GABAAR to neurosteroids. The function of 
recombinant GABAARs containing the 1 or the 3 subunit were enhanced by 
concentrations of allopregnanolone that were more than ten times less than those 
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required for receptors containing the 2 or 4-6 subunits (Belelli et al., 2002). 
GABAARs containing the  subunit, rather than the 2 subunit, exhibit the greatest 
magnitude of response to neurosteroids (Belelli et al., 2002; Brown et al., 2002; 
Mihalek et al., 1999; Wohlfarth et al., 2002). This may be important in the 
mediation of tonic inhibition where GABAARs are exposed to low ambient 
concentrations of GABA (Belelli & Lambert, 2005; Farrant & Nusser, 2005).   
Indeed,  ‘knock-out’ mice have a reduced behavioural response to the anxiolytic, 
hypnotic and convulsant effects of neurosteroids (Mihalek et al., 1999).   
 
In keeping with this behavioural study, electrophysiological investigations have 
demonstrated that the neurosteroids allopregnanolone and 
tetrahydrodeoxycorticosterone (5 -THDOC) have greater efficacy at GABAARs 
expressing the  subunit (Belelli et al., 2002; Brown et al., 2002; Glykys et al., 2007; 
Wohlfarth et al., 2002). In addition, the relatively low efficacy of GABA interacting 
at  GABAARs could be enhanced to high efficacy by neurosteroids modulating 
these receptors (Bianchi & Macdonald, 2003). Whole-cell voltage-clamp studies on 
cerebellar and dentate gyrus granule cells within brain slices found that 5 -THDOC 
enhanced tonic, but not phasic inhibitory currents (Stell et al., 2003). In the same 
study, the magnitude of the tonic current in both dentate gyrus and cerebellar 
granule cells of  ‘knock-out’ mice was reduced c.f. WT. Furthermore, the residual 
tonic current was not enhanced by 5 -THDOC (Stell et al., 2003). These findings 
indicate that interaction of neurosteroids and  GABAARs is complex and other 
factors such as phosphorylation and local metabolism may be influential in the 
neurosteroid modulation of the GABAAR (Belelli & Lambert, 2005; Brussaard et al., 
2000; Harney et al., 2003; Hinkle & Macdonald, 2003; Koksma et al., 2003). 
 
Presynaptic GABAAR activation can increase, or decrease, the frequency of 
postsynaptic events depending on the nature of the chloride ion gradient across 
the membrane (Kullmann et al., 2005). If the intracellular chloride concentration is 
relatively high, GABAAR activation could induce depolarisation of the presynaptic 
membrane. This change in the membrane potential could be sufficient to activate 
voltage-gated calcium channels and lead to an increased release of 
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neurotransmitter (Haage et al., 2002, 2005; Herd et al., 2007; Kullmann et al., 
2005). 
 
 
Phosphorylation of the GABAAR can alter its sensitivity to neurosteroids in a 
complex and variable manner that is yet to be elucidated fully (Brussaard et al., 
2000; Harney et al., 2003; Hinkle & Macdonald, 2003; Hodge et al., 1999; Koksma 
et al., 2003). A specific example of the transient effect that phosphorylation may 
have on the GABAAR has been observed in rats in association with parturition.  In 
pregnant rats, GABAARs mIPSCs of oxytocin-secreting magnocellular neurones of 
the hypothalamic supraoptic nucleus are sensitive to neurosteroids (Brussaard et 
al., 2000; Koksma et al., 2003).  However, on the day of parturition, the endogenous 
neurosteroid tone decreases significantly and the GABAARs become steroid-
insensitive. The net result of this process is that a physiological inhibitory brake is 
removed, thus allowing the release of oxytocin (Brussaard et al., 2000; Koksma et 
al., 2003).  This change to inhibition is of physiological relevance because oxytocin 
plays a crucial role in parturition.  The oxytocin surge is essential for the optimal 
timing of parturition, myometrial contractility and also lactation (Blanks & 
Thornton, 2003).  The change in synaptic GABAAR sensitivity to neurosteroids may 
be mimicked by the manipulation of protein kinase C (PKC) and phosphatases 
(Koksma et al., 2003). 
 
 
1.3.6 Neurodevelopment  
 
During early post-natal development a significant reduction in the duration of the 
decay time of synaptic GABAAR events has been described in numerous regions of 
the CNS including: the spinal cord, thalamus, cerebellum, dentate gyrus, 
hypothalamus and cerebral cortex (Brickley et al., 1996; Draguhn & Heinemann, 
1996; Dunning et al., 1999; Keller et al., 2004; Peden et al., 2008; Schlichter et al., 
2006; Tia et al., 1996). The physiological impact of this process is thought to 
enhance the precision of motor coordination, sensory perception and cognitive 
47 
 
functioning (Takahashi, 2005). Changes in subunit composition with maturation, 
such as incorporation of the 1 subunit result in significantly faster decay kinetics 
of GABAergic synaptic events (Fritchy et al., 1994; Laurie et al., 1992; Okada et al., 
2000; Vicini et al., 2001). However, subunit change is not the only factor to 
influence the exponential decay time of GABAAR-mediated mIPSCs. Indeed, dorsal 
horn neurones of the spinal cord exhibit shorter mIPSC decay times with 
development, P6-8, P13-23 and >P30 without the incorporation of the 1 subunit 
(Keller et al., 2004). In addition, it has been observed that neurones from mice that 
have been genetically modified to lack the gene responsible for the 1 subunit of 
the GABAAR still exhibit shorter mIPSC decay times with development (Bosman et 
al., 2002; Peden et al., 2008).  
 
The reduction of GABAAR mIPSC decay times with development is paralleled by a 
reduction in the level of endogenous neurosteroids within the CNS (Keller et al., 
2004; Grobin & Morrow, 2001; Mellon, 2001). The relative decline of neurosteroid 
levels is likely due to changes in the expression of 3 -HSD and 5 -R that have been 
observed within the CNS (Griffin et al., 2004; Kellogg & Frye, 1999; Mellon, 2001). 
The exact physiological significance of these changes is uncertain, but 
neurosteroids have numerous functions within the developing nervous system 
including proliferation, differentiation, activity and survival of nerve cells (Belelli & 
Lambert, 2005; Do Rego et al., 2009; Mellon, 2007; Mellon et al., 2001). The precise 
mechanisms by which allopregnanolone mediates neurodevelopmental actions is 
uncertain, but GABAAR-mediated depolarising currents (due to the delayed 
expression of the chloride ion transporter KCC2) and a consequent increase of 
intracellular calcium levels by activating voltage-gated calcium channels is a 
potential mechanism (Blaesse et al., 2009; Ben-Ari et al., 2007). Therefore, the 
modulation of GABAARs by allopregnanolone may result in the activation of 
signalling pathways mediated by calcium (Keller et al., 2004; Wang & Brinton, 
2008). 
 
In order to understand the role of neurosteroids in development it may be useful 
to consider a disease associated with a neurosteroid deficit. The 
neurodegenerative condition known as Niemann-Pick disease type C is 
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characterised by the accumulation of neuronal cholesterol, severe progressive CNS 
dysfunction and death in childhood (Griffin et al., 2004). In a mouse model of 
Niemann-Pick disease type C the ability to synthesise allopregnanolone across the 
developmental spectrum is reduced and the neonatal administration of 
allopregnanolone delayed the onset of neurological symptoms (Griffin et al., 2004).   
 
1.3.7 Neurosteroids, pain and the GABAAR 
 
A loss of physiological inhibitory tone is associated with hypersensitivity 
symptoms such as allodynia and hyperalgesia (Chen & Pan, 2002; Munro et al., 
2009; Zeilhofer, 2008). The GABAAR is the major inhibitory receptor in the 
mammalian nervous system and as such it mediates inhibitory tone throughout the 
pain pathway (Munro et al., 2009, 2011; Zeilhofer, 2008). Reduced GABAergic 
inhibition within the dorsal horn of the spinal cord may be implicated in the 
development of hypersensitivity (Knabl et al., 2008; Munro et al., 2009; von Hehn 
et al., 2012; Zeilhofer, 2008).  Therefore, pharmacological agents that enhance 
GABAAR function could be useful to counteract lost inhibitory tone (Knabl et al., 
2008; Munro et al., 2009; Zeilhofer et al., 2009).  Neurosteroids such as 
allopregnanolone are potent allosteric modulators of this receptor (Belelli & 
Lambert, 2005; Callachan et al., 1987).  Indeed, an upregulation in the production 
of endogenous neurosteroids within the spinal cord in response to peripheral 
inflammation has been shown to have an analgesic effect (Poisbeau et al., 2005, 
Schlichter et al., 2006).  The analgesic effect could be suppressed by the 
administration of finasteride to inhibit the enzyme 5 -R, which converts 
progesterone to its more active metabolites (Poisbeau et al., 2005).   
 
Neurosteroids such as progesterone have been studied for their potentially 
protective effects for a number of different neuropathologies including stroke, 
brain and spinal injuries (Mensah-Nyagan et al., 2009; Stein, 2008). Although there 
have been some promising preclinical studies, the mechanism of action is not fully 
understood and they have yet to be translated into useful clinical therapies 
(Leonelli et al., 2007; Mensah-Nyagan et al., 2009; Roglio et al., 2008; Stein, 2008). 
49 
 
In rats given chemotherapy, chronic administration of the neurosteroids 
progesterone, or allopregnanolone, were able to prevent the development of 
painful peripheral neuropathy (Meyer et al., 2010, 2011b).  
 
The effects of progesterone-derived neurosteroids and their interaction with the 
GABAAR has not yet been described in the setting of type-2 diabetes mellitus, but 
ostensibly would seem to be a logical area to study.  Diabetic neuropathy has a 
large impact on society with limited management options.  Mouse models that 
replicate the obesity, hyperglycaemia and neuropathy observed in humans have 
now been characterised (Drel et al., 2006; Latham et al., 2009; Lindstrom et al., 
2007; Sullivan et al., 2007).  Liquid chromatography and tandem mass 
spectrometry studies have demonstrated that the neurosteroid precursors 
pregnenolone and progesterone are decreased in the cerebral cortex, cerebellum 
and spinal cord of mice with streptozotocin-induced diabetes mellitus (Caruso et 
al., 2008).   
 
The potential role of neurosteroids in painful diabetic neuropathy may be 
approached using a number of techniques, including: 1) Electrophysiological study 
of pain pathway neurones to characterise changes in GABAAR function and 
neurosteroid tone at different stages of development and in animals with diabetic 
neuropathy.  2) Behavioural characterisation of mechanical and thermal 
nociceptive thresholds in WT and diabetic mice before and after neurosteroid 
administration.  
 
  
50 
 
Hypotheses 
 
1. Synaptic GABAAR mIPSCs change with development in pain pathway 
neurones. 
2. The developmental change to GABAAR mIPSCs is related, at least in part, to 
fluctuations in the levels of endogenous neurosteroid. 
3. The neurosteroid tone may be altered in pathological states such as in mice 
with diabetic neuropathy. 
4. Neuropathic sensitisation may be due to a reduction of physiological 
GABAergic inhibitory tone. 
5. Replacement of endogenous neurosteroids by synthetic neuroactive 
steroids may be analgesic. 
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Chapter 2. Methods 
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2.1 Electrophysiology  
 
In the twentieth century, the field of electrophysiology evolved in parallel with 
advances in electric circuitry.  A major breakthrough came in 1976 when Neher 
and Sakmann developed the patch-clamp technique, for which they would later be 
awarded the Nobel Prize for Physiology (Hamill et al., 1981; Neher & Sakmann, 
1976).  The whole-cell patch-clamp method involves placing the hollow tip of a 
glass microelectrode directly onto the surface of a neurone under the microscope 
in order to make real-time electrical recordings.  Gentle suction facilitates the 
formation of a tight (giga-Ohm) seal between the glass electrode and the cell 
membrane.  This versatile and sensitive technique is technically challenging to 
perform, but can yield important insights into ion-channel function. An electrical 
circuit is set up that incorporates the neurone, microelectrode, current monitoring 
system and a specialised amplifier (Figure 5).  Within the circuit, the resistance is 
fairly constant and the voltage may be ‘clamped’ at a specific point, thus changes to 
the current associated with ionic flux may be studied using Ohm’s law (I = V/R).  
When an agonist binds to a synaptic receptor it induces a conformational change, 
which opens the channel allowing ions to travel across the membrane according to 
their electrochemical gradient.  This process may be manipulated 
pharmacologically and the effects observed using electrophysiological techniques.   
 
This study focuses on the mIPSCs of GABAARs that are induced only by the mono-
vesicular release of GABA at single synapses.  This is because action potential 
driven multi-vesicular GABA release is often not simultaneous, therefore the 
resultant IPSCs are summated and difficult to interpret accurately.  In order to 
isolate the postsynaptic GABAAR mIPSCs it is necessary to use kynurenic acid and 
strychnine to block glutamate and glycine receptors respectively and tetrodotoxin 
is used to prevent voltage activated sodium channel-mediated action potentials 
and hence prevent evoked IPSCs.   
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Figure 5 Simplified schematic illustrating the approach to obtaining electrophysiological 
recordings from pain pathway neurones. 
  
Cl - Cl -
Postsynaptic neurone
GABA
Presynaptic nerve terminal
GABAAR
A
R
A glass microelectrode with a hollow tip is placed directly onto the surface of a neurone under the 
microscope in order to make real-time electrical recordings using the whole-cell patch-clamp 
method.  An electrical circuit is set up that incorporates the neurone, microelectrode, current 
monitoring system and a specialised amplifier.  Within the circuit, the resistance is fairly constant 
and the voltage may be ‘clamped’ at a specific point, thus changes to the current associated with 
ionic flux may be studied using Ohm’s law (I = V/R).  When an agonist binds to a synaptic receptor it 
induces a conformational change, which opens the channel allowing ions to travel across the 
membrane according to their electrochemical gradient.  This process may be manipulated 
pharmacologically and the effects observed using electrophysiological techniques. 
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2.2 Breeding and housing of mice 
 
The study was performed under the project licences of my supervisors and as such, 
has been subjected to rigorous ethical review. All procedures were carried out in 
compliance with the University of Dundee code of practice. Wild Type (WT) mice 
aged less than 2 months were obtained from an in-house colony. C57/ Bl6J Mice 
aged 2 months were purchased from Charles River, UK while OlaHSD ob/ob mice, 
db/db mice and their respective strain-matched WT littermates were purchased 
from Harlan UK and housed in the same in-house colony. Animals were kept under 
an alternating 12hr light/dark cycle and had ad libitum access to food and water. 
Prior to dissection mice were killed instantly by cervical dislocation in accordance 
with Schedule 1 of the Animals (Scientific Procedures) Act 1986 (UK).   
 
2.3 Spinal cord dissection technique  
 
Spinal cord extraction from a mouse had not been performed within the host 
laboratory before and therefore this technique needed to be developed. This was 
achieved by reviewing the literature, by drawing upon the knowledge of a 
laboratory colleague who had previously worked with rat spinal cord slices in the 
sagittal plane and also by contacting colleagues in other research groups for 
advice. The relatively small size of the mice (particularly early in development) 
presented a considerable technical challenge. The removal of a spinal cord in good 
condition required a significant amount of training and experience. The two main 
techniques for obtaining the spinal cord in rodents are hydraulic extrusion and 
anterior laminectomy (Chery & De Koninck, 1999; Chery et al., 2000; Keller et al., 
2001). After initial success with hydraulic extrusion the anterior laminectomy 
technique was adopted in an effort to improve reliability. Dr Gareth Miles 
(Principle Investigator) and Dr Catherine Dunford (former PhD student) of the 
University of St Andrews use the anterior laminectomy technique and a visit was 
made to their laboratory to observe their approach. After observing these methods 
I adapted their technique for use in my host laboratory. 
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Hydraulic extrusion 
 
Mice were killed using the cervical dislocation method (Schedule 1) and then 
decapitated. The body was then submerged immediately in the prone position into 
a bath of ice-cold oxygenated (95% O2 / 5% CO2) artificial cerebrospinal fluid 
(aCSF) containing: 225mM sucrose, 10mM glucose, 10mM MgSO4, 26mM NaHCO3, 
1.25mM NaH2PO4, 2.5mM KCl, 0.5mM CaCl2, 1mM ascorbic acid and 3mM pyruvic 
acid (total osmolarity ~330mosm/l). Scissors were used to remove a 1cm wide 
strip of skin to expose the fascia-covered dorsal aspect of the spinal column. 
Toothed forceps held the body, while fine scissors were used to extract the entire 
spinal column carefully from the carcass. The spines were palpated to identify the 
presence of any fractures of the (thoracic) vertebrae. Generally, fractures were 
associated with unsuccessful extrusion, but this problem could be minimised by 
trimming the column below the level of the fracture. A razor blade was used to cut 
through the spinal column perpendicularly at the mid-thoracic and sacral levels. 
Any blood and debris was washed off using a 10ml syringe and the caudal end of 
the cord was trimmed further as required using the razor blade. This approach 
allowed the cauda equina to be visualised within the sacral end of the spinal canal. 
A 21-gauge needle (connected to a 20ml syringe filled with sucrose solution) was 
then inserted into the spinal canal. Manual pressure was applied to the plunger, 
which generated hydraulic pressure within the spinal canal, forcing the spinal cord 
to be expelled into the ice-cold solution. The dura was then removed to prevent it 
impairing the process of slicing the spinal cord.  
 
Anterior Laminectomy 
 
Mice were killed by cervical dislocation (Schedule 1) and then decapitated. The 
body was immersed in ice-cold oxygenated, aCSF solution and after placing it 
supine, the limbs were extended and pinned to the floor of a dissection chamber, 
modelled on the vessel used by the Miles laboratory in St Andrews. [The base of a 
small oblong can (Herring in Mustard and Dill Sauce, John West Ltd) was filled with 
black Sylgard to a depth of 1-2 mm to enable the animal body to be pinned down 
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for dissection.] A gaseous mix of 95% O2 / 5% CO2 was bubbled into the chamber 
continuously and it was placed into a tray of ice to maintain the low temperature 
required to preserve the tissue. 
 
Scissors (9cm, No. 14568-09, FST, Heidelberg, Germany) were used to cut away the 
skin to expose the thoracic cage. The ribs were then cut either side of the sternum 
to open the thoracic cavity. The internal organs were removed to reveal the 
anterior aspect of the vertebral column. Small toothed forceps grasped the most 
cephalad vertebral body at the cervical level and the fine scissors (No. 15006-09, 
FST, Heidelberg, Germany) were used to cut the vertebral arches immediately 
posterolateral to the vertebral bodies. By this method the vertebral bodies were 
detached consecutively to reveal an intact spinal cord. The cervical end of the cord 
was then grasped with the fine forceps and peeled out of the vertebral canal gently 
using fine scissors (No. 15008-08, FST, Heidelberg, Germany) to cut through the 
roots. The cord was pinned to the chamber and the remaining dura and nerve 
roots were removed to facilitate optimal slicing. Removal of the dura and nerve 
roots is a crucial step to facilitate the success of the preparation. 
 
2.4 Spinal cord slice preparation 
Initial technique: No supporting block 
 
The cord was removed from the solution by grasping the caudal tip with fine 
forceps and then placed briefly onto moist filter paper to remove excess solution. 
The cord was then placed onto a 1cm cube of polystyrene/Sylgard/agar, which had 
previously been glued onto the metal disc. The flat thoracic end was held in place 
using a small amount of glue on the metal disc and by mild natural adherent 
properties to the cube. A Leica VT1000S vibratome (Heidelberg, Germany) was set 
to a forward speed of ~0.08mm/s and to the maximal side-to-side vibration speed 
of approx. 80Hz. Horizontal, thoracolumbar slices, (300-350 m) were cut and 
transferred onto a nylon mesh platform within a storage chamber containing 
oxygenated (95% O2 / 5% CO2) artificial extracellular solution (aECS) comprising: 
126mM NaCl, 10mM glucose, 2mM MgCl2, 26mM NaHCO3, 1.25mM NaH2PO4, 
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2.95mM KCl, 2mM CaCl2, 1mM ascorbic acid, 3mM pyruvic acid and 2mM 
kynurenic acid (Total osmolarity ~310mOsm/l). Slices were stored at room 
temperature for at least one hour before being used to obtain electrophysiological 
recordings. 
 
Definitive technique: Agar block 
 
This technique was first observed in the Miles Group Laboratory, University of St 
Andrews and modified slightly to suit requirements. Agar powder was dissolved in 
aCSF solution at a concentration of approximately 1% and heated for 
approximately 20-30 seconds in a microwave oven in a glass beaker until just 
before it started to boil. The agar solution was allowed to cool to ~36oC while 
being stirred continuously. The agar was poured into a small agar plate and the 
spinal cord placed into the gel itself before it set. After setting, a cuboid of agar 
containing the cord was then extracted from the plate. The agar cube was glued 
onto the vibratome platform with another cube of sylgard, or agar (10%) alongside 
for support. The agar provided support for the cord and typically released the 
small slices after slicing. 
 
Brain slicing technique 
 
Mice were killed using the cervical dislocation method (Schedule 1) and then 
decapitated. The head was then submerged immediately into a bath of ice-cold 
oxygenated (95% O2 / 5% CO2) aCSF. For all nRT preparations the aCSF solution 
was the same as that described above for spinal cord but the sucrose concentration 
was increased to 234mM giving a total osmolarity of ~340mOsm/l as this 
improved the condition of the slices. For cortical preparations in mice below 2 
months of age the aCSF was the same as for the spinal cord. Neuronal viability 
deteriorates with increasing age and for mice above the age of 2 months, including 
all ob/ob and db/db, a different solution was required to optimise the condition of 
the slices. This consisted of 140mM potassium gluconate, 10mM HEPES, 15mM 
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sodium gluconate, 0.2mM EGTA, 4mM NaCl, 1mM ascorbic acid and 3mM pyruvic 
acid. Sodium hydroxide solution was then added to bring the pH up to 7.2.  The 
brain was removed carefully from the skull and slices were obtained using a 
Vibratome series 1000 PLUS Sectioning System (Intracell, Royston, Hertfordshire, 
UK). Cortical slices were cut in the coronal plane and nRT slices in the horizontal 
plane. Slice thickness was greatest for the youngest mice and least for the oldest 
mice. For instance, at postnatal day 6 (P6) it was 350 M while at postnatal day 60 
(P60) it was 250 M. Slices were transferred immediately to a storage chamber as 
previously described for the spinal cord.  
 
Electrophysiology 
 
Subsequently, the slices were transferred to a recording chamber under an 
Olympus BX51WI fixed-stage upright microscope. An infrared differential 
interference contrast disc and a water immersion objective (x 40) were used for 
visualisation of neurones within the spinal, or brain, tissue. The chamber was 
perfused continuously with oxygenated aECS. Slices were held in position using a 
small grid, fashioned using a flattened platinum wire and pieces of nylon tights. A 
magnification chamber (x 1.6) was also used to increase the magnification of the 
image further. Microscopic images were visualised on a video monitor to facilitate 
the experimental process. 
 
Lamina II (LII) neurones of the dorsal horn of the spinal cord are typically oblong 
in shape. They were selected visually from the translucent band of neural tissue 
that lies between LI and LIII. The dorsal horn of the spinal cord is comprised of LI 
and LII and has an integral role in transmission of nociceptive impulses from the 
periphery to higher centres (D’Mello & Dickenson, 2008). Previous work has 
suggested that loss of fast synaptic inhibition mediated by the GABAAR located on 
LII neurones may be implicated in the development of allodynia and hyperalgesia 
(Keller et al., 2004, Sivilotti & Woolf, 1994).  In addition, the upregulation of 
endogenous neurosteroids in response to peripheral inflammation may mediate an 
endogenous analgesic effect (Poisbeau et al., 2005).   
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Neurones of the nRT are also oblong in shape and form a distinct longitudinal band 
immediately lateral to the perpendicularly striated ventrobasal (VB) complex of 
the thalamus. This anatomical relationship facilitates visual identification. The VB 
complex relays somatosensory impulses from the spinal cord to higher centres. 
Neurones of the nRT mediate GABAergic inhibitory tone over VB neurones, thus 
providing physiological regulation of somatosensory transmission (Arcelli et al., 
1997; Clascá et al., 2012; Cox et al., 1997; Gentet & Ulrich, 2003; Huh, 2012).  
 
Pyramidal neurones located in layer 2-3 of the cerebral cortex are easy to identify 
due to their distinctive shape comprising pyramid-shaped body with prominent 
apical dendrite. There is also a pronounced natural demarcation between layers 1 
and 2 of the cortex. The former contains few cell bodies while the latter contains 
densely packed neurones (mostly pyramidal).  Cortical neurones are organised 
into functional units comprising vertical columns from layer 2-6.  These layers 
receive direct synaptic connections from the thalamus and layer 2-3 pyramidal 
neurones also provide intercortical GABAergic inhibitory modulation (Clascá et al., 
2012; DeFelipe & Farinas, 1992; Mountcastle, 1997). 
 
Whole-cell patch-clamp recordings were obtained using an Axopatch 200B 
amplifier with up to 75% capacitance compensation. All recordings were made at a 
holding potential of -60mV and at a temperature of 35oC. The extracellular solution 
contained kynurenic acid (2mM), strychnine (0.5μM) and tetrodotoxin (0.5μM) to 
antagonise ionotropic glutamate, glycine receptors and voltage-gated sodium 
channels respectively. Patch electrodes were prepared from thick walled 
borosilicate glass capillaries (Garner Glass Co., Claremont, CA, USA). Such 
electrodes had an open-tip resistance of ~4MΩ when filled with intracellular 
solution containing: 135mM CsCl, 10mM HEPES, 10mM EGTA, 1mM CaCl2, 1mM 
MgCl2, 2mM Mg-ATP, 5mM QX-314, pH approx 7.2. The osmolarity was 
approximately 310mOsmol/l.  Typically, the mean whole-cell capacitance was 5-
15pF and only recordings where the series resistance changed by less than 20% 
were analysed. A 2 kHz frequency filter was used for all recordings and analysis of 
each cell was performed offline as described below. 
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2.5 Data analysis 
 
The Strathclyde Electrophysiology Software, WinEDR and WinWCP, (Dr J 
Dempster, University of Strathclyde, Glasgow, UK) was used for the analysis of 
recordings.  Only recordings that met specific quality criteria were included in the 
analysis.  mIPSCs were detected with an amplitude threshold of at least -5pA and 
duration  2ms. Each individual mIPSC was then inspected visually to ensure 
validity and exclude artifactual events. mIPSCs with a rise time of more than 1ms 
were excluded to prevent the inclusion of events originating from a distal source. 
At least 50 events were sought for each recording, and their peak amplitude, rise 
time (10-90%), charge transfer (area under the curve) and T70 (time required to 
decay by 70%), were analysed. The mIPSCs were digitally averaged by alignment 
at the midpoint of the rising phase. The mIPSC decay was fitted by monexponential 
(y(t) = Ae-t/τ) and biexponential (y(t) = Afaste(-t/τfast) + Aslowe(-t/τslow)) functions to 
determine which one was more appropriate. (A is amplitude, t is time and τ is the 
decay time constant; Figure 6).  
 
The mIPSC exponential decay time τw (weighted Tau), is a mathematical constant 
generated by considering the fast initial component of biexponential decay τ1 and 
the later slower component τ2. The value of τw is determined for the mean mIPSC 
for each cell by determining the relative proportion that τ1 and τ2 contribute to the 
biexponetial decay. The following equation was used: τw = τfastP1 + τslowP2, where P1 
and P2 represent the proportions of the synaptic current decay curve described by 
each component (Figure 7). 
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Figure 6 Superimposed individual mIPSCs from spinal & cortical neurones. 
  (A) Superimposed individual mIPSCs from a single spinal neurone showing intra-cell variation in 
the peak amplitude. Note the ‘noisy’ appearance of individual mIPSCs. (B) Superimposed individual 
mIPSCs from a single cortical neurone. (C) An averaged cortical mIPSC composed of 172 individual 
events extracted from one representative (or exemplar) recording. Note the rise time, peak 
amplitude and the decay time constant τw. 
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Figure 7 Determination of GABAAR mIPSC decay time constant. 
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mIPSCs were digitally averaged by alignment at the midpoint of the rising phase. The mIPSC decay 
was fitted by monexponential (y(t) = Ae-t/τ) and biexponential (y(t) = Afaste(-t/τfast) + Aslowe(-t/τslow)) 
functions to determine which one was more appropriate. (A is amplitude, t is time and τ is the 
decay time constant). The mIPSC exponential decay time τw (weighted Tau), is a mathematical 
constant generated by considering the fast initial component of biexponential decay τ1 and the 
later slower component τ2. The value of τw is determined for the mean mIPSC for each cell by 
determining the relative proportion that τ1 and τ2 contribute to the biexponetial decay. The 
following equation was used: τw = τfastP1 + τslowP2, where P1 and P2 represent the proportions of the 
synaptic current decay curve described by each component. 
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The signal-to-noise ratio prevents the meaningful fitting of time constants to 
individual mIPSCs. To investigate the kinetics of individual mIPSCs the parameter 
of T70 was determined. This parameter can be readily determined for individual 
mIPSCs and was chosen rather than the the T90, which is subject to imprecision due 
to artefact, or fluctuations, in the tail of the synaptic event. 
 
The tonic current was analysed with the same software package Win EDR utilised 
for the analysis of the synaptic events (Dr J Dempster, University of Strathclyde, 
Glasgow, UK).  The baseline current and noise were sampled every 51.2ms over a 
60 second period for each section analysed.  At the sampling rate of 10kHz, one 
data point consisted of 512 baseline points. Recordings were scrutinised in order 
to remove mIPSCs and artefacts. Recordings made pre- and post- drug application 
were compared to determine if there were significant changes to the baseline 
holding current. In some recordings, the baseline holding current can drift 
spontaneously over time. Only baseline shifts that were twice the standard 
deviation of the control section were considered genuine effects. This provided a 
systematic and reproducible way of determining if a shift in the baseline current in 
response to an applied drug was genuine, or not. 
 
The frequency of mIPSCs was also analysed using the WinEDR software. An event 
detection protocol was initiated with 1ms dead time over for at least 40 seconds. 
Two separate sections of recording were analysed and the mean value of the two 
sections combined was used to derive the frequency for an individual neurone. 
Each section was inspected carefully to remove spurious ‘hits’ and to insert any 
missed events. If an individual event was contaminated by a second event, then 
both events were counted (in contrast to the analysis of mIPSC decay time, when 
these events were omitted). 
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2.6 Drug and solution preparation and administration 
 
The numerous salts used in the preparation of aECS and aCSF solutions were 
purchased from VWR (West Chester, Pennsylvania, USA). Strychnine (Sigma 
Chemicals, St. Louis, MO, USA), tetrodotoxin (Tocris, Bristol, UK) and bicuculline 
(Axxora, Nottingham, UK) and THIP (generous gift from B Ebert) were prepared as 
concentrated stock solutions in double-filtered water to be added to the aECS. 
Other compounds such as progesterone, ganaxolone, allopregnanolone, dihydroxy-
progesterone, provera, indometacin, finasteride, diazepam and flumazenil were 
(purchased from Tocris or Sigma) and prepared as concentrated stock solutions in 
DMSO. The cyclodextrins (Sigma) were dissolved directly into the aECS, or the 
intracellular solution, as outlined in the results section. 
 
Brain and spinal cord slices were placed under the microscope into a transparent 
plastic chamber filled with aECS. The aECS was perfused through the chamber 
using a rate-adjustable gravity-based system consisting of plastic tubing that 
connected an oxygenated reservoir to the chamber. Simultaneously, a peristaltic 
pump system (Minipuls 3, Gilson, UK) drained the aECS from the opposite side of 
the chamber and recycled it back to the reservoir. The fluid-filled circuit also ran 
through a custom made heating system (G23, UCL, London, UK) controlled by a 
temperature monitoring system (School of Pharmacology, London, UK) that 
maintained the near physiological temperature of 35oC throughout the course of 
every experiment (physiological temperature= 36.5-37.5oC). 
 
2.7 Behavioural experiments 
Drug adminstration 
 
The drug, or vehicle, was administered by intra-peritoneal injection using a fine 
1ml syringe and tail flick recordings were made pre- and post- injection. 
Neurosteroids are lipophilic compounds that have very limited solubility in 
aqueous solution, but can be solubilised in 0.9% saline using 2-hydroxy propyl -
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cyclodextrin to facilitate administration (Besheer et al., 2010; Carter et al., 1997; 
Reddy & Rogawski, 2010).  Neurosteroids were therefore administered in 40% -
cyclodextrin solution. 
Rotarod test 
 
The rotarod test comprises an elevated rotating cylinder upon which a rodent is 
placed (Jones & Roberts, 1968; Pritchett & Mulder, 2003).   In order to avoid falling 
off the rotarod, the mouse must maintain constant motion; hence it is a test of 
forced motor activity (Jones & Roberts, 1968; Pritchett & Mulder, 2003).  To 
remain on the rotarod while it accelerates at a set rate the mouse requires balance 
and coordination.  The rotarod may be used to test motor function after the 
administration of novel agents as part of the drug development process, or to 
characterise neurodegenerative conditions such as Huntington’s disease and 
Parkinson’s disease (Pallier et al., 2009; Shiotsuki et al., 2010).   Mice were placed 
on the rotarod and the accelerating rotarod protocol was used.  Specifically, the 
rod starts to rotate at 6 revolutions per minute (rpm) and is then increased in 4 
rpm increments up to a maximum of 50 rpm.  The experiment continues until the 
mouse falls off, or until the cut-off time of 300 seconds has elapsed.   
 
Thermal nociception 
 
The tail flick test was first described in 1941 as a simple and reproducible measure 
of thermal pain and has become a standard behavioural test in rodents. In the 
initial description, heat from a light bulb was focused directly onto the tail of a rat 
and the latency time until the tail was flicked away was recorded with a stopwatch 
(D’Armour & Smith, 1941, Mogil et al., 2009). For the purposes of the experiments 
described here a modified tail flick test was employed. Thermal nociceptive 
thresholds were assessed by the immersion of 2cm of the animal’s tail in a water 
bath maintained at a specified temperature such as 40-50 oC until the tail flick 
manoeuvre was initiated. The tail flick latency time was recorded and this 
parameter was used to compare the effect of neurosteroids versus injection of 
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control vehicle and baseline measurements. A cut off time of 15 seconds was used 
to minimise the likelihood of tissue damage. The results of each experiment may be 
expressed in seconds, or as a percentage of the maximum possible effect (MPE) i.e. 
a percentage of 15 seconds.  
 
Mechanical nociception 
 
In the late nineteenth century, Max von Frey explored sensory thresholds using a 
variety of objects including tough horsehair. His ideas were developed by others 
and nylon von Frey filaments are now used routinely in human and animal 
research (Mogil et al., 2009, Pearce 2006). A series of calibrated von Frey filaments 
(Ugo Basile, It) were employed to characterise mechanical nociceptive thresholds 
in WT and ob/ob mice. The mice were placed into clear plastic cubicles on top of a 
raised platform (Ugo Basile, Italy) with a meshed surface and allowed to 
acclimatise to the new environment for 30 minutes. The tip of the von Frey 
filament was pressed carefully onto the middle of the ventral (‘palmar’) surface of 
the hindpaw. Sufficient force to induce bending of the shaft of the filament was 
applied for up to 5 seconds and the presence of a withdrawal response noted if it 
occurred. The procedure was repeated until each hindpaw had received 5 presses 
of the filament. Only robust and immediate withdrawal responses were considered 
as positive. Each mouse could have a maximum score of 10 (five for each paw). 
Testing would commence with the thinnest filament used and then progress to 
thicker filaments. Pilot studies were carried out to determine the optimal four 
filaments to be used in the mice; 0.16g, 0.4g, 0.6g and 1g filaments. They elicited a 
response in approximately 20%, 40%, 60% and 90% of occasions when applied to 
adult WT mice. This meant that these filaments could be used to test for the 
presence of mechanical allodynia, hyperalgesia and nociceptive pain in the ob/ob 
mouse. This method was adapted from work published in rats with neuropathic 
sensitisation (Meyer et al., 2011). 
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Cold allodynia test 
 
The sensing of a wide range of environmental temperatures is a useful 
physiological process that confers survival advantages in many species. Indeed, 
adapting to a cold external environment can be as important as withdrawing from 
a burning hot stimulus. The thermal gated ion channels TRPM8 and TRPA1 appear 
to be important to the generation of an afferent neural impulse in response to a 
cold stimulus in the noxious range. Increased sensitivity to cold stimuli is a 
common symptom associated with neural injury and although the underlying 
mechanisms responsible for this phenomenon are poorly understood it may be 
related to increased expression of TRPM8 and TRPA1 channels (Belmonte et al., 
2009; Knowlton et al., 2010). Conversely, knockout of TRPM8 in mice results in a 
significantly reduced response to cold stimuli such as topical acetone (Belmonte et 
al., 2009). When acetone is applied topically to the skin it evaporates and induces a 
cold sensation. When neural hypersensitivity is present acetone may induce a 
temporary noxious stimulus. Acetone has therefore been used to elicit cold 
allodynia in animals with chemotherapy-induced neuropathic hypersensitivity 
(Flatters & Bennett, 2004, Gauchan et al., 2009, Meyer et al., 2011).  
 
Mice were placed into the same apparatus as described previously in the 
mechanical nociception section. A drop of acetone was applied to the ventral 
(palmar) surface of the animal’s hindpaw using a modified 1ml syringe. A 
standardised scoring procedure was used to record the effect of acetone 
application with slight modification of that described previously in the literature 
(Flatters & Bennett, 2004). After the application of acetone, the mouse was 
observed for 20 seconds and if a response was elicited, the animal was observed 
for an additional 20 seconds in order to ensure that pain related behaviour was 
evoked rather than merely a startle response. The process was performed twice on 
each hindpaw after an interval period. In the event that it was felt that the drop 
had missed the paw it was reapplied immediately. 
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The following scoring system was used: 
 
0 No response 
 
1 Quick withdrawal, flick or stamp of the paw only 
 
2 Prolonged/repeated flicking of the paw and/or abnormal hindlimb posture/limping 
 
3 Same as (2) but with additional licking of the ventral surface of the affected paw 
 
 
 
2.8 Statistical analysis 
 
All data in the results section are expressed as the arithmetic mean  the standard 
deviation (SD). The following statistical tests were employed where appropriate 
for the electrophysiological data: Student’s t test (Excel, Microsoft Office), One-way 
ANOVA, One-way and Two-way RM ANOVA (Sigmastat) and the Kilmogovov 
Smirnoff test (SPSS software, IL, USA). The following non-parametric statistical 
tests were employed for the behavioural data: Mann-Whitney Rank Sum test, 
Kruskal Wallis one-way ANOVA on ranks and the Wilcoxon signed rank test 
(before & after; Sigmastat). 
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Chapter 3: A characterisation of GABA-ergic synaptic 
events with development at three levels of the pain 
pathway in WT mice. 
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Inhibitory synaptic transmission innervating neurones at three levels of the pain 
pathway was studied using the whole-cell patch-clamp electrophysiological 
technique. Neuronal recordings were made from C57/Bl6 mice in lamina II (LII) of 
the dorsal horn of the spinal cord, the nucleus reticularis (nRT) of the thalamus 
and layer 2/3 of the cerebral cortex (See Figure 8).  These neurones were selected 
for study due to their modulatory role in nociceptive transmission, associated with 
the perception of pain in humans (Clascá et al., 2012; Cox et al., 1997; DeFelipe & 
Farinas 1992; D’Mello & Dickenson 2008; Gentet & Ulrich 2003). Previous work in 
the host laboratory (Brown, 2012) on mouse neurones of the cortex and 
thalamocortical neurones of the ventrobasal thalamus revealed that fluctuations in 
the endogenous neurosteroid tone during development (P7–P24) influenced the 
duration of miniature inhibitory postsynaptic currents (mIPSCs).  Such events 
arise from the activation of synaptic GABAARs by synaptic GABA released from a 
single vesicle (as described in Part 2 of the Introduction).  Previous studies have 
proposed that similar changes to the properties of spinal LII mIPSCs may occur 
with development in rats (Inquimbert et al., 2007; Keller et al., 2001, Keller et al., 
2004; Poisbeau et al., 2005) and mice (Rajalu et al., 2009).  
 
3.1 The decay time of GABAAR mIPSCs of LII spinal neurones decreases with 
development. 
 
Whole-cell voltage-clamp recordings from LII neurones of the dorsal horn were 
made for C57/BL6 mice of both sexes from three post-natal age groups: 8-11 days, 
17-25 days and 60-75 days. Analysis of phasic inhibition (as described in the 
Methods section) included the amplitude, the decay kinetics, the charge transfer, 
the frequency and the rise time of mIPSCs recorded from lamina II neurones of the 
mouse spinal cord. The mean peak amplitude of LII mIPSCs for the three age 
groups studied here (P8-11 = -45  4 pA, n = 26 neurones; P17-25 = -43  2.7 pA, n 
= 31 neurones; P60 = -41  4.6 pA, n = 13 neurones) did not differ significantly 
with development (One way ANOVA, P >0.05; Table 1).  
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Figure 8 Representative current traces from neurones aged P17-25 exhibiting GABAAR 
mIPSCs from three levels of the pain pathway illustrating the regional variations. 
 
P17-25 LII Spinal
P17-25 nRT
P17-25 L2/3 cortex
50pA
200ms
A
B
C
(A) A two second section of current recording from a representative LII spinal neurone voltage 
clamped at ----60mV and recorded in the presence of 0.5 M TTX, 0.5 M strychnine and 2mM 
kynurenic acid. The downward deflections are GABAAR mIPSCs. (B & C) Current recordings from 
representative nRT and L2/3 cortical neurones aged P17-25 under the same conditions.  Note that 
mIPSCs from nRT and LII neurones have a similar appearance, while the cortical mIPSCs have a 
much shorter duration. 
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Table 1  The decay time of GABAAR mIPSCs of LII spinal neurones decreases with 
development 
 
 
 
 
 
 
 
 
**P < 0.05; One-way ANOVA, statistically significant in comparison to P60-75 
n  =  number of neurones 
 
Previous studies of LII neurones revealed the mIPSC time course of decay may 
reduce with development, a perturbation that may be caused by the loss of an 
endogenous steroid tone (Keller et al., 2001, Keller et al., 2004, Rajalu et al., 2009). 
The mIPSC decay (τW) decreased with development (P8-11 = 24.8 ± 2 ms; n = 26; 
P17-25 = 19.4 ± 1.8 ms, n = 31; P60-75 = 17.5 ± 1.8 ms, n = 13; One-way ANOVA, P 
<0.05 - Table 1; Figure 9). The τW is approximately equivalent to the time taken for 
the mIPSC to decrease by 67% from the peak amplitude. The unfavourable signal-
to-noise of individual mIPSCs precludes the accurate fitting of the τW to individual 
mIPSCs. Therefore, this function is fitted to the mean mIPSC derived for each 
neurone i.e. a comparison of the ‘mean of the mean’. Consequently, subtle 
differences may be obscured when making comparisons between different age 
groups. The T70 (time taken for the mIPSC to decay by 70% from the peak 
amplitude) is readily derived for individual mIPSCs. This parameter also changed 
significantly with development: (P8-11 = 26.5  2.7 ms; n = 26; P17-25 = 19.6 ± 1.8 
ms, n =31, P60-75 = 17.6 ms  1.8 ms, n = 13 (One-way ANOVA, P <0.05; Table 1).  
  
 P8-11 
 
(n=26) 
P17-25 
 
(n=31) 
P60-75 
 
(n=13) 
Peak 
amplitude (pA) 
-45 ± 4 -43 ± 3 -41 ± 5 
Rise Time (ms) 0.6 ± 0.1 0.6 ± 0.1 0.5  ± 0.1 
Charge transfer 
(fC)  
**-965 ± 82 -821 ± 89 -652 ± 80 
T70 (ms) **26.5 ± 3 **19.6 ± 2 17.6  ± 2 
Tau w (ms) **24.8 ± 2 **19.4 ± 2 17.5  ± 2 
Frequency (Hz) 1.1 ± 0.2 0.6 ± 0.1 0.7  ± 0.2 
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Figure 9 The decay time of GABAAR mIPSCs of neurones from three levels of the pain 
pathway decreases with development.   
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(A) Superimposed exemplar GABAAR-mediated mIPSCs recorded from representative spinal 
neurones from three stages of development: P8-11 (light grey), P17-25 (grey) and P60-75 (black). 
Note the reduction of GABAAR mIPSC decay time that occurs with development. (B) Histogram 
illustrating the shortening of GABAAR mIPSC decay time (τW) with development (P8-11 = 24.8 ± 2 
ms; P17-25 = 19.4 ± 1.8 ms; P60-75 = 17.5 ± 1.8 ms; One-way ANOVA *P < 0.05; n = 13-31). (C & D)  
A parallel developmental change is observed in nRT neurones (P6-7 = 33.2  1 ms; P9-10 = 22.5  
0.7 ms; P17-25 = 19.6  0.7 ms; One-way ANOVA P < 0.05. Post hoc Newman Keul’s test revealed 
significant differences between all groups, **P < 0.05; n = 14-24).  (E & F) A parallel developmental 
change is observed in L2/3 cortical neurones (P6-7 = 12.7  1.2ms; P9-10 = 10  0.7ms; P17-25 = 
5.5  0.4ms, n = 8; P60-75 = 4  0.1ms; One-way ANOVA P < 0.05. Post hoc Newman Keul’s test 
revealed significant differences between all groups, **P < 0.05; n = 7-35). 
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Irrespective of the mechanism, these data suggest that the majority of these 
developmental changes to inhibitory synaptic transmission in LII neurones have 
occurred by the age of ~17 days. There was no significant difference in the T70 
between the immature male and female mice (spinal LII P8-11: female = 26.1 ± 3.8 
ms, male = 27.1 ± 3.7 ms; spinal LII P17-25: female = 18.6 ± 1.7 ms, male = 21 ± 3.5 
ms; Student’s unpaired t tests, P >0.05). These findings are consistent with 
previous work performed on rats by a former colleague (Mitchell et al., 2007; 
Table 2). The parameter of mIPSC charge transfer (i.e. the mIPSC area) is 
influenced by changes to kinetics and amplitude and is readily determined for each 
mIPSC. It also changed significantly with development: (P8-11 = 965 ± 82 fC; P17-
25 = 821  89 fC; P60-75 = 652 ± 80 fC; One-way ANOVA, P <0.05; Table 1).  The 
frequency of mIPSCs is influenced by the probability of vesicular release, which is 
determined by presynaptic neuronal function and modulation and factors such as 
the number of inhibitory synapses per LII neurone (Farrant & Nusser, 2005).  
Taken as a whole, these results are consistent with previously published data 
(Inquimbert et al., 2007; Keller et al., 2001, Keller et al., 2004; Poisbeau et al., 
2005; Rajalu et al., 2009).  
 
Table 2 The properties of GABAAR-mediated mIPSCs in mice (P17-25) versus data recorded 
by a former laboratory colleague in rats (P15-21; Mitchell et al., 2007). 
 
 
 
 
 
 
 
 
*P < 0.05; unpaired Student’s t test in comparison to mice 
 Mice P17-25 
 
(n=31) 
Rats P15-21 
 
(n=77) 
Peak 
amplitude (pA) 
-43 ± 3 *-68 ± 3 
Rise Time (ms) 0.6 ± 0.1 0.5  ± 0.1 
Charge 
transfer (fC)  
-821 ± 89 *-1258 ± 61 
T70 (ms) 19.4 ± 2 N/A 
Tau w (ms) 19.6 ± 2 *17.2  ± 0.6 
Frequency 
(Hz) 
0.6 ± 0.1 *1.6  ± 0.1 
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3.2 Glycinergic mIPSCs of lamina II neurones of the dorsal horn of the spinal 
cord. 
 
The glycine receptor (GlyR) is an important mediator of neural inhibition within 
the spinal cord (Baer et al., 2009; Lynch, 2009).  Inhibitory glycinergic synaptic 
transmission innervating LII neurones within the dorsal horn of the mouse spinal 
cord was also studied using the whole-cell patch-clamp electrophysiological 
technique.  There is a significant heterogeneity of GABAAR mIPSC decay kinetics 
within lamina II neurones of rats, but the decay kinetics of strychnine-sensitive 
glycine receptor mediated mIPSCs are much more homogeneous (Mitchell et al., 
2007). Here, both of these findings were replicated for dorsal horn neurones of 
mice aged 17-25 days (Figure 10; Figure 11). I have presented my data from mouse 
LII neurones here alongside published data on rat LII neurones from the host 
laboratory for comparison (Mitchell et al., 2007).  Note that rats reach maturity at a 
later age than mice and also that the rats studied were aged 15-21 days.  The 
following data for GlyR mIPSCs is summarised in Table 3 alongside the rat data for 
comparison. 
Table 3 The properties of glycine receptor mediated mIPSCs in LII spinal neurones of mice 
(P17-25) versus data recorded by a former laboratory colleague in rats (P15-21; Mitchell et 
al., 2007). 
 
 
 
 
 
 
  
 
*P < 0.05; unpaired Student’s t test in comparison to mice 
 Mice P17-25 
 
(n=23) 
Rats P15-21 
 
(n=77) 
Peak 
amplitude (pA) 
-93 ± 10 *-121 ± 6 
Rise Time (ms) 0.4 ± 0.1 0.4  ± 0.1 
Charge 
transfer (fC)  
-321 ± 40 *-474 ± 27 
T70 (ms) 3.9 ± 0.3 N/A 
Tau w (ms) 3.1 ± 0.2 3.1  ± 0.1 
Frequency (Hz) 1.1 ± 0.3 *2.4  ± 0.3 
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Figure 10 Representative current traces from LII spinal neurones aged P17-25 exhibiting 
GABAAR & GlyR mIPSCs.  
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(A) Histogram of the distribution pattern of T70 values of spinal GlyR mIPSCs indicating the 
relatively homogenous exponential decay times of synaptic glycinergic events. (B) A two second 
section of current recording from a representative LII spinal neurone voltage clamped at -60mV 
and recorded in the presence of 0.5 M TTX, 0.5 M strychnine and 30 M bicuculline. The 
downward deflections are GlyR mIPSCs. (C) Histogram of the distribution pattern of T70 values of 
spinal GABAAR mIPSCs indicating the relatively heterogenous exponential decay times of synaptic 
GABAergic events. (D) A two second section of current recording from a representative LII spinal 
neurone voltage clamped at -60mV and recorded in the presence of 0.5 M TTX and 2mM kynurenic 
acid. The downward deflections are GABAAR mIPSCs. 
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Figure 11 The distribution pattern of T70 values of GABAAR mIPSCs varies in neurones from 
three different levels of the pain pathway. 
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(A) Histogram of the distribution pattern of T70 values of spinal GABAAR mIPSCs indicating the 
relatively heterogenous exponential decay times of synaptic GABAergic events in these neurones. 
(B) Histogram of the distribution pattern of T70 values of nRT GABAAR mIPSCs indicating the more 
homogenous exponential decay times of synaptic GABAergic events. (C) Histogram of the 
distribution pattern of T70 values of L2/3 cortical GABAAR mIPSCs indicating the relatively 
homogenous exponential decay times of synaptic GABAergic events in these neurones. (D) 
Histogram of the distribution pattern of T70 values of GABAAR mIPSCs from three levels of the pain 
pathway superimposed to illustrate the differing distribution patterns of GABAAR mIPSC decay 
time.  
 
 
78 
 
The mean peak amplitudes of glycine receptor mIPSCs (P17-25 mice = -92.6 ± 
10pA, n = 23) were smaller than in rats.  The mIPSC rise time of glycine receptor 
mIPSCs was similar for both groups (P17-25 mice = 0.4 ± 0.1 ms, n = 23).  The 
mIPSC decay (τW) of glycine receptor mIPSCs was also very similar for both groups 
(P17-25 mice = 3.1 ± 0.2 ms, n = 23). The T70 (time taken for the mIPSC to decay to 
30% of peak amplitude) for P17-25 mice was 3.9 ± 0.3ms (no value available for 
rats).  The parameter of mIPSC charge transfer was different between the two 
types (P17-25 mice = -321 ± 40fC, n = 23; P15-21 rats = 474 ± 27fC, n = 77).  The 
frequency of mIPSCs was also different for the two species (P17-25 mice = 1.1 ± 0.3 
Hz, n = 20; P15-21 rats = 2.4 ± 0.3 Hz, n = 77) but this may be related to differences 
in the technique used to slice the spinal cord tissue.  The larger rat spinal cord was 
sliced in a parasagittal plane, while the smaller mouse spinal cord was embedded 
in agar and then sliced perpendicularly, in the horizontal plane.  This is relevant 
because the synaptic projections run longitudinally in the spinal cord and more of 
these may be preserved with the parasagittal technique.  Therefore, the frequency 
of synaptic events may be higher in the rat.  In summary, there were only minor 
differences in the synaptic GABAergic and glycinergic data obtained from mouse 
LII neurones in comparison to an equivalent study performed with rat LII 
neurones.  
 
3.3 The decay time of synaptic GABAARs of nucleus reticularis (nRT) 
neurones decreases with development. 
 
The nRT is the main source of GABAergic input into the thalamus and there are 
reciprocal GABAergic loops of innervation between nRT neurones and those of the 
VB. The two types of neurones, nRT and VB; regulate each other’s function by this 
mutual inhibitory mechanism (Arcelli et al., 1997; Cox et al., 1997; Gentet & Ulrich, 
2003; Guillery & Harting, 2003; Huh et al., 2012).  The inter-relationship between 
the nRT and VB acts to modulate nociceptive transmission and can therefore 
ultimately influence nociceptive behaviour in live animals (Huh et al., 2012).  
Whole-cell voltage-clamp recordings from nRT neurones were made from 
C57/BL6 mice at three developmental stages: P6-7, P9-10 and P17-25. 
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Unfortunately, it is not practical to make such recordings from mice over the age of 
P25 due to the high density of axonal projections (Cox et al., 1997; Pinault & 
Deschenes, 1998).  Analysis of phasic inhibition included the mIPSC amplitude, 
decay kinetics, charge transfer and frequency. The analysis revealed changes to all 
of these parameters with development as detailed in Table 4.  However, the 
principle focus here is on the decay kinetics of nRT GABA mediated mIPSCs. The 
mIPSC decay (τW) of nRT neurones decreased significantly with development (P6-
7 = 33.2  1 ms, n = 24; P9-10 = 22.5  0.7 ms, n = 14; P17-25 = 18.2  0.6 ms, n = 
32; One-way ANOVA, P < 0.05; post hoc Newman Keul’s test revealed significant 
differences between all groups, P <0.05; Table 4; Figure 9).  As expected, in 
common with the τW, the mIPSC T70 was markedly different at the three stages of 
development (P6-7= 35.8  1 ms, n= 24; P9-10 = 25.4  0.8 ms, n = 14; P17-25 = 
20.1  0.6ms, n = 32; One-way ANOVA, P <0.05; post hoc Newman Keul’s test 
revealed significant differences between all groups, P <0.05; Table 4). These 
results demonstrate that in common with LII spinal neurones, the GABAAR mIPSC 
decay time of nRT neurones becomes significantly shorter during development 
(P6–P25).  
 
Table 4 The decay time of GABAAR mIPSCs of nRT neurones decreases with development  
 
 
 
 
 
 
 
 
**P < 0.05; One-way ANOVA, in comparison to P17-25 
 P6-7 
 
(n=24) 
P9-10 
 
(n=14) 
P17-25 
 
(n=32) 
Peak 
amplitude (pA) 
**-56 ± 3 **54 ± 2 -46 ± 2 
Rise Time (ms) **0.7 ± 0.1 **0.7 ± 0.1 0.6 ± 0.1 
Charge 
transfer (fC)  
**-1475 ± 83 **-1089 ± 51 -750 ± 28 
T70 (ms) **35.8 ± 1 **25.4 ± 0.8 20.1 ± 0.6 
Tau w (ms) **33.2 ± 1 **22.5 ± 0.7 18.2 ± 0.6 
Frequency (Hz) *2.2 ± 0.4 6.9 ± 0.7 8.4 ± 1 
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3.4 The decay time of synaptic GABAARs of cortical layer 2/3 neurones 
decreases with development. 
 
GABAergic inhibitory neurones are present in all layers of the cortex but are most 
abundant in layers 2/3 and lower in layer 4 (Meyer et al., 2011).  They project 
vertically down to the deeper layers, exerting GABAergic inhibitory tone on 
pyramidal cells within the column (Helmstaedter et al., 2009; Mountcastle, 1997).  
Electrophysiological recordings were made from cortical layer 2/3 neurones from 
C57/BL6 mice at four stages of development: P6-7, P9-10, P17-25 and P60-75. 
Analysis of phasic inhibition included the mIPSC amplitude, decay kinetics, charge 
transfer and frequency. The analysis revealed changes to all of these parameters 
with development as detailed in Table 5. However, here the principle focus again is 
on the decay kinetics of cortical GABA mediated mIPSCs.  Previous studies of spinal 
neurones have revealed that the mIPSC decay time course decreases with 
development, a perturbation that may be caused by the loss of an endogenous 
steroid tone (Keller et al., 2001, Keller et al., 2004, Rajalu et al., 2009). Work by a 
former laboratory colleague in cortical layer 2/3 pyramidal neurones (P7 - P24) is 
also consistent with these observations (Brown, 2012). 
Table 5 The decay time of GABAAR mIPSCs of layer 2/3 cortical neurones decreases with 
development  
 
**P < 0.05; One-way ANOVA, in comparison to P60-75 
 P6-7 
 
(n=7) 
P9-10 
 
(n=8) 
P17-25 
 
(n=8) 
P60-75 
 
(n=35) 
Peak 
amplitude (pA) 
-60 ± 7 **-36 ± 2 **-37 ± 2 -59 ± 2 
Rise Time (ms) **0.6 ± 0.1 **0.7 ± 0.1 **0.5 ± 0.1 0.4  ± 0.1 
Charge transfer 
(fC)  
**-675 ± 62 **-331± 21 -181 ± 12 -242 ± 9 
T70 (ms) **14.6 ± 1 **10.2 ± 0.4 5.8 ± 0.4 5.2  ± 0.2 
Tau w (ms) **12.7 ± 1 **10 ± 0.7 **5.5 ± 0.3 4.0  ± 0.1 
Frequency (Hz) **1.7 ± 0.2 **3.3 ± 0.5 **8.7 ± 1.5 17  ± 2 
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The mIPSC decay (τW) of cortical layer 2/3 neurones decreased significantly with 
development: (P6-7 = 12.7  1.2 ms, n = 7; P9-10 = 10  0.7 ms, n = 8; P17-25 = 5.5 
 0.3 ms, n = 8; P60-75 = 4  0.1 ms, n = 35; One-way ANOVA, P < 0.05; post hoc 
Newman Keul’s test revealed significant differences between all groups, P <0.05; 
Table 5; Figure 9).  As expected, in common with the τW, the mIPSC T70 also 
decreased significantly with development (P6-7= 14.6  1.2 ms, n = 7; P9-10 = 10.2 
 0.4 ms, n = 8; P17-25 = 5.8  0.4 ms, n = 8; P60-75 = 5.2  0.2 ms, n = 35).  All the 
intergroup differences were statistically significantly different from each other 
except P17-25 vs. P60-75 (One-way ANOVA, with post hoc Newman Keul’s test P 
<0.01; Table 5). These data are consistent with previous work from the host 
laboratory, but also extend the observed changes to adult mice (P60-75). 
 
3.5 The acute application of allopregnanolone prolongs the decay time of 
GABAAR mIPSCs more effectively in spinal LII neurones from older mice. 
 
The neurosteroid allopregnanolone (3 -hydroxy-5 -pregnan-20-one) and a 
closely related synthetic structural analogue ganaxolone (3 -methyl-3 -ol-5 -
pregnan-20-one) have proven efficacy in enhancing the function of synaptic 
GABAARs in other regions of the central nervous system such as the dentate gyrus 
and the rat spinal cord (Belelli & Herd 2003; Mitchell et al., 2007).  
Allopregnanolone (1µM) was bath-applied following at least four minutes of stable 
control recording.  Previous work by a former laboratory colleague has revealed an 
endogenous neurosteroid tone in the cortical neurones of immature mice (P8-11), 
sufficient to influence the time course of mIPSCs (Brown, 2012). Work at other 
centres has also suggested that a similar phenomenon may be observed in the LII 
neurones of the dorsal horn of the spinal cord (Poisbeau et al., 2005, Rajalu et al., 
2009).  I investigated the influence of the neurosteroid on the mIPSCs of LII 
neurones at two developmental stages: P8-11 and P17-25. Particular attention was 
given to the putative actions of the steroid to prolong the mIPSC decay time, as 
previous studies have revealed this to be a sensitive parameter (Mitchell et al., 
2007).  For P8-11 neurones the mean τW was increased by 22 ± 6 % (n = 7) by 1μM 
allopregnanolone. By contrast, for P17-25 neurones the steroid appeared more 
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effective, increasing τW by 97 ± 47% (P8-11, control = 20 ± 1.7ms, 1μM 
allopregnanolone = 24.5 ± 2.4ms, n = 7, Student’s paired t test, P <0.05; P17-25, 
control = 21.5 ± 5ms, allopregnanolone = 39.8 ± 9ms, n = 6, Student’s paired t test, 
P <0.05).  When the effect of 1μM allopregnanolone was normalised for 
comparison, the neurosteroid had a greater impact on GABAAR mIPSC τW at the 
later stage of development (Two-way RM ANOVA, P <0.05; Table 6; Figure 12). As 
described above, the parameter of T70 can readily be determined for each mIPSC 
and the impact of the steroid on this parameter differed for the two age groups. At 
P8-11 the T70 was increased by 34 ± 8% (n = 7) by 1μM allopregnanolone, whereas 
again the steroid appeared more effective on P17-25 neurons, the mean T70 
increased by 68 ± 29%, n = 6 (P8-11, control = 20.2 ± 1.7ms, allopregnanolone = 
26.5 ± 2.3ms, Student’s paired t test, P <0.05; P17-25, control = 23.6 ± 6ms, 
allopregnanolone = 39 ± 10ms, Student’s paired t test, P <0.05).  When the effect of 
1μM allopregnanolone was normalised for comparison, the neurosteroid had a 
greater impact on GABAAR mIPSC T70 at the later stage of development, Two-way 
RM ANOVA, P <0.05; Table 6; Figure 12). Studies from the host laboratory have 
previously reported a similar observation for LII neurones of rats (P15 - P21; 
Mitchell et al., 2007). These data are consistent with the hypothesis that the 
neurosteroid tone of LII neurones decreases with development. However, other 
factors such as changes in the relative proportion of different types of subunit and 
altered neurosteroid-sensitivity of the synaptic GABAARs may also be of 
significance (these issues are explored in the Discussion).  
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 (A & C) Superimposed exemplar GABAAR-mediated mIPSCs from LII spinal neurones, aged P8-11 
and P17-25 respectively, before and after acute exposure to 1 M allopregnanolone.     (B & D) 
Histograms illustrating the relative magnitude of effect of allopregnanolone at the two stages of 
development.  For P8-11 neurones the mean τw was increased by 22 ± 6 % (n = 7) by 1μM 
allopregnanolone. By contrast, for P17-25 neurones, the steroid appeared more effective, 
increasing τw by 97 ± 47% (P8-11, control = 20 ± 1.7ms, 1μM allopregnanolone = 24.5 ± 2.4ms, n = 
7; P17-25, control = 21.5 ± 5ms, allopregnanolone = 39.8 ± 9ms, n = 6; Two-way RM ANOVA P 
<0.05). Allo = allopregnanolone, Ctrl = control. 
 
 
Figure 12 Acute exposure (10-20mins) to allopregnanolone (1 M) has a greater effect on the 
function of synaptic GABAARs from mature spinal LII neurones compared to immature 
neurones. 
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Table 6 The acute application of allopregnanolone (Allo) prolongs the decay time of GABAAR 
mIPSCs more effectively in spinal LII neurones from older mice. 
 
 P8-11 
Control 
 
(n=7) 
P8-11 
1μM Allo  
 
(n=7) 
P17-25 
Control 
 
(n=6) 
P17-25 
1μM Allo  
 
(n=6) 
Peak 
amplitude (pA) 
-39  5 -51  7 -39  7 -45  5 
Rise Time (ms) 
 
0.6  0.1 0.6  0.1 0.7  0.1 0.7  0.1 
Charge 
transfer (fC) 
-703  81 *-1154  207 -907  296 -1566  396 
T70 (ms) 
 
20.2  1.7 *26.5  2.3 23.6  6 *39.0  10 
Tau w (ms) 
 
20  1.7 *24.5  2.4 21.5  5 *39.8  9 
Frequency (Hz) 
 
2  0.9 1  0.3 0.5  0.1 0.4  0.1 
  
*P < 0.05; paired Student’s t test, in comparison to control 
 
3.6 The acute application of ganaxolone prolongs the decay time of GABAAR 
mIPSCs in nRT neurones (P17-25). 
 
Ganaxolone 1μM was bath-applied after obtaining at least four minutes of stable 
control recording and induced a prolongation of the exponential decay time of 
mIPSCs (τW: control = 15.2  1.2 ms, n = 6; ganaxolone 1μM = 18.2  1.8 ms, n = 6; 
Student’s paired t test, P <0.05; Table 7; Figure 13). Similarly, the T70 was 
prolonged by steroid treatment: (control = 18.1  1.2 ms, n = 6; ganaxolone 1μM = 
21.7  2 ms, n = 6; Student’s paired t test, P <0.05; Table 7).   These data confirm 
the activity of neurosteroids in the nRT.  
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Figure 13 Acute exposure (10-20mins) of nRT neurones to ganaxolone (1 M) modestly 
enhances the function of synaptic GABAARs.   
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(A) Superimposed exemplar GABAAR-mediated mIPSCs from nRT neurones aged P17-25 before 
and after acute exposure to 1 M ganaxolone. (B) Histogram illustrating the significant effect of 
1 M ganaxolone on GABAAR mIPSCs of nRT neurones (τw in ms: P17-25 control = 15.2  1.2ms, n = 
6; P17-25 1μM ganaxolone = 18.2  1.8ms; Student’s paired t test *P <0.05; n = 6). Ganax = 
ganaxolone, Ctrl = control. 
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Table 7 The acute application of ganaxolone (Ganax) prolongs the decay time of GABAAR 
mIPSCs in nRT neurones (P17-25). 
 
 P17-25 nRT 
Control 
 
(n=6) 
P17-25 nRT 
1μM Ganax  
 
(n=6) 
Peak amplitude 
(pA) 
-49  4 -49  4 
Rise Time (ms) 
 
0.6  0.1 0.6  0.1 
Charge transfer 
(fC) 
-721  94 -807  113 
T70 (ms) 
 
18.1  1.2 *21.7  2 
Tau w (ms) 
 
15.2  1.2 *18.2  1.8 
Frequency (Hz) 
 
6  2 6  3 
  
*P < 0.05; paired Student’s t test, in comparison to control 
Table 8 The acute application of allopregnanolone (Allo) and its synthetic analogue 
ganaxolone (Ganax) prolongs the decay time of GABAAR mIPSCs of layer 2/3 cortical 
neurones from mature WT mice (P60-75). 
 
 P60-75 
Control 
 
(n=6) 
P60-75 
1μM Allo  
 
(n=6) 
P60-75 
Control 
 
(n=6) 
P60-75 
1μM Ganax  
 
(n=6) 
Peak 
amplitude (pA) 
-68  3 -67  3 -57  4 *-66  6 
Rise Time (ms) 
 
0.4  0.1 0.4  0.1 0.5  0.1 0.5  0.1 
Charge 
transfer (fC) 
-284  7 -305  14 -232  15 *-309  31 
T70 (ms) 
 
5.1  0.5 *5.6  0.5 5.2  0.2 *6.0  0.4 
Tau w (ms) 
 
3.9  0.3 *4.4  0.4 4.0  0.2 *4.7  0.2 
Frequency (Hz) 
 
29  6 24  3 22  5 21  5 
  
*P < 0.05; paired Student’s t test, in comparison to control 
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3.7 The acute application of allopregnanolone and its synthetic analogue 
ganaxolone prolongs the decay time of GABAAR mIPSCs of layer 2/3 neurones 
in mature WT mice (P60-75). 
Allopregnanolone 1μM was bath-applied following at least four minutes of stable 
control recording. The steroid induced a modest prolongation of exponential decay 
time of GABAAR mIPSCs of mature layer 2/3 neurones (τW: control = 3.9  0.3 ms, n 
= 6; allopregnanolone 1μM = 4.4  0.4 ms, n = 6; Paired Student’s t test, P <0.05; 
Table 8; Figure 14). Similarly, the mIPSC T70 was modestly prolonged by the 
steroid: (control = 5.1  0.5 ms, n = 6; allopregnanolone 1μM = 5.6  0.5 ms, n = 6; 
Student’s paired t test, P <0.05; Table 8). Ganaxolone 1μM was introduced in a 
similar fashion and it also induced a modest prolongation of the mIPSC exponential 
decay time (τW: control = 4  0.2 ms, n = 6; ganaxolone 1μM = 4.7  0.2 ms, n = 6; 
Student’s paired t test, P <0.05). Similarly, the mIPSC T70 was modestly prolonged 
by ganaxolone: (control = 5.2  0.2 ms, ganaxolone 1μM = 6  0.4 ms, n = 6; 
Student’s paired t test, P <0.05; Table 8).  When the data for τW and T70 were 
normalised for comparison, there was no significant difference between 
allopregnanolone (12 ± 3%) and ganaxolone (19 ± 4%) at P60-75 (Two-way RM 
ANOVA, P >0.05).    
The acute application of a 3-fold greater concentration of ganaxolone (3μM) 
produced a similar prolongation of the mIPSC exponential decay time (20 ± 7%) to 
that caused by 1µM of this steroid (τW: control = 3.5  0.2ms, n = 4; ganaxolone 
3μM = 4.2  0.2ms, n = 4; Student’s paired t test, P <0.05; Figure 14). The mIPSC T70 
was similarly prolonged by 3 µM ganaxolone (control = 4.8  0.3ms, n = 4; 
ganaxolone 3μM = 5.9  0.3ms, n = 4; Student’s paired t test, P <0.05).  When the 
data for τW and T70 were normalised for comparison, there was no significant 
difference between ganaxolone 1μM (12 ± 3%) and ganaxolone 3μM (20 ± 7%) at 
P60-75 (Two-way RM ANOVA, P >0.05).   
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Figure 14 The acute exposure (10-20mins) of mature cortical neurones to allopregnanolone 
(1 M), or ganaxolone (1-3 M) modestly enhances the function of synaptic GABAARs. 
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(A, C & E) Superimposed traces of exemplar GABAAR-mediated mIPSCs from L2/3 cortical 
neurones aged P60-75 before and after acute exposure to 1 M allopregnanolone or 1-3 M 
ganaxolone respectively. To facilitate comparison of their kinetics, the amplitude of the mIPSCs are 
normalised to that of the control averaged mIPSC. (B, D & F) Histograms illustrating the significant 
effect of 1 M allopregnanolone and 1-3 M ganaxolone on the time course of decay (τw in ms) of 
GABAAR mIPSCs of L2/3 cortical neurones (Student’s paired t test *P <0.05 for each drug treatment 
vs. its’ paired control recording; n = 7).  
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3.8 The effect of γ-cyclodextrin (γ-CD) applied by three different methods on 
nRT GABAAR mIPSCs (P6-7). 
 
Recordings were made from P6-7 nRT neurones using three methods of 
application of γ-CD to confirm which method was optimal. The γ-CD was presented 
within the recording electrode (intracellularly), applied via the extracellular 
solution, or by inclusion in the pipette, in the extracellular recording solution and 
in the incubation chamber containing the brain slice preparation prior to recording 
(i.e. 2 hours of preincubation).  When γ-CD (1mM) was present in the extracellular 
solution (ECS) for at least 5 minutes, the mIPSC decay (τW) was not decreased 
significantly (P6-7 control = 31.1  2 ms, n = 6, P6-7 γ -CD (ECS) = 28.7  2.8 ms, n 
= 6; Student’s paired t test, P <0.05; Table 9). Similarly, γ-CD had no significant 
effect on the mIPSC T70 (P6-7 control = 34.6  2 ms, n = 6, P6-7 γ-CD (ECS) = 30.0  
2 ms, n = 6; Student’s paired t test, P > 0.05; Table 9). When the γ-CD was present 
both intracellularly (0.5mM), extracellularly (1mM) and had previously been 
incubated with the brain slice preparation in the holding chamber (1mM) i.e. the 
“triple treatment”, the mIPSC decay (τW) was significantly decreased. However, this 
protocol was no more effective than when the γ-CD was present only 
intracellularly (P6-7 control = 33.2  1 ms, n = 24, P6-7 γ-CD [“triple treatment”] = 
23.7  1 ms, n = 13; Student’s unpaired t test, P < 0.05; Table 10; Figure 15). The 
T70 was similarly decreased by this treatment regimen (P6-7 control = 35.8  1 ms, 
n = 24; P6-7 γ-CD [triple treatment] = 22.3  1 ms, n = 13; Student’s unpaired t test, 
P < 0.01). These results indicate that intracellular application of γ-CD via the 
recording pipette is the optimal method of application and is consistent with the 
hypothesis that the GABAAR-active neurosteroids are synthesised within the pain 
pathway neurones themselves (Akk et al., 2009; Chisari et al., 2009; Tsutsui, 2008). 
The effects of other types of cyclodextrin are explored in Results section 4.4.  
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Table 9 The effect of bath applied γ-cyclodextrin (CD) on nRT GABAAR mIPSCs (P6-7). 
 
 P6-7 
Paired Control 
 
(n= 6) 
P6-7 -CD in  
ECS only 
 
(n=6) 
Peak amplitude 
(pA) 
-66  6 -65  4 
Rise Time (ms) 
 
0.7  0.1 0.6  0.1 
Charge transfer 
(fC) 
-1704  208 -1557  137 
T70 (ms) 
 
34.6  2 *30.0  2 
Tau w (ms) 
 
31.1  2 *28.7  3 
Frequency (Hz) 
 
3  1 3  1 
  
*P < 0.05; paired Student’s t test, in comparison to control 
 
Table 10 The effect of γ-cyclodextrin (CD) applied by three different methods on nRT 
GABAAR mIPSCs (P6-7). 
 
 P6-7 
Control 
 
(n= 24) 
P6-7 -CD in  
ECS only 
 
(n=6) 
P6-7 -CD in 
pipette only 
 
(n=8) 
P6-7 -CD in 
pipette, ECS & 
storage 
chamber (n= 
13) 
Peak amplitude 
(pA) 
-56  3 -65  4 -52  3 -44  3 
Rise Time (ms) 
 
0.7  0.1 0.6  0.1 0.6  0.1 0.7  0.1 
Charge transfer 
(fC) 
-1475  83 -1557  137 **-981  81 **-946  91 
T70 (ms) 
 
35.8  1 30.0  2 **22.0  1 **25.3  1 
Tau w (ms) 
 
33.2  1 28.7  3 **21.6  1 **23.7  1 
Frequency (Hz) 
 
2  0.4 3  1 3  0.5 3.8  0.7 
  
**P < 0.05; One-way ANOVA, in comparison to P6-7 control  
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Figure 15 The effect of -CD on P6-7 nRT neurones varies according to the method of 
administration. 
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(A) Superimposed exemplar GABAARs mIPSCs from nRT neurones aged P6-7 before and after acute 
exposure to 0.5mM -CD applied via the extracellular solution (ECS). (B) Histogram illustrating the 
lack of significant effect of extracellularly-applied 0.5mM -CD on GABAAR mIPSCs of nRT neurones 
(P6-7 Ctrl = 31.1  2 ms, n = 6, P6-7 γ -CD (ECS) = 28.7  2.8 ms; Student’s paired t test P >0.05; n = 
6). (C) Superimposed exemplar GABAARs mIPSCs from nRT neurones aged P6-7 illustrating the 
difference between unmatched control recordings and recordings made with 0.5mM -CD applied 
via the ECS, within the pipette and within the incubating chamber prior to recording. (D) 
Histogram illustrating the significant effect of 0.5mM -CD applied via the three methods described 
above in comparison to unmatched control recordings (P6-7 Ctrl = 33.2  1 ms, n = 24; P6-7 γ-CD 
[“triple treatment”] = 23.7  1ms, n = 13; Student’s unpaired t test P < 0.05). (E) Superimposed 
exemplar GABAARs mIPSCs from nRT neurones aged P6-7 illustrating the difference between 
unmatched control recordings and recordings made with 0.5mM -CD applied only intracellularly 
via the recording pipette. (F) Histogram illustrating the significant effect of 0.5mM -CD applied 
only intracellularly via the recording pipette on GABAAR mIPSCs of nRT neurones aged P6-7 (P6-7 
Ctrl = 33.2  1 ms, n = 24; P6-7 γ-CD pipette = 21.6  1ms, n = 8; Student’s unpaired t test P < 0.05 
in comparison to unmatched control recordings). These results indicate that intracellular 
application of γ-CD via the recording pipette is the optimal method of application and is consistent 
with the hypothesis that the GABAAR-active neurosteroids are synthesised within the pain pathway 
neurones themselves. CD = cyclodextrin; ECS = extracellular solution; Ctrl = control. 
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3.9 The effect of γ-CD 0.5mM in the recording pipette on nRT GABAAR-
mediated mIPSCs at three stages of development. 
γ-CD is a barrel shaped molecule that has been shown to sequester endogenous 
neurosteroid compounds within cortical neurones (Brown, 2012). Thus, this large 
hydrophilic molecule can be used as an experimental tool to reverse the 
modulatory action of endogenous neurosteroid (Shu et al., 2007). Recordings were 
made at three stages of development in order to explore fluctuations in the 
endogenous neurosteroid tone of nRT neurones from P6–P25. γ-CD 0.5mM was 
present only within the recording electrode. The rationale for this method of 
application will be discussed subsequently. 
Note in this study recordings were made and compared from a population of 
control and γ-CD treated (in the recording pipette) nRT neurones i.e. the 
recordings were not paired. The mIPSC decay (τW) of P6-7 nRT neurones was 
decreased by the presence of γ-CD (P6-7 control = 33.2  1 ms, n = 24, P6-7 γ-CD = 
21.6  1.4 ms, n = 8; Student’s unpaired t test, P <0.01 Table 11; Figure 16). The T70 
was similarly decreased by γ-CD (P6-7 control = 36  0.4 ms, n = 24, P6-7 γ-CD = 
22.2  0.2 ms, n = 24; Student’s unpaired t test, P <0.01; Table 11). Consistent with 
these observations, the parameter of mIPSC charge transfer (i.e. the mIPSC area) 
was also decreased by γ-CD (Table 11). 
The mIPSC decay (τW) of P10 nRT neurones was not decreased significantly by the 
presence of γ-CD (P10 control = 22.5  0.7 ms, n = 14, P10 γ-CD = 22.1  0.6 ms, n = 
13; Student’s unpaired t test, < 0.05; Table 11; Figure 16). The T70 was similarly 
unchanged by γ-CD (P10 control 25.4  0.8 ms, n = 14, P10 γ-CD = 25  0.6 ms, n = 
13; Student’s unpaired t test, >0.05). The parameter of mIPSC charge transfer (i.e. 
the mIPSC area) was also unchanged by γ-CD (Table 11). 
The mIPSC decay (τW) of P17-25 nRT neurones was not decreased by the presence 
of γ-CD (P17-25 control = 18.2  0.6 ms, n = 21, P17-25 γ-CD = 19  1 ms, n = 15; 
Student’s unpaired t test, >0.05; Table 11 Figure 16). Similarly, the T70 was not 
significantly decreased by γ-CD (P17-25 = 20.1  0.6 ms, n = 21, P17-25 γ-CD = 
19.3  1 ms, n = 15; Student’s unpaired t test, >0.05). The parameter of mIPSC 
charge transfer (ie. the mIPSC area) was unchanged by γ-CD (Table 11). 
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Table 11 The effect of γ-cyclodextrin (CD) 0.5mM in the recording pipette on nRT GABAAR-
mediated mIPSCs at three stages of development. 
 P6-7 
Control 
 
(n= 24) 
P6-7 
 -CD  
 
(n=8) 
P10 
Control 
 
(n= 14) 
P10 
γ-CD  
 
(n= 13) 
P17-24 
Control 
 
(n=21) 
P17-24 
γ-CD  
 
(n=15) 
Peak amplitude 
(pA) 
-56  3 -52  3 -54  2 -56  3 -46  1 -47  3 
Rise Time (ms) 
 
0.7  0.1 0.6  0.1 0.7  0.1 0.7  1 0.6  0.1 0.6  1 
Charge transfer 
(fC) 
-1475  83 *-981  81 -1089  51 -1131  69 -745  28 -771  50 
T70 (ms) 
 
35.8  1 *22.0  
1.4 
25.4  0.8 25.0  0.6 20.1  0.6 19.3  1 
Tau w (ms) 
 
33.2  1 *21.6  
1.4 
22.5  0.7 22.1  0.6 18.2  0.6 19.0  1 
Frequency (Hz) 
 
2  0.4 3  0.5 7  0.7 7  0.8 8  0.8 8  1 
 
*P < 0.05; unpaired Student’s t test, in comparison to age-matched control 
 
Table 12 Pipette-applied γ-cyclodextrin (CD) reduces decay time of GABAA mIPSCs of layer 
2/3 cortical neurones at two stages of development (P9-10 and P60-75). 
 P9-10 
Control 
 
(n=8) 
P9-10 
γ-CD 
 
(n=6) 
P60-75 
Control 
 
(n=35) 
P60-75 
γ-CD 
 
(n=15) 
Peak amplitude 
(pA) 
-36 ± 2 -35 ± 3 -59 ± 2 -58 ± 2 
Rise Time (ms) 0.7 ± 0.1 0.7 ± 0.1 0.4  ± 0.1 0.4 ± 0.1 
Charge transfer 
(fC)  
-333± 20 *-266 ± 22 -242 ± 9 *-185 ± 8 
T70 (ms) 
 
10.3 ± 0.3 *8.7 ± 0.6 5.2  ± 0.2 *3.7 ± 0.2 
Tau w (ms) 
 
10.0 ± 0.6 *7.4 ± 0.4 4.0  ± 0.1 *2.9 ±0.1 
Frequency (Hz) 3 ± 0.5 *1.6 ± 0.5 17  ± 2 18 ± 2 
 
*P < 0.05; unpaired Student’s t test, in comparison to age-matched control  
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Figure 16 Effect of -CD applied intracellularly on nRT neurones varies depending on stage of 
development. 
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(A) Superimposed exemplar GABAARs mIPSCs from nRT neurones aged P6-7 illustrating the 
difference between unmatched control recordings and recordings made with 0.5mM -CD applied 
only intracellularly via the recording pipette. (B & C) Superimposed exemplar GABAARs mIPSCs 
from nRT neurones aged P9-10 and P17-25 respectively illustrating the lack of effect of 0.5mM -
CD applied only intracellularly via the recording pipette at these stages of development. (D) 
Histogram illustrating the significant effect of 0.5mM -CD applied only intracellularly via the 
recording pipette on GABAAR mIPSCs of nRT neurones aged P6-7 (P6-7 Ctrl = 33.2  1 ms; P6-7 γ-
CD pipette = 21.6  1ms; P < 0.05) but not P9-10 (P9-10 Ctrl = 22.5  0.7 ms; P9-10 γ-CD pipette = 
22.1  0.6ms; P > 0.05) or P17-25 (P17-25 Ctrl = 18.1  0.6 ms; P17-25 γ-CD pipette = 19  1ms; 
Student’s unpaired t test P > 0.05 vs unmatched control; n = 8-24). CD = cyclodextrin; Ctrl = control. 
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3.10 Pipette-applied γ-CD reduces decay time of GABAAR mIPSCs of layer 2/3 
cortical neurones at two stages of development. 
 
To follow on from previous work in the nRT, recordings were made from L2/3 
cortical neurones at two stages of maturity (P9-10 and P60-75) with γ-CD applied 
intracellularly. The mIPSC decay (τW) of P9-10 cortical neurones was significantly 
decreased in the presence of γ-CD (P9-10 control = 10.0  0.6 ms, n = 8, P9-10 γ-CD 
= 7.4  0.4 ms, n = 6; Student’s unpaired t test, P < 0.05; Table 12; Figure 17). The 
T70 was similarly decreased by γ-CD treatment (P9-10 control = 10.3  0.3 ms, n=8, 
P9-10 γ-CD = 8.7  0.6 ms, n =6; Student’s unpaired t test, P <0.05; Table 12).  
The mIPSC decay (τW) of P60-75 cortical neurones was significantly decreased in 
the presence of γ-CD (P60-75 control = 4.0  0.1 ms, n = 35, P 60-75 γ-CD = 2.9  
0.1 ms, n = 15; Student’s unpaired t test, P <0.05; Table 12; Figure 17). The T70 was 
similarly decreased by γ-CD (P60-75 control = 5.2  0.2 ms, n = 35, P60-75 γ-CD = 
3.7  0.2 ms, n = 15; Student’s unpaired t test, P <0.05; Table 12). These data are in 
contrast to the lack of effect of γ-CD observed in nRT neurones at P9-10 and P17-
24 (Figure 16). However, the data for P9/10 L2/3 cortical neurons are consistent 
with data obtained by a former laboratory colleague (Brown, 2012). Different 
regions of the nervous system reach maturation at different ages and it is possible 
that this may account for the regional variations observed in these experiments. 
Perhaps the most interesting finding is that the endogenous neurosteroid tone that 
previously appeared to be lost with maturation re-emerges in the adult mouse 
cortex, which may have a significant physiological role. 
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Figure 17 -CD applied intracellularly shortens the duration of GABAAR mIPSCs in L2/3 
cortical neurones at age P9-10 & P60-75. 
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(A & B) Superimposed exemplar GABAARs mIPSCs from L2/3 cortical neurones aged P9-10 and 
P60-75 respectively illustrating the significant effect of 0.5mM -CD applied only intracellularly via 
the recording pipette at these two stages of development. (C) Histogram illustrating the significant 
effect of 0.5mM -CD applied only intracellularly via the recording pipette on GABAAR mIPSCs of 
L2/3 cortical neurones aged P9-10 (P9-10 Ctrl = 10.0  0.6 ms, n = 8, P9-10 γ-CD = 7.4  0.4 ms, n = 
6; P < 0.05) and P60-75 (P60-75 Ctrl = 4.0  0.1ms, n = 35, P 60-75 γ-CD = 2.9  0.1ms, n = 15; 
Student’s unpaired t test P < 0.05 vs unmatched control). These results are consistent with the idea 
that there is an endogenous neurosteroid tone present in early development in pain pathway 
neurones, which decreases during maturation, but can reappear with full maturity.  CD = 
cyclodextrin; Ctrl = control 
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Chapter 4: The role of neurosteroids on mature layer 2/3 
neurones from the cerebral cortex of WT mice.  
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Neurosteroids are effective modulators of the GABAAR and have an important role 
in neurodevelopment and the maintenance of physiological inhibitory tone (Agis-
Balboa et al., 2006; Baulieu et al., 2001; Belelli & Lambert, 2005; Belelli et al., 
2006). Changes in the levels of endogenous neurosteroids occur with certain forms 
of depression, epilepsy, schizophrenia and Alzheimer’s disease and therefore 
manipulation of their levels could be of therapeutic benefit (Belelli et al., 2006; 
Gunn et al., 2011; Luchetti et al., 2011; Reddy, 2010). Of particular relevance to the 
present study, neurosteroid synthesis in dorsal horn neurones of the spinal cord is 
up-regulated in response to inflammatory pain to provide a form of endogenous 
analgesia (Poisbeau et al., 2005). As detailed in Part 3 of the Introduction, the 
synthesis pathway for allopregnanolone is as follows: 1) pregnenolone is 
converted to progesterone by 3 -hydroxysteroid dehydrogenase (3 -HSD). 2) 
progesterone is converted to 5 -dihydroxyprogesterone (DHP) by 5 -reductase 
(5 -R). 3) DHP is converted to allopregnanolone (5 3 ) by 3 -hydroxysteroid 
dehydrogenase (3 -HSD). In addition, the active compound allopregnanolone may 
be converted back to DHP by 3 -HSD, or to the inactive epiallopregnanolone 
(3 5 ) (Belelli & Lambert, 2005; Mellon et al., 2001; Rupprecht et al., 2010; 
Schumacher et al., 2012; Stoffel-Wagner, 2003;  Figure 3.) 
The first results chapter described how endogenous neurosteroid tone fluctuates 
with development and the impact that this has on GABAAR-mediated mIPSCs of 
neurones known to be part of a pain pathway. This chapter describes the influence 
of neurosteroids on cortical mIPSCs recorded from brain slice preparations made 
from adult (P60-75) WT mice. The steroid was administered i) acutely, ii) as a two-
hour brain slice incubation treatment or iii) delivered to the intracellular 
compartment of the neurone via the recording pipette. Additionally, the influence 
of cyclodextrin on the endogenous neurosteroid tone was investigated. It is 
technically more challenging to obtain whole-cell voltage-clamp recordings from 
mice aged P60-75, than from younger animals. Typically only neurones from 
deeper within the slice are viable and the slice tissue is denser in older animals, 
which makes the visualisation of neurones more challenging. In Chapter 3, the 
properties of certain neurones of the pain pathway (spinal cord, thalamic and 
cortical neurones) were investigated at different stages of development. As the 
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behavioural studies were to be conducted in adult mice, it was decided to make 
recordings from adult layer 2/3 cortical neurones for three reasons: 1) viable 
recordings of nRT neurones of older animals are compromised by the high density 
of axonal projections (Cox et al., 1997; Pinault & Deschenes, 1998). 2) values for 
the mean τW of L2/3 cortical GABAAR mIPSCs are relatively homogenous, in 
contrast to the mean τW values of GABAAR mIPSCs of LII neurones which are 
heterogenous, which makes inter-group comparison more difficult (as detailed in 
the previous chapter; Figure 11). 3) Layer 2/3 cortical neurones are part of the 
pain pathway.  
 
4.1 The effect of the acute application of allopregnanolone or ganaxolone on 
GABAAR mIPSCs in mature WT mice (P60-75). 
 
Allopregnanolone (3 -hydroxy-5 -pregnan-20-one) is an effective modulator of 
synaptic GABAAR function in multiple regions of the nervous system, including the 
spinal cord, thalamus, cerebral cortex and the hippocampus (Belelli & Herd, 2003; 
Belelli & Lambert, 2005; Brown, 2012; Inquimbert et al., 2007; Keller et al., 2004; 
Mitchell et al., 2007). The neuroactive steroid ganaxolone, is a potent positive 
allosteric modulator of the GABAAR (Carter et al., 1997; Belelli & Herd 2003). 
Ganaxolone is a metabolically stable synthetic analogue of allopregnanolone, the 
molecular structure of which differs only by having an extra methyl group 
(adjacent to the hydroxyl group at the 3 position of the A-ring) that prevents 
oxidation to an inactive form (Carter et al., 1997). The extra methyl group means 
that in vivo it may have a longer duration of action than allopregnanolone, a feature 
which may enhance its therapeutic potential for conditions such as epilepsy, or 
neuropathic pain (Carter et al., 1997).  In order to enhance the flow and clarity of 
the thesis and to allow this Chapter to stand alone, data from section 3.7 referring 
to the acute application of allopregnanolone and ganaxolone is intentionally 
reiterated in this section (4.1). 
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Table 13 The acute application of allopregnanolone (Allo) or ganaxolone (Ganax) prolongs the decay time of GABAAR mIPSCs of L2/3 cortical neurones 
(P60-75) of WT mice. 
 
 WT 
Pre  
1 M Allo 
 
 
( n=7) 
WT 
Post  
1 M Allo 
 
( n=7) 
WT 
Pre  
1 M Ganax  
 
(n=6) 
WT 
Post  
1 M Ganax 
 
(n=6) 
WT 
Pre  
3 M Ganax 
 
(n=4) 
WT 
Post  
3 M Ganax 
 
(n=4) 
Peak amplitude 
(pA) 
-68 ± 3 -67 ± 5 -57 ± 4 *-66 ± 6 -65 ± 2 -67 ± 5 
Rise Time (ms) 0.4 ± 0.1 0.4 ± 0.1 0.5  ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
Charge transfer 
(fC)  
-284 ± 7 -305 ± 14 -232 ± 15 *-309 ± 31 
 
-245 ± 21 -295 ± 21 
T70 (ms) 
 
5.2 ± 0.4 *5.8 ± 0.5 5.2  ± 0.2 *6.1 ± 0.4 4.8 ± 0.3 *5.9 ± 0.3 
Tau w (ms) 
 
4.0 ± 0.3 *4.5 ± 0.4 4.0  ± 0.2 *4.7 ± 0.2 3.6 ± 0.3 *4.2 ± 0.2 
Frequency (Hz) 26 ± 6 21 ± 4 22  ± 5 21 ± 5 28 ± 3 31 ± 4 
 
*P < 0.05; paired Student’s t test, in comparison to age-matched control 
n = number of neurones 
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Table 14 The effect of prolonged incubation of allopregnanolone (Allo) or ganaxolone (Ganax) on GABAAR  mIPSCs of L2/3 cortical neurones (P60-75) of 
WT mice 
 WT 
Control 
 
 
( n=35) 
WT 
100nM Allo 
 
( n=9) 
WT 
300nM 
Allo 
 
 ( n=9) 
WT 
30nM 
Ganax 
  
( n=10) 
WT 
100nM 
Ganax  
 
( n=10) 
WT 
300nM 
Ganax 
  
( n=10) 
WT 
1 M 
Ganax 
  
( n=10) 
WT 
3 M 
Ganax 
  
( n=8) 
Peak 
amplitude (pA) 
-59 ± 2 **-78  ± 2 **-87 ± 5 **-61  ± 3 **-66 ± 4 **-82  ± 6 **-97 ± 9 **-153 ± 6 
Rise Time (ms) 0.4  ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 
Charge 
transfer (fC)  
-242 ± 9 **-932 ± 84 **-1489 ± 136 **-300 ± 26 **-440 ± 39 **-749 ± 88 **-1575 ± 195 **-4396 ± 268 
T70 (ms) 
 
5.2  ± 0.2 **18.6 ± 1 **27 ± 1 **6.3 ± 0.4 **9.6 ± 0.6 **13.4 ± 1 **24.2 ± 1 **44.2 ± 2 
Tau w (ms) 
 
4.0  ± 0.1 **12.5 ± 1 **19 ± 1 **5.1 ± 0.3 **7.2 ± 0.5 **10.9 ± 1 **18.8 ± 1 **32.5 ± 1 
Frequency 
(Hz) 
17  ± 2 15 ± 3 **11 ± 1 **11 ± 1 15 ± 3 20 ± 3 13.5 ± 2 **8 ± 1 
 
**P < 0.05; One-way ANOVA in comparison to age-matched control 
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Whole-cell voltage-clamp recordings were made in L2/3 cortical neurones before 
and after the bath application of allopregnanolone, or ganaxolone. The 
neurosteroid was bath-applied after at least four minutes of stable recording, 
(during which time control mIPSCs were obtained) enabling the comparison of 
paired recordings.  Analysis of GABAAR-mediated phasic inhibition included the 
mIPSC amplitude, rise time, charge transfer, decay kinetics and frequency as 
detailed in Table 13.   
After ten minutes application, allopregnanolone induced only a modest (12  3%) 
prolongation of the exponential decay time in the GABAAR-mediated mIPSCs of WT 
L2/3 cortical neurones (τW: control = 4.0  0.3 ms, n = 7; allopregnanolone 1 μM = 
4.5  0.4 ms, n = 7; paired Student’s t test, P <0.05; Table 13; Figure 18). In 
agreement with the effects of the steroid on the decay constant (τW) of the 
averaged mIPSC, the mIPSC T70 was similarly modestly prolonged by 
allopregnanolone (Table 13). It is conceivable that the limited effect of acute 
allopregnanalone is in part a consequence of local metabolism occurring within the 
slice to a GABA-inactive product (Mellon et al., 2001; Schumacher et al., 2012; 
Stoffel-Wagner, 2003). Therefore, I investigated the acute effects of ganaxolone, 
the metabolically stable analogue of allopregnanolone. However, in common with 
allopregnanolone, ganaxolone (1μM) induced only a modest (19  4%) 
prolongation of exponential decay time of the GABAAR-mediated mIPSCs of WT 
layer 2/3 cortical neurones after ten minutes application (τW: control = 4  0.2 ms, 
n = 6; ganaxolone 1 μM = 4.7  0.2 ms, n = 6; Student’s paired t test, P <0.05; Table 
13; Figure 18). Similarly, the mIPSC T70 was modestly prolonged by ganaxolone 
(Table 13). Furthermore, the acute application of a 3-fold greater concentration of 
ganaxolone (3μM) only produced a similar (20  7%) prolongation of the GABAAR 
mIPSC exponential decay time of WT L2/3 cortical neurones to that caused by 1µM 
of this steroid (τW: control = 3.6  0.3 ms, n = 4; ganaxolone 3 μM = 4.2  0.2 ms, n = 
4; Student’s paired t test, P <0.05; Table 13; Figure 18). The mIPSC T70 was 
similarly modestly prolonged by 3 µM ganaxolone (Table 13). These results 
illustrate that ganaxolone modulates synaptic GABAAR function in mature L2/3 
cortical neurones of WT mice when applied acutely and further suggest that the 
limited effects of allopregnanolone are not a consequence of local metabolism.  
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Figure 18 The acute exposure (10-20mins) of mature cortical neurones to allopregnanolone 
(1 M), or ganaxolone (1-3 M) modestly enhances the function of synaptic GABAARs. 
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(A-C) Superimposed traces of exemplar GABAAR-mediated mIPSCs from L2/3 cortical neurones 
aged P60-75 before and after acute exposure to 1 M allopregnanolone or 1-3 M ganaxolone 
respectively. To facilitate comparison of their kinetics, the amplitude of the mIPSCs are normalised 
to that of the control averaged mIPSC. (D-F) Histograms illustrating the significant effect of 1 M 
allopregnanolone and 1-3 M ganaxolone on the time course of decay (τw in ms) of GABAAR mIPSCs 
of L2/3 cortical neurones (Student’s paired t test *P <0.05 for each drug treatment vs. its’ paired 
control recording; n = 7). (G) Histogram illustrating the effect of the neuroactive steroids with the 
data normalised relative to control recordings (i.e. expressed as a percentage of the control 
recording). When the data for τw was normalised to allow comparison of the effect of the two 
steroids, there was no significant difference between the effect produced by allopregnanolone 1 μM 
(12 ± 3%) and that produced by ganaxolone 1 μM (19 ± 4%), or by 3 μM (20 ± 7%) respectively 
(Two-way RM ANOVA **P >0.05; n = 4-7). Allo = allopregnanolone; Ganax = ganaxolone; Ctrl = 
control. 
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The relatively modest prolongation of GABAAR mIPSC decay time (even for the 
higher concentration of ganaxolone) raises the question of how well the 
neurosteroids are penetrating the brain slice. When the data for τW was 
normalised, there was no significant difference between allopregnanolone 1 μM 
(12 ± 3%), ganaxolone 1 μM (19 ± 4%) and 3μM (20 ± 7%) respectively (Two-way 
RM ANOVA, P >0.05).  The next series of experiments explore the effect of 
incubating the preparation with the neurosteroids (allopregnanolone and 
ganaxolone) for at least two hours. 
4.2 The effect of prolonged incubation of allopregnanolone (100 - 300 nM), 
or ganaxolone (30 nM - 3 μM), on cortical GABAAR-mediated mIPSCs of adult 
WT mice. 
The lipophilic intravenous anaesthetics etomidate and propofol, which in common 
with neuroactive steroids enhance the function of GABAARs, require relatively 
prolonged incubation times to approach equilibrium in a brain slice preparation 
(over 1-2 hours; Benkwitz et al., 2007; Gredell et al., 2004).  Therefore in case the 
same is true for neursteroids, recordings were made after incubation treatment 
with allopregnanolone and ganaxolone. 
In this set of experiments the analysis of GABAAR-mediated phasic inhibition 
included the mIPSC amplitude, decay kinetics, charge transfer and frequency 
(Table 14). In contrast to the relatively modest prolongation of mIPSCs described 
above with an acute steroid application protocol, a two-hour incubation of the 
brain slice preparation with ~ 3 to 10 times lower concentrations of 
allopregnanolone (100 – 300 nM) produced a dramatic concentration-dependent 
increase of the WT layer 2/3 cortical GABAAR mIPSC exponential decay time (τW: 
control = 4.0  0.1 ms, n = 35; allopregnanolone 100 nM = 12.5  1 ms, n = 9; 
allopregnanolone 300 nM = 19.0  1 ms, n = 9; One-way ANOVA, P <0.05; post hoc 
Newman Keul’s test revealed significant differences between all three treatments 
and the two concentrations of allopregnanolone increased τW to 313  25% and 
480  22% of control respectively, One-way RM ANOVA, P <0.05; Table 14; Figure 
19). Similarly, the mIPSC T70 was significantly prolonged by allopregnanolone 
(Table 14).  
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Figure 19 The prolonged exposure (~2 hrs) of mature cortical neurones to relatively low 
concentrations of allopregnanolone (100-300 nM) greatly enhances the function of synaptic 
GABAARs. 
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(A) Superimposed traces of exemplar GABAAR-mediated mIPSCs acquired from a representative 
control mature L2/3 cortical neurone and from equivalent neurones after ~2 hour incubation of 
the brain slice with 100 nM and 300 nM allopregnanolone. To facilitate comparison of their time 
course the averaged mean mIPSCs are normalised to the peak amplitude of the representative 
control mean mIPSC. (B) Histogram illustrating the dramatic concentration-dependent effect of 
allopregnanolone on the duration of GABAAR-mediated mIPSCs (the time course of decay- τw in ms; 
One-way ANOVA *P <0.05; n = 9-10). (C) Histogram illustrating the concentration-dependent effect 
of allopregnanolone on the duration of GABAAR-mediated mIPSC (τw expressed as a percentage of 
control). Note 100 nM and 300 nM allopregnanolone increased τw to 313  25% and 480  22% of 
control respectively (One-way RM ANOVA P <0.05. Post hoc Newman Keul’s test revealed 
significant differences between control and both concentrations of allopregnanolone **P <0.05 n = 
9-10). Allo = allopregnanolone; Ctrl = control. 
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These results indicate that allopregnanolone is a potent modulator of synaptic 
GABAARs in mature WT L2/3 cortical neurones, but additionally demonstrate that 
the steroid effect is greatly underestimated when applied acutely. The large 
difference between acute bath application and the two-hour incubation is probably 
a consequence of the time required for the steroid to approach equilibrium within 
the brain slice (Benkwitz et al., 2007; Gredell et al., 2004). No such effect was 
observed in time matched controls.  Of note, allopregnanolone may be converted 
back to DHP, or to the inactive epiallopregnanolone (3 5 ) (Belelli & Lambert, 
2005; Mellon et al., 2001; Schumacher et al., 2012; Stoffel-Wagner, 2003).  
As described above, acute ganaxolone had a similar effect to allopregnanolone in 
causing only a modest prolongation of the GABAAR-mediated mIPSC. A two-hour 
incubation of the brain slice preparation with ganaxolone produced a significant 
concentration-dependent increase of the WT L2/3 cortical GABAAR mIPSC 
exponential decay time, although the magnitude of the effect was less than that 
induced by allopregnanolone (τW: control = 4.0  0.1 ms, n = 35; ganaxolone 30 nM 
= 5.1  0.3 ms, n = 10; ganaxolone 100 nM = 7.2  0.5 ms, n = 10; ganaxolone 300 
nM = 10.9  1 ms, n = 10; ganaxolone 1 μM = 18.8  1 ms, n = 10; ganaxolone 3 μM 
= 32.5  1 ms, n = 8; One-way ANOVA, P <0.05; post hoc Newman Keul’s test 
revealed significant differences between all the concentrations of ganaxolone, τW 
was increased to 126  8%, 180  11%, 273  32%, 468  32% and 811  42% of 
control respectively, One-way RM ANOVA, P <0.05; Table 14; Figure 20). Similarly, 
the mIPSC T70 was significantly prolonged by ganaxolone (Table 14). These results 
reveal that in common with allopregnanolone, the prolonged incubation of the 
brain tissue with ganaxolone is far more effective than the acute application 
protocol. However, although highly effective, ganaxolone appears less efficacious 
than allopregnanolone in modulating GABAAR-mediated mIPSCs in mature layer 
2/3 cortical neurones of WT mice. Indeed, allopregnanolone had greater potency 
than ganaxolone at the same concentrations: 100 nM (313  25% vs. 180  11%; 
One-way RM ANOVA, P <0.05) and 300 nM (480  22% vs. 273  32%; One-way 
RM ANOVA, P <0.05). (Table 14, Figure 21).   
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Figure 20 The prolonged exposure (~2 hrs) of mature cortical neurones to ganaxolone (30 
nM- 3 M) greatly enhances the function of synaptic GABAARs in a concentration-dependent 
manner. 
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(A) Traces of superimposed exemplar GABAAR-mediated mIPSCs from a representative control 
mature L2/3 cortical neurone and from equivalent neurones after ~2 hour incubation of the brain 
slice with 30 nM - 3 M ganaxolone. (B) Histogram illustrating the dramatic concentration-
dependent effect of ganaxolone on the duration of GABAAR-mediated mIPSCs (the time course of 
decay, τw in ms; One-way ANOVA *P <0.05; n = 8-10). (C) Histogram illustrating the concentration-
dependent effect of ganaxolone on the duration of GABAAR-mediated mIPSCs (τw expressed as a 
percentage of control). Note 30 nM - 3 M ganaxolone increased τw to 126  8%, 180  11%, 273  
32%, 468  32% and 811  42% of control respectively (One-way RM ANOVA P <0.05. Post hoc 
Newman Keul’s test revealed significant differences between all the concentrations of ganaxolone 
**P <0.05; n = 8-10).  Ganax = ganaxolone; Ctrl = control. 
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Figure 21 A comparison of the effects of prolonged exposure (~2 hrs) of mature cortical 
neurones to allopregnanolone (100-300 nM) and ganaxolone (100-300 nM) on synaptic 
GABAAR function. 
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(A & B) Superimposed exemplar GABAAR-mediated mIPSCs acquired from representative control 
mature L2/3 cortical neurones and from equivalent neurones after an ~2 hour incubation of the 
brain slice with 100 nM and 300 nM allopregnanolone, or ganaxolone. (C) Histogram comparing 
the concentration-dependent effects of allopregnanolone and ganaxolone on the duration of 
GABAAR-mediated mIPSCs (the time course of decay τw expressed as a percentage of control). The 
histogram illustrates the significantly greater effect of allopregnanolone compared to ganaxolone 
when tested at the same concentrations: 100 nM (313  25% vs. 180  11%; *P <0.05; n = 9-10) 
and 300 nM (480  22% vs. 273  32%; One-way RM ANOVA **P <0.05; n = 9-10). Allo = 
allopregnanolone; Ganax = ganaxolone; Ctrl = control. 
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4.3 The effect of intracellular allopregnanolone or ganaxolone (3-10 M) on 
layer 2/3 cortical GABAA mIPSCs in mature WT mice (P60-75) 
 
As descried above, acute allopregnanolone had only a modest effect on the 
GABAAR-mediated mIPSCs decay time, but was far more efficacious in this respect 
when brain tissue slices were incubated with steroid for > 2 hours, suggesting that 
the steroid is relatively slow to equilibrate within the tissue. It has been proposed 
that endogenous neurosteroids may be synthesised in the postsynaptic neurone 
and act in an autocrine manner to influence GABA-ergic transmission (Agis Balboa 
et al., 2006; Lambert et al., 2009).  It is implicit in this model that intracellular 
steroid would modulate the GABAARs of the postsynaptic neurone and the 
recording pipette can be employed to deliver drugs to the neurone interior (Evans 
& Marty, 1986). Whole-cell voltage-clamp recordings were made in L2/3 cortical 
neurones with allopregnanolone, or ganaxolone present in the recording pipette to 
explore whether the steroid could modulate synaptic GABAARs when delivered to 
the intracellular compartment. These recordings were compared to separate 
control recordings (i.e. they were not paired). Analysis of GABAAR-mediated phasic 
inhibition included the mIPSC amplitude, rise time, charge transfer, decay kinetics 
and frequency as detailed in Table 15.   
The presence of allopregnanolone in the recording pipette significantly increased 
the mIPSC decay of WT L2/3 cortical neurones in a concentration-dependent 
manner (τW: control = 4.0  0.1 ms, n = 35; 3 M allopregnanolone = 5.8  0.8 ms, n 
= 6; 10 M allopregnanolone = 16.1  1.3 ms, n = 7; One-way ANOVA, P < 0.05; post 
hoc Newman Keul’s test revealed significant differences between all three 
treatments, P < 0.05. Table 15, Figure 22). In agreement with the effects of the 
steroid on the decay constant (τW) of the averaged mIPSC, the mIPSC T70 was 
similarly modestly prolonged by allopregnanolone (Table 15). Here, the higher 
concentration of allopregnanolone (10 µM) had a comparatively large 
concentration-dependent effect on cortical GABAAR mIPSCs when presented 
acutely within the recording electrode. This finding indicates that neurosteroids 
are able to exert their effect via the intracellular compartment and is in agreement 
with the literature (Akk et al., 2005; See Discussion section 7.4 for further details).  
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Table 15 The effect of intracellular allopregnanolone (Allo) or ganaxolone (Ganax) on 
GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT mice 
 
 
**P < 0.05; One-way ANOVA, in comparison to age-matched control 
 
The concentrations of pipette-applied allopregnanolone are relatively high, but the 
time scale from application to recording is short (< 10 minutes) and dialysis rate of 
the intracellular contents may be an influential limiting factor.  The presence of 
ganaxolone in the recording pipette also significantly increased the mIPSC decay of 
WT L2/3 cortical neurones in a concentration-dependent manner (τW: control = 
4.0  0.1 ms, n = 35; 3 M ganaxolone = 5.5  0.4 ms, n = 6; 10 M ganaxolone = 6.1 
 0.3 ms, n = 6; One-way ANOVA, P < 0.05; Table 15, Figure 23). In agreement with 
the effects of the steroid on the decay constant (τW) of the averaged mIPSC, the 
mIPSC T70 was similarly modestly prolonged by ganaxolone (Table 15). The effect 
of pipette-applied ganaxolone is consistent with the recordings described above 
with allopregnanolone, although ganaxolone had a less pronounced effect on 
GABAAR mIPSCs. Collectively these experiments illustrate that steroid penetration 
of brain slice tissue is a significant limiting factor, the intracellular application is an 
effective method of presenting neuroactive steroids to GABAARs (Figure 24) and 
that, in these neurones, allopregnanolone is a more effective modulator of the 
synaptic GABAAR than ganaxolone (Figure 21 & Figure 25). 
 WT   
Control 
 
(n=35) 
WT 
3μM Allo 
 
(n=6) 
WT 
10μM Allo 
 
(n=7) 
WT 
3μM Ganax 
 
(n=6) 
WT 
10μM Ganax 
 
(n=6) 
Peak amp 
(pA) 
-59 ± 2 -64 ± 3 **-95 ± 4 -63 ± 4 -69 ± 6 
Rise Time 
(ms) 
0.4  ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
Charge 
transfer (fC) 
-242 ± 9 -354 ± 49 **-1389 ± 139 **-347 ± 15 **-420 ± 55 
T70 (ms) 5.2  ± 0.2 **7.7 ± 1 **22.3 ± 1.4 **7.1 ± 0.4 **8.1 ± 0.6 
Tau w (ms) 4.0  ± 0.1 **5.8 ± 0.8 **16.1 ± 1.3 **5.5 ± 0.4 **6.1 ± 0.3 
Frequency 
(Hz) 
17  ± 2 22 ± 4 20 ± 3 18 ± 4 16 ± 2 
111 
 
 
Figure 22 Intracellular allopregnanolone enhances synaptic GABAAR function of mature 
cortical neurones. 
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(A) Superimposed exemplar GABAAR-mediated mIPSCs from a representative control mature L2/3 
cortical neurone and from equivalent neurones treated with allopregnanolone (3 - 10 M) 
administered intracellularly via the recording patch-electrode. Note recordings of mIPSCs for both 
control and steroid-treated neurones did not commence for ~6 mins after establishing the whole-
cell voltage-clamp to allow the steroid to equilibrate (Evans & Marty, 1986). To facilitate 
comparison of their kinetics, the amplitudes of the mIPSCs are normalised to that of the control 
averaged mIPSC. (B) Histogram illustrating the concentration-dependent effect of intracellular 
allopregnanolone on the duration of the GABAAR-mediated mIPSCs (time course of decay τw in ms; 
One-way ANOVA *P <0.05; n = 6-7). C. Histogram illustrating the concentration-dependent effect of 
intracellular allopregnanolone on the duration of GABAAR-mediated mIPSCs (τw expressed as a 
percentage of control 145  19% and 378  28%; n = 6-7; One-way RM ANOVA **P <0.05 vs. 
control.  Post hoc Newman Keul’s test revealed significant differences between the two 
concentrations of allopregnanolone, P <0.05). Allo = allopregnanolone; Ctrl = control. 
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Figure 23 Intracellular ganaxolone enhances the synaptic GABAAR function of mature 
cortical neurones. 
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(A) Superimposed exemplar GABAAR-mediated averaged mIPSCs from a representative control 
mature L2/3 cortical neurone and from equivalent neurones with 3 - 10 M ganaxolone 
administered intracellularly via the recording patch-electrode. Note recordings of mIPSCs for both 
control and steroid-treated neurones did not commence for ~6 mins after establishing the whole-
cell voltage-clamp to allow the steroid to equilibrate (Evans & Marty, 1986). To facilitate 
comparison of their kinetics, the amplitude of the mIPSCs are normalised to that of the control 
averaged mIPSC. (B) Histogram illustrating the concentration-dependent effect of intracellular 
ganaxolone on the duration of GABAAR-mediated mIPSCs (time course of decay τw in ms; One-way 
ANOVA *P <0.05; n = 6). (C) Histogram illustrating the effect of intracellular ganaxolone on the 
duration of GABAAR-mediated mIPSCs (τw expressed as a percentage of control 138  9% and 151 
 8% n = 6; One-way RM ANOVA **P <0.05 vs. control Post hoc Newman Keul’s test revealed no 
significant difference between the two concentrations of ganaxolone, P >0.05). Ganax = ganaxolone; 
Ctrl = control. 
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Figure 24 A comparison of the effects of extracellular acute, or prolonged and intracellular 
allopregnanolone on the function of synaptic GABAARs of mature cortical neurones. 
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Histogram comparing the effectiveness of allopregnanolone administered by different methods to 
prolong GABAAR-mediated mIPSCs (τw expressed as a percentage of control). In this regard 
allopregnanolone is clearly most effective when the brain slices are incubated with the drug for ~2 
hours. Incub = ~2 hour incubation with allopregnanolone (n = 6-9). Pipette = steroid delivered 
intracellularly via the patch pipette. Acute = bath applied steroid with recordings commencing ~10 
minutes after steroid perfusion. 
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Figure 25 Comparison of the effects of intracellular allopregnanolone & ganaxolone on the 
function of synaptic GABAARs of mature cortical neurones. 
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(A & B) Superimposed exemplar averaged GABAAR-mediated mIPSCs from representative control 
mature L2/3 cortical neurones and from equivalent neurones with 3 - 10 M allopregnanolone, or 
ganaxolone administered intracellularly via the recording patch-electrode. (C) Histogram 
comparing the concentration-dependent effect of intracellularly allopregnanolone and ganaxolone 
on the duration of GABAAR-mediated mIPSCs (time course of decay τw expressed as a percentage of 
control). The histogram illustrates the significantly greater effect of allopregnanolone compared to 
ganaxolone at the higher (10 µM) concentration: 3 M (145  19% vs. 138  9%; P >0.05; n = 6) 
and 10 M (378  28% vs. 151  8%; n = 6-7 One-way RM ANOVA **P <0.05). Allo = 
allopregnanolone; Ganax = ganaxolone; Ctrl = control. 
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4.4 The effect of cyclodextrins on layer 2/3 cortical GABAA mIPSCs in mature 
WT mice. 
As described in the Introduction, the cyclodextrins are relatively large barrel-
shaped molecules that may be classified according to the number of glucose 
residues they contain (Brown, 2012; Shu et al., 2004, 2007). The three principle 
types of cyclodextrins (CD) are the -CD hexamer, the -CD heptamer and the -CD 
octomer (Cooper et al., 2005; Davis & Brewster, 2004; See Discussion: section 7.5 
for further details). In the previous chapter, -CD was effective at revealing the 
presence of an endogenous neurosteroid tone that varied with development in 
nRT neurones, while in layer 2/3 cortical neurones it was discovered that the 
neurosteroid tone reappeared by P60-75. Whole-cell voltage-clamp recordings 
were made in layer 2/3 cortical pyramidal neurones with cyclodextrin present in 
the recording pipette (i.e. the optimal method of administration as described in the 
previous chapter). These recordings were compared against separate control 
recordings (i.e. they were not paired), where the recording pipette contained only 
the intracellular solution. Analysis of GABAAR-mediated phasic inhibition included 
the mIPSC amplitude, rise time, charge transfer, decay kinetics and frequency as 
detailed in Table 16. 
The GABAAR mIPSC decay (τW) of L2/3 cortical pyramidal neurones of WT mice 
was significantly decreased in the presence of -CD, but not by -CD, or -CD (τW 
control = 4.0  0.1 ms, n = 35; γ-CD = 2.9  0.1 ms, n = 15; -CD = 4.1  0.5 ms, n = 
7; -CD = 4.5  0.4 ms, n = 6; One-way ANOVA, P < 0.05; Table 16, Figure 26). The 
T70 was similarly decreased in the presence of γ-CD but not by -CD or by -CD 
Table 16). -CD has been reported to have no direct effect on the GABAAR (Shu et 
al., 2004, 2007) and the data reported has demonstrated that neither of the smaller 
molecules, -CD or -CD, had an impact on GABAAR-mediated mIPSC decay time 
(See Discussion: section 7.5 for further details).  These data agree with previous 
studies (Brown, 2012; Shu et al., 2004, 2007), but the -CD data potentially 
conflicts with Pytel et al., (2006) who reported that -CD decreased the 
desensitisation kinetics of the GABAAR to GABA by direct modulation of the 
receptor itself within outside-out patches of cultured hippocampal neurones. The 
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mechanism for the direct modulation by -CD was uncertain and the findings of 
Pytel et al., (2006) have yet to be replicated. 
The results are consistent with the hypothesis that -CD may shorten GABAAR-
mediated mIPSC decay time indirectly by the sequestration of endogenous 
neurosteroid compounds. A former laboratory colleague discovered that -CD had 
no effect on GABAAR mIPSCs of layer 2/3 cortical neurones ~P20, indicating that 
endogenous neurosteroid tone is absent at that stage of development (Brown, 
2012).  The developmental data from the P20 cortical neurones serves as a control 
for my findings at P60-75. 
 
Table 16 The effect of intracellular /β/γ – cyclodextrin (CD) 0.5mM on GABAAR mIPSCs of 
layer 2/3 cortical neurones (P60-75) of WT mice. 
 
 WT 
Control 
 
( n=35) 
WT 
-CD 
 
( n=7) 
WT 
β-CD 
 
( n=6) 
WT 
γ-CD 
 
( n=15) 
Peak amp (pA) -59 ± 2 -55  ± 3 -56 ± 3 -58 ± 2 
Rise Time 
(ms) 
0.4  ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
Charge 
transfer (fC)  
-242 ± 9 -243 ± 15 -261 ± 16 **-185 ± 8 
T70 (ms) 
 
5.2  ± 0.2 5.7 ± 0.6 5.9 ± 0.5 **3.7 ± 0.2 
Tau w (ms) 
 
4.0  ± 0.1 4.1 ± 0.5 4.5 ± 0.4 **2.9 ±0.1 
Frequency 
(Hz) 
17  ± 2 18 ± 4 18 ± 5 18 ± 2 
 
**P < 0.05; one-way ANOVA, in comparison to age-matched control 
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Figure 26 Intracellular -CD reduces the duration of GABAAR-mediated mIPSCs of mature 
cortical neurones: evidence for an endogenous neurosteroid tone. 
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(A-C) Superimposed exemplar averaged GABAAR-mediated mIPSCs from a representative control 
mature L2/3 cortical neurone and from equivalent neurones treated with 0.5 mM -CD, β-CD or -
CD administered intracellularly via the recording patch-pipette. Note recordings of mIPSCs for both 
control and cyclodextrin-treated neurones did not commence for ~6 mins after establishing the 
whole-cell voltage-clamp to allow the compound to equilibrate (Evans & Marty, 1986). To facilitate 
comparison of their kinetics, the amplitude of the mIPSCs are normalised to that of the control 
averaged mIPSC. Note only γ-CD was effective in reducing the duration of the mIPSCs. (D) 
Histogram illustrating that intracellular -CD (but not -CD or β-CD) decreases the GABAAR mIPSC 
τw (in ms) of mature L2/3 cortical neurones (One-way ANOVA *P < 0.05; n = 6-15). (E) Histogram 
illustrating that intracellular -CD (but not -CD or β-CD) decreases the GABAAR-mediated mIPSC 
τw (expressed as a percentage of control) of mature L2/3 cortical neurones (73  3%, 104  11%, 
112  11% respectively vs. unpaired representative control n = 6-15; One-way RM ANOVA *P < 
0.05). Dotted line indicates the control condition. Ctrl = control; -CD = -cyclodextrin (5 mM). 
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4.5 Is the effect of prolonged ganaxolone incubation on cortical GABAAR-
mediated mIPSCs influenced by intracellular -CD? 
 
I have demonstrated that in mature L2/3 cortical neurones pipette-applied -CD 
can shorten the duration of mIPSCs, a finding consistent with the depletion of an 
endogenous neurosteroid tone. Furthermore, I have shown that prolonged 
ganaxolone incubation induces a marked prolongation of the mIPSC decay time. To 
probe whether the cyclodextrin effect is a consequence of neurosteroid 
sequestration I investigated whether intracellular -CD could reverse the 
ganaxolone-mediated modulation of the GABAAR. Whole-cell voltage-clamp 
recordings were made in mature L2/3 cortical neurones of WT mice after at least 
two hours of incubation with ganaxolone with -CD applied in the recording 
pipette.  Analysis of GABAAR-mediated phasic inhibition included the mIPSC 
amplitude, rise time, decay kinetics, charge transfer and frequency (Table 17).    
Pipette-applied -CD reduced significantly the effect of long incubation with 
ganaxolone, but did not reverse it completely (τW: control = 4.0  0.1 ms, n = 35; -
CD 0.5 mM = 2.9  0.1 ms, n = 15; ganaxolone 300 nM = 10.9  1 ms, n = 10; -CD 
0.5 mM & ganaxolone 300 nM = 6.7  0.9 ms, n = 7; One-way RM ANOVA, P <0.05; 
post hoc Newman Keul’s test revealed a significant difference between ganaxolone 
alone and ganaxolone with -CD, P <0.05; Table 17; Figure 27).  The same effect on 
the mIPSC T70 was observed (Table 17). These results confirm that -CD is able to 
sequester neuroactive steroids such as ganaxolone. It appears that in the 
experiment described above, γ-CD may have become saturated by the relatively 
high concentrations of the neurosteroids in the brain slice tissue. These results 
support the proposal that the γ-CD effect observed for WT cortical neurones 
reflects the removal of an endogenous neurosteroid tone.  
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4.6 Can mature layer 2/3 cortical neurones synthesise neurosteroids? 
 
As discussed above, progesterone and its’ metabolite dihydroxy-progesterone 
(DHP) do not modulate GABAARs directly (Belelli & Herd, 2003; Brown, 2012), but 
require the activity of the enzymes 5 -R and 3 -HSD in order to synthesise 
allopregnanolone (Figure 3; Belelli & Lambert, 2005; Mellon et al., 2001; 
Schumacher et al., 2012; Stoffel-Wagner, 2003). Here the effects on mIPSCs of 
incubating the brain slices with the allopregnanolone precursors progesterone and 
DHP are investigated (Refer to neurosteroid synthesis pathway ; Figure 3). 
 
Table 17 The effect of ganaxolone (Ganax) incubation treatment with -CD presented 
intracellularly, on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT mice. 
 
 
 
 
 
 
 
 
 
 
 
**P < 0.05; One-way RM ANOVA (with Post hoc Newman Keul’s test), in comparison to 300nM 
Ganaxolone 
  
 WT  
Control 
 
 
(n=35) 
WT 
300nM Ganax  
 
 
(n=10) 
WT 
300nM Ganax  & 
0.5mM -CD 
 
(n=7) 
Peak amplitude 
(pA) 
-59 ± 2 -82 ± 6 **-62 ± 8 
Rise Time (ms) 0.4  ± 0.1 0.5 ± 0.1 0.5 ± 0.1 
Charge transfer 
(fC) 
-242 ± 9 -749 ± 88 **-418 ± 87 
T70 (ms) 5.2  ± 0.2 13.4 ± 1 **9.4 ± 1 
Tau w (ms) 4.0  ± 0.1 10.9 ± 1 **6.7 ± 0.9 
Frequency (Hz) 17  ± 2 20 ± 3 14 ± 6 
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Figure 27 Intracellular -CD reduces the effect of extracellular ganaxolone on GABAAR-
mediated mIPSCs of mature cortical neurones. 
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(A) Superimposed exemplar averaged GABAAR-mediated mIPSCs acquired from a representative 
control mature L2/3 cortical neurone and from equivalent neurones after pre-incubating the brain 
slice preparation with 300 nM ganaxolone (~2 hours), with, or without, intracellular 0.5 mM -CD. 
Note recordings of mIPSCs for both control and cyclodextrin-treated neurones did not commence 
for ~6 mins after establishing the whole-cell voltage-clamp to allow the compound to equilibrate 
(Evans & Marty, 1986). To facilitate comparison of their kinetics, the amplitude of the mIPSCs are 
normalised to that of the control averaged mIPSC. (B) Histogram illustrating that intracellular 0.5 
mM -CD significantly reduces the effectiveness of extracellular 300 nM ganaxolone to prolong the 
mIPSC decay (τw in ms; One-way RM ANOVA *P <0.05. Post hoc Newman Keul’s test revealed a 
significant difference between ganaxolone alone and ganaxolone with -CD, P <0.05, n = 7-10. (C) 
Histogram illustrating that intracellular 0.5 mM -CD significantly reduces the effectiveness of 300 
nM ganaxolone to prolong the mIPSC decay time (τw, expressed as a percentage of control 273  
32% vs. 167  21%; n = 7-10 ; One-way RM ANOVA  **P <0.05). Ganax = ganaxolone; Ctrl = control; 
γ-CD = γ-cyclodextrin; incub = ~ 2 hours pre-incubation. 
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4.7 The effect of prolonged progesterone incubation (1-50μM) on cortical 
GABAAR-mediated mIPSCs of mature WT mice. 
 
Whole-cell voltage-clamp recordings were made from L2/3 cortical neurones after 
at least two hours of pre-incubation of the preparation with progesterone. Analysis 
of GABAAR-mediated phasic inhibition included the mIPSC amplitude, rise time, 
decay kinetics, charge transfer and frequency (Table 18). Progesterone produced a 
relatively modest prolongation of GABAAR-mediated mIPSC decay time in WT 
mice. Interestingly, the highest concentration of progesterone tested was only 
slightly more effective than the lowest concentration investigated here (τW: control 
= 4.0  0.1 ms, n = 35; progesterone 1 μM = 4.7  0.3 ms, n = 6; progesterone 3 μM 
= 5.2  0.2 ms, n = 8; progesterone 10 μM = 5.1  0.3 ms, n = 9; progesterone 50 μM 
= 5.3  0.2 ms, n = 9; One-way ANOVA, P <0.05; Table 18; Figure 28). Similarly, the 
mIPSC T70 was prolonged by progesterone incubation treatment (Table 18). These 
results suggest that the enzymatic function (5 -R and 3 -HSD) of mature L2/3 
cortical neurones of WT mice is intact and that they are able to synthesise 
neurosteroids when their precursor (progesterone) is incubated with the brain 
slice preparation.  
 
4.8 Does the 5α-reductase inhibitor finasteride block the effect of 
progesterone on the cortical mIPSCs of WT mice? 
Finasteride itself has no direct effect on GABAAR mIPSCs, but pre-treatment with 
this enzyme inhibitor prevents the conversion of progesterone into GABAAR- active 
neurosteroid metabolites in the hippocampal CA1 neurones of mature mice (Sanna 
et al., 2004). Finasteride reduced the duration of synaptic GABAergic events in 
spinal LII neurones of immature rats, but had no effect on mature rats (Inquimbert 
et al., 2007; Keller et al., 2004). A similar phenomenon was observed in the cortical 
neurones of immature mice that were treated with another 5 -R inhibitor, SKF 
105111 (Puia et al., 2003). These findings are consistent with the hypothesis that 
there is a substantial endogenous neurosteroid tone in immature animals that has 
a significant modulatory effect on the GABAAR (Keller et al., 2004).
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Table 18 The effect of progesterone (Prog) incubation treatment on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT mice. 
 
 WT 
Control 
 
 
( n=35) 
WT 
1 M Prog 
 
 
( n=6) 
WT 
3μM Prog 
 
 
( n=8) 
WT 
10μM Prog 
 
 
( n=9) 
WT 
50μM Prog 
 
 
(n=9) 
WT 
50μM Finast 
 
 
(n=7) 
WT 
50μM Prog 
& 50μM Finast 
 
(n=7) 
Peak amp 
(pA) 
-59 ± 2 -65 ± 2 -64  ± 3 **-70 ± 2 **-91 ± 5 **-67 ± 3 -64 ± 3 
Rise Time 
(ms) 
0.4  ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
Charge 
transfer (fC)  
-242 ± 9 **-319 ± 19 **-339 ± 26 **-373 ± 20 **-515 ± 34 **-299 ± 19 -269 ± 10 
T70 (ms) 
 
5.2  ± 0.2 **6.5 ± 0.5 **6.8 ± 0.2 **7.3 ± 0.4 **7.6 ± 0.2 5.7 ± 0.2 5.7 ± 0.1 
Tau w (ms) 
 
4.0 ± 0.1 **4.7 ± 0.3 **5.2 ± 0.2 **5.1 ± 0.3 **5.3 ± 0.2 4.2 ± 0.1 4.1 ± 0.1 
Frequency 
(Hz) 
17  ± 2 16 ± 2 17 ± 2 19 ± 2 **31 ± 3 **28 ± 5 19 ± 1.5 
 
**P < 0.05; One-way ANOVA in comparison to age-matched control, (with Post hoc Newman Keul’s test).  
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Figure 28 Prolonged exposure (~2 hrs) of mature cortical neurones to progesterone (1-50 
M) enhances the function of synaptic GABAARs, suggesting that these neurones can 
synthesise allopregnanolone. 
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(A) Superimposed exemplar averaged GABAAR-mediated mIPSCs acquired from a representative 
control mature L2/3 cortical neurone and from equivalent neurones after ~2 hour pre-incubation 
of the brain slice with 1 M - 50 M progesterone. (B) Histogram illustrating the significant, but 
modest effect of progesterone on duration of GABAAR-mediated mIPSCs (decay time τw in ms;. One-
way ANOVA *P <0.05. Post hoc Newman Keul’s test revealed no significant inter-group difference 
between the concentrations of progesterone, P >0.05 n = 6-9). (C) Histogram illustrating the effect 
of progesterone (1 - 50 M) on the duration of GABAAR-mediated mIPSCs (τw expressed as a 
percentage of control). Progesterone increased τw (1 µM = 118  8%, 3 µM = 129  5%, 10 µM = 
129  6% and 30 µM = 133  4% of control respectively; n = 6-9; One-way RM ANOVA **P >0.05). 
Note the dotted line indicates the control condition. Ctrl = control; Prog = progesterone. 
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Figure 29 The 5 -reductase inhibitor finasteride prevents the effects of progesterone 
incubation on synaptic GABAARs of mature cortical neurones. 
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(A) Superimposed exemplar averaged GABAAR-mediated mIPSCs acquired from a representative 
control mature L2/3 cortical neurone and from equivalent neurones after ~2 hour pre-incubation 
of the brain slice with either 50 M finasteride alone, or co-applied with 50 M progesterone. (B) 
Histogram illustrating that finasteride prevents the effect of progesterone to prolong the GABAAR-
mediated mIPSC τw (in ms); One-way ANOVA P <0.05. Post hoc Newman Keul’s test revealed a 
significant difference for progesterone alone c.f. when progesterone is co-applied with finasteride 
*P <0.05; n = 7-9 X). (C) Histogram illustrating that finasteride prevents the effect of progesterone 
to prolong GABAAR-mediated mIPSCs (τw expressed as a percentage of control: 106  3%, 103  
3% and 133  4% respectively, n = 7-9; One-way RM ANOVA P <0.05. Post hoc Newman Keul’s test 
revealed differences for progesterone 50 μM with or without finasteride 50 μM, **P <0.05). Ctrl. = 
control; Prog = progesterone; Finast = finasteride.  
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Whole-cell voltage-clamp recordings were made in L2/3 cortical neurones of WT 
mice after at least two hours of incubation with finasteride and progesterone. 
Analysis of GABAAR-mediated phasic inhibition included the mIPSC amplitude, 
decay kinetics, charge transfer and frequency (Table 18).  Finasteride alone had no 
effect on L2/3 cortical neurone GABAAR mIPSC decay time in WT mice, but it did 
prevent the effect of progesterone (τW: control = 4.0  0.1 ms, n = 35; finasteride 50 
μM = 4.2  0.1 ms, n = 7; progesterone 50 μM = 5.3  0.2 ms, n = 9; finasteride 50 
μM & progesterone 50 μM = 4.1  0.1 ms, n = 7; One-way ANOVA, P <0.05; post hoc 
Newman Keul’s test revealed differences for progesterone 50 μM with, or without, 
finasteride (50 μM, P <0.05; Table 18; Figure 29). Similarly, the mIPSC T70 was 
unaffected by finasteride, but this enzyme inhibitor prevented the effect of 
progesterone (Table 18). These results indicate that progesterone requires the 
enzymatic activity of 5 -R for it to be converted to its’ active metabolites. Of 
interest, the observation that finasteride alone had no effect on GABAAR mIPSC 
decay time, despite the suggested presence of a modest endogenous neurosteroid 
tone in mature WT mice, was made. This apparent paradox may be explained by 
comparing how finasteride and CD act. CD will remove the endogenous 
neurosteroid present, whereas although finasteride should prevent new 
allopregnanolone synthesis, it will have little impact on that already present. 
Therefore, the apparent lack of an effect of finasteride may reflect the relatively 
slow turnover of pre-synthesised allopregnanolone.  
 
4.9 The effect of acute DHP & prolonged DHP incubation on cortical GABAAR 
mIPSCs of mature WT mice. 
 
Whole-cell voltage-clamp recordings were made in L2/3 cortical neurones before 
and after the bath application of DHP. The neurosteroid was bath-applied after at 
least four minutes of stable recording enabling the comparison of paired 
recordings. Analysis of GABAAR-mediated phasic inhibition included the mIPSC 
amplitude, rise time, decay kinetics, charge transfer and frequency (Table 19).  
After ten minutes application, DHP (3μM) had no effect on the properties of 
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synaptic GABAAR events in WT layer 2/3 cortical neurones (τW: Control = 5  0.3 
ms, n = 4; 3 μM DHP = 4.7  0.3 ms, n = 4; Student’s paired t test, P > 0.05). The T70 
was similarly little influenced by this steroid; Table 19; Figure 30).  These findings 
are consistent with work carried out by a former laboratory colleague in 
ventrobasal neurones of the thalamus in the earlier stages of development (Brown, 
2012). The lack of effect after the acute application of DHP contrasts to the clear, 
albeit modest, effects of acutely applied allopregnanolone and ganaxolone. Given 
the lack of effect of acute DHP, I investigated whether prolonged incubation with 
this allopregnanolone precursor was effective in prolonging GABAAR-mediated 
mIPSCs.  
Whole-cell voltage-clamp recordings were made in L2/3 cortical neurones after at 
least two hours of brain slice incubation with DHP. Analysis of GABAAR-mediated 
phasic inhibition included the mIPSC amplitude, rise time, decay kinetics, charge 
transfer and frequency (Table 20). Two hours of brain slice incubation with DHP (1 
– 3 µM) produced a significant, concentration-dependent prolongation of layer 2/3 
cortical GABAAR-mediated mIPSC decay time in WT mice (τW: control = 4.0  0.1 
ms, n = 35; DHP 1 μM = 5.9  0.2ms, n = 14; DHP 3 μM = 10.2  0.1 ms, n = 9; One-
way ANOVA, P <0.05; post hoc Newman Keul’s test revealed intergroup differences 
between all three treatments, P <0.05; Table 20; Figure 30). Similarly, the mIPSC 
T70 was significantly prolonged by DHP (Table 20). These results indicate that 
mature WT L2/3 cortical neurones have intact 3 -HSD enzymatic function and are 
able to convert DHP into the active metabolite allopregnanolone. 
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Table 19 The effect of DHP applied acutely via the intracellular or extracellular routes on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT 
mice. 
 
 
 
 
 
 
 
 
 
 
 
**P < 0.05; One-way ANOVA, in comparison to age-matched control 
 
  
 WT  
Control 
 
 
(n=35) 
WT 
3μM DHP  
in pipette 
 
(n = 6) 
WT 
10μM DHP 
in pipette 
 
(n = 6) 
WT 
Pre 3 M DHP  
in ECS 
 
( n=4) 
WT 
Post 3 M DHP  
In ECS 
 
(n=4) 
Peak amplitude 
(pA) 
-59 ± 2 -55 ± 2 -67 ± 4 -60 ± 4 -61 ± 2 
Rise Time (ms) 0.4  ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5  ± 0.1 0.5 ± 0.1 
Charge transfer 
(fC) 
-242 ± 9 -229 ± 14 **-302 ± 12 -302 ± 4 -292 ± 8 
 
T70 (ms) 5.2  ± 0.2 5.3 ± 0.2 5.5 ± 0.4 6.6  ± 0.6 6.3 ± 0.6 
Tau w (ms) 4.0  ± 0.1 3.9 ± 0.1 4.3 ± 0.3 5.0  ± 0.3 4.7 ± 0.3 
Frequency (Hz) 17  ± 2 22 ± 1 18 ± 2 19  ± 3 20 ± 6 
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Table 20 The effect of DHP incubation treatment (with -CD presented intracellularly), on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT 
mice. 
 
 WT 
Control 
 
 
( n=35) 
WT 
1 M DHP 
  
 
( n=14) 
WT 
3μM DHP 
  
(n=9) 
WT 
3μM DHP 
& 0.5mM 
-CD 
(n=5) 
Peak amp (pA) -59 ± 2 **-73 ± 4 **-69 ± 5 -73 ± 10 
Rise Time (ms) 0.4  ± 0.1 0.4 ± 0.1 0.5 ±0.1 0.5 ± 0.1 
Charge transfer 
(fC)  
-242 ± 9 **-433 ± 31 **-646 ± 33 -552 ± 80 
T70 (ms) 
 
5.2  ± 0.2 **8 ± 0.4 **13.9 ± 1 *9.9 ± 0.4 
Tau w (ms) 
 
4.0  ± 0.1 **5.9 ± 0.2 **10.2 ± 1 *7.3 ± 0.1 
Frequency (Hz) 17  ± 2 16 ± 2 19 ± 6 12 ± 2 
 
*P < 0.05; One-way RM ANOVA in comparison to 3 M DHP (with Post hoc Newman Keul’s test).  
**P < 0.05; One-way ANOVA in comparison to control (with Post hoc Newman Keul’s test). 
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Figure 30 Prolonged exposure (~2 hrs) of mature cortical neurones to DHP greatly enhances 
the function of synaptic GABAARs, but acute extracellular or intracellular DHP is inert. 
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(A) Superimposed exemplar averaged GABAAR-mediated mIPSCs acquired from a representative 
control mature L2/3 cortical neurone and from equivalent neurones after an ~2 hour pre-
incubation of the brain slice with 1 - 3 M DHP. (B) Histogram illustrating the considerable 
concentration-dependent effect of DHP on the duration of GABAAR-mediated mIPSCs (τw in ms; 
One-way ANOVA *P <0.05. Post hoc analysis revealed intergroup differences between 1 μM and 3 
μM n = 9-14, Newman Keuls **P <0.05). (C) Superimposed exemplar averaged GABAAR-mediated 
mIPSCs acquired from a mature cortical neurone before and after acute exposure to 3 M DHP. (D) 
Histogram illustrating the lack of effect of acutely applied 3 M DHP on GABAAR-mediated mIPSCs 
(τw in ms, Student’s paired t test P >0.05 vs. control n = 4). (E) Superimposed exemplar averaged 
GABAAR-mediated mIPSCs acquired from a representative control cortical neurone and from 
equivalent neurones treated with DHP (3 - 10 M) administered intracellularly via the recording 
patch-electrode. Note recordings of mIPSCs for both control and steroid-treated neurones did not 
commence for ~6 mins after establishing the whole-cell voltage-clamp to allow the steroid to 
equilibrate (Evans & Marty, 1986). To facilitate comparison of their kinetics, the amplitude of the 
mIPSCs are normalised to that of the control averaged mIPSC. (F) A histogram illustrating the lack 
of effect of intracellular DHP on the duration of GABAAR-mediated mIPSCs (τw in ms, n = 6, One-
way ANOVA P >0.05 vs. control). Ctrl = control; DHP = dihydroxyprogesterone, incub = incubation. 
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4.10 Does intracellular cyclodextrin influence the effect of pre-incubated 
DHP on cortical mIPSCs of WT mice?  
 
I have previously demonstrated that pipette-applied -CD can reduce the duration 
of cortical mIPSCs (see Sections 3.10 & 4.4) an effect interpreted as occurring as a 
consequence of removing an endogenous neurosteroid tone. In support of this, 
intracellular γ-CD reduced the effect of ganaxolone on mIPSCs. DHP incubation 
treatment of brain slice tissue induces a marked prolongation of GABAAR mIPSC 
decay time, which raised the question of whether pipette-applied -CD could 
reduce the modulatory effect of DHP incubation as it had done with ganaxolone. 
Whole-cell voltage-clamp recordings were made in mature L2/3 cortical neurones 
of WT mice after at least two hours of incubation with DHP with -CD applied in 
the recording pipette.  Analysis of GABAAR-mediated phasic inhibition included the 
mIPSC amplitude, decay kinetics, charge transfer and frequency (Table 20.). 
Pipette-applied -CD reduced the effect of incubation with DHP (τW: control = 4.0  
0.1 ms, n = 35; -CD 0.5 mM = 2.9  0.1 ms, n = 15; DHP 3 μM = 10.2  1 ms, n = 9; -
CD 0.5 mM & DHP 3 μM = 7.3  0.1 ms, n = 5; One-way RM ANOVA, P <0.05; post 
hoc Newman Keul’s test revealed a significant difference between DHP alone and 
DHP with -CD, P <0.05; Table 20; Figure 31). The same effect on the mIPSC T70 
was observed (Table 20). These results confirm that -CD is also able to sequester 
the GABA-active neurosteroid metabolite of DHP. In common with the ganaxolone 
experiments, γ-CD did not fully reverse the effect of DHP suggesting that γ-CD may 
have become saturated by the relatively high concentrations of the neurosteroids 
in the brain slice tissue.  
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Figure 31 Intracellular -CD reduces the effect of DHP incubation on GABAAR mIPSCs of 
mature cortical neurones. 
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(A) Superimposed exemplar averaged GABAAR-mediated mIPSCs from a representative control 
mature L2/3 cortical neurone and from equivalent neurones after 3 M DHP (~2 hour) pre-
incubation or 3 M DHP pre-incubation with 0.5 mM -CD administered intracellularly via the 
recording patch-electrode. Note recordings of mIPSCs for both control and cyclodextrin-treated 
neurones did not commence for ~6 mins after establishing the whole-cell voltage-clamp to allow 
the steroid scavenger to equilibrate (Evans & Marty, 1986). To facilitate comparison of their 
kinetics, the amplitude of the mIPSCs are normalised to that of the control averaged mIPSC. (B) 
Histogram illustrating that intracellular 0.5 mM -CD significantly reduces the effect of 3 M DHP 
pre-incubation to prolong the mIPSC duration (τw in ms; One-way ANOVA *P <0.05; n = 5-9). (C) 
Histogram illustrating that intracellular 0.5 mM -CD significantly reduces the effect of 3 M DHP 
pre-incubation on the mIPSC duration (τw expressed as a percentage of control 256  25% vs. 183  
3% n = 5-9 (one-way RM ANOVA **P <0.05). Ctrl = control; DHP = dihydroxyprogesterone, -CD = 
-cyclodextrin, incub = incubation. 
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4.11 The effect of intracellular DHP on layer 2/3 cortical GABAA-mediated 
mIPSCs of mature WT mice. 
 
Whole-cell voltage-clamp recordings were made in L2/3 cortical neurones with 
DHP present in the recording pipette. These recordings were compared to a 
separate set of control recordings (i.e. they were not paired). Analysis of GABAAR-
mediated phasic inhibition included the mIPSC amplitude, decay kinetics, charge 
transfer and frequency (Table 19). Pipette-applied DHP (3 M - 10 M) had no 
effect on the properties of GABAAR mIPSCs of WT layer 2/3 cortical neurones ( W 
control = 4.0  0.1 ms, n = 35, 3 M DHP = 3.9  0.1 ms, n = 6; 10 M DHP = 4.3  
0.3 ms, n = 6; One-way ANOVA, P > 0.05; Table 19; Figure 30). The T70 was 
similarly unaffected by the presence of DHP (Table 19). These results contrast with 
the effects of pipette-applied allopregnanolone and ganaxolone described above 
(Figure 32). The lack of effect of intracellular DHP suggests that the neurone being 
recorded from cannot synthesise allopregnanolone either because the neurone is 
not a site of synthesis, or more probably that pipette dialysis has compromised 
neurosteroid synthesis.  
 
4.12 Provera, an inhibitor of 3α-HSD, prevents the effects of DHP but not 
ganaxolone on cortical mIPSCs of mature WT mice. 
As described previously, provera inhibits 3 -HSD, consequently preventing the 
conversion of DHP to allopregnanolone (Belelli & Herd, 2003; Belelli & Lambert, 
2005; Sunde et al., 1982).  Provera is also known to modulate GABAAR mIPSCs in 
dentate gyrus neurones, perhaps as a consequence of the differential expression of 
different isoforms of 3α-HSD in these neurones (Belelli & Herd, 2003). Whole-cell 
voltage-clamp recordings were made in mature layer 2/3 cortical neurones of wild 
type mice after at least two hours of incubation with provera and DHP, or provera 
and ganaxolone. Analysis of GABAAR-mediated phasic inhibition included the 
mIPSC amplitude, decay kinetics, charge transfer and frequency (Table 21).   
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Figure 32 By contrast to allopregnanolone and ganaxolone, intracellular DHP has no effect 
on the function of synaptic GABAARs of mature cortical neurones. 
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(A) Superimposed exemplar averaged GABAAR-mediated mIPSCs acquired from a control cortical 
neurone and from equivalent neurones with 3 - 10 M DHP administered intracellularly via the 
recording patch-electrode. Note recordings of mIPSCs for both control and steroid-treated 
neurones did not commence for ~6 mins after establishing the whole-cell voltage-clamp to allow 
the steroid to equilibrate (Evans & Marty, 1986). To facilitate comparison of their kinetics, the 
amplitude of the mIPSCs are normalised to that of the control averaged mIPSC. (B) Histogram 
illustrating that intracellular DHP (3 - 10 M) has no effect on the duration of GABAAR-mediated 
mIPSCs (τw expressed as a percentage of control; one-way RM ANOVA P >0.05; n = 6), by contrast 
to allopregnanolone (3 – 10 µM) and ganaxolone (3 - 10µM). The dotted line indicates control. (C & 
D) Superimposed exemplar averaged GABAAR-mediated mIPSC acquired from a representative 
control cortical neurone and from equivalent neurones internally dialysed with allopregnanolone 
(3 - 10 M), or ganaxolone (3 - 10 M). Ctrl = control; Allo = allopregnanolone; Ganax = 
ganaxolone; DHP = dihydroxyprogesterone 
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Table 21 The 3 -HSD inhibitor provera reduces the effect of DHP but not ganaxolone (Ganax) incubation treatment on GABAAR mIPSCs of layer 2/3 
cortical neurones (P60-75) of WT mice. 
 
 
 
 
 
 
 
 
**P < 0.05; One-way ANOVA (with Post hoc Newman Keul’s test) in comparison to 3 M DHP 
 
 WT 
Control 
 
 
(n=35) 
WT 
1uM 
Provera 
 
( n=6) 
WT 
3μM 
DHP 
 
(n=9) 
WT 
Provera & 3uM 
DHP 
 
(n=7) 
WT 
300nM Ganax 
 
(n=10) 
WT 
Provera & 
300nM Ganax 
(n=7) 
Peak 
amplitude (pA) 
-59 ± 2 -66  ± 5 -69 ± 5 -61 ± 3 -82  ± 6 -75 ± 4 
Rise Time (ms) 0.4  ± 0.1 0.5  ± 0.1 0.5 ±0.1 0.4 ± 0.1 0.5  ± 0.1 0.5 ± 0.1 
Charge transfer 
(fC) 
-242 ± 9 -310  ± 23 -646 ± 33 **-327 ± 19 -749  ± 88 -778 ± 46 
T70 (ms) 5.2  ± 0.2 6.3  ± 0.3 13.9 ± 1 ** 6.9 ± 0.1 13.4  ± 1 15.5 ± 0.7 
Tau w (ms) 4.0  ± 0.1 4.6  ± 0.2 10.2 ± 1 ** 5.2 ± 0.1 10.9  ± 1 10.9 ± 0.7 
Frequency (Hz) 17  ± 2 23 ± 4 19 ± 6 16 ± 3 20  ± 3 17 ± 3 
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Provera alone exerted a modest effect on L2/3 cortical neurone GABAAR mIPSC 
decay time but, in addition, it prevented the effect of DHP (τW: control = 4.0  0.1 
ms, n = 35; provera 1 μM = 4.6  0.2 ms, n = 6; DHP 3 μM = 10.2  1 ms, n = 9; 
provera 1 μM & DHP 3 μM = 5.2  0.1 ms, n = 7; One-way ANOVA, P <0.05; post hoc 
Newman Keul’s test revealed differences for DHP 3 μM with or without provera 1 
μM, P <0.05; Table 21; Figure 33). The same effect on the mIPSC T70 was observed 
(Table 21). 
As anticipated, provera did not inhibit the effect of ganaxolone on GABAAR mIPSCs 
in mature L2/3 cortical neurones of WT mice (τW: control = 4.0  0.1 ms, n = 35; 
provera 1 μM = 4.6  0.2 ms, n = 6; ganaxolone 300 nM = 10.9  1 ms, n = 10; 
provera 1 μM & ganaxolone 300 nM = 10.9  0.7 ms, n = 7; One-way ANOVA, P 
<0.05; post hoc Newman Keul’s test revealed no differences for ganaxolone 300 nM 
with, or without, provera 1 μM, P >0.05; Table 21; Figure 33). The same effect on 
the mIPSC T70 was observed (Table 21). These results confirm that DHP requires 
enzymatic conversion by 3 -HSD for it to induce a prolongation in the decay time 
of GABAAR mIPSCs. In contrast, ganaxolone was unaffected by 3 -HSD inhibition 
with provera.  
 
4.13 The 3α-HSD inhibitor indometacin prevents the effect of DHP but not 
allopregnanolone on cortical mIPSCs of mature WT mice. 
Indometacin has an entirely different molecular structure to provera, but in 
common it is also an effective inhibitor of the enzyme 3 -HSD (Askonas et al., 
1991; Belelli & Herd, 2003; Belelli & Lambert, 2005; Duax et al., 1978; Hori et al., 
2006; Sunde et al., 1982). Whole-cell voltage-clamp recordings were made in 
mature L2/3 cortical neurones of wild type mice after at least two hours of 
incubation with indometacin and DHP. Analysis of GABAAR-mediated phasic 
inhibition included the mIPSC amplitude, decay kinetics, charge transfer and 
frequency (Table 22).  
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Figure 33 The 3 -HSD enzyme inhibitor provera suppresses the effects of DHP, but not 
ganaxolone on GABAAR-mediated mIPSCs of mature cortical neurones. 
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(A) Superimposed exemplar averaged GABAAR-mediated mIPSCs from a representative control 
cortical neurone and from equivalent neurones after an ~2 hour pre-incubation of the brain slice 
with provera (1 M), DHP (3 M), or both. To facilitate comparison of their kinetics, the amplitude 
of the mIPSCs are normalised to that of the control averaged mIPSC (B) Histogram illustrating that 
provera prevents the effect of DHP pre-incubation to prolong GABAAR-mediated mIPSCs (τw in ms; 
one-way ANOVA P <0.05. Post hoc Newman Keul’s test revealed differences for DHP (3 μM) with or 
without provera (1 μM), *P <0.05, n = 7-9). (C) Superimposed exemplar averaged GABAAR-
mediated mIPSCs from a representative control cortical neurone and from equivalent neurones 
after an ~2 hour pre-incubation of the brain slice with provera (1 M), ganaxolone (300 nM), or 
both. (D) Histogram illustrating that provera did not prevent the effect of ganaxolone on the 
duration of GABAAR-mediated mIPSCs (τw in ms; one-way ANOVA P <0.05. Post hoc Newman Keul’s 
test revealed no difference for the effects of ganaxolone (300 nM) with, or without provera (1 μM), 
P >0.05, n = 7-10). (E) Histogram illustrating the selective effect of the 3 -HSD enzyme inhibitor 
provera to suppress the effect of DHP on the mIPSC τw (expressed as a percentage of control), but 
not that of ganaxolone. Ctrl = control; DHP = dihydroxyprogesterone 
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Table 22 The 3 -HSD inhibitor indometacin (indo) reduces the effect of DHP incubation treatment on GABAAR mIPSCs of layer 2/3 cortical neurones 
(P60-75) of WT mice 
 
 
 
 
 
 
 
 
**P < 0.05; One-way ANOVA (with Post hoc Newman Keul’s test) in comparison to 3 M DHP 
 
 WT  
Control 
 
 (n=35) 
WT 
30μM Indo 
 
(n=6) 
WT 
3μM DHP 
 
(n=9) 
WT 
3μM DHP & 
30μM Indo 
 (n=6) 
Peak amplitude 
(pA) 
-59 ± 2 -53 ± 2 -69 ± 5 **-56 ± 4 
Rise Time (ms) 0.4  ± 0.1 0.4 ± 0.1 0.5 ±0.1 0.4 ± 0.1 
Charge transfer 
(fC) 
-242 ± 9 -222 ± 6 -646 ± 33 **-263 ± 23 
T70 (ms) 5.2  ± 0.2 5.1 ± 0.2 13.9 ± 1 **5.8 ± 0.3 
Tau w (ms) 4.0  ± 0.1 4.6 ± 0.2 10.2 ± 1 ** 5.0 ± 0.3 
Frequency (Hz) 17 ± 2 14 ± 2 19 ± 6 14 ± 2 
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Indometacin alone had no effect on the properties of GABAAR mIPSCs, including 
decay time, but it prevented the effect of DHP (τW: control = 4.0  0.1 ms, n = 35; 
indometacin 30 μM = 4.6  0.2 ms, n = 6; DHP 3 μM = 10.2  1 ms, n = 9; 
indometacin 30 μM & DHP 3 μM = 5  0.3 ms, n = 6; One-way ANOVA, P <0.05; post 
hoc Newman Keul’s test revealed differences for DHP 3 μM with or without 
indometacin 100 μM, P <0.05; Table 22; Figure 34). The same effect on the mIPSC 
T70 was observed (Table 22).  
By contrast, indometacin had no effect on the prolongation of mIPSCs by pre-
incubated allopregnanolone (τW: control = 4.0  0.1 ms, n = 35; indometacin 100 
μM = 4.2  0.1 ms, n = 7; allopregnanolone 100 nM = 12.5  1 ms, n = 9; 
indometacin 100 μM & allopregnanolone 100 nM = 13.5  0.8ms, n = 7; One-way 
ANOVA, P <0.05; post hoc Newman Keul’s test revealed no differences for 
allopregnanolone 100 nM with or without indometacin 100 μM, P >0.05; Table 23; 
Figure 34).  The same effect on the mIPSC T70 was observed (Table 23). These 
results confirm that allopregnanolone does not require 3 -HSD in order to 
modulate GABAAR mIPSCs in mature L2/3 cortical neurones. It is interesting that 
indometacin did not increase the effect of allopregnanolone by potentially 
inhibiting its metabolism to an inactive form.  These experiments with another 3 -
HSD enzyme inhibitor confirm that DHP requires conversion to a more active form 
by 3 -HSD in order for it to induce prolongation of GABAAR mIPSC decay time. 
In contrast to the findings with allopregnanolone, indometacin exhibited 
concentration-dependent inhibition of ganaxolone incubation treatment (τW: 
control = 4.0  0.1 ms, n = 35; indometacin 30 μM = 4.6  0.2 ms, n = 6; 
indometacin 100 μM = 4.6  0.1 ms, n = 7; ganaxolone 300 nM = 10.9  1 ms, n = 
10; indometacin 30 μM & ganaxolone 300 nM =6.2  0.5 ms, n = 10; indometacin 
100 μM & ganaxolone 300 nM = 5.4  0.3 ms, n = 8; One-way ANOVA, P <0.05; post 
hoc Newman Keul’s test revealed significant differences between three of the 
treatment groups: ganaxolone 300nM alone, ganaxolone 300nM with indometacin 
30 μM and ganaxolone 300nM with indometacin 100 μM, P <0.05; Table 23; Figure 
34).  The same effect on the mIPSC T70 was observed (Table 23).   
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Figure 34 The 3 -HSD enzyme inhibitor indometacin suppresses the effects of DHP and 
ganaxolone, but not those of allopregnanolone on GABAAR-mediated mIPSCs of mature 
cortical neurones. 
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 (A) Superimposed exemplar averaged GABAAR-mediated mIPSCs acquired from a representative 
control cortical neurone and from equivalent neurones after ~2 hours pre-incubation of the brain 
slice with indometacin (30 M), DHP (3 M), or both. (B) Histogram illustrating that indometacin 
prevents the effect of DHP on the duration of the GABAAR-mediated mIPSCs (τw in ms, one-way 
ANOVA P <0.05. Post hoc Newman Keul’s test revealed differences for DHP 3 μM with or without 
indometacin 100 μM, *P <0.05, n = 6-9). (C) Superimposed exemplar averaged GABAAR-mediated 
mIPSCs acquired from a representative control neurone and from equivalent neurones after an ~2 
hour pre-incubation of the brain slice with indometacin (100 M), allopregnanolone (100 nM), or 
both. (D) Histogram illustrating that indometacin does not prevent the effect of allopregnanolone to 
prolong the duration of the GABAAR-mediated mIPSC (τw in ms, one-way ANOVA P >0.05. Post hoc 
Newman Keul’s test revealed no differences for allopregnanolone with or without indometacin, P 
>0.05, n =7-9). (E) Superimposed exemplar averaged GABAAR-mediated mIPSCs acquired from a 
representative control neurone and from equivalent neurones after an ~2 hour incubation of the 
brain slice with indometacin (100 µM), ganaxolone (300 nM), or both. Note for panels A, C and D the 
mIPSC amplitude is normalised to that of the control averaged mIPSC to facilitate comparison of 
their kinetics. (F) Histogram illustrating that indometacin in a concentration-dependant manner (30 
– 100 µM) prevents the effect of ganaxolone to prolong the GABAAR-mediated mIPSC (τw in ms; one-
way ANOVA P < 0.05. Post hoc Newman Keul’s test revealed differences for ganaxolone 300 nM with 
or without indometacin 30 -100 μM, **P < 0.05, n = 8-10.   Ctrl = control; Allo = allopregnanolone; 
Ganax = ganaxolone; DHP = dihydroxyprogesterone; Indo = indometacin 
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Table 23 The 3 -HSD inhibitor indometacin (indo) reduces the effect of ganaxolone (Ganax) but not allopregnanolone (Allo) incubation treatment on 
GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT mice. 
 
 
 
**P < 0.05; One-way ANOVA (with Post hoc Newman Keul’s test) in comparison to 300nM ganaxolone 
 
 WT 
Control 
 
 
(n=35) 
WT 
30μM Indo 
 
 
(n=6) 
WT 
100μM Indo 
 
 
(n=7) 
WT 
100nM Allo 
 
 
(n=9) 
WT 
100nM Allo 
& 100μM 
Indo 
(n=7) 
WT 
300nM Ganax 
 
 
(n=10) 
WT 
300nM Ganax 
& 30μM Indo 
 
(n=10) 
WT 
300nM Ganax  
&  100μM 
Indo 
(n=8) 
Peak amp (pA) -59 ± 2 -53 ± 2 -53 ± 2 -78 ± 2 -77 ± 4 -82 ± 6 **-63 ± 3 **-54 ± 4 
Rise Time 
(ms) 
0.4  ± 0.1 0.4 ± 0.1 0.4 ±0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 
Charge 
transfer (fC) 
-242 ± 9 -222 ± 6 -235 ± 13.5 -932 ± 84 -915 ± 10 -749 ± 88 **-374 ± 39 **-289 ± 30 
T70 (ms) 5.2  ± 0.2 5.1 ± 0.2 5.8 ± 0.2 18.6 ± 1.4 17.0 ± 0.5 13.4 ± 1 **8.7 ± 0.7 **6.3 ± 0.3 
Tau w (ms) 4.0  ± 0.1 4.6 ± 0.2 4.2 ± 0.1 12.5 ± 1 13.5 ± 0.8 10.9 ± 1 **6.2 ± 0.5 **5.4 ± 0.3 
Frequency 
(Hz) 
17  ± 2 14 ± 2 14 ± 2 15 ± 3 10 ± 2 20 ± 3 23 ± 2 #9.3 ± 1 
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These results with ganaxolone were unexpected given the lack of impact that 
indometacin had on the effectiveness of allopregnanolone. Indeed, inhibiting 3 -
HSD with provera had no impact on ganaxolone, but prevented the effect of DHP 
on GABAAR mIPSCs in layer 2/3 cortical neurones.  This raises the question as to 
whether ganaxolone is an allosteric modulator of the GABAAR and a precursor to a 
more active neurosteroid such as allopregnanolone.  Alternatively, could 
indometacin be a silent competitive steroid antagonist at the GABAAR and prevent 
the action of ganaxolone by that mechanism? (These questions are explored in the 
Discussion). 
 
4.14 The effect of pipette-applied ganaxolone and indometacin on layer 2/3 
cortical GABAA mIPSCs in mature WT mice (P60-75). 
 
In order to explore whether indometacin could be a silent competitive antagonist 
at the GABAAR (and therefore prevent modulation by ganaxolone), recordings 
were made with indometacin in the pipette. Whole-cell voltage-clamp recordings 
were made in L2/3 cortical neurones with indometacin  ganaxolone presented in 
the recording pipette. These recordings were compared against separate control 
recordings (i.e. they were not paired).  Analysis of GABAAR-mediated phasic 
inhibition included the mIPSC amplitude, decay kinetics, charge transfer and 
frequency (Table 24).   
 
The mIPSC decay (τW) of L2/3 cortical neurones of WT mice was unchanged by the 
presence of indometacin in the recording pipette and indometacin had no effect on 
the modulatory action of ganaxolone (τW: control = 4.0  0.1 ms, n = 35, 
indometacin 100 M = 3.9  0.4 ms, n = 5; ganaxolone 10 M = 6.1  0.3 ms, n = 6; 
ganaxolone 10 M & indometacin 100 M = 7.3  0.6 ms, n = 4; One-way ANOVA 
with Post hoc Newman Keul’s test revealed that indometacin did not affect the 
baseline decay time of mIPSCs (P >0.05) and there was no difference between 
ganaxolone 10 M vs. ganaxolone 10 M with indometacin 100 M, P >0.05; Table 
24; Figure 35).  The T70 was similarly unaffected by the presence of indometacin 
(Table 24). The inability of indometacin to prevent the modulation of the GABAAR 
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mIPSCs by ganaxolone is inconsistent with the concept that indometacin could be a 
silent antagonist of the GABAAR.  Consequently, it seems more likely that 
indometacin may inhibit the action of ganaxolone by preventing its conversion to a 
more active compound (such as allopregnanlone). 
 
 
 
Table 24 The effect of pipette-applied ganaxolone and indometacin on layer 2/3 cortical 
GABAAR mIPSCs in mature WT mice (P60-75). 
 
 
 WT  
Control 
 
(n=35) 
WT 
100μM Indo 
 
(n=5) 
WT 
10μM Ganax 
 
(n=6) 
WT 
10μM Ganax & 
100μM Indo 
(n=4) 
Peak 
amplitude (pA) 
-59 ± 2 -75 ± 2 -69 ± 6 -72 ± 7 
Rise Time (ms) 0.4  ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 
Charge transfer 
(fC) 
-242 ± 9 -306 ± 28 -420 ± 55 -494 ± 68 
T70 (ms) 5.2  ± 0.2 4.8 ± 0.2 8.1 ± 0.6 9.4 ± 0.5 
Tau w (ms) 4.0  ± 0.1 3.9 ± 0.4 6.1 ± 0.3 7.3 ± 0.6 
Frequency (Hz) 17  ± 2 16 ± 4 16 ± 2 14 ± 2 
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Figure 35 The 3 -HSD enzyme inhibitor indometacin does not suppress the acute effects of 
intracellularly applied ganaxolone on GABAAR mIPSCs of mature cortical neurones (in 
contrast to its inhibitory effect on ganaxolone incubation treatment). 
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(A) Superimposed exemplar averaged GABAAR-mediated mIPSCs acquired from a representative 
control mature L2/3 cortical neurone and from equivalent neurones after the intracellular 
application of ganaxolone (10 M), indometacin (100 M) or both. (B) Histogram illustrating that 
intracellular indometacin made no impact on the effectiveness of intracellular ganaxolone 
(Student’s unpaired t tests P > 0.05 for ganaxolone 10 M vs. ganaxolone 10 M with indometacin 
100 M, n = 4-6). (C) Histogram illustrating that intracellular indometacin made no impact on the 
effectiveness of intracellular ganaxolone expressed as a percentage of control (Student’s unpaired t 
tests P > 0.05 for ganaxolone 10 M vs. ganaxolone 10 M with indometacin 100 M, n = 4-6). Ctrl = 
control; Ganax = ganaxolone; Indo = indometacin 
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Chapter 5: The role of neurosteroids on mature layer 2/3 
neurones from the cerebral cortex of ob/ob and db/db 
mice. 
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The previous Chapter characterised the neurosteroid modulation of the L2/3 
cortical GABAARs in mature WT mice. This late stage of development was chosen 
because it facilitated a comparison with the ob/ob mouse model of type-2 diabetes 
mellitus (T2DM). The ob/ob mouse develops super-morbid obesity and exhibits a 
neuropathic phenotype and consequently develops hypersensitivity to pain by the 
age of P60-75 (Drel et al., 2006; Latham et al., 2009). To date, there are no 
published reports of the electrophysiological characterisation of GABAAR function 
for the ob/ob mouse. Whole-cell voltage-clamp recordings of synaptic GABAAR 
mIPSCs from cortical L2/3 neurones were made from mature C57/BL6 wild type 
mice, ob/ob mice and also from wild type mice from the same genetic background 
strain as the ob/ob mouse B6.V-Lep+/OlaHsd (aged P60-75).  
 
The ob/ob mice are deficient in the hormone leptin and it was considered that 
leptin itself might modulate GABAAR function (Solovyova et al., 2009). In order to 
exclude such a direct effect of leptin as a cause of any changes observed, recordings 
were additionally made in a second mouse model of T2DM, the db/db mouse. As 
described in the Introduction section, the db/db mouse is able to synthesise leptin 
but lacks the leptin receptor, consequently developing super-morbid obesity and a 
more severe diabetic phenotype than the ob/ob mouse (Bates et al., 2005; Cefalu, 
2006; Neubauer & Kulkarni, 2006). The db/db mouse also exhibits a neuropathic 
phenotype at P60-75, which includes significant impairments of thermal 
nociception and nerve conduction velocity, consistent with sensory loss (Sullivan 
et al., 2006).   
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Mice that were used for electrophysiological (or behavioural experiments) were 
weighed in order to confirm the presence of obesity.  The ob/ob and db/db mice 
(P60-75) both had significantly greater body weights than the respective WT 
animals of the same age (C57/BL6 = 26.8  0.3g, n = 32; B6.V-Lep+ = 24.7  0.3g, n = 
49; BKS.Cg-Dock7m+ = 22.8  1g, n = 5; ob/ob = 35.6  0.4g, n = 50; db/db = 42.2  
0.8g, n = 9; One-way ANOVA, P < 0.05; post hoc Newman Keul’s test revealed 
significant differences between both diabetic mice and all three strains of WT mice, 
P < 0.05; Figure 36).  These data are consistent with reports of ob/ob and db/db 
body mass in the literature (Latham et al., 2009; Bates et al., 2005). 
 
5.1 A comparison of synaptic GABAAR mIPSCs of cortical layer 2/3 neurones 
in adult WT, ob/ob and db/db mice. 
 
Whole-cell voltage-clamp recordings were made from L2/3 pyramidal neurones of 
the cerebral cortex of C57/BL6 (WT) mice, ob/ob mice and db/db mice in addition 
to the lean WT littermates for both models of T2DM (B6.V-Lep+/OlaHsd and 
BKS.Cg-Dock7m+/Dock7m+/OlaHsd respectively). Analysis of GABAAR-mediated 
phasic inhibition included the mIPSC amplitude, decay kinetics, charge transfer 
and frequency (Table 25). 
There was a modest but significant reduction in the mIPSC decay (τW) of cortical 
L2/3 pyramidal neurones between the diabetic mice and the corresponding WT 
littermates (Lep+/OlaHsd = 3.9  0.2 ms, n = 18; ob/ob = 3.5  0.1 ms, n = 25; 
Student’s unpaired t test, P <0.05; BKS.Cg-Dock7m+ = 4.3  0.3 ms, n = 8; db/db = 
3.5  0.1 ms, n = 18; Student’s unpaired t test, P <0.05; Table 25; Figure 37). The 
mIPSC T70 was also significantly different between the diabetic mice and the WT 
littermates (Table 25). However, there was no significant difference in the τW, or 
the T70, between the three WT strains, suggesting that the observed reduction of 
mIPSC decay time in the ob/ob and db/db mouse models was not related to inter-
strain variability (see Table 25; Figure 37). These findings suggest that either the 
GABAARs of the T2DM mice may be less sensitive to endogenous neurosteroids, or 
the levels of endogenous neurosteroid is reduced in T2DM, or both. 
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Figure 36 Ob/ob & db/db mice exhibit a morbid obesity phenotype on a normal diet, 
consistent with reports in the literature. 
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Histogram illustrating that the mature ob/ob and db/db mice used experimentally had significantly 
greater body weights than the respective WT animals of the same age. (C57/BL6 = 26.8  0.3g, n = 
32, B6.V-Lep+ = 24.7  0.3g, n = 49; BKS.Cg-Dock7m+ = 22.8  1g, n = 5; ob/ob = 35.6  0.4g, n = 50; 
db/db = 42.2  0.8g, n = 9; One-way ANOVA P < 0.05.  Post hoc Newman Keuls test revealed 
significant differences between both diabetic mice and all three strains of WT mice *P < 0.05).   
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Table 25 A comparison of synaptic GABAAR mIPSCs of cortical layer 2/3 neurones in adult 
WT, ob/ob and db/db mice. 
 
 WT 
C57 BL6 
Control 
 
(n=35) 
WT 
B6.V-Lep+/ 
OlaHsd 
 
(n=18) 
WT 
BKS.Cg- 
Dock7m+ 
 
(n=8) 
Ob/ob 
 
 
 
(n=25) 
Db/db 
 
 
 
(n=18) 
Peak amp 
(pA) 
-59 ± 2 -64  ± 2 -74 ± 5 -66 ± 2 -60 ± 2 
Rise Time 
(ms) 
0.4  ± 0.1 0.5 ±0.1 0.4  ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
Charge 
transfer (fC)  
-242 ± 9 -265 ±11 -333 ± 26 -255 ± 12 
 
-223 ± 8 
 
T70 (ms) 
 
5.2  ± 0.2 5.3  ± 0.2 5.6  ± 0.4 *4.7 ± 0.1 *4.6 ± 0.1 
Tau w (ms) 
 
4.0  ± 0.1 3.9  ± 0.2 4.3  ± 0.3 *3.5 ± 0.1 *3.5 ± 0.1 
Frequency 
(Hz) 
17 ± 2 24 ± 2 14.8  ± 2 21 ± 3 19 ± 3 
 
*P < 0.05; unpaired Student’s t test, in comparison to appropriate strain-matched control (P60-75) 
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Figure 37 Mature cortical neurones of ob/ob & db/db mice exhibit shorter GABAAR mIPSCs 
compared to those from three different WT strains. 
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(A)  Superimposed exemplar GABAARs mIPSCs from a representative control mature L2/3 cortical 
neurone of three WT strains (black) and two diabetic phenotypes (grey). (B) Histogram illustrating 
the shorter cortical GABAAR mIPSC τw of the diabetic mice and their corresponding WT strains 
(Lep+/OlaHsd = 3.9  0.2 ms, n = 18; ob/ob = 3.5  0.1 ms, n = 25; Student’s unpaired t test *P <0.05; 
BKS.Cg-Dock7m+ = 4.3  0.3 ms, n = 8; db/db = 3.5  0.1 ms, n = 18; Student’s unpaired t test *P 
<0.05). 
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5.2 The effect of cyclodextrin on layer 2/3 cortical GABAA mIPSCs in mature 
ob/ob mice (P60-75). 
 
As described in the Introduction section, the cyclodextrins (CDs) are relatively 
large barrel-shaped molecules that may be classified according to the number of 
glucose residues (Brown, 2012; Shu et al., 2004, 2007). The three principle types of 
CD are the -CD hexamer, the -CD heptamer and the -CD octomer (Cooper et al., 
2005; Davis & Brewster, 2004). The largest of these cyclodextrins, -CD appears to 
be the most effective for the sequestration of neurosteroids (Brown, 2012; Shu et 
al., 2004, 2007).  Whole-cell voltage-clamp recordings were made in layer 2/3 
cortical pyramidal neurones with cyclodextrin present in the recording pipette (i.e. 
the optimal method of administration as described in the previous chapter). These 
recordings were compared to separate control recordings (i.e. they were not 
paired), where the recording pipette contained only the intracellular solution. 
Analysis of GABAAR-mediated phasic inhibition included the mIPSC amplitude, 
decay kinetics, charge transfer and frequency (Table 26). 
The mIPSC decay (τW) of L2/3 cortical pyramidal neurones of the ob/ob mouse 
was significantly decreased in the presence of -CD, but not by -CD, or by -CD 
(ob/ob control = 3.5  0.1 ms, n = 25; ob/ob γ-CD = 3.0  0.2 ms, n = 6; ob/ob -CD 
= 3.7  0.2 ms, n = 5; ob/ob -CD = 3.6  0.2 ms, n = 6; One-way ANOVA, P < 0.05; 
post hoc Newman Keul’s test revealed that the γ-CD group were significantly 
different from all of the other groups, P < 0.05; Table 26; Figure 38). The T70 was 
similarly decreased in the presence of γ-CD, but not by -CD, or by -CD; Table 26). 
These data are consistent with those described for the WT mouse in the previous 
chapter.  These results suggest that there is a still a neurosteroid tone in the ob/ob 
mouse, but that either it is reduced in comparison to the WT, or the GABAARs of the 
ob/ob mouse are less sensitive to neurosteroids. 
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Table 26 The effect of intracellular /β/γ – cyclodextrin (CD) 0.5mM on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT and ob/ob  mice. 
 
 WT 
Control 
 
( n=35) 
WT 
-CD 
 
( n=7) 
WT 
β-CD 
 
( n=6) 
WT 
γ-CD 
 
( n=15) 
Ob/ob 
 
 
(n=25) 
Ob/ob 
-CD 
 
( n=5) 
Ob/ob 
β-CD 
 
( n=6) 
Ob/ob 
γ-CD 
 
( n=6) 
Peak amp (pA) -59 ± 2 -55  ± 3 -56 ± 3 -58 ± 2 -66 ± 2 -65 ± 3 -57  ± 3 -71  ± 5 
Rise Time 
(ms) 
0.4  ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
Charge 
transfer (fC)  
-242 ± 9 -243 ± 15 -261 ± 16 **-185 ± 8 -255 ± 12 
 
-260 ± 16 -222 ± 14 -225 ± 18 
T70 (ms) 
 
5.2  ± 0.2 5.7 ± 0.6 5.9 ± 0.5 **3.7 ± 0.2 4.7 ± 0.1 4.8 ± 0.2 4.6 ± 0.2 **3.8 ± 0.2 
Tau w (ms) 
 
4.0  ± 0.1 4.1 ± 0.5 4.5 ± 0.4 **2.9 ±0.1 3.5 ± 0.1 3.7 ± 0.2 3.6 ± 0.2 **3.0 ± 0.2 
Frequency 
(Hz) 
17  ± 2 18 ± 4 18 ± 5 18 ± 2 21 ± 3 17 ± 3 20 ± 4 19 ± 3 
 
**P < 0.05; one-way ANOVA (with Post hoc Newman Keul’s test), in comparison to strain-matched control (P60-75) 
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Figure 38 Intracellular -CD (but not -CD or β-CD) reduces the duration of GABAAR mIPSCs 
of mature cortical neurones from WT and ob/ob mice. 
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(A-C) Superimposed exemplar GABAAR-mediated mIPSCs from representative mature L2/3 
cortical neurones of ob/ob mice and from equivalent neurones with 0.5 M -CD, β-CD or -CD 
administered intracellularly via the recording pipette. Note recordings of mIPSCs for both control 
and cyclodextrin-treated neurones did not commence for ~6 mins after establishing the whole-cell 
voltage-clamp to allow the compound to equilibrate (Evans & Marty, 1986).  (D-F) Superimposed 
exemplar GABAARs mIPSCs from representative mature L2/3 cortical neurones of WT mice and 
from equivalent neurones with 0.5 M -CD, β-CD or -CD administered intracellularly.  (G) 
Histogram illustrating that intracellular -CD (but not -CD or β-CD) decreases the GABAAR mIPSC 
τw of mature L2/3 cortical neurones of ob/ob mice (ob/ob Ctrl = 3.5  0.1 ms, n = 25, ob/ob γ-CD = 
3.0  0.2 ms, n = 6; ob/ob -CD = 3.7  0.2 ms, n = 5; ob/ob -CD = 3.6  0.2 ms, n = 6; One-way 
ANOVA P < 0.05. Post hoc Newman Keul’s test revealed that the γ-CD group were significantly 
different from all of the other groups, *P < 0.05).  The values for WT mice (black bars) are 
incorporated for comparison and to highlight that the τw value is the same for WT and ob/ob mice 
in the presence of -CD. (H)  Histogram illustrating that intracellular -CD (but not -CD or β-CD) 
decreases the GABAAR mIPSC τw of mature L2/3 cortical neurones of ob/ob mice (grey bars; 
expressed as a percentage of control) 85  4%, 105  5%, 101  5% respectively vs. unpaired 
representative ob/ob Ctrl (One-way RM ANOVA **P < 0.05).  Ctrl = control. CD = cyclodextrin. 
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5.3 A comparison of the effects of γ-cyclodextrin on cortical mIPSCs of adult 
WT, ob/ob and db/db mice.  
 
As described above, γ-CD reduced the decay time of GABAAR mIPSCs in ob/ob and 
WT mice. In order to determine that neither the strain, nor the lack of leptin 
(directly) was an important factor in the shortening of GABAAR mIPSC decay time, 
it was decided to make recordings from a second mouse model of T2DM and the 
appropriate strain-matched WT. Whole-cell voltage-clamp recordings were made 
from L2/3 neurones of the cerebral cortex of C57/BL6 (WT) mice, ob/ob mice and 
db/db mice, in addition to the lean WT littermates for both models of T2DM (B6.V-
Lep+/OlaHsd and BKS.Cg-Dock7m+/Dock7m+/OlaHsd respectively), with γ-CD 
present in the pipette. Analysis of GABAAR-mediated phasic inhibition included the 
mIPSC amplitude, decay kinetics, charge transfer and frequency (Table 27). 
 
 
Table 27 A comparison of the effects of 0.5mM γ-cyclodextrin (γ-CD) on cortical GABAAR 
mIPSCs of adult WT, ob/ob and db/db mice (P60-75). 
 
 WT 
C57 BL6 
Control  
γ-CD 
 
( n=15) 
WT 
B6.V-Lep+/ 
OlaHsd 
γ-CD  
 
( n=11) 
WT 
BKS.Cg- 
Dock7m+ 
γ-CD 
 
(n=5) 
Ob/ob 
γ-CD 
 
 
 
( n=6) 
Db/db 
γ-CD 
 
 
 
(n=9) 
Peak amp (pA) -58 ± 2 -55 ± 1 -58 ± 3 -71  ± 5 -54 ± 2 
Rise Time (ms) 0.4 ± 0.1 0.4 ± 0.1 0.4  ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
Charge transfer 
(fC)  
-185 ± 8 -175 ± 7 -214 ± 19 -225 ± 18 -170 ± 11 
 
T70 (ms) 
 
3.7 ± 0.2 3.8 ± 0.2 4.4 ± 0.2 3.8 ± 0.2 3.9 ± 0.1 
Tau w (ms) 
 
2.9 ± 0.1 3.0 ± 0.1 3.3 ± 0.2 3.0 ± 0.2 2.9 ± 0.1 
Frequency (Hz) 18 ± 2 *25 ± 3 12  ± 1 19 ± 3 13 ± 3 
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In the presence of intracellular γ-CD, there was no significant difference in the 
mIPSC decay (τW) of cortical layer 2/3 neurones between all five types of mice 
(C57/BL6 γ-CD = 2.9  0.1 ms, n = 15; Lep+/OlaHsd γ-CD = 3.0  0.1 ms, n = 11; 
BKS.Cg-Dock7m+ γ-CD = 3.3  0.2 ms, n = 5; ob/ob γ-CD = 3.0  0.2 ms, n = 6; db/db 
γ-CD = 2.9  0.2 ms, n = 9; One-way ANOVA, P > 0.05; Table 27; Figure 28).  When 
the data were normalised and expressed as a percentage of their respective 
controls, there were no significant differences in the effect of γ-CD between all five 
types of mice (C57/BL6 γ-CD = 73  3%, n = 15; Lep+/OlaHsd γ-CD = 76  3%, n = 
11; BKS.Cg-Dock7m+ γ-CD = 77  4%, n = 5; ob/ob γ-CD = 85  4%, n = 6; db/db γ-
CD = 82  5%, n = 9; One-way RM ANOVA, P > 0.05).   
Similarly, there was no significant difference in the T70 of GABAAR-mediated 
mIPSCs with pipette-applied γ-CD (Table 27). These findings suggest that synaptic 
GABAAR function is very similar across all the types of mice included in the study 
when the endogenous neurosteroid tone is removed by γ-CD. The results are also 
consistent with the hypothesis that there is a neurosteroid tone at P60-75, but that 
it is reduced in both mouse models of diabetic neuropathy. However, the data do 
not exclude the possibility that the sensitivity of L2/3 cortical GABAARs to 
neurosteroids may be reduced.  
5.4 The effect of the acute application of allopregnanolone, or ganaxolone, on 
GABAAR mIPSCs of mature ob/ob mice. 
In the previous chapter, the acute bath application of allopregnanolone and 
ganaxolone induced modest prolongations of the GABAAR mIPSC decay time in 
L2/3 cortical neurones of WT mice. In this section, the effect of the acute 
application of these neuroactive steroids is investigated in order to examine 
GABAAR sensitivity in the ob/ob mouse. Whole-cell voltage-clamp recordings were 
made in L2/3 cortical neurones from ob/ob mice before and ten minutes after the 
bath application of allopregnanolone, or ganaxolone. The neuroactive steroids 
were bath-applied after at least four minutes of stable recording enabling the 
comparison of paired recordings. Analysis of GABAAR-mediated phasic inhibition 
included the mIPSC amplitude, decay kinetics, charge transfer and frequency 
(Table 28). 
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Figure 39 Intracellular -CD reduces the duration of GABAAR mIPSCs of mature cortical 
neurones from five different types of mice to a similar baseline level. 
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(A) Superimposed exemplar GABAAR-mediated mIPSCs from a representative control mature L2/3 
cortical neurone of three WT strains (black) and two diabetic phenotypes (grey) with 0.5 M -CD 
administered intracellularly. (B) Histogram illustrating that there was no significant difference 
between all five strains of mice in the presence of intracellular -CD (C57/BL6 γ-CD = 2.9  0.1 ms, 
n = 15, Lep+/OlaHsd γ-CD = 3.0  0.1 ms, n = 11; BKS.Cg-Dock7m+ γ-CD = 3.3  0.2 ms, n = 5; ob/ob 
γ-CD = 3.0  0.2 ms, n = 6; db/db γ-CD = 2.9  0.2 ms, n = 9; One-way ANOVA P > 0.05). The relevant 
controls are presented in Figure 37. 
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Table 28 The acute application of allopregnanolone (Allo) or ganaxolone (Ganax) prolongs the decay time of GABAAR mIPSCs of L2/3 cortical neurones 
(P60-75) of WT and ob/ob mice. 
 
 WT 
Pre 1 M 
Allo 
  
( n=7) 
WT 
Post 1 M 
Allo 
  
( n=7) 
Ob/ob 
Pre 1 M 
Allo 
  
( n=7) 
Ob/ob 
Post 1 M 
Allo 
 
 ( n=7) 
WT 
Pre 1 M 
Ganax  
 
(n=6) 
WT 
Post 1 M 
Ganax  
 
(n=6) 
Ob/ob 
Pre 1 M 
Ganax 
 
(n=6) 
Ob/ob 
Post 1 M 
Ganax 
  
(n=6) 
Peak amp (pA) -68 ± 3 -67 ± 5 -64 ± 2 *-71  ± 3 -57 ± 4 *-66 ± 6 -75 ± 5 -80  ± 3 
Rise Time (ms) 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5  ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 
Charge 
transfer (fC)  
-284 ± 7 -305 ± 14 -253 ± 15 *-323 ± 18 -232 ± 15 *-309 ± 31 
 
-325 ± 27 -372 ± 35 
T70 (ms) 
 
5.2 ± 0.4 *5.8 ± 0.5 4.9 ± 0.2 *5.9 ± 0.3 5.2  ± 0.2 *6.1 ± 0.4 5.1 ± 0.2 *5.6 ± 0.3 
Tau w (ms) 
 
4.0 ± 0.3 *4.5 ± 0.4 3.7 ± 0.1 *4.4 ± 0.2 4.0  ± 0.2 *4.7 ± 0.2 3.8 ± 0.2 *4.4 ± 0.2 
Frequency 
(Hz) 
26 ± 6 21 ± 4 11 ± 1 11 ± 1 22  ± 5 21 ± 5 16 ± 3 17 ± 1 
 
*P < 0.05; paired Student’s t test, in comparison to strain-matched control (P60-75) 
 
157 
 
In the ob/ob mouse, allopregnanolone produced a modest (18  4%) prolongation 
of exponential decay time in the GABAAR-mediated mIPSCs of layer 2/3 cortical 
neurones (τW: control = 3.7  0.1 ms, n = 7; allopregnanolone 1 μM = 4.4  0.2 ms, n 
= 7; Paired Student’s t test, P <0.05).  When the data for τW were normalised, there 
was no significant difference between allopregnanolone 1 μM in the WT (12 ± 3%) 
and the ob/ob mice (18 ± 4%) respectively (Two-way RM ANOVA, P >0.05; Figure 
40).    Similarly, allopregnanolone induced a modest prolongation of the mIPSC T70 
(Table 28). In the ob/ob mouse, ganaxolone (1μM) also induced only a modest (15 
 4%) prolongation of exponential decay time of the GABAAR-mediated mIPSCs 
(τW: control = 3.8  0.2 ms, n = 6; ganaxolone 1 μM = 4.4  0.2 ms, n = 6; Student’s 
paired t test, P <0.05). When the data for τW were normalised, there was no 
significant difference between ganaxolone 1 μM in the WT (19 ± 4%) and the ob/ob 
mice (15 ± 4%) respectively (Two-way RM ANOVA, P >0.05; Figure 40).  The 
mIPSC T70 was also modestly prolonged by ganaxolone (Table 28). These data 
indicate that the acute application of allopregnanolone, or ganaxolone, has a 
similarly modest effect on the GABAAR mIPSCs of ob/ob cortical neurones to that 
described for WT in the previous Chapter.  Furthermore, these results suggest that 
the GABAARs of cortical neurones from both types of mice may exhibit comparable 
sensitivity to neuroactive steroids (Figure 40).  
5.5 The effect of prolonged incubation of allopregnanolone, on GABAAR-
mediated mIPSCs of mature ob/ob and db/db mice. 
As described in the previous Chapter, the pre-incubation of the brain slice 
preparation with allopregnanolone, or ganaxolone, produced a concentration-
dependent prolongation of cortical GABAAR-mediated mIPSCs of adult WT mice. To 
explore the sensitivity of cortical synaptic GABAARs of ob/ob and db/db mice to 
allopregnanolone and ganaxolone, whole-cell voltage-clamp recordings were made 
in layer 2/3 cortical neurones after approximately two hours incubation with these 
neuroactive steroids. Such recordings were compared to those of separate control 
recordings (i.e. they were not paired). Analysis of GABAAR-mediated phasic 
inhibition included the mIPSC amplitude, rise time, charge transfer, decay kinetics 
and frequency (Table 29). 
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Figure 40 Acute exposure (10-20mins) of WT & ob/ob mature cortical neurones to 
allopregnanolone (1 M) or ganaxolone (1 M) modestly enhances the function of synaptic 
GABAARs by a similar margin. 
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(A & B) Superimposed exemplar GABAAR-mediated mIPSCs from cortical neurones of ob/ob mice 
before and after acute exposure to 1 M allopregnanolone, or ganaxolone.  (C & D) Superimposed 
exemplar GABAARs mIPSCs from cortical neurones of WT mice before and after acute exposure to 
1 M allopregnanolone, or ganaxolone. (E & F) Histograms illustrating the significant effect of 1 M 
allopregnanolone, or ganaxolone on GABAAR mIPSCs of ob/ob cortical neurones (grey bars; 
Student’s paired t test *P <0.05 for each drug treatment vs. its paired control recording).  The 
values for WT cortical neurones (black bars) are included for comparison. (G) Histogram 
illustrating the effect of the neurosteroids with the data normalised relative to control recordings 
(i.e. expressed as a percentage of the control recording). When the data for τw was normalised, 
there was no significant difference between the WT and ob/ob mice for allopregnanolone 
treatment (WT = 12 ± 3%; ob/ob = 18 ± 4%; Two-way RM ANOVA P >0.05), or ganaxolone 
treatment (WT = 19 ± 4%; ob/ob = 15 ± 4%; Two-way RM ANOVA P >0.05). Ctrl = control; Allo = 
allopregnanolone; Ganax = ganaxolone. 
 
 
159 
 
Table 29 The effect of allopregnanolone (Allo) incubation treatment on GABAAR mIPSCs of L2/3 cortical neurones (P60-75) of WT, ob/ob and db/db 
mice. 
 
 
 
WT 
Control 
 
( n=35) 
Ob/ob 
 
 
(n=25) 
Db/db 
 
 
(n=18) 
WT 
100nM Allo 
 
( n=9) 
Ob/ob 
100nM Allo 
 
( n=6) 
WT 
300nM Allo 
 
( n=9) 
Ob/ob 
300nM Allo 
 
( n=8) 
Db/db 
300nM Allo 
 
( n=6) 
Peak amp (pA) -59 ± 2 -66 ± 2 -60 ± 2 **-78  ± 2 **-81 ± 2 **-87 ± 5 **-94 ± 4 *-99  ± 3 
Rise Time (ms) 0.4  ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 
Charge transfer 
(fC)  
-242 ± 9 -255 ± 12 
 
-223 ± 8 
 
**-932 ± 84 **-987 ± 82 **-1489 ± 136 **-1540 ± 100 *-1604 ± 81 
T70 (ms) 
 
5.2  ± 0.2 4.7 ± 0.1 4.6 ± 0.1 **18.6 ± 1 **18.7 ± 1 **27 ± 1 **25.8 ± 0.9 *25.4 ± 0.6 
Tau w (ms) 
 
4.0  ± 0.1 3.5 ± 0.1 3.5 ± 0.1 **12.5 ± 1 **12.8 ± 1 **19 ± 1 **18.8 ± 1 *18.6 ± 0.6 
Frequency (Hz) 17  ± 2 21 ± 3 19 ± 3 15 ± 3 **10 ± 1 **11 ± 1 **11 ± 2 13 ± 2 
 
**P < 0.05; One-way ANOVA (with Post hoc Newman Keul’s test) in comparison to strain-matched control (P60-75) 
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A two-hour incubation of the ob/ob brain slice preparation with allopregnanolone 
produced a clear concentration-dependent prolongation of the duration of cortical 
GABAAR-mediated mIPSCs (τW: control = 3.5  0.1 ms, n = 25; allopregnanolone 
100 nM = 12.8  1 ms, n = 6; allopregnanolone 300 nM = 18.8  1 ms, n = 8; One-
way ANOVA, P <0.05; post hoc Newman Keul’s test revealed significant differences 
between control and both concentrations of allopregnanolone, which increased τW 
to 362  27% and 534  28% of control respectively (P <0.05; Figure 41). Similarly, 
the mIPSC T70 was significantly prolonged by allopregnanolone (Table 29).  
A two-hour incubation of the db/db brain slice with allopregnanolone (300nM) had 
a similar effect to that of the ob/ob neurones on the duration of the cortical 
GABAAR-mediated mIPSCs (τW: control = 3.5  0.1 ms, n = 18; allopregnanolone 
300 nM = 18.6  0.6 ms, n = 6; Student’s t test, P >0.05; Table 29; Figure 41). 
Similarly, the mIPSC T70 was significantly prolonged by allopregnanolone (Table 
29). These results reveal that allopregnanolone has a similar effect on L2/3 cortical 
GABAAR mIPSC decay time of WT, ob/ob and db/db mice (τW: C57/BL6 WT 
allopregnanolone 300 nM = 19.0  1ms, n = 9; ob/ob allopregnanolone 300 nM = 
18.8  1 ms, n = 8; db/db allopregnanolone 300 nM = 18.6  0.6 ms, n = 6; One-way 
ANOVA, P > 0.05; Table 29; Figure 41).  In view of the fact that the control mIPSC 
decay times for the WT and diabetic mice (Table 29) are distinctly shorter, the data 
for τW were normalised, but there was no significant difference in the effect of 
between the three types of mice.  Allopregnanolone 300 nM increased τW to similar 
percentages of the strain representative controls (C57/BL6 WT = 480 ± 22%, n = 9; 
ob/ob = 534 ± 28%, n = 8; db/db = 534 ± 18%, n = 6; One-way RM ANOVA, P > 0.05; 
Figure 41; Figure 50).  These results suggest that the sensitivity of cortical 
GABAARs in diabetic mice is similar to aged-matched WT mice. 
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Figure 41 Prolonged exposure (~2 hrs) of WT & ob/ob mature cortical neurones to 
allopregnanolone (100-300 nM) greatly enhances the function of synaptic GABAARs by a 
similar margin. 
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(A) Superimposed exemplar GABAAR-mediated mIPSCs from representative control cortical 
neurones from mature WT mice and from equivalent neurones after ~2 hour brain slice incubation 
with 100 nM and 300 nM allopregnanolone. (B) Superimposed exemplar GABAARs mIPSCs from 
representative control cortical neurones from mature ob/ob mice and from equivalent neurones 
after ~2 hour brain slice incubation with 100 nM and 300 nM allopregnanolone. (C) Histogram 
illustrating the concentration-dependent effect of allopregnanolone on the cortical GABAAR mIPSCs 
of ob/ob mice (grey; ob/ob control = 3.5  0.1 ms, n = 25; allopregnanolone 100 nM = 12.8  1 ms, n 
= 6; allopregnanolone 300 nM = 18.8  1 ms, n = 8; One-way ANOVA P <0.05.  Post hoc Newman 
Keuls test revealed significant differences between control and both concentrations of 
allopregnanolone, which increased τw to 362  27% and 534  28% of control respectively *P 
<0.05).  Note that there is no significant difference in response between the two types of mice (WT 
300 nM Allo = 19.0  1 ms, n = 9; ob/ob 300 nM Allo =18.8  1 ms, n = 8; One-way RM ANOVA P > 
0.05). (D) Histogram comparing the concentration-dependent effects of allopregnanolone on the 
duration of GABAARs mIPSC τw expressed as a percentage of control for WT (black) and ob/ob 
(grey) mice. The histogram illustrates that there is no significant difference in the effect of 300 nM 
allopregnanolone on the cortical GABAARs mIPSCs of WT and ob/ob neurones (C57/BL6 WT = 480 
± 22%, n = 9; ob/ob = 534 ± 28%, n = 8; One-way RM ANOVA P > 0.05). Ctrl = control; Allo = 
allopregnanolone. 
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5.6 The effect of ganaxolone incubation on GABAAR mIPSCs in mature ob/ob 
and db/db mice. 
 
A two-hour incubation of the ob/ob brain slice preparation with ganaxolone 
produced a clear concentration-dependent increase of the duration of cortical 
GABAAR mIPSCs. Interestingly, the prolongation was comparatively greater than 
for equivalent WT neurones (τW: control = 3.5  0.1 ms, n = 25; ganaxolone 30 nM 
= 7.2  0.5 ms, n = 11; ganaxolone 100 nM = 8.4  0.7 ms, n = 10; ganaxolone 300 
nM = 15.4  1 ms, n = 9; ganaxolone 1 μM = 20.6  1 ms, n = 10 One-way ANOVA, P 
<0.05; Table 30; Table 31; Figure 42).  When the values were expressed as a 
percentage of control, there were significant differences between all the 
concentrations of ganaxolone, τW was increased to 204  13%, 237  20%, 437  
42% and 584  29% of control respectively, One-way RM ANOVA, with post hoc 
Newman Keul’s test, P <0.05; Figure 42). Similarly, the mIPSC T70 was significantly 
prolonged by ganaxolone (Table 30; Table 31).   
In the db/db layer 2/3 cortical neurones, GABAAR mIPSCs were prolonged by a 
similar extent to that observed in the ob/ob mouse (τW: control = 3.5  0.1 ms, n = 
18; ganaxolone 300 nM = 14.8  0.4 ms, n = 4; ganaxolone 1 μM = 22.0  1.6 ms, n = 
8; One-way ANOVA, P < 0.05; post hoc Newman Keul’s test revealed significant 
differences between all three treatments, P <0.05; Table 30; Table 31). The mIPSC 
T70 was also significantly prolonged by ganaxolone (Table 30; Table 31). These 
results reveal that a two-hour pre-incubation with ganaxolone caused a more 
pronounced prolongation of cortical mIPSCs of ob/ob and db/db c.f. WT (τW: WT 
ganaxolone 300 nM = 10.9  1 ms, n = 10; ob/ob ganaxolone 300 nM = 15.4  1 ms, 
n = 9; db/db ganaxolone 300 nM = 14.8  0.4 ms, n = 4; One-way ANOVA, P < 0.05; 
post hoc Newman Keul’s test revealed significant differences between all three 
strains, P < 0.05; Table 31).  In view of the fact that the control mIPSC decay times 
for the WT and diabetic mice (Table 31) are distinct, the data for τW were 
normalised, and there were significant difference in the effect of between the three 
types of mice.   
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Table 30 The effect of ganaxolone (Ganax) incubation treatment (30-100nM) on GABAAR mIPSCs of L2/3 cortical neurones (P60-75) of WT, ob/ob and 
db/db mice 
 
 
 WT 
Control 
 
 
( n=35) 
Ob/ob 
 
 
 
(n=25) 
Db/db 
 
 
 
(n=18) 
WT 
30nM 
Ganax 
  
( n=10) 
Ob/ob 
30nM Ganax  
  
( n=11) 
WT 
100nM 
Ganax  
 
( n=10) 
Ob/ob 
100nM 
Ganax  
 
( n=10) 
Peak amp (pA) -59 ± 2 -66 ± 2 -60 ± 2 **-61  ± 3 -60  ± 4 **-66 ± 4 **-74 ± 4 
Rise Time 
(ms) 
0.4  ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 
Charge 
transfer (fC)  
-242 ± 9 -255 ± 12 
 
-223 ± 8 
 
**-300 ± 26 -399 ± 35 **-440 ± 39 **-573 ± 66 
T70 (ms) 
 
5.2  ± 0.2 4.7 ± 0.1 4.6 ± 0.1 **6.3 ± 0.4 **9.3 ± 0.5 **9.6 ± 0.6 **11.6 ± 0.9 
Tau w (ms) 
 
4.0  ± 0.1 3.5 ± 0.1 3.5 ± 0.1 **5.1 ± 0.3 **7.2 ± 0.5 **7.2 ± 0.5 **8.4 ± 0.7 
Frequency 
(Hz) 
17  ± 2 21 ± 3 19 ± 3 **11 ± 1 13 ± 2 15 ± 3 17 ± 4 
 
**P < 0.05; One-way ANOVA, (with Post hoc Newman Keul’s test), in comparison to strain-matched control (P60-75) 
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Table 31 The effect of ganaxolone (Ganax) incubation treatment (300nM, 1μM or 3μM) on GABAAR mIPSCs of L2/3 cortical neurones (P60-75) of WT, 
ob/ob and db/db mice 
 
 WT 
Control 
 
 
( n=35) 
Ob/ob 
 
 
 
(n=25) 
Db/db 
 
 
 
(n=18) 
WT 
300nM 
Ganax 
 
( n=10) 
Ob/ob 
300nM 
Ganax 
 
( n=9) 
Db/db 
300nM 
Ganax 
 
( n=4) 
WT 
1 M Ganax 
 
( n=10) 
Ob/ob 
1μM 
Ganax 
 
( n=10) 
Db/db 
1μM 
Ganax 
 
( n=8) 
WT 
3 M 
Ganax 
 
( n=8) 
Peak amp 
(pA) 
-59 ± 2 -66 ± 2 -60 ± 2 **-82  ± 6 **-80 ± 7 **-79 ± 8 **-97 ± 9 **-126 ± 5 **-117 ± 3 **-153 ± 6 
Rise Time 
(ms) 
0.4  ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 
Charge 
transfer (fC)  
-242 ± 9 -255 ± 12 
 
-223 ± 8 
 
**-749  
± 88 
**-1104  
 ± 178 
**-1004  
± 81 
**-1575  
± 195 
**-2267  
± 162 
**-2193  
± 83 
**-4396  
± 268 
T70 (ms) 
 
5.2  ± 0.2 4.7 ± 0.1 4.6 ± 0.1 **13.4 ± 1 **20.7 ± 2 **19.3  
± 0.7 
**24.2 ± 1 **27.5 ± 1 **28.5  
± 1.4 
**44.2 ± 2 
Tau w (ms) 
 
4.0  ± 0.1 3.5 ± 0.1 3.5 ± 0.1 **10.9 ± 1 **15.4 ± 1 **14.8  
± 0.4 
**18.8 ± 1 **20.6 ± 1 **22 ± 1.6 **32.5 ± 1 
Frequency 
(Hz) 
17  ± 2 21 ± 3 19 ± 3 20 ± 3 13 ± 2 10 ± 2 13.5 ± 2 12 ± 1 10 ± 2 **8 ± 1 
 
**P < 0.05; One-way ANOVA (with Post hoc Newman Keul’s test) in comparison to strain-matched control (P60-75) 
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Figure 42 Prolonged exposure (~2 hrs) of mature cortical neurones to ganaxolone (30 nM- 1 
M) greatly enhances the function of synaptic GABAARs in a concentration-dependent 
manner and has an exaggerated effect in ob/ob mice compared to WT mice. 
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(A) Superimposed exemplar GABAAR-mediated mIPSCs from representative control cortical 
neurones from mature WT mice and from equivalent neurones after ~2 hour brain slice incubation 
with 30 nM - 1 M ganaxolone. (B) Superimposed exemplar GABAARs mIPSCs from representative 
control cortical neurones from mature ob/ob mice and from equivalent neurones after ~2 hour 
brain slice incubation with 30 nM - 1 M ganaxolone. (C) Histogram illustrating the concentration-
dependent effect of ganaxolone 30 nM - 1 M on the cortical GABAARs mIPSCs of ob/ob mice (grey 
bars; One-way ANOVA P <0.05). Note the exaggerated effect of ganaxolone incubation treatment on 
the cortical GABAARs mIPSCs of ob/ob mice (grey bars) in comparison to WT mice (black bars) for 
30 nM and 300 nM ganaxolone (One-way RM ANOVA, *P < 0.05 respectively). (D) Histogram 
comparing the concentration-dependent effects of ganaxolone on the duration of GABAARs mIPSC 
τw expressed as a percentage of control for WT (black) and ob/ob (grey) mice. The histogram 
illustrates that ganaxolone has an exaggerated effect in ob/ob mice (WT 30 nM = 126 ± 8%, ob/ob = 
204 ± 13%, **P < 0.05; WT 100 nM = 180 ± 11%, ob/ob 100 nM = 237 ± 20%, **P < 0.05; WT 300 
nM = 273 ± 32%, ob/ob 300 nM= 437 ± 42%, **P < 0.05; WT 1 M = 468 ± 32%; ob/ob 1 M= 584 ± 
29%; One-way RM ANOVA **P < 0.05). Ctrl = control; Ganax = ganaxolone. 
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Ganaxolone 300 nM increased τW to greater percentages of the strain 
representative controls in the diabetic mice in comparison to the WT mice 
(C57/BL6 WT = 273 ± 32%, n = 10; ob/ob = 437 ± 42%, n = 9; db/db = 426 ± 13%, 
n = 4; One-way RM ANOVA, P < 0.05; post hoc Newman Keul’s test revealed 
significant differences between the diabetic mice and the WT, P < 0.05, but there 
was no significant difference between the ob/ob and db/db mice, P > 0.05; Figure 
50).  These observations contrast with that of allopregnanolone, which caused a 
similar effect in all genotypes, even after normalising for different baseline values. 
These findings suggest that there is a difference in the effect of ganaxolone 
incubation treatment (but not allopregnanolone) in the ob/ob and db/db mice 
compared to the WT mice. 
 
5.7 The effect of intracellular allopregnanolone, or ganaxolone, on layer 2/3 
cortical GABAAR mIPSCs of mature ob/ob mice. 
 
For both the WT and ob/ob mice acutely applied allopregnanolone and ganaxolone 
had modest effects on GABAAR mIPSCs exponential decay time, but were far more 
effective in this respect when the cortical slices were pre-incubated with the 
steroid for more than two hours. Pre-incubation with ganaxolone had a 
comparatively greater effect on cortical GABAAR-mediated mIPSCs derived from 
the ob/ob than from WT mice, whereas allopregnanolone had a similar effect in 
both types of mice.  Whole-cell voltage-clamp recordings were made in ob/ob L2/3 
cortical neurones with allopregnanolone, or ganaxolone, present in the recording 
pipette. These recordings were compared against separate control recordings (i.e. 
they were not paired).  Analysis of GABAAR-mediated phasic inhibition included 
the mIPSC amplitude, decay kinetics, charge transfer and frequency (Table 32).  
The mIPSC decay (τW) of L2/3 cortical neurones of ob/ob mice was increased by 
the presence of allopregnanolone in the recording pipette (ob/ob control = 3.5  
0.1 ms, n = 25, ob/ob 3 M allopregnanolone = 5.7  0.4 ms, n = 7; ob/ob 10 M 
allopregnanolone = 15.5  2 ms, n = 5; One-way ANOVA, P < 0.05; post hoc Newman 
Keul’s test revealed significant differences between all groups, P < 0.05;  Table 32, 
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Figure 43). In view of the fact that the control mIPSC decay times for the WT and 
diabetic mice (Table 32) are distinct, the data for τW were normalised for 
comparison.  Intracellular allopregnanolone 3 - 10 M increased τW to similar 
percentages of the strain representative controls (C57/BL6 WT 3 M = 145 ± 19%, 
n = 6; ob/ob 3 M = 161 ± 11%, n = 7; Two-way RM ANOVA, P > 0.05; C57/BL6 WT 
10 M = 403 ± 34%, n = 7; ob/ob 10 M = 439 ± 60%, n = 5; Two-way RM ANOVA, 
P > 0.05; Figure 43).  The T70 was similarly increased in the presence of 
allopregnanolone (Table 32).  These findings are consistent with the recordings 
described in the previous chapter and with the hypothesis that there is no 
difference in the sensitivity of the cortical GABAAR to neurosteroids between the 
ob/ob and WT mice. 
The mIPSC decay (τW) of L2/3 cortical neurones of ob/ob mice was increased by 
the presence of ganaxolone in the recording pipette (ob/ob control = 3.5  0.1 ms, 
n = 25; ob/ob 3 M ganaxolone = 5.0  0.3 ms, n = 6; ob/ob 10 M ganaxolone = 6.4 
 0.6 ms, n = 6; One-way ANOVA, P < 0.05; post hoc Newman Keul’s test revealed 
no significant difference between the two concentrations of ganaxolone, P >0.05; 
Table 33, Figure 44). In view of the fact that the control mIPSC decay times for the 
WT and diabetic mice (Table 33) are distinct, the data for τW were normalised for 
comparison.  Intracellular ganaxolone 3 - 10 M increased τW to similar 
percentages of the strain representative controls (C57/BL6 WT 3 M = 138 ± 9%, 
n = 6; ob/ob 3 M = 142 ± 7%, n = 6; One-way RM ANOVA, P > 0.05; C57/BL6 WT 
10 M = 151 ± 8%, n = 6; ob/ob 10 M = 182 ± 18%, n = 6; One-way RM ANOVA, P 
> 0.05; Figure 44). The T70 was similarly increased in the presence of ganaxolone 
(Table 33). Here, ganaxolone did not have a concentration-dependent effect on 
ob/ob cortical GABAAR mIPSCs when acutely delivered intracellularly and the 
magnitude of the effect was less than that produced by equivalent pipette 
concentrations of allopregnanolone (Table 33; Figure 44). Note there was no 
difference in the GABAAR-mediated mIPSC decay time between the ob/ob and the 
WT mouse when treated with intracellular ganaxolone. This finding is consistent 
with the recordings described above with allopregnanolone, although intracellular 
ganaxolone had a less pronounced effect c.f. allopregnanolone on GABAAR mIPSCs.
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Table 32 The effect of intracellular allopregnanolone (Allo) on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT or ob/ob mice. 
 
 
 
 
 
 
 
 
**P < 0.05; One-way ANOVA, in comparison to strain-matched control 
 
 WT  
Control 
 
(n=35) 
WT 
3μM Allo 
 
(n=6) 
WT 
10μM Allo 
 
(n=7) 
Ob/ob  
 
 
 (n=25) 
Ob/ob 
3μM Allo 
 
(n=7) 
Ob/ob  
10μM Allo 
 
(n=5) 
Peak amp (pA) -59 ± 2 -64 ± 3 **-95 ± 4 -66 ± 2 -61 ± 2 **-79 ± 6 
Rise Time 
(ms) 
0.4  ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.5  ± 0.1 
Charge 
transfer (fC) 
-242 ± 9 -354 ± 49 **-1389 ± 139 -255 ± 12 
 
-342 ± 27 **-1140 ± 173 
T70 (ms) 5.2  ± 0.2 **7.7 ± 1 **22.3 ± 1.4 4.7 ± 0.1 **7.4 ± 0.5 **23.0  ± 2 
Tau w (ms) 4.0  ± 0.1 **5.8 ± 0.8 **16.1 ± 1.3 3.5 ± 0.1 **5.7 ± 0.4 **15.5  ± 2 
Frequency 
(Hz) 
17  ± 2 22 ± 4 20 ± 3 16 ± 3 20 ± 4 14  ± 5 
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Table 33 The effect of intracellular ganaxolone (Ganax) on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT or ob/ob mice. 
 
 
 
 
 
 
 
 
**P < 0.05; One-way ANOVA, in comparison to strain-matched control.  
 WT  
Control 
 
(n=35) 
WT 
3μM Ganax 
 
(n=6) 
WT 
10μM Ganax 
 
(n=6) 
Ob/ob  
 
 
(n=25) 
Ob/ob 
3μM Ganax 
 
(n=6) 
Ob/ob  
10μM Ganax 
 
(n=6) 
Peak amp (pA) -59 ± 2 -63 ± 4 -69 ± 6 -66 ± 2 -60 ± 2 -66 ± 4 
Rise Time 
(ms) 
0.4  ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
Charge 
transfer (fC) 
-242 ± 9 **-347 ± 15 **-420 ± 55 -255 ± 12 
 
-302 ± 21 **-401 ± 50 
T70 (ms) 5.2  ± 0.2 **7.1 ± 0.4 **8.1 ± 0.6 4.7 ± 0.1 **6.9 ± 0.3 **8.2 ± 0.7 
Tau w (ms) 4.0  ± 0.1 **5.5 ± 0.4 **6.1 ± 0.3 3.5 ± 0.1 **5.0 ± 0.3 **6.4 ± 0.6 
Frequency 
(Hz) 
17  ± 2 18 ± 4 16 ± 2 16 ± 3 12 ± 3 12  ± 1 
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Figure 43 The intracellular application of allopregnanolone to mature cortical neurones 
enhances synaptic GABAAR function by a similar margin in WT and ob/ob mice. 
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(A & B) Superimposed exemplar GABAAR-mediated mIPSCs from a representative control WT and 
ob/ob cortical neurones and from equivalent neurones with 3 - 10 M allopregnanolone 
administered intracellularly. (C) Histogram illustrating the concentration-dependent effect of the 
intracellular application of allopregnanolone on the duration of GABAARs mIPSC τw in ob/ob 
cortical neurones (grey bars; ob/ob control = 3.5  0.1 ms, n = 25, ob/ob 3 M allopregnanolone = 
5.7  0.4 ms, n = 7; ob/ob 10 M allopregnanolone = 15.5  2 ms, n = 5; One-way ANOVA *P < 0.05). 
(D) Histogram illustrating the concentration-dependent effect of allopregnanolone on the duration 
of GABAARs mIPSC τw of WT (black) and ob/ob cortical neurones (grey) expressed as a percentage 
of control.  There was no significant difference in the effect of allopregnanolone on WT vs. ob/ob 
cortical GABAARs mIPSCs (C57/BL6 WT 3 M = 145 ± 19%, n = 6; ob/ob 3 M = 161 ± 11%, n = 7; P 
> 0.05; C57/BL6 WT 10 M = 403 ± 34%, n = 7; ob/ob 10 M = 439 ± 60%, n = 5; One-way RM 
ANOVA P > 0.05). Ctrl = control; Allo = allopregnanolone. 
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Figure 44 The intracellular application of ganaxolone to mature cortical neurones enhances 
synaptic GABAAR function by a similar margin in WT and ob/ob mice. 
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(A & B) Superimposed exemplar GABAARs mIPSCs from a representative control WT and ob/ob 
cortical neurones and from equivalent neurones with 3 - 10 M ganaxolone administered 
intracellularly. (C) Histogram illustrating the concentration-dependent effect of the intracellular 
application of ganaxolone on the duration of GABAARs mIPSC τw in ob/ob cortical neurones (grey 
bars; ob/ob control = 3.5  0.1 ms, n = 25, ob/ob 3 M ganaxolone = 5.0  0.3 ms, n = 6; ob/ob 10 
M ganaxolone = 6.4  .6 ms, n = 6; One-way ANOVA *P < 0.05). (D) Histogram illustrating the 
concentration-dependent effect of ganaxolone on the duration of GABAARs mIPSC τw of WT (black) 
and ob/ob cortical neurones (grey) expressed as a percentage of control.  There was no significant 
difference in the effect of ganaxolone on WT vs. ob/ob cortical GABAARs mIPSCs (C57/BL6 WT 3 
M = 138 ± 9%, n = 6; ob/ob 3 M = 142 ± 7%, n = 6; P > 0.05; C57/BL6 WT 10 M = 151 ± 8%, n = 
6; ob/ob 10 M = 182 ± 18%, n = 6; One-way RM ANOVA P > 0.05). Ctrl = control; Ganax = 
ganaxolone. 
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5.8 The effect of pipette-applied ganaxolone and indometacin on layer 2/3 
cortical GABAA mIPSCs in mature ob/ob and WT mice (P60-75). 
 
In the previous chapter, pipette-applied indometacin had no impact on cortical 
GABAAR mIPSCs in WT mice and did not alter the modulatory effect of pipette-
applied ganaxolone.  In order to explore whether indometacin may have a different 
effect on the cortical GABAAR mIPSCs of diabetic mice the experiments were 
repeated for the ob/ob mice.  Whole-cell voltage-clamp recordings were made in 
ob/ob L2/3 cortical neurones with indometacin  ganaxolone presented in the 
recording pipette.  These recordings were compared against separate control 
recordings (i.e. they were not paired).  Analysis of GABAAR-mediated phasic 
inhibition included the mIPSC amplitude, decay kinetics, charge transfer and 
frequency (Table 34).   
 
The mIPSC decay (τW) of L2/3 cortical neurones of ob/ob mice was unaffected by 
the presence of indometacin in the recording pipette and indometacin had no 
effect on the modulatory action of ganaxolone (ob/ob control = 3.5  0.1 ms, n = 25; 
ob/ob 100 M indometacin = 3.7  0.3 ms, n = 5; ob/ob 10 M ganaxolone = 6.4  
0.6 ms, n = 6; ob/ob 10 M ganaxolone & 100 M indometacin = 6.9  0.4 ms, n = 4; 
One-way ANOVA. Post hoc Newman Keul’s test revealed that indometacin did not 
affect the baseline decay time of mIPSCs (P >0.05) and there was no difference 
between ganaxolone 10 M vs. ganaxolone 10 M with indometacin 100 M, P 
>0.05; Table 34; Figure 45).  The T70 was similarly unchanged in the presence of 
indometacin (Table 34).  The inability of indometacin to prevent the modulation of 
the GABAAR mIPSCs by ganaxolone is inconsistent with the concept that 
indometacin could be a silent antagonist of the GABAAR in ob/ob cortical neurones. 
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Table 34 The effect of pipette-applied ganaxolone and indometacin on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT or ob/ob mice. 
 
 
 
 
 
 
 WT  
Control 
 
 
(n=35) 
WT 
100μM Indo 
 
 
(n=5) 
WT 
10μM Ganax 
 
 
(n=6) 
WT 
10μM Ganax 
&100μM Indo 
 
(n=4) 
Ob/ob  
 
 
 
(n=25) 
Ob/ob 
100μM Indo 
 
 
(n=5) 
Ob/ob  
10μM Ganax 
 
 
(n=6) 
Ob/ob  
10μM Ganax 
&100μM Indo 
 
(n=4) 
Peak amp 
(pA) 
-59 ± 2 -75 ± 2 -69 ± 6 -72 ± 7 -66 ± 2 -75 ± 2 -66 ± 4 -72 ± 5 
Rise Time 
(ms) 
0.4  ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 
Charge 
transfer (fC) 
-242 ± 9 -306 ± 28 -420 ± 55 -494 ± 68 -255 ± 12 
 
-228 ± 22 -401 ± 50 -497 ± 39 
T70 (ms) 5.2  ± 0.2 4.8 ± 0.2 8.1 ± 0.6 9.4 ± 0.5 4.7 ± 0.1 4.9 ± 0.3 8.2 ± 0.7 9.5 ± 0.3 
Tau w (ms) 4.0  ± 0.1 3.9 ± 0.4 6.1 ± 0.3 7.3 ± 0.6 3.5 ± 0.1 3.7 ± 0.3 6.4 ± 0.6 6.9 ± 0.4 
Frequency 
(Hz) 
17  ± 2 16 ± 4 16 ± 2 14 ± 2 16 ± 3 19 ± 5 12  ± 1 14  ± 1 
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Table 35 The effect of progesterone (Prog) incubation treatment on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT, ob/ob or db/db mice. 
 
 WT 
Control 
 
 
( n=35) 
WT 
1 M  
Prog 
 
( n=6) 
WT 
3μM  
Prog 
 
( n=8) 
WT 
10μM Prog 
 
 
( n=9) 
WT 
50μM 
Prog 
  
(n=9) 
Ob/ob 
 
 
 
(n=25) 
Ob/ob 
1 M 
Prog 
 
 (n=5) 
Ob/ob 
3 M 
Prog 
 
 (n=10) 
Ob/ob 
10 M 
Prog 
  
( n=7) 
Ob/ob 
50μM 
Prog 
  
(n=12) 
db/db 
50μM 
Prog 
  
(n = 6) 
Peak amp 
(pA) 
-59 ± 2 -65 ± 2 -64  ± 3 **-70 ± 2 **-91 ± 5 -66 ± 2 -68 ± 5 -78 ± 3 -79 ± 3 **-84 ± 4 -79 ± 4 
Rise Time 
(ms) 
0.4  ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 
Charge 
transfer 
-242 ± 9 **-319 ± 19 **-339 ± 26 **-373 ± 20 **-515 ± 34 -255 ± 12 **-352 ± 34 **-409 ± 24 **-474 ± 31 **-499 ± 
24 
-446 ± 24 
T70 (ms) 
 
5.2  ± 0.2 **6.5 ± 0.5 **6.8 ± 0.2 **7.3 ± 0.4 **7.6 ± 0.2 4.7 ± 0.1 **6.8 ± 0.7 **6.9 ± 0.2 **8.4 ± 0.6 **8.1 ± 0.4 7.8 ± 0.3 
Tau w 
(ms) 
4.0 ± 0.1 **4.7 ± 0.3 **5.2 ± 0.2 **5.1 ± 0.3 **5.3 ± 0.2 3.5 ± 0.1 **5.1 ± 0.3 **5.1 ± 0.1 **6.1 ± 0.4 **5.9 ± 0.3 5.5 ± 0.2 
Frequency 
(Hz) 
17  ± 2 16 ± 2 17 ± 2 19 ± 2 **31 ± 3 21 ± 3 1 ± 2 **27 ± 3 17 ± 4 **29 ± 3 25 ± 4 
 
**P < 0.05; One-way ANOVA (with Post hoc Newman Keul’s test) in comparison to strain-matched control (P60-75) 
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Figure 45 The 3 -HSD enzyme inhibitor indometacin does not suppress the acute effects of 
intracellularly applied ganaxolone on GABAAR mIPSCs of mature cortical neurones of WT or 
ob/ob mice (in contrast to its inhibitory effect on ganaxolone incubation treatment). 
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(A) Superimposed exemplar GABAAR-mediated mIPSCs from a representative control mature WT 
cortical neurone and from equivalent neurones after the intracellular application of 10 M 
ganaxolone, 100 M indometacin or both. (B) Superimposed exemplar GABAARs mIPSCs from a 
representative control mature ob/ob cortical neurone and from equivalent neurones after the 
intracellular application of 10 M ganaxolone, 100 M indometacin or both. (C) Histogram 
illustrating that intracellular indometacin made no impact on the modulatory action of ganaxolone 
(ob/ob Ctrl = 3.5  0.1 ms, n = 25, ob/ob 100 M indometacin = 3.7  0.3 ms, n = 5; ob/ob 10 M 
ganaxolone = 6.4  0.6 ms, n = 6; ob/ob 10 M ganaxolone & 100 M indometacin = 6.9  0.4 ms, n 
= 4, one-way ANOVA with post hoc Newman Keul’s test revealed that indometacin did not affect the 
baseline decay time of mIPSCs (P >0.05) and there was no difference between ganaxolone 10 M 
vs. ganaxolone 10 M with indometacin 100 M, P >0.05).  (D) Histogram illustrating that 
intracellular indometacin made no impact on the effectiveness of intracellular ganaxolone 
expressed as a percentage of control (One-way RM ANOVA, P > 0.05 for ganaxolone 10 M vs. 
ganaxolone 10 M with indometacin 100 M). Ctrl = control; Ganax = ganaxolone; Indo = 
indometacin. 
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5.9 The effect of prolonged pre-incubation with indometacin on GABAAR 
mIPSCs of mature ob/ob mice. 
 
In addition to the experiments with indometacin in the recording pipette (above) 
two hour incubation with indometacin had no effect on GABAAR mIPSC decay time 
in layer 2/3 cortical neurones of ob/ob mice (τW: control = 3.5  0.1 ms, n = 25; 
indometacin 100 μM = 3.8  0.1 ms, n = 8; unpaired Student’s t test, P <0.05).  
There was also no effect on the mIPSC T70 following two hours of incubation with 
indometacin.  The lack of effect of indometacin in the ob/ob is consistent with data 
obtained in the WT and the idea that indometacin does not modulate the GABAAR.   
 
 
5.10 Can mature layer 2/3 cortical neurones from diabetic mice synthesise 
neurosteroids? 
 
In the previous chapter I established that the enzymatic function (5 -R and 3 -
HSD) of mature cortex of WT mice is intact and that they are able to synthesise 
neurosteroids when their precursors (progesterone, or DHP) are incubated with 
the brain slice preparation. The modulatory effects of both progesterone and DHP 
on GABAAR mIPSCs could be prevented by enzymatic inhibition, consistent with 
these neurosteroids being precursors for allopregnanolone (Belelli & Herd, 2003; 
Belelli & Lambert, 2005; Brown, 2012; Mellon et al., 2001; Schumacher et al., 2012; 
Stoffel-Wagner, 2003; Figure 3). In this chapter I have established that cortical 
GABAARs of ob/ob mice are sensitive to neurosteroids and in this section I will 
explore the neurosteroid synthesis pathway in these diabetic mice. Whole-cell 
voltage-clamp recordings were made in L2/3 cortical neurones of diabetic mice 
after at least two hours of pre-incubation with the neurosteroid precursors. 
Analysis of GABAAR-mediated phasic inhibition included the mIPSC amplitude, 
decay kinetics, charge transfer and frequency (Table 35).  
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5.11 The effect of progesterone pre-incubation on cortical mIPSCs of mature 
ob/ob mice. 
Two hours of brain slice incubation with progesterone produced a relatively 
modest prolongation of GABAAR-mediated mIPSC decay time in the ob/ob mouse 
(τW: control = 3.5  0.1 ms, n = 25; progesterone 1 μM = 5.1  0.3 ms, n = 5; 
progesterone 3 μM = 5.1  0.1 ms, n = 10; progesterone 10 μM = 6.1  0.4 ms, n = 7; 
progesterone 50 μM = 5.9  0.3 ms, n = 12; One-way ANOVA, P <0.05; Table 35; 
Figure 46).  Similarly, the mIPSC T70 was modestly prolonged by the steroid (Table 
35).  In db/db L2/3 cortical neurones, two hours of pre-incubation with 
progesterone (50 μM) produced a similar effect to that observed in the ob/ob and 
the WT (τW: WT progesterone 50μM = 5.3  0.2ms, n = 9; ob/ob progesterone 
50μM = 5.9  0.3ms, n = 12; db/db progesterone 50μM = 5.5  0.2ms, n = 6; One-
way ANOVA, P > 0.05; Table 35; Figure 46).  In view of the fact that the control 
mIPSC decay times for the WT and diabetic mice (Table 35) are distinct, the data 
for τW were normalised. When the effects of 10 M and 50 M progesterone were 
expressed as a percentage of the representative control, the steroid had a greater 
impact on the diabetic mice (C57/BL6 WT = 134 ± 4%, n = 9; ob/ob = 166 ± 7%, n = 
12; db/db = 159 ± 6%, n = 6; One-way RM ANOVA, P < 0.05; post hoc Newman 
Keul’s test revealed significant differences between the WT and both types of 
diabetic mice, P < 0.05, but there was no intergroup difference between the ob/ob 
and db/db mice, P > 0.05; Figure 46; Figure 50). 
These results suggest that mature L2/3 cortical neurones of ob/ob and db/db mice 
are able to synthesise GABAAR-modulatory neurosteroids when their precursor 
(progesterone) is pre-incubated with the brain slice preparation. Despite the 
shorter control decay time of GABAAR mIPSCs in the ob/ob and db/db cortical 
neurones c.f. WT, progesterone treatment prolonged the duration of the mIPSCs to 
an absolute value similar to that produced by the steroid in equivalent WT 
neurones. This observation suggests that not only is enzymatic function (5 -R and 
3 -HSD) intact in ob/ob and db/db mice, but that it may in fact be up-regulated.  
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Figure 46 Prolonged exposure (~2 hrs) of mature cortical neurones to progesterone (1-50 
μM) enhances the function of synaptic GABAARs, suggesting that both WT & ob/ob neurones 
can synthesise allopregnanolone. 
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(A) Superimposed exemplar GABAAR-mediated mIPSCs from a representative control mature WT 
cortical neurone and from equivalent neurones after ~2 hour brain slice incubation with 1 M - 50 
M progesterone. (B) Superimposed exemplar GABAARs mIPSCs from a representative control 
mature ob/ob cortical neurone and from equivalent neurones after ~2 hour brain slice incubation 
with 1 M - 50 M progesterone. (C) Histogram illustrating the significant but modest effect of 
progesterone incubation treatment on ob/ob cortical GABAARs mIPSCs (grey) that was not 
concentration-dependent (One-way ANOVA *P <0.05). (D) Histogram illustrating the 
concentration-independent effect of progesterone on the duration of ob/ob GABAARs mIPSC τw 
expressed as a percentage of control. Note that when the effect of progesterone 50 M was 
expressed as a percentage of the representative control, the steroid had a greater impact on the 
ob/ob mice (C57/BL6 WT 10 M = 129 ± 6%, n = 10, ob/ob 10 M = 172 ± 10%, n = 7, P < 0.05; 
C57/BL6 WT 50 M = 134 ± 4%, n = 9, ob/ob 50 M = 166 ± 7%, n = 12, One-way RM ANOVA **P < 
0.05).  Ctrl = control; Prog = progesterone. 
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5.12 The influence of finasteride on the effects of progesterone on cortical 
mIPSCs of mature ob/ob mice. 
In the previous Chapter I demonstrated that finasteride inhibited the effect of 
progesterone on the duration of cortical mIPSCs of WT mice. Whole-cell voltage-
clamp recordings were made from L2/3 cortical neurones of ob/ob mice pre-
incubated for two hours with both finasteride and progesterone. Analysis of 
GABAAR-mediated phasic inhibition included the mIPSC amplitude, decay kinetics, 
charge transfer and frequency (Table 36). Finasteride alone had no effect on 
cortical mIPSC decay time of ob/ob mice, but it did prevent the effect of 
progesterone (τW: control = 3.5  0.1 ms, n = 25; finasteride 50 μM = 3.7  0.2 ms, n 
= 6; progesterone 50 μM = 5.9  0.3 ms, n = 12; finasteride 50 μM & progesterone 
50 μM = 3.4  0.2 ms, n = 6; One-way ANOVA, P < 0.05;  post hoc Newman Keul’s 
test revealed that progesterone 50 μM treatment was different from all the other 
groups, P < 0.05, but that there were no other intergroup differences, P > 0.05; 
Table 36; Figure 47). Similarly, the mIPSC T70 was unaffected by finasteride, but 
finasteride prevented the effect of progesterone (Table 36).  These results confirm 
that in mature L2/3 cortical neurones of ob/ob (and WT mice), progesterone 
requires to be metabolised by 5 -R in order for it to induce prolongation of 
GABAAR mIPSCs.  
5.13 The effect of DHP on GABAAR mIPSCs of mature ob/ob and db/db mice. 
As discussed above, the progesterone metabolite DHP is the precursor of 
allopregnanolone, (Figure 3), but this steroid does not modulate the GABAAR 
directly (Belelli & Herd, 2003; Brown, 2012). Therefore, in order to modulate 
GABAAR mIPSCs, it requires the activity of the enzyme 3 -HSD (Belelli & Lambert, 
2005; Mellon et al., 2001; Schumacher et al., 2012; Stoffel-Wagner, 2003). In the 
previous chapter I demonstrated that 3 -HSD activity is preserved in mature WT 
cortical neurones. Whole-cell voltage-clamp recordings were made in L2/3 cortical 
neurones of ob/ob mice after two hours of incubation with DHP to investigate 3 -
HSD function in these diabetic mice. Analysis of GABAAR-mediated phasic 
inhibition included the mIPSC amplitude, decay kinetics, charge transfer and 
frequency (Table 37).  
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Figure 47 The 5 -reductase enzyme inhibitor finasteride prevents the effects of 
progesterone incubation treatment on synaptic GABAARs of mature cortical neurones of WT 
& ob/ob mice. 
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(A) Superimposed exemplar GABAAR-mediated mIPSCs from a representative control mature WT 
cortical neurone and from equivalent neurones after ~2 hour brain slice incubation with 50 M 
finasteride, 50 M progesterone, or both. (B) Superimposed exemplar GABAARs mIPSCs from a 
representative control mature ob/ob cortical neurone and from equivalent neurones after ~2 hour 
brain slice incubation with 50 M finasteride, 50 M progesterone, or both. (C) Histogram 
illustrating the ability of finasteride to prevent the effect of progesterone incubation treatment on 
ob/ob cortical GABAARs mIPSC τw (grey bars; One-way ANOVA P <0.05. Post hoc Newman Keul’s 
test revealed that progesterone 50 μM treatment was different from all the other groups, *P < 0.05, 
but that there were no other intergroup differences, P > 0.05). (D) Histogram illustrating the ability 
of finasteride to prevent the effect of progesterone incubation treatment on ob/ob cortical 
GABAARs mIPSC τw (grey bars) expressed as a percentage of control (finasteride = 105  4%, n = 6; 
finasteride & progesterone = 97  4%, n= 6; progesterone = 166  7%, n = 12; One-way RM ANOVA 
**P <0.05). Ctrl = control; Prog = progesterone; Finast = finasteride. 
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Table 36 Finasteride (Finast) prevents the effect of progesterone (Prog) incubation treatment on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-
75) of WT, ob/ob or db/db mice. 
 
 
**P < 0.05; One-way ANOVA (with Post hoc Newman Keul’s test), in comparison to strain-matched control 
 
 WT  
Control 
 
 
(n=35) 
WT 
50μM Finast 
  
 
(n=7) 
WT 
50μM Prog 
 
 
(n=9) 
WT 
50μM Prog  
& 50μM Finast  
 
(n=7) 
Ob/ob 
 
 
 
(n=25) 
Ob/ob 
50μM Prog 
  
 
(n=12) 
Ob/ob 
50μM Finast 
  
 
(n=6) 
Ob/ob 
50μM Prog 
& 50μM Finast 
 
(n=6) 
Peak amp (pA) -59 ± 2 **-67 ± 3 **-91 ± 5 -64 ± 3 -66 ± 2 **-84 ± 4 -58 ± 3 -65 ± 3 
Rise Time (ms) 0.4  ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
Charge 
transfer (fC) 
-242 ± 9 **-299 ± 19 **-515 ± 34 -269 ± 10 -255 ± 12 
 
**-499 ± 24 -233 ± 18 -232 ± 16 
T70 (ms) 5.2  ± 0.2 5.7 ± 0.2 **7.6 ± 0.2 5.7 ± 0.1 4.7 ± 0.1 **8.1 ± 0.4 5.0 ± 0.2 4.9 ± 0.2 
Tau w (ms) 4.0  ± 0.1 4.2 ± 0.1 **5.3 ± 0.2 4.1 ± 0.1 3.5 ± 0.1 **5.9 ± 0.3 3.7 ± 0.2 3.4 ± 0.2 
Frequency (Hz) 17  ± 2 **23 ± 2 **31 ± 3 19 ± 1.5 21 ± 3 *29 ± 3 13 ± 3 12 ± 2 
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Table 37 The effect of DHP incubation treatment on GABAAR mIPSCs of layer 2/3 cortical neurones (P60-75) of WT, ob/ob and db/db mice. 
 
 WT 
Control 
 
( n=35) 
WT 
1 M DHP 
 
( n=14) 
WT 
3μM DHP 
 
(n=9) 
Ob/ob 
 
 
(n=25) 
Ob/ob 
1 M DHP 
 
(n=18) 
Ob/ob 
3 M DHP 
 
(n=10) 
Db/db 
 
 
(n=18) 
Db/db 
3 M DHP 
 
( n=8) 
Peak amp (pA) -59 ± 2 **-73 ± 4 **-69 ± 5 -66 ± 2 **-75 ± 3 -70 ± 3 -60 ± 2 *-83 ± 3 
Rise Time (ms) 0.4  ± 0.1 0.4 ± 0.1 0.5 ±0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 
Charge transfer 
(fC)  
-242 ± 9 **-433 ± 31 **-646 ± 33 -255 ± 12 **-792 ± 63 **-825 ± 62 -223 ± 8 *-1034 ± 57 
T70 (ms) 
 
5.2  ± 0.2 **8 ± 0.4 **13.9 ± 1 4.7 ± 0.1 **15.6 ± 1 **17.6 ± 0.8 4.6 ± 0.1 *19.1 ± 0.6 
Tau w (ms) 
 
4.0  ± 0.1 **5.9 ± 0.2 **10.2 ± 1 3.5 ± 0.1 **10.9 ± 0.6 **12.3 ± 0.7 3.5 ± 0.1 *13.4 ± 0.6 
Frequency (Hz) 17  ± 2 16 ± 2 19 ± 6 21 ± 3 13 ± 1 14 ± 0.6 19 ± 3 16 ± 2 
 
**P < 0.05; One-way ANOVA (with Post hoc Newman Keul’s test) in comparison to strain-matched control (P60-75) 
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Two hours of brain slice pre-incubation with DHP (1 – 3 µM) produced a 
significant, concentration-dependent prolongation of layer 2/3 cortical GABAAR-
mediated mIPSC decay time in ob/ob mice (τW: control = 3.5  0.1 ms, n = 25; DHP 
1 μM = 10.9  0.6 ms, n = 18; DHP 3 μM = 12.3  0.7 ms, n = 10; One-way ANOVA, P 
< 0.05; Table 37; Figure 48). Similarly, the mIPSC T70 was significantly prolonged 
by DHP (Table 37). Two hours pre-incubation with 3μM DHP produced a similarly 
pronounced effect in L2/3 cortical neurones of the db/db mouse compared to the 
WT (τW: WT DHP 3 μM = 10.2  0.1 ms, n = 9; ob/ob DHP 3 μM = 12.3  0.7 ms, n = 
10; db/db DHP 3 μM = 13.4  0.6 ms, n = 8; One-way ANOVA, P <0.05; post hoc 
Newman Keul’s analysis revealed intergroup differences between the WT and the 
diabetic mice, P <0.05; Table 37). In view of the fact that the control mIPSC decay 
times for the WT and diabetic mice (Table 37) are distinct, the data for τW were 
normalised. When the effect of DHP 3 M was expressed as a percentage of the 
representative control, the steroid had a greater impact on the diabetic mice 
(C57/BL6 WT = 256 ± 25%, n = 9; ob/ob = 348 ± 20%, n = 10; db/db = 384 ± 17%, 
n = 8; One-way RM ANOVA, P < 0.05; post hoc Newman Keul’s test revealed 
significant differences between the WT and both types of diabetic mice, P < 0.05, 
but there was no intergroup difference between the ob/ob and db/db mice, P > 
0.05; Figure 48; Figure 50).  These results indicate that not only is 3 -HSD 
enzymatic function preserved in mature mice with type-2 diabetic neuropathy, but 
it may actually be up-regulated. The observation that a similarly large effect of DHP 
is observed in both ob/ob and db/db cortical neurones also suggests that the effect 
is unrelated to the absence of a theoretical direct modulatory effect of leptin on the 
GABAARs. Indeed, while the endogenous neurosteroid levels of both the ob/ob and 
db/db mice appears to be reduced compared to the WT, the activity of the enzyme 
3 -HSD exhibits compensatory up-regulation.   
In order to confirm by another method that DHP does not influence cortical 
GABAARs directly, whole-cell voltage-clamp recordings were made in ob/ob L2/3 
cortical neurones with DHP present in the recording pipette. These recordings 
were compared against separate control recordings (i.e. they were not paired).  
Analysis of GABAAR-mediated phasic inhibition included the mIPSC amplitude, 
decay kinetics, charge transfer and frequency.  
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Figure 48 Prolonged exposure (~2 hrs) of mature cortical neurones to DHP (1-3 M) greatly 
enhances the function of synaptic GABAARs and has an exaggerated effect on the cortical 
neurones of ob/ob mice in comparison to WT mice. 
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(A) Superimposed exemplar GABAAR-mediated mIPSCs from a representative control mature WT 
cortical neurone and from equivalent neurones after ~2 hour brain slice incubation with 1 - 3 M 
DHP. (B) Superimposed exemplar GABAARs mIPSCs from a representative control mature ob/ob 
cortical neurone and from equivalent neurones after ~2 hour brain slice incubation with 1 - 3 M 
DHP.  (C) Histogram illustrating the significant concentration-dependent effect of DHP on the 
duration of ob/ob cortical GABAARs mIPSCs (grey bars; ob/ob control = 3.5  0.1 ms, n = 25; DHP 1 
μM = 10.9  0.6 ms, n = 18; DHP 3 μM = 12.3  0.7 ms, n = 10; One-way ANOVA P <0.05). Note the 
exaggerated response of the ob/ob vs. the WT cortical neurones for 1 μM DHP (C57/BL6 WT 1 M = 
5.9 ± 0.2 ms, n = 14, ob/ob 1 M = 10.9 ± 0.6 ms, n = 18, *P < 0.05) and for 3 μM DHP (C57/BL6 WT 
3 M = 10.2 ± 0.1 ms, n = 9, ob/ob 3 M = 12.3 ± 0.7 ms, n = 10, one-way ANOVA *P < 0.05). (D) 
Histogram illustrating that 1 - 3 M DHP has an exaggerated effect in ob/ob (grey) vs. WT (black) 
mice when the effect is expressed as a percentage of the respective control value (C57/BL6 WT 1 
M = 147 ± 6%, ob/ob 1 M = 308 ± 18%, **P < 0.05; C57/BL6 WT 3 M = 256 ± 25%, ob/ob 3 M 
= 348 ± 20%, One-way RM ANOVA **P < 0.05). Ctrl = control; DHP = dihydroxyprogesterone. 
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The mIPSC decay (τW) of L2/3 cortical neurones of ob/ob mice was unaffected by 
the presence of DHP in the recording pipette (ob/ob control = 3.5  0.1 ms, n = 25, 
ob/ob 3 M DHP = 3.6  0.1 ms, n = 6; ob/ob 10 M DHP = 3.7  0.2 ms, n = 4; One-
way ANOVA, P > 0.05; Figure 49). In view of the fact that the control mIPSC decay 
times for the WT and diabetic mice are distinct, the data for τW were normalised 
for comparison.  Intracellular DHP 3 - 10 M made no impact on τW expressed as a 
percentage of it’s strain representative control (C57/BL6 WT 3 M = 98 ± 3%, n = 
6; ob/ob 3 M = 101 ± 3, n = 6; Two-way RM ANOVA, P > 0.05; C57/BL6 WT 10 M 
= 108 ± 7%, n = 6; ob/ob 10 M = 104 ± 6%, n = 4; Two-way RM ANOVA, P > 0.05; 
Figure 49).  The T70 was similarly unaffected in the presence of intracellular DHP.  
These findings contrast with the significant effects of intracellular 
allopregnanolone and ganaxolone and are consistent with the idea that DHP is a 
precursor compound (Figure 49).  Considering all the results in this chapter it is 
difficult to make the case for the alternative hypothesis that GABAAR sensitivity is 
increased in ob/ob and db/db mice.  
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Figure 49 Intracellular DHP has no effect on the function of synaptic GABAARs of mature 
cortical neurones of WT or ob/ob mice (in contrast to allopregnanolone & ganaxolone). 
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(A) Superimposed exemplar GABAAR-mediated mIPSCs from a representative control mature WT 
cortical neurone and from equivalent neurones with 3 - 10 M DHP administered intracellularly. 
(B) Superimposed exemplar GABAARs mIPSCs from a representative control mature ob/ob cortical 
neurone and from equivalent neurones with 3 - 10 M DHP administered intracellularly. (C) 
Histogram illustrating the lack of effect of the intracellular application of 3 - 10 M DHP (white 
bars) on the duration of ob/ob cortical GABAARs mIPSC τw (One-way ANOVA P > 0.05) in contrast 
to the effectiveness of allopregnanolone and ganaxolone. (D) Histogram illustrating the lack of 
effect of the intracellular application of 3 - 10 M DHP on the duration of ob/ob cortical GABAARs 
mIPSC τw expressed as a percentage of the representative control value (One-way RM ANOVA P 
>0.05) in contrast to the effectiveness of allopregnanolone and ganaxolone. Ctrl = control; Allo = 
allopregnanolone; Ganax = ganaxolone; DHP = dihydroxyprogesterone. 
 
 
187 
 
 
 
 
Figure 50 Comparison of the effect of prolonged exposure to several neuroactive steroids on 
mature cortical neurones of three strains of mice: WT, ob/ob and db/db. 
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Histogram summarising the relative differences in the potencies of certain neurosteroidal 
compounds (allopregnanolone, ganaxolone, DHP and progesterone) in three strains of mice (WT, 
ob/ob and db/db) after ~2 hours brain-slice exposure. In view of the fact that the control mIPSC 
decay times for the WT and “diabetic” mice are distinct, the data for τw were normalised for 
comparison (data included in previous figures and tables). Note that the compounds 
allopregnanolone and ganaxolone, which modulate the GABAAR directly, have the greatest potency, 
while the neurosteroid precursors DHP and progesterone have the least potency. It is also 
interesting to observe that there is no significant difference in the effect of allopregnanolone on the 
three strains of mice (C57/BL6 WT = 480 ± 22%, n = 9; ob/ob = 534 ± 28%, n = 8; db/db = 534 ± 
18%, n = 6; One-way RM ANOVA P > 0.05).  In contrast, the precursor DHP had a greater impact on 
the diabetic mice (C57/BL6 WT = 256 ± 25%, n = 9; ob/ob = 348 ± 20%, n = 10; db/db = 384 ± 17%, 
n = 8; One-way RM ANOVA *P < 0.05. Post hoc Newman Keul’s test revealed significant differences 
between the WT and both types of diabetic mice, *P < 0.05, but there was no intergroup difference 
between the ob/ob and db/db mice, P > 0.05). The precursor progesterone, also had a greater 
impact on the diabetic mice C57/BL6 WT = 134 ± 4%, n = 9; ob/ob = 166 ± 7%, n = 12; db/db = 159 
± 6%, n = 6; One-way RM ANOVA P < 0.05. Post hoc Newman Keul’s test revealed significant 
differences between the WT and both types of diabetic mice, P < 0.05, but there was no intergroup 
difference between the ob/ob and db/db mice, P > 0.05).  These data are consistent with the 
hypothesis that the sensitivity of the cortical GABAARs is unchanged in diabetic neuropathy, but 
that the neurosteroid synthesising enzymes may be upregulated. A surprise finding was that 
ganaxolone 300 nM (and 1 M – data not shown) had a greater effect in both strains of diabetic 
mice compared to WT controls (C57/BL6 WT = 273 ± 32%, n = 10; ob/ob = 437 ± 42%, n = 9; db/db 
= 426 ± 13%, n = 4; One-way RM ANOVA P < 0.05.  Post hoc Newman Keul’s test revealed significant 
differences between the diabetic mice and the WT, *P < 0.05, but there was no significant 
difference between the ob/ob and db/db mice, P > 0.05). This data is consistent with the idea that 
ganaxolone may modulate the GABAAR directly, but that it is also a precursor for allopregnanolone, 
which can be blocked by indometacin incubation treatment, but indometacin has no effect when 
both drugs are applied acutely via the recording pipette.  
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Chapter 6: Behavioural work  
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Neuropathic pain places a huge burden on society and the current treatment 
options available are limited (Bouhassira et al., 2008; Dworkin et al., 2007; Harstall 
& Ospina, 2003).  Type 2 diabetes mellitus (T2DM) is a major cause of painful 
peripheral neuropathy and symptoms in humans may include spontaneous sharp, 
shooting, or burning sensations associated with sensory loss and paradoxical 
hypersensitivity (Costigan et al., 2009; Kehlet et al., 2006). Hyperalgesia describes 
an exaggerated response to a painful stimulus, while allodynia describes an 
unpleasant or painful response associated with an innocuous stimulus (Merskey & 
Bogduk, 1994). Both peripheral and central sensitisation are implicated in the 
development of painful diabetic neuropathy (Fischer & Waxman, 2010).  
Hypersensitivity of the spinothalamic tract has been described in animal models of 
type I diabetes (Chen & Pan, 2002, Pertovaara et al., 2001).  GABAARs are the major 
inhibitory receptors in the mammalian nervous system and a reduction of their 
function is associated with hypersensitivity manifested as allodynia, or 
hyperalgesia (Munro et al., 2009; von Hehn et al., 2012; Yaksh, 1989; Zeilhofer, 
2008).  Conversely, endogenous neurosteroid production may increase in response 
to peripheral inflammatory pain, thus exerting a putative compensatory analgesic 
effect (Poisbeau et al., 2005).  In addition, GABAAR ligands that target the 2 and 
3 subunits of the receptor specifically are effective against inflammatory and 
neuropathic pain without side effects such as sedation, tolerance and ataxia (Knabl 
et al., 2008).   
 
The ob/ob mouse develops a predictable neuropathic phenotype by 8 weeks of age 
comparable to that observed in humans with T2DM, thus making it a useful model 
(Drel et al., 2006; Latham et al., 2009; Lindstrom, 2009; Vareniuk et al., 2007). Drel 
et al., reported that ob/ob mice develop mechanical hypersensitivity and thermal 
hyposensitivity, while Latham et al., reported both mechanical and thermal 
hypersensitivity (Drel et al., 2006; Latham et al., 2009).  The authors of these 
papers used paw withdrawal latency to a radiant heat source and paw withdrawal 
threshold to von Frey (vF) filaments (Drel et al., 2006; Latham et al., 2009).   
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In the previous results chapters (3-5), I have described the impact of the 
endogenous neurosteroid tone on synaptic GABAAR function in pain pathway 
neurones of WT and diabetic mice.  In particular, I discovered that the endogenous 
neurosteroid tone is reduced in layer 2/3 cortical neurones of mature ob/ob mice 
(aged P60-75 or ~9-11 weeks).  In addition, mIPSCs mediated by layer 2/3 cortical 
GABAARs of ob/ob mice also exhibited an increased response to ganaxolone and 
DHP when compared to mIPSCs recorded from WT cortical neurones.  These 
findings suggest that a decreased neurosteroid tone may be implicated in 
neuropathic hypersensitivity exhibited by these mice.  Therefore, it is reasonable 
to consider that the administration of exogenous neurosteroids could potentially 
be analgesic in ob/ob mice.  Indeed, allopregnanolone, DHP and progesterone have 
had promising effects in the prevention of chemotherapy-induced neuropathic 
pain (Meyer et al., 2010; 2011).  
In my experiments, the tail flick test and vF filaments were used to determine 
thermal and mechanical nociceptive thresholds respectively in WT and ob/ob mice 
aged ~9-11 weeks (P60-75; D’Armour & Smith, 1941, Mogil et al., 2009).  In 
addition, acetone was applied topically in order to induce a rapid cooling effect, 
which may be uncomfortable in hypersensitive states (Flatters & Bennett, 2004, 
Gauchan et al., 2009, Meyer et al., 2011).  I also used the rotarod test to assess 
sensorimotor coordination in both strains of mice. 
 
6.1 ob/ob mice have impaired sensorimotor coordination in comparison to 
WT mice.  
 
ob/ob mice have reduced motor and sensory nerve conduction velocities in 
comparison to WT mice (associated with reduced nerve fibre density), which 
impairs balance and coordination (Drel et al., 2006; Vareniuk et al., 2007).  The 
rotarod test comprises an elevated rotating cylinder upon which a rodent is placed.   
In order to avoid falling off the rotarod, the mouse must keep moving; hence it is a 
test of forced motor activity (Jones & Roberts, 1968; Pritchett & Mulder, 2003).  To 
remain on the rotarod while it accelerates at a set rate the mouse requires balance 
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and coordination.  The rotarod may therefore be used to test motor function after 
the administration of novel agents as part of the drug development process or to 
characterise neurodegenerative conditions (Pallier et al., 2009; Shiotsuki et al., 
2010).  WT or ob/ob mice were placed on the rotarod and the amount of time that 
they remained on the accelerating rod was recorded, the maximum of which was 
300 seconds.  The ob/ob mice were able to remain on the rotarod for a significantly 
shorter time than were WT mice (WT = 216 ± 14 s, n = 15; ob/ob = 21 ± 5 s, n = 15; 
Mann-Whitney Rank Sum test, P < 0.001; Figure 51 A).  The impaired rotarod 
performance of the ob/ob mouse is consistent with a previous report (Mayers et 
al., 2009). 
 
6.2 ob/ob mice exhibit prolonged tail withdrawal from noxious heat in 
comparison to WT mice. 
 
The tail flick test was first described using a light bulb to apply a heat stimulus to 
the mouse’s tail and is now one of the standard tests of thermal nociceptive pain 
(D’Amour & Smith, 1941; Morgan et al., 2006).  Here, the mouse’s tail was placed 
into a bath filled with hot water and the time taken for tail withdrawal was 
recorded.  A maximum withdrawal latency of 15 seconds was enforced to minimise 
the possibility of tissue damage.  This approach was used to characterise the 
response of the WT and the ob/ob mouse to three distinct temperatures: 46 oC, 48 
oC and 50 oC.  At 48 oC and 50 oC ob/ob mice exhibited significantly longer tail 
withdrawal latencies compared to wild type mice (WT 48 oC = 5.4 ± 0.8s; ob/ob 48 
oC = 7.5 ± 0.9s, P < 0.05; WT 50 oC = 2.5 ± 0.2s; ob/ob 50 oC = 5.0 ± 1s, P < 0.05; 
Figure 51). By contrast, there was no significant difference with a water 
temperature of 46 oC (WT = 12.1 ± 1s; ob/ob = 14.1 ± 0.6s, n = 20 per group, Mann-
Whitney Rank Sum test, P > 0.05; Figure 51).   These findings are consistent with 
the phenomenon of thermal hypoalgesia in ob/ob mice reported by Drel et al., 
(2006), but conflict with the thermal hyperalgesia reported by Latham et al., 
(2009).   
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Figure 51 Ob/ob mice have impaired sensorimotor coordination and exhibit prolonged tail 
withdrawal from noxious heat in comparison to WT mice. 
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(A) Histogram illustrating the dramatic impairment of sensorimotor function exhibited by mature 
ob/ob mice. The ob/ob mice were able to remain on the accelerating rotarod for a significantly 
shorter time than were WT mice (WT = 216 ± 14 s, n = 15; ob/ob = 21 ± 5 s, n = 15; Mann-Whitney 
Rank Sum test P < 0.001).  (B) Histogram illustrating that mature ob/ob mice have a delayed 
response to thermal noxious stimuli in comparison to age-matched WT mice. (WT 48 oC = 5.4 ± 
0.8s; ob/ob 48 oC = 7.5 ± 0.9s, P < 0.05; WT 50 oC = 2.5 ± 0.2s; ob/ob 50 oC = 5.0 ± 1s, P < 0.05). There 
was no significant difference at the less noxious temperature of 46 oC (WT = 12.1 ± 1s; ob/ob = 14.1 
± 0.6s, n = 20 per group, Mann-Whitney Rank Sum test P > 0.05).  A maximum withdrawal latency 
of 15 seconds was enforced to minimise the possibility of tissue damage.   
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The discrepancy is considered further in the Discussion: Section 7.11 and means 
that the tail flick test is not suitable for investigating potential analgesic, or 
antihyperalgesic effects of drugs such as neurosteroids in ob/ob mice.  However, 
these data indicate that 50 oC is an appropriate temperature to test for noxious 
heat and to determine the analgesic potential of specific drugs in WT mice. 
6.3 Ganaxolone increases tail withdrawal latency in WT mice. 
 
The spinal (intrathecal) administration of ganaxolone has recently been shown to 
reduce thermal nociception using the tail flick test, but systemic (intraperitoneal) 
administration has not been investigated (Asiedu et al., 2012).  Other structurally 
related GABA-active steroids also exhibit analgesic effects (Poisbeau et al., 2005, 
Charlet et al., 2008, Meyer et al., 2008; 2010; 2011).  The tail flick test is a useful 
tool for assessing thermal nociception, therefore the analgesic effect of ganaxolone 
was assessed at three different doses. Ganaxolone required to be solubilised with 
hydroxypropyl β-cyclodextrin (β-CD) prior to intraperitoneal injection (Besheer et 
al., 2010; Carter et al., 1997; Reddy et al., 2010).  The cyclodextrins are effective 
solubilising agents and do not cause a localised inflammatory response at the 
injection site, which is a relatively common side effect of some alternative solvents 
such as DMSO (Loftsson & Brewster, 1996; Willson et al., 1965).   
There were no significant differences in the baseline withdrawal latencies in 
response to a noxious thermal stimulus (50 oC) between the four groups of mice 
used to examine the effects of ganaxolone (β-CD = 1.9 ± 0.3 s, ganax 3 mg/kg = 1.1 
± 0.1 s, 10 mg/kg = 1.5 ± 0.1 s, 30 mg/kg = 2.8 ± 0.7 s, P > 0.05) and the solubilising 
vehicle β-CD also had no effect (β-CD 30 mins = 2.0 ± 0.1 s, β-CD 60 mins = 2.5 ± 0.2 
s, β-CD 120 mins = 2.7 ± 0.3 s, P > 0.05).  Ganaxolone induced a dose-dependent 
prolongation of tail withdrawal latency in WT mice after 30 minutes (ganax 3 
mg/kg 30 mins = 1.5 ± 0.2 s, 10 mg/kg 30 mins = 6.1 ± 1.8 s, 30 mg/kg 30 mins = 
6.0 ± 2 s, P < 0.05) and this effect lasted more than 90 minutes (ganax 3 mg/kg 60 
mins = 2.1 ± 0.3 s, 10 mg/kg 60 mins = 5.2 ± 1.7 s, 30 mg/kg 60 mins = 8.8 ± 2 s, P < 
0.05; ganax 3 mg/kg 120 mins = 3.8 ± 1.3 s, 10 mg/kg 120 mins = 7.3 ± 2.1 s, 30 
mg/kg 120 mins = 11.5 ± 1.8 s, n = 10 per group, Kruskall Wallis One-way ANOVA, 
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on ranks P < 0.05; Figure 52). These data suggest that ganaxolone exhibits a dose-
dependent analgesic effect in a test of thermal nociception in WT mice.  This 
finding is consistent with the intrathecal administration of ganaxolone (Asiedu et 
al., 2012) and also other reports of the analgesic effects of similar neurosteroids in 
rats in the setting of post-chemotherapy neuropathy (Meyer et al., 2010; 2011).  
However, during the experiments it was noted that the mice appeared sedated 
with ganaxolone 30 mg/kg (but not the lower doses).  Therefore rotarod 
experiments were carried out with ganaxolone to determine if the apparent 
analgesic effect may in fact be due to sedation, or sensorimotor impairment. 
 
6.4 High doses of ganaxolone impair rotarod performance of WT mice. 
 
The accelerating rotarod test was used to assess forced motor activity before and 
after the intraperitoneal administration of ganaxolone at three doses.  Only the 
highest dose of ganaxolone significantly impaired the performance of WT mice on 
the rotarod.  There was no significant difference in the baseline rotarod 
performance of the four groups in the study  (β-CD baseline = 215 ± 28 s, ganax 5 
mg/kg baseline = 155 ± 16 s, 10 mg/kg baseline = 216 ± 24 s, 30 mg/kg baseline = 
211 ± 40 s, P > 0.05) and the solubilising vehicle β-CD had no effect on rotarod 
performance (β-CD 15 mins = 208 ± 28s, β-CD 30mins = 243 ± 27s, β-CD 60mins = 
182 ± 35s, β-CD 120mins = 208 ± 45s, P > 0.05; Figure 53). However, at 15, 30 and 
60 minutes post-injection the highest dose of ganaxolone (30 mg/kg) significantly 
impaired performance of WT mice on the rotarod (ganax 5 mg/kg 15 mins = 165 ± 
33 s, 10 mg/kg 15 mins = 136 ± 20 s, 30 mg/kg 15 mins = 42 ± 33 s, P < 0.05; ganax 
5 mg/kg 30 mins = 211 ± 28 s, 10 mg/kg 30 mins = 161 ± 30 s, 30 mg/kg 30 mins = 
54 ± 41 s, P < 0.05; ganax 5 mg/kg 60 mins = 172 ± 32 s, 10 mg/kg 60 mins = 196 ± 
21 s, 30 mg/kg 60 mins = 36 ± 26 s, P < 0.05).  The effect of ganaxolone (30 mg/kg) 
was no longer apparent at 120 minutes post-injection (ganax 5 mg/kg 120 mins = 
220 ± 17 s, 10 mg/kg 120 mins = 221 ± 12 s, 30 mg/kg 120 mins = 155 ± 65 s, n = 5 
per group, Kruskall Wallis One-way ANOVA, on ranks P > 0.05; Figure 53).   
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Figure 52 Ganaxolone increases the latency for tail withdrawal from noxious heat in WT 
mice. 
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Histogram illustrating that ganaxolone induced a dose-dependent prolongation of tail withdrawal 
latency in WT mice after 30 minutes (ganax 3 mg/kg 30 mins = 1.5 ± 0.2 s, 10 mg/kg 30 mins = 6.1 
± 1.8 s, 30 mg/kg 30 mins = 6.0 ± 2 s, P < 0.05) and this effect lasted more than 90 minutes (ganax 3 
mg/kg 60 mins = 2.1 ± 0.3 s, 10 mg/kg 60 mins = 5.2 ± 1.7 s, 30 mg/kg 60 mins = 8.8 ± 2 s, P < 0.05; 
ganax 3 mg/kg 120 mins = 3.8 ± 1.3 s, 10 mg/kg 120 mins = 7.3 ± 2.1 s, 30 mg/kg 120 mins = 11.5 ± 
1.8 s, n = 10 per group, P < 0.05).  The solubilising vehicle β-CD had no effect (β-CD 30 mins = 2.0 ± 
0.1 s, β-CD 60 mins = 2.5 ± 0.2 s, β-CD 120 mins = 2.7 ± 0.3 s; Kruskall Wallis One-Way ANOVA on 
ranks P > 0.05).   
 
196 
 
 
 
 
Figure 53 The highest dose of ganaxolone impairs the rotarod performance of WT mice. 
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Histogram showing that at 15, 30 and 60 minutes post-injection the highest dose of ganaxolone (30 
mg/kg) significantly impaired performance of WT mice on the rotarod (ganax 5 mg/kg 15 mins = 
165 ± 33 s, 10 mg/kg 15 mins = 136 ± 20 s, 30 mg/kg 15 mins = 42 ± 33 s, P < 0.05; ganax 5 mg/kg 
30 mins = 211 ± 28 s, 10 mg/kg 30 mins = 161 ± 30 s, 30 mg/kg 30 mins = 54 ± 41 s, P < 0.05; 
ganax 5 mg/kg 60 mins = 172 ± 32 s, 10 mg/kg 60 mins = 196 ± 21 s, 30 mg/kg 60 mins = 36 ± 26 s, 
P < 0.05).  The effect of ganaxolone (30 mg/kg) was no longer apparent at 120 minutes post-
injection (ganax 5 mg/kg 120 mins = 220 ± 17 s, 10 mg/kg 120 mins = 221 ± 12 s, 30 mg/kg 120 
mins = 155 ± 65 s, n = 5 per group, P > 0.05). The solubilising vehicle β-CD had no effect on rotarod 
performance (β-CD 15 mins = 208 ± 28s, β-CD 30mins = 243 ± 27s, β-CD 60mins = 182 ± 35s, β-CD 
120mins = 208 ± 45s, Kruskall Wallis One-Way ANOVA on ranks P > 0.05). 
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Taken in conjunction with the tail flick data, these data suggest that ganaxolone 
exhibits an analgesic effect at a dose of 10 mg/kg but only impairs rotarod 
performance in WT mice at higher doses such as 30 mg/kg.  In addition, the dose-
dependent effect on rotarod performance is consistent with the literature (Carter 
et al., 1997). 
 
6.5 ob/ob mice exhibit cold allodynia in comparison to WT mice. 
 
Increased sensitivity to cold stimuli is a common symptom associated with neural 
injury.  The cooling sensation associated with the evaporation of topically applied 
acetone may induce a temporary noxious stimulus.  Acetone has therefore been 
used to elicit cold allodynia in animals with chemotherapy-induced neuropathic 
hypersensitivity (Flatters & Bennett, 2004, Gauchan et al., 2009, Meyer et al., 
2011).   
In my study, mice were placed onto an elevated grid-platform, a drop of acetone 
was applied to the ventral (plantar) surface of the animal’s hindpaw and the mouse 
was observed for 20 seconds.  The following scoring system was used: (0 = No 
response; 1 = Quick withdrawal, flick or stamp of the paw only; 2 = 
Prolonged/repeated flicking of the paw and/or abnormal hind limb 
posture/limping; 3 = The same as above but also licking of the ventral surface of 
the affected paw) (Flatters & Bennett, 2004).  The ob/ob mouse exhibited a 
significantly greater response to the application of topical acetone (WT acetone = 
0.96 ± 0.1, n = 20; ob/ob acetone = 2.2 ± 0.1, n = 20; Mann-Whitney Rank Sum test, 
P < 0.05; Figure 54).  This result is consistent with the presence of cold allodynia in 
ob/ob mice.  However, this test proved to be problematic for further study because 
in subsequent pilot experiments repeated exposure of ob/ob mice to acetone 
(required to evaluate the subsequent effects of neurosteroids) led to a loss of the 
allodynia response (pre-vehicle = 2.2 ± 0.2, post-vehicle = 1.7 ± 0.2, n = 5; Mann-
Whitney Rank Sum test P < 0.05). 
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Figure 54 Ob/ob mice exhibit cold allodynia in comparison to WT mice.   
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Histogram illustrating that ob/ob mice exhibit cold allodynia in comparison to WT mice.  The mice 
were placed onto an elevated grid-platform, a drop of acetone was applied to the ventral (plantar) 
surface of the animal’s hindpaw and the mouse was observed for 20 seconds.  The following 
scoring system was used: (0 = No response; 1 = Quick withdrawal, flick or stamp of the paw only; 2 
= Prolonged/repeated flicking of the paw and/or abnormal hind limb posture/limping; 3 = The 
same as for score 2 but with the addition of licking of the ventral surface of the affected paw). The 
ob/ob mouse exhibited a significantly greater response to the application of topical acetone (WT 
acetone = 0.96 ± 0.1, n = 20 mice; ob/ob acetone = 2.2 ± 0.1, n = 20 mice, Mann-Whitney Rank Sum 
test P < 0.05).   
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6.6 ob/ob mice exhibit mechanical hypersensitivity in comparison to WT 
mice. 
 
The calibrated series of von Frey (vF) filaments are standard equipment for 
assessing mechanical nociceptive thresholds in animal models and also in humans 
(Mogil et al., 2009; Pearce, 2006).  vF filaments have previously been employed via 
the up-down method to demonstrate that the ob/ob mouse exhibits mechanical 
hypersensitivity by the age of P60 (Drel et al., 2006; Latham et al., 2009). I carried 
out pilot studies to determine the optimal four filaments to be used in WT mice; 
these were the 0.16 g, 0.4 g, 0.6 g and 1 g filaments.  Mice were placed onto an 
elevated grid-platform and each vF filament was applied to the plantar surfaces of 
the left and right hind paws five times.  The number of withdrawals out of a 
maximum of ten was recorded for a particular filament in each mouse. 
The 0.16 g and 0.4 g vF filaments elicit withdrawal responses on 25% and 40% of 
occasions respectively in WT mice and were therefore considered to be mild 
stimuli.  If the ob/ob mouse has an exaggerated response to these filaments this 
would be consistent with allodynia.  The 0.6 g vF filament elicited a response on 
over 60% of occasions in the WT mouse, therefore it is considered painful and if 
the ob/ob mouse had an exaggerated response to this filament it would be 
consistent with hyperalgesia (Merskey & Bogduk, 1994).  The 1 g vF filament 
elicited a withdrawal response on approximately 90% of occasions, therefore it is 
considered to be a clear test of mechanical nociceptive pain in the WT mouse.  This 
method was adapted from work published in rats with neuropathic sensitisation 
(Meyer et al., 2011). 
The ob/ob mice responded significantly more frequently than the WT mice to the 
0.16 g, 0.4 g and 0.6 g filaments (WT 0.16 g = 30.9 ± 3.2%, n = 33; ob/ob 0.16 g = 
41.8 ± 3.9%, P < 0.05; WT 0.4 g = 56.4 ± 3.7%; ob/ob 0.4 g = 68.8 ± 3.8%, P < 0.05; 
WT 0.6 g = 69.1 ± 3.5%; ob/ob 0.6 g = 85.2 ± 2.5%, P < 0.05; Figure 55).  By 
contrast, there was no significant difference in the frequency of responses to the 1 
g vF filament (WT = 84.8 ± 2.9%, n = 33; ob/ob = 92.7 ± 1.7%, n = 33 per group; 
Mann-Whitney Rank Sum test, P > 0.05). These results confirm the presence of 
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mechanical hypersensitivity in the ob/ob mouse, which is consistent with reports 
in the literature (Drel et al., 2006; Latham et al., 2009).  
 
 
 
Figure 55 Ob/ob mice exhibit mechanical hypersensitivity in comparison to WT mice. 
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Histogram illustrating that ob/ob mice exhibit mechanical hypersensitivity in comparison to WT 
mice.  The mice were placed onto an elevated grid-platform and each vF filament (0.16 g – 1 g) was 
applied to the plantar surfaces of the left and right hind paws five times.  The number of 
withdrawals out of a maximum of ten was recorded for a particular filament in each mouse. The 
ob/ob mice responded significantly more frequently than the WT mice to the 0.16 g, 0.4 g and 0.6 g 
filaments (WT 0.16 g = 30.9 ± 3.2%, n = 33; ob/ob 0.16 g = 41.8 ± 3.9%, P < 0.05; WT 0.4 g = 56.4 ± 
3.7%; ob/ob 0.4 g = 68.8 ± 3.8%, P < 0.05; WT 0.6 g = 69.1 ± 3.5%; ob/ob 0.6 g = 85.2 ± 2.5%, P < 
0.05). By contrast, there was no significant difference in the frequency of responses to the 1 g vF 
filament (WT = 84.8 ± 2.9%, n = 33; ob/ob = 92.7 ± 1.7%, n = 33 per group; Mann-Whitney Rank 
Sum test P > 0.05). These results confirm the presence of mechanical hypersensitivity in the ob/ob 
mouse. 
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6.7 Ganaxolone reduces mechanical hypersensitivity in ob/ob mice and 
reduces mechanical nociceptive pain in both WT and ob/ob mice. 
 
β-CD vehicle alone or β-CD plus ganaxolone was administered via the 
intraperitoneal route.  The same series of vF filaments were used as described for 
the comparison of mechanical sensitivity of WT and ob/ob mice (0.16 g, 0.4 g, 0.6 g 
and 1 g).  After control recordings were obtained, the drug was injected and the 
assay was repeated one hour later.   
The β-CD vehicle had no impact on the response to any of the vF filaments in WT 
mice (0.16 g pre β-CD = 36 ± 6%, 0.16 g post β-CD = 46 ± 5%, P > 0.05; 0.4 g pre = 
70 ± 6%, 0.4 g post = 68 ± 7%, P > 0.05; 0.6 g pre = 77 ± 6%, 0.6 g post = 74 ± 6%, P 
> 0.05; 1 g pre = 90 ± 5%, 1 g post = 88 ± 6%, P > 0.05) or ob/ob mice (0.16 g pre β-
CD = 43 ± 6%, 0.16 g post β-CD = 39 ± 5%, P > 0.05; 0.4 g pre = 63 ± 7%, 0.4 g post 
= 53 ± 5%, P > 0.05; 0.6 g pre = 83 ± 5%, 0.6 g post = 74 ± 5%, P > 0.05; 1 g pre = 89 
± 5%, 1 g post = 84 ± 4%, P > 0.05; Figure 56). 
Ganaxolone (10 mg/kg) had no impact on the response to the 0.16 g, 0.4 g or 0.6 g 
vF filaments in the WT mouse (0.16 g pre ganax = 31 ± 6%, 0.16 g post ganax = 42 
± 6%, 0.4 g pre = 61 ± 6%, 0.4 g post = 57 ± 7%, 0.6 g pre = 79 ± 4%, 0.6 g post = 65 
± 6%, P > 0.05) but ganaxolone did reduce the response of WT mice to the 1.0 g vF 
filament (pre ganax = 94 ± 3%, post ganax = 82 ± 5%, n = 10 per group, Wilcoxon 
signed rank test (before & after), P < 0.05; Figure 57).  These data suggest that 
ganaxolone is analgesic for mechanical nociceptive pain in WT mice.  By definition, 
WT mice do not exhibit allodynia or hyperalgesia under normal conditions; 
therefore it is perhaps unsurprising that these drugs did not impact on the 
response to the smaller vF filaments.  
Ganaxolone had no impact on the response rate to the 0.16 g vF filament in ob/ob 
mice (pre ganax = 42 ± 7%, post ganax = 38 ± 8%, P > 0.05).   In contrast, 
ganaxolone reduced the response rate of ob/ob mice  to the 0.4 g, 0.6 g and 1 g vF 
filaments (0.4 g pre ganax = 66 ± 7%, 0.4 g post ganax = 49 ± 6%, P < 0.05; 0.6 g pre 
= 82 ± 5%, 0.6 g post = 59 ± 7%, P < 0.05; 1 g pre = 92 ± 4%, 1 g post = 74 ± 8%, n = 
10 per group, Wilcoxon signed rank test (before & after), P < 0.05; Figure 57). 
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Figure 56 Vehicle has no significant effect in ob/ob mice or WT mice. 
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(A & B) Histograms illustrating (for control purposes) that the β-CD vehicle had no impact on the 
response to any of the vF filaments in WT mice (0.16 g pre β-CD = 36 ± 6%, 0.16 g post β-CD = 46 ± 
5%, P > 0.05; 0.4 g pre = 70 ± 6%, 0.4 g post = 68 ± 7%, P > 0.05; 0.6 g pre = 77 ± 6%, 0.6 g post = 74 
± 6%, P > 0.05; 1 g pre = 90 ± 5%, 1 g post = 88 ± 6%, P > 0.05) or ob/ob mice (0.16 g pre β-CD = 43 
± 6%, 0.16 g post β-CD = 39 ± 5%, P > 0.05; 0.4 g pre = 63 ± 7%, 0.4 g post = 53 ± 5%, P > 0.05; 0.6 g 
pre = 83 ± 5%, 0.6 g post = 74 ± 5%, P > 0.05; 1 g pre = 89 ± 5%, 1 g post = 84 ± 4%, P > 0.05). 
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Figure 57 Ganaxolone reduces mechanical hypersensitivity in ob/ob mice and reduces 
mechanical nociceptive pain in both WT and ob/ob mice. 
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(A) Histogram illustrating that ganaxolone had no impact on the response to the 0.16 g, 0.4 g or 0.6 
g vF filaments in WT mice (0.16 g pre ganax = 31 ± 6%, 0.16 g post ganax = 42 ± 6%, 0.4 g pre = 61 
± 6%, 0.4 g post = 57 ± 7%, 0.6 g pre = 79 ± 4%, 0.6 g post = 65 ± 6%, P > 0.05) but ganaxolone did 
reduce the response of WT mice to the 1.0 g vF filament (pre ganax = 94 ± 3%, post ganax = 82 ± 
5%, n = 10 per group, Wilcoxon signed rank test (before & after) P < 0.05). (B) Histogram 
illustrating that ganaxolone had no impact on the response to the 0.16 g vF filament the ob/ob 
mouse (pre-ganax = 42 ± 7%, post-ganax = 38 ± 8%, P > 0.05).   In contrast, ganaxolone reduced the 
response of the ob/ob mouse to the 0.4 g, 0.6 g and 1 g vF filaments (0.4 g pre-ganax = 66 ± 7%, 0.4 
g post-ganax = 49 ± 6%, P < 0.05; 0.6 g pre = 82 ± 5%, 0.6 g post = 59 ± 7%, P < 0.05; 1 g pre = 92 ± 
4%, 1 g post = 74 ± 8%, n = 10 per group, Wilcoxon signed rank test (before & after) P < 0.05).   
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As described earlier, ob/ob mice have exaggerated baseline response rates to the 
0.16 g, 0.4 g and 0.6 g vF filaments in comparison to WT mice (Figure 55).   
Therefore, ob/ob mice could be considered to have mechanical allodynia and 
mechanical hyperalgesia.  Ganaxolone reduced the response rates of ob/ob mice to 
the 0.4 g vF filament, which is consistent with the idea that these neurosteroids 
may reduce mechanical allodynia.  Ganaxolone also reduced the response rates of 
ob/ob mice to the 0.6 g vF filament, which is consistent with the idea that it 
reduces mechanical hyperalgesia.  As described earlier, the 1.0 g vF filament 
induces a withdrawal response on ~85% of occasions in WT mice and ~93% in 
ob/ob mice (Figure 55) and may therefore be considered as an unambiguous test 
of mechanical nociceptive pain.  Taken as a whole, these results show that 
ganaxolone was effective for mechanical nociceptive pain in both strains of mice.   
 
As described in Chapters 4 and 5, DHP (the precursor for allopregnanolone) 
induced a dramatic prolongation of GABAAR mIPSC decay time in layer 2/3 cortical 
neurones of WT mice.  Interestingly, DHP (in common with ganaxolone) had an 
exaggerated effect on cortical GABAAR mIPSCs of ob/ob mice compared to WT 
mice.  Loss of GABAAR-mediated inhibition is associated with hypersensitivity 
(Munro et al., 2009; von Hehn et al., 2012; Yaksh, 1989; Zeilhofer, 2008), therefore 
DHP (which prolongs GABAAR mIPSCs) was also used to investigate mechanical 
nociception.  DHP had no impact on the rates of response to any of the vF filaments 
in WT mice (0.16 g pre DHP = 37 ± 5%, 0.16 g post DHP = 44 ± 8%, P > 0.05; 0.4 g 
pre = 64 ± 6%, 0.4 g post = 55 ± 9%, P > 0.05; 0.6 g pre = 73 ± 6%, 0.6 g post = 67 ± 
7%, P > 0.05; 1 g pre = 87 ± 4%, 1 g post = 69 ± 7%, P > 0.05; Figure 58).  DHP had 
no impact on the response rate to the 0.16 g, 0.6 g and 1 g vF filaments in ob/ob 
mice (0.16 g pre DHP = 35 ± 7%, 0.16 g post DHP = 36 ± 7%, P > 0.05; 0.6 g pre = 
76 ± 6%, 0.6 g post = 63 ± 7%, 1 g pre = 87 ± 4%, 1 g post = 78 ± 7%, P > 0.05), but 
DHP did reduce the response rates of ob/ob mice to the 0.4 g filament (pre DHP = 
66 ± 8%, post DHP = 44 ± 8%, P < 0.05; Figure 58).  This is consistent with DHP 
reducing mechanical allodynia, but having no effect on mechanical nociceptive 
pain. 
205 
 
 
 
Figure 58 DHP reduces mechanical allodynia in ob/ob mice but has no significant effect in 
WT mice. 
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(A) Histogram illustrating that DHP (the precursor for allopregnanolone) had no impact on the 
response to any of the vF filaments in the WT mouse (0.16 g pre DHP = 37 ± 5%, 0.16 g post DHP = 
44 ± 8%, P > 0.05; 0.4 g pre = 64 ± 6%, 0.4 g post = 55 ± 9%, P > 0.05; 0.6 g pre = 73 ± 6%, 0.6 g post 
= 67 ± 7%, P > 0.05; 1 g pre = 87 ± 4%, 1 g post = 69 ± 7%, P > 0.05). (B) Histogram illustrating that 
DHP had no impact on the response to the 0.16 g, 0.6 g and 1 g vF filaments in the ob/ob mouse 
(0.16 g pre DHP = 35 ± 7%, 0.16 g post DHP = 36 ± 7%, P > 0.05; 0.6 g pre = 76 ± 6%, 0.6 g post = 63 
± 7%, 1 g pre = 87 ± 4%, 1 g post = 78 ± 7%, P > 0.05), but DHP did reduce the response of the the 
ob/ob mouse to the 0.4 g filament (pre DHP = 66 ± 8%, post DHP = 44 ± 8%, P < 0.05).  This is 
consistent with DHP reducing mechanical allodynia, but having no effect on mechanical nociceptive 
pain.  
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In summary, ob/ob mice exhibit thermal hypoalgesia, cold allodynia, mechanical 
allodynia, mechanical hyperalgesia and impaired balance and coordination.  In WT 
mice, the neuroactive steroid ganaxolone is analgesic for thermal and mechanical 
nociceptive pain at 10 mg/kg but impairs rotarod performance at 30 mg/kg.  In 
ob/ob mice, ganaxolone (10 mg/kg) is analgesic for mechanical nociceptive pain 
but, more interestingly, is also effective in reducing mechanical allodynia and 
mechanical hyperalgesia.   In addition, DHP may also be effective for mechanical 
allodynia.  These findings are consistent with the electrophysiological results 
described in previous chapters, which demonstrate that there is a reduced 
endogenous neurosteroid tone in mature ob/ob mice.  Specifically, GABAAR mIPSCs 
from layer 2/3 cortical neurones of ob/ob mice have a greater response to 
neuroactive steroids such as ganaxolone than is observed in WT mice. 
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Chapter 7: Discussion 
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As discussed in sections 1.2.6 and 1.3.6 of the Introduction, GABA and the GABAAR 
have important roles in neurodevelopment.  GABA influences neuronal 
proliferation, migration, differentiation, synapse maturation and signalling during 
the maturation process (Ben Ari et al., 2007; Di Cristo, 2007; Owens & Kriegstein, 
2002).  The whole-cell voltage-clamp technique was used to study the changes to 
GABAAR-mediated mIPSCs that occur during development in neurones from LII of 
the spinal cord, the nRT and Layer 2/3 of the cerebral cortex.  These mIPSCs were 
mediated by GABAARs and as such they were inhibited by the GABAAR antagonist 
bicuculline. 
 
7.1 The decay time of GABAAR mIPSCs decreases with development at three 
levels of the pain pathway.  
 
During development (P6-P60) there was a reduction of the mIPSC decay time in all 
three levels of the pain pathway, which was shown to be particularly dramatic 
within the first three weeks of life (see Figure 10).  It is possible that the rate of 
development may be staggered with different regions reaching maturity at 
different ages as has been reported in the spinal cord (Inquimbert et al., 2008), but 
the data amassed was not extensive enough to make firm conclusions on this issue.  
In neurones from the nRT and layer 2/3 of the cerebral cortex the peak amplitude, 
rise time, charge transfer and frequency of GABAAR mIPSCs were all shown to 
change with development as well.   
 
In LII neurones of the spinal cord, the peak amplitude, rise time and frequency of 
GABAAR mIPSCs did not alter significantly, but the charge transfer i.e. the area of 
the mIPSC, decreased with development.  This parameter is influenced by peak 
amplitude and decay time, it is therefore unsurprising that it changed in parallel 
with changes in decay time.  Subsequent electrophysiological work focused on the 
mature WT L2/3 cortical neurones to facilitate comparison with neurones from 
mice with neuropathy caused by type-2 diabetes mellitus (T2DM). Results from 
these experiments informed the behavioural studies that followed.  The 
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behavioural work translated the electrophysiological findings into measurable 
anti-nociceptive effects in live mice.  The mechanical hypersensitivity of ob/ob 
mice and the increased response to ganaxolone reflected my earlier 
electrophysiological findings.  
The electrophysiological data were obtained specifically from neurones of the pain 
pathway and made under standardised conditions i.e. -60 mV and 35oC (see Figure 
10; Brown, 2012; Mitchell et al., 2008; Peden et al., 2008).  It is worth noting that 
the recordings were made at the near physiological temperature of 35oC, while 
recordings made by other authors are typically made at room temperature (~20 
oC) and mIPSC decay time is highly sensitive to temperature (Collingridge et al., 
1984).  Interestingly, although recordings made at non-physiological room 
temperature by other authors may have different individual values for GABAAR 
mIPSC decay time, they have also observed a relative reduction of decay time with 
development in multiple regions of the CNS (Brickley et al., 1996; Draguhn & 
Heinemann, 1996; Dunning et al., 1999; Keller et al., 2001; 2004; Rajalu et al., 
2009; Schlichter et al., 2006; Tia et al., 1996).   The reduced decay time may reflect 
the complex maturation process of neural networks and the greater precision of 
synaptic transmission and is thought to confer an enhancement of sensory 
perception, motor coordination and cognitive function (Ben Ari et al., 2007; Cohen 
et al., 2000; Takahashi, 2005).  Changes in the subunit composition of GABAARs 
with development such as 1 subunit expression also account for a significant part 
of the shorter decay time of GABAAR-mediated synaptic events (Fritchy et al., 
1994; Laurie et al., 1992; Okada et al., 2000; Vicini et al., 2001).   
Indeed, the subunit composition of GABAARs influences their functional properties 
i.e. they may have a higher affinity for GABA and remain in the open configuration 
for a relatively longer duration, resulting in longer mIPSC decay times (Verdoorn, 
1994).  In dorsal horn neurones of the spinal cord, GABAARs with the 2 and 3 
subunits are expressed most frequently, resulting in the characteristically long 
decay times of GABAAR mIPSCs (Bohlhalter et al., 1996; Knabl et al., 2008).  
Neurones of the nRT also express GABAARs containing 3 subunits primarily and 
subsequently these exhibit relatively long GABAAR mIPSC decay times (Bohlhalter 
et al., 1996; D’Hulst et al., 2009; Knabl et al., 2008; Peden et al., 2008; Sieghart & 
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Sperk, 2002).  In contrast to the other two regions discussed above, the GABAARs 
of layer 2/3 cortical neurones express the 2 and 3 subunits principally in early 
life, but during the maturation process the 1 subunit becomes predominant 
(Bosman et al., 2002; Fritschy et al., 1994).  This is relevant because 
pharmacological agents that target the 2 and 3 subunits preferentially may be 
useful for treating pathological pain conditions related to a lack of physiological 
GABAergic inhibition (Knabl et al., 2008). Such pharmacological agents could avoid 
the undesirable anaesthetic and sedative effects of GABAAR modulation by 
‘sparing’ GABAARs within the brain that express the 1 subunit that is involved in 
the mediation of these effects (Knabl et al., 2008; Sieghart & Sperk, 2002).  Layer 
2/3 cortical neurones that have GABAARs containing the 1 subunit exhibit 
significantly shorter mIPSC decay times and the difference is clearly apparent in 
my recordings.  Indeed, the decay time of P60-75 GABAAR mIPSCs is approximately 
one third of that observed in P6-7 mIPSCs.  However, it seems likely that the 
developmental changes observed at all three levels of the pain pathway may be 
influenced by multiple factors i.e. not just subunit composition (Keller et al., 2004; 
Peden et al., 2008).   In regions of the CNS where the 1 subunit is not expressed, 
such as the dorsal horn of the spinal cord, a reduction in the decay time of GABAAR 
mIPSCs is also observed (Keller et al., 2004).  Moreover, mice that have been 
genetically modified to lack the gene responsible for the 1 subunit of the GABAAR 
exhibit shorter mIPSC decay times with development (Bosman et al., 2002; Peden 
et al., 2008).  A shorter decay time of GABAAR mIPSCs with maturation is 
associated with a parallel decrease in the endogenous neurosteroid tone in the CNS 
(Keller et al., 2004; Grobin & Morrow, 2001; Mellon, 2001).  In addition, 
neurosteroids are implicated in the proliferation, differentiation, survival and 
activation of neurones within the developing nervous system (Belelli & Lambert, 
2005; Do Rego et al., 2009; Mellon, 2007; Mellon et al., 2001).  Fluctuations in the 
endogenous neurosteroid tone of pain pathway neurones may therefore play a 
significant role in the observed reduction of GABAAR mIPSC decay time (Keller et 
al., 2004).  
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7.2 Region specific properties of pain pathway neurones. 
 
Neurosteroids were the focus of the thesis because they are known to modulate 
the GABAAR and therefore potentially enhance neural inhibitory tone, which may 
be altered in pathological states such as type-1 diabetes mellitus (T1DM; Chen & 
Pan, 2002).  Reduced inhibitory tone is associated with hypersensitivity to pain 
and neurosteroids may have analgesic effects in inflammatory pain (Chen & Pan, 
2002; Poisbeau et al., 2005).  Pharmacological blockade of either the GABAAR, or 
the GlyR, results in hyper-excitability of dorsal horn neurones, which is associated 
with neuropathic pain symptoms (Charlet et al., 2008; Yaksh, 1989). The LII 
neurones of the dorsal horn of the spinal cord receive fast synaptic inhibition 
mediated by GlyRs and GABAARs (Chery & De Koninck, 1999; Keller et al., 2001).  
The organisation of LII is complex, but there are thought to be four main cell-types, 
including: islet, vertical, radial and central cells (Yasaka et al., 2010).  The four 
different cell types within LII enable this layer to have a critical role in the 
transmission, integration and modulation of nociceptive signals within the dorsal 
horn (Poisbeau et al., 2005).  However, the heterogeneity of cell types and 
therefore also the synaptic connections was reflected in the decay time of GABAAR 
mIPSCs of LII neurones.  This meant that while there was a clear reduction of the 
decay time of GABAAR mIPSCs of LII neurones with development, there could also 
be considerable difference in mIPSC decay time between two neurones from the 
same slice of spinal tissue and also within an individual neurone.  The relatively 
wide variation in decay time of LII GABAAR mIPSCs was consistent with the 
literature (Mitchell et al., 2007) but made it very challenging to assess the effects of 
pharmacological agents on decay time.  In contrast, nRT neurones are more 
uniform and exhibit relatively homogenous GABAAR mIPSCs with higher frequency 
than LII neurones. These properties facilitate the use of pharmacological 
manipulation in order to assess GABAAR function with greater precision.  For this 
reason, the initial recordings with -CD to investigate the neurosteroid tone were 
performed in nRT neurones in order to establish the optimum method of 
administration and to characterise its effects at different stages of development.  
However, it is not practical to make recordings from the nRT neurones of mice 
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over the age of P25 due to the high density of axonal projections that obscures 
visualisation of individual neurones (Cox et al., 1997; Pinault & Deschenes, 1998).  
Therefore, the nRT was an unsuitable region to study the impact of T2DM in the 
ob/ob mouse, which manifests diabetic neuropathy by the age of ~P60 (Drel et al., 
2006; Latham et al., 2009).  Layer 2/3 neurones of the cerebral cortex are involved 
in the pain pathway, exhibit relatively homogenous GABAAR mIPSCs at high 
frequency and do not have dense axonal projections.  Therefore, cortical neurones 
provided an opportunity to study GABAAR mIPSCs of mature WT and diabetic mice 
and also facilitated the effect of neurosteroid compounds to be studied.  However, 
while cortical neurones were used for the later electrophysiological experiments, 
the effects of neurosteroids were studied at all three levels of the pain pathway.   
 
7.3 GABAARs from pain pathway neurones are sensitive to modulation by 
neurosteroids. 
 
The neurosteroid allopregnanolone and the closely related synthetic analogue 
ganaxolone have proven efficacy in enhancing the function of synaptic GABAARs in 
the murine dentate gyrus, ventrobasal thalamus, cerebral cortex and the rat spinal 
cord (Belelli & Herd 2003; Brown, 2012; Hosie et al., 2006; Mitchell et al., 2007). 
Importantly, in LII spinal neurones, acutely applied allopregnanolone exerted a 
significantly greater prolongation of GABAAR mIPSC decay time at P17-25 than at 
P8-11. This is consistent with the hypothesis that the neurosteroid tone of LII 
neurones decreases with development, although an altered neurosteroid-
sensitivity of the synaptic GABAARs cannot be excluded.  P17-25 neurones of the 
nRT were sensitive to the modulatory effect of ganaxolone, which induced an 
increase in GABAAR mIPSC decay time.  However, the effect was significantly less 
than allopregnanolone had in LII spinal neurones of the same developmental age.  
Both allopregnanolone and ganaxolone were applied acutely to adult layer 2/3 
neurones of the cerebral cortex to confirm that the GABAAR mIPSCs of these 
neurones were sensitive to these neurosteroid agents.  At a concentration of 1 μM 
both compounds increased the decay time of cortical GABAAR mIPSCs by a 
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similarly modest amount, as did ganaxolone (3 μM).  This raised the question of 
whether the synaptic GABAARs were in conditions of saturation, or (more likely) 
whether slice tissue penetration was a major rate-limiting factor.  Nevertheless, 
neurones from all three levels of the pain pathway express GABAARs that are 
sensitive to the effect of neurosteroids.    
In order to explore the role that an endogenous neurosteroid tone may have in 
modulating the GABAARs of pain pathway neurones, experiments were performed 
with γ-CD (a barrel-shaped cyclic oligomer of glucose).  γ-CD does not modulate 
the GABAAR directly, but is able to scavenge lipophilic agents such as neurosteroids 
and thus prevent them from exerting their effects on the membrane-bound 
GABAARs (Shu et al., 2004, 2007).  Keller et al., (2004) proposed that there is a 
relatively high neurosteroid tone early in development that is significantly 
diminished with maturation.  This hypothesis has been confirmed in VB neurones 
of the thalamus where -CD reduced the decay time of GABAAR mIPSCs at P7-8, but 
not at P10 or P20-24 (Brown, 2012).  In order to confirm the optimal method of 
administration of -CD, I made recordings from P6-7 nRT neurones using three 
methods of application.  1) γ-CD was presented intracelluarly within the recording 
electrode, 2) γ-CD was applied via the extracellular solution, or 3) γ-CD was 
included in the pipette, in the extracellular recording solution and in the 
incubation chamber containing the brain slice preparation prior to recording (i.e. 2 
hours of preincubation). The intracellular application of γ-CD significantly 
decreased exponential decay time of synaptic GABAergic events in P6-7 nRT 
neurones.  However, when γ-CD was only present in the extracellular solution for 
at least 5 minutes, the mIPSC decay (τW) was not decreased significantly.  
Furthermore, when γ-CD was present intracellularly, extracellulary and within the 
pre-incubation chamber it exerted no more effect than when it was only present 
intracellularly.   This finding was consistent with what has been observed in 
neurones of the ventrobasal thalamus, which have a reciprocal synaptic 
arrangement with nRT neurones (see Introduction: section 1.1.7; Brown, 2012).   
Subsequent to the experiments at P6-7, recordings were made from nRT neurones 
aged P9-10 and P17-25.  In contrast to the significant effect of pipette-applied γ-CD 
nRT GABAAR mIPSCs on at P6-7, γ-CD had no effect at P9-10 and P17-25.  This 
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finding is also consistent with data for neurones of the ventrobasal thalamus at 
similar stages of development (Brown, 2012).  Taking this into consideration, the 
findings in the nRT neurones are consistent with the hypothesis that there is a 
relatively high neurosteroid tone early in development that is significantly 
diminished with maturation (Keller et al., 2004).    
In parallel with the γ-CD experiments in the nRT and ventrobasal thalamus, the 
effect of γ-CD has also been investigated in layer 2/3 neurones of the cerebral 
cortex (Brown, 2012).  Previous investigations have revealed that there is also an 
endogenous neurosteroid tone early in development (P7-P15) that is lost by ~P20 
(Brown, 2012).  I made recordings with γ-CD at P9-10 and P60-75 to confirm these 
results.  Interestingly, I obtained very similar results at P9-10, but at the much 
later stage of P60-75 I discovered that a modest endogenous neurosteroid tone 
appeared to have re-emerged as revealed by the impact of -CD at this stage.  The 
change at P60-75 was unexpected and indicates that the loss of neurosteroid tone 
at P20 may only be a temporary developmental phenomenon.  This finding raises 
the possibility that an endogenous neurosteroid tone may play an active role in the 
maintenance of GABAergic physiological neural inhibition in adult animals as γ-CD 
does not influence the GABAAR directly (Shu et al., 2004, 2007) and will be 
discussed further below. 
 
7.4 The role of neurosteroids on mature layer 2/3 neurones from the 
cerebral cortex of WT mice. 
 
My data confirming that there is a neurosteroid tone present in pain pathway 
neurones is important because the loss of GABAergic spinal descending inhibitory 
tone is associated with neuropathic hypersensitivity (Munro et al., 2009; von Hehn 
et al., 2012; Yaksh, 1989; Zeilhofer, 2008). Consequently, progesterone-derived 
neurosteroid compounds have been investigated as possible analgesic agents for 
inflammatory, nociceptive and neuropathic pain (Asiedu et al., 2012; Meyer et al., 
2010; 2011; Poisbeau et al., 2005). Although there are numerous causes of 
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neuropathic pain, T2DM is one of the most common worldwide and therefore of 
specific societal relevance (Davies et al., 2006; Edwards et al., 2008; Kaplan, 2006).  
Mouse models for T2DM such as the ob/ob and db/db mice have been 
characterised and established as being reliable and spontaneous exhibitors of 
neuropathy by the age of P60-75, which facilitated their use in my project (Drel et 
al., 2006, Latham et al., 2009; Sullivan et al., 2006). However, before performing 
experiments on mice with T2DM, it was necessary to explore the effects of 
neurosteroids on inhibitory synapses of L2/3 cortical neurones of WT control 
mice, (refer to Figure 3 for details of the neurosteroid synthesis pathway).  
Subsequently my work focused solely on L2/3 neurones of the cerebral cortex in 
order to explore whether these neurones are sensitive to neurosteroids and 
whether they have the enzymes necessary for endogenous synthesis.   
Allopregnanolone and its synthetic analogue ganaxolone exerted a similarly 
modest prolongation of the decay time of GABAAR mIPSCs in mature WT L2/3 
cortical neurones when applied acutely via the extracellular bath.  In addition, a 
three-fold increase in the concentration of acutely applied ganaxolone made no 
difference to the magnitude of this effect. These results may suggest that such 
steroids have a limited efficacy at these inhibitory synapses of mature cortical 
neurons, or alternatively the results are consistent with the concept that drug 
penetration of the brain slice tissue may be a significant effect-limiting factor 
(Benkwitz et al., 2007; Gredell et al., 2004).  In contrast to the relatively modest 
prolongation of GABAAR mIPSCs by acute allopregnanolone described above, a 
two-hour pre-incubation of the brain slice with allopregnanolone produced a large 
increase in the decay time of cortical GABAAR mIPSCs in a concentration-
dependant manner.  
Acute ganaxolone also had a similar modulatory effect on GABAAR mIPSCs as 
allopregnanolone. In common with allopregnanolone, pre-incubation greatly 
increased the effect of ganaxolone on mIPSC duration, although it was still not as 
potent in this respect as allopregnanolone. The lower potency of ganaxolone is 
broadly consistent with previous work in rat brain cortical membranes, which 
indicated that allopregnanolone was 1.6-fold more potent than ganaxolone in that 
setting (Carter et al., 1997).   Ganaxolone is a synthetic neuroactive steroid with a 
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very similar structure to allopregnanolone except for the addition of a methyl 
group at the 3 position of the steroid A-ring.  The methyl group, protects the 
critical 3α- hydroxyl group from metabolism to DHP (Carter et al., 1997). The 
apparent metabolic stability makes it more effective than allopregnanolone in 
dentate gyrus neurones, which express the enzyme 3 -HSD (Belelli & Herd, 2003) 
and enhances its therapeutic potential as it has a long half-life (~20 hours; 
Luszczki, 2009; Monaghan et al., 1997; Nohria & Giller, 2007).  In humans, 
ganaxolone is metabolised by the hepatic cytochrome enzyme CYP3A4 to 16-OH-
GNX and undergoes renal and alimentary elimination (Luszczki, 2009; Nohria & 
Giller, 2007).   
The large difference in the effect of acute application and two-hour incubation of 
allopregnanolone and ganaxolone is consistent with the slow brain slice 
penetration time observed with the lipophilic anaesthetics etomidate and propofol 
(Benkwitz et al., 2007; Gredell et al., 2004).  However, the difference in the efficacy 
between allopregnanolone and ganaxolone incubation treatments raises the 
question of why the apparently more metabolically stable compound is less 
effective. The next section considers the effect of the intracellular application of 
these drugs via the recording pipette, which overcomes the issue of brain slice 
penetration, while minimising the potential for metabolism to occur.  This method 
also explores the potential for autocrine modulation of the GABAAR by 
neurosteroid compounds. 
Pipette-applied allopregnanolone has previously been investigated in hippocampal 
neurones without evidence of efficacy. However, the authors had only used 
nanomolar concentrations of the steroid (Park et al., 2011).  In contrast, Akk et al., 
(2005) were able to confirm that the pipette is a viable method of drug application 
using the synthetic neuroactive steroid (3 5 ,17 )-3-hydroxyandrostane-17-
carbonitrile in HEK293 cells.  This steroid is membrane-impermeable and was able 
to modulate the GABAAR when administered intracellularly.  In keeping with the 
results from Akk et al., (2005), pipette-applied allopregnanolone and ganaxolone 
induced significant increases in the GABAAR-mediated mIPSC decay time of L2/3 
cortical neurones. Interestingly, intracellular allopregnanolone induced a greater 
prolongation of GABAAR mIPSC decay time than ganaxolone. Collectively, these 
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results are consistent with the proposal that allopregnanolone has a greater 
potency for cortical GABAARs than ganaxolone and/or that ganaxolone is 
converted to allopregnanolone.  The effectiveness of intracellular neuroactive 
steroid administration is also consistent with the reduction of GABAAR mIPSC 
decay time observed in the presence of intracellular γ-CD.  Hence, GABAARs may be 
subject to physiological autocrine modulation by endogenous neurosteroids (Akk 
et al., 2005; Chisari et al., 2009).  
 
7.5 Intracellularly applied γ-CD reduces the decay time of GABAAR mIPSCs of 
layer 2/3 cortical neurones in mature WT mice. 
 
In the first Results section, γ-CD was used to reveal the presence of endogenous 
neurosteroids at different stages of development and at different levels of the pain 
pathway. The results were consistent with the presence of a relatively high 
neurosteroid tone in early life that diminishes during development, but reappears 
in mature cortical neurons, suggesting a physiological role.  For example, in 
inflammatory pain neurosteroid levels may be up-regulated in spinal cord 
neurones in order to mediate an endogenous analgesic effect (Poisbeau et al., 
2005).  The CDs were used to investigate the apparent neurosteroid tone in mature 
L2/3 cortical neurones based on previous experience with these compounds.  In 
order to address the issue that -CD itself may be affecting GABAAR function 
directly, recordings with -CD and -CD were made in L2/3 cortical neurones of 
mature WT mice.  The three principle types of CD are the -CD hexamer, the -CD 
heptamer and the -CD octomer and they have internal diameters of 5.2 nm, 6.4 nm 
and 8.3 nm respectively (Cooper et al., 2005; Davis & Brewster, 2004; Ohtani et al., 
1989; see section 1.3.3 of the Introduction for more details).  My recordings 
confirmed that the smaller -CD and -CD had no impact on GABAAR mIPSCs. This 
suggests that the size and structure of the CD ring may be critical to its ability to 
sequester lipophilic compounds such as neurosteroids efficiently and also that -
CD may not exert a significant direct effect on cortical GABAARs or the lipid 
membrane itself, which is consistent with the findings of Shu et al., (2007).  
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The apparent removal of neurosteroid tone observed with -CD is consistent with 
the literature (Brown, 2012; Shu et al., 2004; 2007) as was the lack of effect of -
CD (Brown, 2012; Shu et al., 2004). The lack of effect of -CD on the GABAAR is 
consistent with data published by Shu et al. (2004).  However, it conflicts with 
conclusions reached by Pytel et al. (2006), that -CD decreased the desensitisation 
kinetics of the GABAAR to GABA by direct modulation of the receptor itself within 
outside-out patches of cultured hippocampal neurones.  The mechanism for this 
direct modulation was uncertain and the findings of Pytel et al. (2006) have yet to 
be replicated.  Separately, incubation with ADVASEP-7 (a different isomer of -CD) 
was shown to be able to prevent allopregnanolone from augmenting the effect of 
ethanol incubation in hippocampal neurones within brain slices (Murayama et al., 
2006). 
The three types of CD discussed above may be relatively non-specific scavengers of 
lipophilic compounds, which raises the possibility that they could remove other 
endogenous GABAAR-modulatory compounds. For instance, γ-CD is able to 
sequester 9-tetrahydrocannabinol, but is less effective than both -CD and -CD, 
which are used as vehicles to sequester cannabinoids and deliver them in patients 
with eye disorders such as glaucoma (Hippalgaonkar et al., 2011; Kearse & Green, 
2000; Loftsson & Brewster, 2011; Mannila et al., 2005). In my experiments, 
pipette-applied -CD and -CD had no effect on cortical GABAAR mIPSC decay time, 
while γ-CD induced a significant effect.  Unpublished data by a former laboratory 
colleague found that in HEK cells, γ-CD was unable to sequester cannabinoids 
effectively (Holmgren, Unpublished).  Thus the possibility that the γ-CD effect in 
my experiments is related to the sequestration of endocannabinoids is unlikely.  In 
addition, while γ-CD is able to sequester allopregnanolone, it is not able to 
sequester the benzodiazepine lorazepam (Shu et al., 2004), making the 
involvement of any theoretical endogenous benodiazepines also unlikely. 
If -CD is able to sequester endogenous neurosteroids, then it should also be able 
to do likewise for exogenously applied neurosteroids. Following brain slice 
incubation with ganaxolone, or DHP, pipette-applied -CD reduced but did not 
eliminate the effects of the neuroactive steroid, or the neurosteroid precursor. 
These findings are consistent with the idea that -CD is indeed able to sequester 
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neuroactive steroids in this setting, but that -CD may become saturated (Loftsson 
& Brewster, 1996) and therefore surplus neurosteroid would be able to modulate 
the GABAAR (Shu et al., 2004). These findings are also consistent with reports in 
the literature of -CD being able to reverse the effect of allopregnanolone on 
GABAARs of Xenopus laevis oocytes (Shu et al., 2004; 2007).  In addition, using 
cultured hippocampal neurones, Shu et al., (2007) found that the intracellular 
accumulation of the fluorescently-tagged analogue of allopregnanolone, C11-NBD-
3 5  could be reduced by the application of -CD.  The effect of -CD was thought 
to be due to the sequestration of C11-NBD-3 5  from the neuronal membrane.  
Shu et al., (2007) also reported that -CD sequestered other neuroactive steroids 
such as alphaxolone, pregnane sulphate and 3 5β-THDOC in cultured hippocampal 
neurones.  
 
7.6 Can mature layer 2/3 cortical neurones synthesise neurosteroids?  
 
My previous experiments have demonstrated that L2/3 cortical GABAARs are 
sensitive to neurosteroids and that there appears to be an endogenous 
neurosteroid tone.  The next part of my study explored the neurosteroid synthesis 
pathway (Figure 3) in order to test whether L2/3 cortical neurones are able to 
manufacture progesterone-derived neurosteroids.  Two hours of incubation with 
the neurosteroid precursor progesterone produced a modest prolongation of 
cortical GABAAR mIPSC decay time in WT mice that was not concentration-
dependent from 1 M - 50 M. These data indicate that L2/3 cortical neurones are 
able to synthesise GABAAR-modulatory neurosteroids when their precursor is 
administered by brain slice incubation, suggesting that enzymatic function (5 -R 
and 3 -HSD) is intact.  This is consistent with a previous report in spinal dorsal 
horn neurones from rats (Inquimbert et al., 2008), in which the authors found that 
incubation of spinal cord slice tissue with progesterone prolonged the decay time 
of GABAAR mIPSCs.  Interestingly, the authors also demonstrated that co-
incubation with the 5 -R inhibitor finasteride prevented the effect of progesterone 
on GABAAR mIPSCs but had no impact when administered alone (Inquimbert et al., 
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2008).  Finasteride pre-treatment is also known to be able to prevent the 
conversion of progesterone into its active neurosteroid metabolites in the 
hippocampal CA1 neurones of mature mice (Sanna et al., 2004). Inhibition of 5 -R 
activity also reduces the duration of synaptic GABAergic events in immature 
neurones of LII of the spinal cord, the ventrobasal thalamus and of the cerebral 
cortex (Brown, 2012; Inquimbert et al., 2007; Keller et al., 2004; Puia et al., 2003). 
However, finasteride was ineffective in LII neurones of rats aged > P30 (Keller et 
al., 2004) and separately in LII neurones aged > P21 (Inquimbert et al., 2008). 
These reports are consistent with the hypothesis that there is a high endogenous 
neurosteroid tone in immature animals that has a significant modulatory effect on 
the GABAAR (Inquimbert et al., 2008; Keller et al., 2004). Consistent with these 
reports, in my experiments, finasteride had no effect on GABAAR mIPSCs, but was 
able to block the effect of progesterone. However, the lack of effect of finasteride 
on GABAAR mIPSCs contrasts to the significant effect of -CD described earlier.  
This difference may be accounted for as follows: -CD was pipette-applied directly 
into the intracellular compartment of the neurone and could thus exert an 
immediate scavenging effect.  Finasteride is able to prevent the conversion of 
progesterone to more active metabolites, but it would not be able to remove the 
active neurosteroids that were already present.  Further experiments with much 
longer finasteride incubations could attempt to investigate this matter but it would 
be challenging to keep the brain tissue from mature animals viable for such a long 
duration (i.e. 6-12 hours).  Poisbeau et al., (2005) reported that spinal cord slice 
incubation with finasteride for more than six hours had no impact on the decay 
time of GABAAR mIPSCs in LII neurones of rats aged >P30.  However, they also 
found that it took at least five hours of incubation with finasteride to inhibit the 
prolongation of GABAAR mIPSCs associated with carrageenan (seaweed) - induced 
peripheral inflammation (Poisbeau et al., 2005).  Alternatively, finasteride could be 
injected systemically into live mice at specific times before performing 
electrophysiological work on their brain tissue to confirm the presence of the 
endogenous neurosteroid tone by another method.  Indeed, Puia et al., (2003) 
found that a single in vivo intraperitoneal injection of the 5 -R inhibitor 
SKF105111 caused a rapid decrease in the duration of synaptic GABAergic events 
that lasted more than five hours in the cortical neurones of mice.  Intraperitoneal 
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application of SKF105111 was significantly more effective and occurred sooner 
than was observed with brain slice incubation treatment (Puia et al., 2003). 
The progesterone metabolite DHP is the direct precursor of allopregnanolone, but 
does not modulate the GABAAR directly (Belelli & Herd, 2003; Brown, 2012).  In 
keeping with this fact, I found that when DHP was applied acutely either via the 
extracellular bath or via the pipette it had no effect on cortical GABAAR mIPSCs.  In 
contrast, two-hours of incubation with DHP produced a significant, concentration-
dependent prolongation of L2/3 cortical GABAAR-mediated mIPSC decay time in 
WT mice suggesting that 3 -HSD function is both required and also preserved in 
this setting (Belelli & Lambert, 2005; Mellon et al., 2001; Schumacher et al., 2012; 
Stoffel-Wagner, 2003).  A former laboratory colleague discovered previously that 
DHP reached its peak effect after two hours, at which time there was a plateau in 
the modulation of GABAAR mIPSCs in neurones of the ventrobasal thalamus 
(Brown, 2012).  In addition, the effect of DHP incubation treatment could be 
reduced by pipette-applied -CD in a similar fashion to that of ganaxolone 
incubation treatment, consistent with the idea that DHP is metabolised to GABAAR 
modulatory neurosteroid metabolites.   
To further investigate the concept of DHP as a precursor, I investigated the effect of 
inhibitors of 3-αHSD, including provera and indometacin.  Provera inhibits 3 -HSD 
and therefore prevents the conversion of DHP to allopregnanolone (Belelli & Herd, 
2003; Belelli & Lambert, 2005; Sunde et al., 1982).  As described in section 1.3.3 of 
the Introduction, 3 -HSD can also catalyse the reverse reaction of 
allopregnanolone to DHP, thus inhibition of this enzyme enhances the effect of 
exogenously applied allopregnanolone in dentate gyrus neurones of rats (Belelli & 
Herd, 2003). Interestingly, in such dentate gyrus neurones, the synthetic 
neurosteroid ganaxolone had a greater effect on GABAergic synaptic events than 
allopregnanolone, which could be inactivated by 3 -HSD (Belelli & Herd, 2003). In 
my studies, provera inhibited the effect of DHP but not ganaxolone, which was 
consistent with reports in the literature and also the idea that inhibition of 3 -HSD 
has no direct effect on the GABAAR in itself (Belelli & Herd, 2003). 
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Indometacin has an entirely different molecular structure to provera, but it is also 
an effective inhibitor of the enzyme 3 -HSD (Askonas et al., 1991; Belelli & Herd, 
2003; Belelli & Lambert, 2005; Duax et al., 1978; Hori et al., 2006; Inquimbert et al., 
2008; Sunde et al., 1982). Indometacin prevented the effect of DHP on GABAAR 
mIPSCs, which was consistent with the effect of provera.  However, indometacin 
also inhibited the effect of ganaxolone incubation treatment on GABAAR mIPSC 
duration. These results were unexpected, given that ganaxolone is a closely related 
synthetic structural analogue of allopregnanolone and interacts directly with the 
GABAAR to enhance function (Belelli & Herd, 2003; Belelli & Lambert, 2005; Carter 
et al., 1997). One possible explanation for these findings would be that 
indometacin, although having no effect on GABAAR function per se competes for the 
GABAAR binding site with ganaxolone, but not allopregnanolone, although given 
their structural similarity this appears unlikely.  Another possible explanation is 
that ganaxolone could be a precursor for allopregnanone and indometacin is 
preventing the enzymatic demethylation of ganaxolone.   
In order to investigate if indometacin had a direct modulatory effect on the cortical 
GABAARs, recordings were made in WT mice after at least two hours of incubation 
with the drug. Indometacin had no effect on the GABAAR mIPSC decay time of 
cortical neurones from either WT or diabetic mice.  This contrasts to the modest 
modulatory effect of provera in WT cortical neurones (see Section 4.12) and also to 
the previous report of the ability of indometacin (and provera) to prolong the 
GABAAR mIPSC decay time of dentate gyrus neurones by inhibiting the inactivation 
of allopregnanolone (Belelli & Herd, 2003).  However in other experiments by the 
same authors, neither indometacin nor provera prolonged the decay time of 
GABAAR mIPSCs of hippocampal CA1 pyramidal neurones (Belelli & Herd, 2003).  
Indeed, the differential impact of neurosteroids may be related to neurone-specific 
differences in local steroid metabolism (Belelli & Herd, 2003).  My studies also 
included recordings where indometacin was applied intracellulary via the 
recording pipette.  Indometacin had no effect on cortical GABAAR mIPSCs of L2/3 
cortical neurones and when it was co-applied with ganaxolone in the pipette it did 
not alter the impact of ganaxolone.  These findings are inconsistent with the idea 
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that indometacin could be preventing the effect of ganaxolone incubation 
treatment by competing for the GABAAR with ganaxolone. 
Interestingly, in humans, indometacin itself is metabolised by hepatic 
demethylation to inactive metabolites principally by the enzyme CYP2C9, a 
subtype of the cytochrome P450 family of enzymes (Nakajima et al., 1998).   The 
expression of the CYP2C subfamily of enzymes is variable between mammalian 
species, but it is expressed in several regions including the CNS of humans and 
rodents and notably, the cerebral cortex (Gervasini et al., 2001; McFadyen et al., 
1998; Miksys & Tyndale, 2002; Oyama et al., 2004).  The CYP2C subfamily of 
enzymes is known to metabolise neurosteroids (McFadyen et al., 1998; Miksys & 
Tyndale, 2002) and cholesterol is metabolised to pregnenolone by the enzyme 
CYP450scc (Miksys & Tyndale, 2002; Schumacher et al., 2012). Therefore, it is 
theoretically possible that indometacin could compete with ganaxolone for the 
demethylating effects of the CYP2C9 enzyme.  This would explain why ganaxolone 
incubation treatment is less effective than allopregnanolone and inhibited by 
indometacin but not provera (in contrast to DHP which is inhibited by both drugs).  
It would also explain why pipette-applied ganaxolone is less effective than 
allopregnanolone and is not inhibited by indometacin in the pipette.  The putative 
demethylation of ganaxolone within the cortical neurones could be investigated in 
future experiments using inhibitors and inducers of the CYP2C9 enzyme such as 
valproic acid and rifampicin respectively (Chen et al., 2004; Chen & Goldstein, 
2009; Wen et al., 2001). 
My experiments using neurosteroid precursors and enzyme inhibitors indicate 
that enzymatic function (5 -R and 3 -HSD) and therefore neurosteroidogensis is 
preserved in mature L2/3 cortical neurones.  The effect of neurosteroids on 
GABAAR mIPSCs after two-hour incubation is as follows: allopregnanolone > 
ganaxolone > DHP > progesterone.  The differences in effect on GABAAR mIPSCs 
decay times is considerable and is consistent with the concept of sequential rate-
limiting enzymatic steps between progesterone and allopregnanolone (Mellon et 
al., 2001; Rupprecht et al., 2010; Schumacher et al., 2012; Stoffel-Wagner, 2003).   
It could be of physiological benefit for neurones to possess a reservoir of inactive 
precursors that could be converted to modulate the GABAAR only when required.  
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In this way, GABAAR function could be fine-tuned up or down, rapidly and 
reversibly in an autocrine manner. 
Indeed, -CD (but not -CD or β-CD) is able to sequester neurosteroids when 
applied intracellularly and is in fact most effective when applied via this route 
(rather than extracellular bath application).  In addition, the neuroactive steroids 
allopregnanolone and ganaxolone (but not DHP) are able to modulate GABAAR 
function when applied intracellularly.  These findings do not prove that 
neurosteroids may act in an autocrine manner in cortical neurones, but that is the 
most likely explanation and is consistent with data published previously by Akk et 
al., (2005) using a membrane-impermeable steroid.  Experiments with isolated 
neurones in culture could also explore this issue further in order to determine 
conclusively whether autocrine modulation is occurring.  These could involve 
making electrophysiological recordings before the application of the lowest 
concentration of -CD required to remove the endogenous neurosteroid tone, then 
continuing to record for prolonged periods of time to allow for de novo 
neurosteroidogenesis.  Additionally, precursors and inhibitors could also be 
employed in these isolated neurones in a similar fashion to my experiments in 
brain slice tissue. 
 
7.7 The role of neurosteroids on mature layer 2/3 neurones from the 
cerebral cortex of ob/ob and db/db mice. 
 
As yet, there are no published reports of the electrophysiological characterisation 
of synaptic GABAAR function for T2DM.  It was therefore unknown whether 
neurosteroid tone would be altered in mice with diabetic neuropathy.  In 
inflammatory pain, neurosteroidogenesis is up-regulated to mediate a form of 
endogenous analgesia by enhancing GABAergic neural inhibition (Poisbeau et al., 
2005). The ob/ob model of T2DM is particularly useful for the study of neuropathic 
pain because it develops a more clinically relevant form of diabetes than other 
models (Cefalu, 2006; Drel et al., 2006; Latham et al., 2009; Lindstrom, 2009; 
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Neubauer and Kulkarni, 2006; Sullivan et al., 2007).  However, it should be noted 
that no animal model of diabetes fully replicates the human phenotype.   ob/ob 
mice are deficient of the hormone leptin and it was considered that leptin itself 
may modulate GABAAR function (Solovyova et al., 2009).  Therefore, in order to 
exclude leptin as a potential cause of any changes observed, recordings were made 
in a second mouse model of T2DM, the db/db mouse.   As described in the 
introduction section, the db/db mouse is able to synthesise leptin but lacks the 
leptin receptor.  As a result, the db/db mouse develops super-morbid obesity, but 
has a more dramatic diabetic phenotype than the ob/ob and also manifests a more 
severe form of neuropathy at the same age (Bates et al., 2005; Cefalu, 06; Neubauer 
& Kulkarni, 2006).   
I discovered that the GABAAR mIPSCs from both ob/ob and db/db mice had 
significantly shorter decay times than the three WT strains.  There are numerous 
possible reasons for this finding including changes to the sensitivity of the GABAAR 
itself or changes in the levels of endogenous modulators such as neurosteroids.   In 
view of the fact that the same changes were present in both models of T2DM it 
appears that leptin is unlikely to be involved.  The ob/ob and db/db mice have 
entirely different mutations, which suggest it is also unlikely that there is a 
unifying intrinsic genetic modification of the GABAAR itself such as an alteration in 
subunit composition (Chen et al., 1996; Chung et al., 1996; Zhang et al., 1994).  A 
decrease in the sensitivity of the GABAAR to allosteric modulators such as 
neurosteroids is a possible explanation for the shorter GABAAR mIPSC decay times.  
However, reduced GABAAR sensitivity is inconsistent with the exaggerated effect of 
ganaxolone and DHP in ob/ob cortical neurones and the similar effect of 
allopregnanolone in both WT and diabetic cortical neurones.  A possible 
explanation may be that in ob/ob and db/db mice there is a reduction in the 
endogenous neurosteroid tone, which is caused by a common pathological insult 
associated with T2DM.  A reduced neurosteroid tone could result in diminished 
GABAergic inhibition and subsequently a hypersensitive phenotype as explored in 
the behavioural experiments.  It is possible that other endogenous compounds that 
modulate the GABAAR such as cannabinoids or the theoretical endozepines may be 
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affected by a common mechanism in T2DM; however the selective effects of -CD 
(in comparison to the lack of effect with -CD and β-CD) make this less likely.    
There are also reports in the literature that relatively minor genetic differences 
between mouse colonies could have significant functional impacts in 
neurodegenerative conditions (Chandra et al., 2005; LaCroix-Fralish et al., 2009; 
Wijnvoord et al., 2010).   The initial control recordings were carried out in WT 
mice (Charles River UK Ltd), however, the ob/ob and db/db mice are only available 
in the UK from a single source (Harlan Laboratories, UK) and the background 
strains are different for each type of mouse.  The three strains are: C57/BL6, B6.V-
Lep+/OlaHsd and BKS.Cg-Dock7m+/Dock7m+/OlaHsd respectively.  To control for 
potential differences in strains, recordings were made from the lean WT 
littermates of both models of T2DM, and there were no differences between the 
three WT strains.   
My experiments with γ-CD indicate the presence of a relatively high neurosteroid 
tone in early life that diminishes during development, but reappears in mature 
L2/3 cortical neurones.   Recordings were made with γ-CD in ob/ob and the db/db 
mice and in the three representative WT strains to explore the putative 
endogenous neurosteroid tone.  Interestingly, γ-CD (but not -CD and -CD) 
reduced the GABAAR mIPSC decay time to similar baseline values for all five lines 
of mice.  These findings are consistent with the hypothesis that mature WT mice 
possess an endogenous neurosteroid tone that is reduced in ob/ob and the db/db 
mice, but that underlying GABAAR function and sensitivity are otherwise 
unchanged in cortical neurones from diabetic mice.  Thus, in neuropathic pain 
associated with diabetes neurosteroid levels may be reduced, which contrasts to 
inflammatory pain, where neurosteroid levels may be up-regulated in order to 
mediate an endogenous analgesic effect (Poisbeau et al., 2005).  This is important 
because ob/ob mice exhibit hypersensitivity to mechanical stimuli and loss of 
neuronal inhibition may also be associated with hypersensitivity (Eto et al., 2011).   
 
227 
 
7.8 The effect of neurosteroids on the decay time of GABAAR mIPSCs from 
mature layer 2/3 cortical neurones of ob/ob mice. 
 
Interestingly, despite the shorter baseline decay time of GABAAR mIPSCs from 
layer 2/3 cortical neurones of ob/ob mice, the acute application of 
allopregnanolone or ganaxolone exerted the same modest effects as they had in the 
WT mice.  In addition, two-hour brain slice incubation with allopregnanolone 
produced the same dramatic concentration-dependent increase in GABAAR mIPSC 
decay time in diabetic mice that it had done in WT mice.  In keeping with these 
findings, pipette-applied allopregnanolone induced the same concentration-
dependent increase in GABAAR mIPSC decay time, in ob/ob mice as it had done in 
WT mice.  These results are consistent with the idea that GABAAR sensitivity to 
allopregnanolone may be very similar in both WT and diabetic mice because 
allopregnanolone does not require enzymatic conversion to exert its effects on the 
GABAAR.  They are also consistent with the idea that the shorter decay time of 
GABAAR mIPSCs of L2/3 cortical neurones of ob/ob mice is due to a reduction in 
endogenous neurosteroid tone that can be rescued by allopregnanolone.  The 
alternative explanation, i.e. that the GABAARs of ob/ob mice are less sensitive to 
endogenous allopregnanolone is unlikely because exogenously applied 
allopregnanolone has the same effect in both WT and ob/ob mice. 
When ganaxolone was applied acutely via the extracellular bath or intracellularly 
via the recording electrode, the drug had the same effect in both ob/ob and WT 
mice, which supports the argument that there is no difference in the sensitivity of 
the GABAAR to this neuroactive steroid in diabetic mice.  However, these results 
contrast with the greater impact of ganaxolone incubation treatment observed in 
ob/ob mice compared with WT mice and permits the possibility that ganaxolone 
may potentially be demethylated to allopregnanolone in order to exert maximal 
effect on cortical GABAARs.  The idea of ganaxolone as both an agonist and 
precursor to allopregnanolone would also be consistent with the relatively larger 
effect of ganaxolone incubation in ob/ob mice, which may exhibit an upregulation 
of key enzymes such as CYP2C and 3 -HSD as indicated by the increased effect of 
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DHP (the endogenous precursor of allopregnanolone) on ob/ob cortical neurones.  
The inhibitory effect of indometacin on ganaxolone incubation treatment is also 
consistent with the notion of ganaxolone as an active precursor of 
allopregnanolone as discussed in the previous chapter.  In keeping with the data 
obtained from WT L2/3 cortical neurones, indometacin had no impact on ob/ob 
cortical neurones when present in the pipette or after two hours of incubation 
treatment.  In addition, when indometacin and ganaxolone were co-applied within 
the pipette, indometacin had no impact on the ability of ganaxolone to prolong 
cortical GABAAR mIPSCs.  
 
7.9 Can mature layer 2/3 cortical neurones from diabetic mice synthesise 
neurosteroids? 
 
An alternative explanation for the shorter decay time of cortical GABAAR mIPSCs 
from diabetic mice relative to the three WT strains is that there is a reduction in 
neurosteroid synthesis.  Indeed, the consistent impact of allopregnanolone in both 
WT and ob/ob mice and the exaggerated impact of ganaxolone incubation 
treatment in the latter suggest that reduced sensitivity to neurosteroids is an 
unlikely explanation for the shorter GABAAR mIPSCs.  Therefore it may be due to 
reduced neurosteroid synthesis in mice with diabetic neuropathy.  To test whether 
ob/ob mice are able to synthesise endogenous neurosteroids effectively, 
recordings were made with the precursors progesterone and DHP (see Figure 3). 
At least two hours of incubation with progesterone produced a modest 
prolongation of cortical GABAAR mIPSC decay time in ob/ob mice that was similar 
to WT controls and was not concentration-dependent from 1 M - 50 M.  
Additional recordings made at the highest progesterone concentration in db/db 
mice were no different to those of the WT or ob/ob.  These data are consistent with 
the idea that L2/3 cortical neurones of T2DM mice are able to synthesise GABAAR-
modulatory neurosteroids when their precursor (progesterone) is administered by 
brain slice incubation.  Progesterone induced a similar final prolongation of 
GABAergic exponential decay time in neurones from the diabetic mice.  This 
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suggests that enzymatic function responsible for the endogenous synthesis of 
allopregnanolone (5 -R and 3 -HSD; Figure 3) is intact in mature layer 2/3 
cortical neurones of the ob/ob and db/db mice.   Indeed, due to the shorter baseline 
decay time of L2/3 cortical GABAAR mIPSCs of ob/ob and db/db mice, progesterone 
actually had a proportionately greater effect in the diabetic mice than it had done 
in the WT controls.  In keeping with what had been observed in the WT mice, 
incubation treatment with finasteride (a 5 -R inhibitor) also had no effect on 
ob/ob cortical GABAAR mIPSCs directly, but was able to block the effect of 
progesterone in ob/ob mice.   
Two-hour incubation with DHP (the progesterone metabolite) produced a 
significant, concentration-dependent prolongation of L2/3 cortical GABAAR-
mediated mIPSC decay time in diabetic mice.  Interestingly, DHP (the 
allopregnanolone precursor) produced a greater effect in diabetic mice compared 
to WT controls despite the shorter baseline GABAAR decay time in the T2DM 
cortical GABAAR mIPSCs.  This finding suggests that not only is 3 -HSD enzymatic 
function preserved in mature mice with T2DM, but it may actually be upregulated.  
Specifically, an increase in 3 -HSD activity may be a partial compensation for a 
reduced baseline endogenous neurosteroid tone in diabetic mice.  In keeping with 
what had been observed in WT mice, pipette-applied DHP also had no effect on the 
cortical GABAAR mIPSCs of ob/ob mice.  The lack of effect of DHP is consistent with 
the DHP’s role as a metabolic precursor to the active compound allopregnanolone 
(Figure 3), i.e. there is not enough time for DHP to be metabolised and/or the 
enzyme 3 -HSD is removed by pipette dialysis. 
The underlying mechanism responsible for the reduced neurosteroid tone in the 
diabetic mice is uncertain, but may be due to mitochondrial dysfunction (Bordet et 
al., 2008; Chowdhury et al., 2012; Edwards et al., 2008; Fernyhough et al., 2010; 
Vincent et al., 2010).  It has been postulated that hyperglycaemia (high blood 
glucose concentration) has several detrimental effects including the excessive 
donation of electrons to the mitochondrial electron transport chain, which induces 
an increased production of reactive oxygen species (Chowdhury et al., 2012; 
Fernyhough et al., 2010; Vincent et al., 2010).  The increased availability of 
electrons may lead to the partial reduction of oxygen to neurotoxic superoxide 
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radicals (Chowdhury et al., 2012; Fernyhough et al., 2010).  Mitochondrial 
dysfunction could also account for both mechanical hypersensitivity associated 
with a reduction in mitochondrial-derived neurosteroids and also for thermal 
hyposensitivity associated with axonal degeneration (Chowdhury et al., 2012; Drel 
et al., 2006; Latham et al., 2009; Vincent et al., 2010).   Further detailed 
information regarding the mechanisms of mitochondrial dysfunction in diabetic 
neuropathy has been covered by other authors (Chowdhury et al., 2012; 
Fernyhough et al., 2010; Vincent et al., 2010).  The results from my behavioural 
experiments characterising the diabetic neuropathy phenotype and the response 
to the neuroactive steroid ganaxolone are considered below in further detail in the 
final section of this discussion. 
 
7.10 Overview of electrophysiological data. 
 
Analysis of the kinetics of GABAAR mIPSCs from mouse neurones in slices of tissue 
from the spinal cord, nRT and the cerebral cortex reveal that the decay time is 
reduced with development (from day 6 to 60 postpartum).  Neurones from these 
three levels of the pain pathway are also sensitive to modulation by neurosteroids. 
The use of -CD to sequester endogenous neurosteroids is known to cause faster 
mIPSC deactivation in cortical neurons during early stages of development 
implying the presence of a tone of positive allosteric modulation, a phenomenon 
that declined to negligible levels by age P20 (Brown, 2012).  However, I discovered 
that the endogenous neurosteroid tone reappears by the age of 60 days, suggesting 
that it may have a physiological role at this age. The effect of -CD on the kinetics of 
mIPSCs recorded from cortical neurons of ob/ob mice of a similar age was 
significantly smaller, implying a deficit in endogenous neurosteroid in these 
animals.  Furthermore, the mIPSCs of ob/ob mice were more responsive to the 
neurosteroid precursors DHP and progesterone.  The increased response to the 
precursors may be due to an upregulation of enzyme activity to compensate for a 
lower basal neurosteroid tone.  However there was no change in the dose-
response relationship for allopregnanolone between WT and ob/ob mice implying 
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that the sensitivity of GABAARs to neurosteroids remains unchanged even though 
the ob/ob mice start from a lower baseline.  Ganaxolone is less effective at cortical 
GABAARs than allopregnanolone, and despite having been developed as a 
metabolically stable analogue of allopregnanolone, its activity was inhibited by 
indometacin (but not provera).  In fact, ganaxolone behaves more like the 
allopregnanolone precursor DHP in that it has greater efficacy in ob/ob mice than 
WT mice.  It is possible that the demethylation of ganaxolone to allopregnanolone 
is prevented by indometacin as discussed earlier. 
The electrophysiological data suggest that there are deficiencies in GABAergic 
inhibition associated with a reduced neurosteroid tone in ob/ob mice.  Therefore I 
examined whether these deficits contributed to aberrant nociception in ob/ob 
mice, such as allodynia and hyperalgesia.  The next section will discuss the results 
of behavioural experiments in WT and ob/ob mice, with a focus on ganaxolone, 
which is considered to have greater bioavailability than allopregnanolone (Carter 
et al., 1997; Gee et al., 1995) using tests of thermal and mechanical nociception.  
 
7.11 The impact of neuropathy on behavioural measures of hypersensitivity 
and the response to neuroactive steroids.  
 
Diabetes is one of the principle causes of neuropathic pain in the human 
population and, at present, the available therapies are often ineffective 
(Bouhassira et al., 2008; Dworkin et al., 2007; Harstall & Ospina, 2003). 
Nociceptive (or physiological) pain has a protective role, alerting the individual to 
the presence of a harmful situation from which they should withdraw (Caterina et 
al., 2005; Costigan et al., 2009; Woolf & Salter, 2000).  In contrast, neuropathic pain 
results from a dysfunctional or damaged nervous system and may be associated 
with pathological hypersensitivity of the peripheral or central nervous system 
(Fischer & Waxman, 2010; Harvey & Dickenson, 2008; Merskey & Bogduk, 1994, 
Woolf & Salter, 2000). Hyperalgesia describes an exaggerated response to a painful 
stimulus, while allodynia describes an unpleasant or painful response associated 
with an innocuous stimulus (Merskey & Bogduk, 1994). Of specific relevance, 
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hypersensitivity of the spinothalamic tract has been reported in animal models of 
T1DM (Chen et al., 2001, Pertovaara et al., 2001).   
GABAARs are the major inhibitory receptors in the mammalian nervous system and 
a reduction of their function is associated with allodynia and hyperalgesia (Munro 
et al., 2009; von Hehn et al., 2012; Yaksh, 1989; Zeilhofer, 2008).  Ligands that 
specifically target the benzodiazepine binding site on GABAARs containing either 
2 or 3 subunits are effective against inflammatory and neuropathic pain without 
side effects such as sedation, tolerance and ataxia that are associated with 
anxiolytic benzodiazepines (Knabl et al., 2008).  In addition, Poisbeau et al., (2005) 
discovered an increase in neurosteroid production by spinal neurones associated 
with peripheral inflammatory pain, providing compensatory analgesia.  My 
electrophysiological experiments revealed that diabetic mice had a reduced 
endogenous neurosteroid tone, but that the neuroactive steroid ganaxolone had an 
exaggerated effect on cortical GABAAR mIPSCs.  A previous report using the tail 
flick test found that ganaxolone administered via the spinal (or intrathecal) route 
reduced thermal nociception (Asiedu et al., 2012).  In addition, systemic 
allopregnanolone, DHP and progesterone have had promising effects in rodents for 
the prevention of chemotherapy-induced neuropathic pain (Meyer et al., 2010; 
2011). 
Animal models are essential for the effective study of neuropathic diseases before 
clinical studies can be justified (Mogil et al., 2010).  However, this is particularly 
true for diabetic neuropathy because the efficacy of interventions may be studied 
over weeks or months rather than decades as is the case in human studies (Cefalu, 
2006; Kaplan & Wagner, 2006; Neubauer and Kulkarni, 2006; Rees & Alcolado, 
2005).  Specifically, if it takes twenty years for significant diabetic neuropathy to 
develop after diagnosis, then it could take a relatively similar length to determine 
(with a reasonable degree of confidence) if a novel drug is effective at preventing 
or reducing neuropathy. This contrasts with mouse models in which it can take 
two months for diabetic neuropathy to develop. 
No single animal model fully replicates diabetes in humans and all models have 
advantages and disadvantages (Cefalu, 2006; Kaplan and Wagner, 2006; Mathis et 
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al., 2001; Sullivan et al., 2007).  The ob/ob mouse was chosen for study because it 
develops a predictable neuropathic phenotype by 8 weeks of age, which is 
comparable to that observed in humans with T2DM (Drel et al., 2006; Latham et al., 
2009; Lindstrom, 2009; Vareniuk et al., 2007). Indeed, peripheral neuropathy and 
associated hypersensitivity have previously been characterized in ob/ob mice 
(Drel et al., 2006; Latham et al., 2009). The first behavioural experiments that I 
carried out on ob/ob mice were to confirm the reported phenotype; these tests 
included the rotarod, the von Frey (vF) filaments and the tail flick test.  In a 
manner consistent with the literature, the ob/ob mice exhibited super-morbid 
obesity and a dramatically impaired performance on the rotarod test, which 
assesses sensorimotor coordination (Mayers et al., 2009).  This is consistent with 
the reduced motor and sensory nerve conduction velocities of ob/ob mice, which 
impairs their balance and coordination (Drel et al., 2006; Vareniuk et al., 2007).   
The ob/ob mice also exhibited significantly longer tail flick withdrawal latencies at 
48 oC and 50 oC than WT controls. These findings are consistent with the 
phenomenon of thermal hypoalgesia measured by paw withdrawal latency in 
ob/ob mice reported by Drel et al., (2006), but conflict with the thermal 
hyperalgesia reported by Latham et al., (2009).  Latham et al., (2009) raise 
numerous potential reasons for the discrepancy in findings, which include: 
methodological differences in testing, internal biological variability and different 
environmental, nutritional and housing conditions.  In addition, Latham et al., 
(2009) focused on female ob/ob mice while the sex of the mice in the paper by Drel 
et al., (2006) is unreported.  All the ob/ob mice in my behavioural and 
electrophysiological studies were male, but it would be presumptive to infer 
gender as the explanation for the difference.  Of note, the neuroprotection of 
allopregnanolone in a mouse model of global cerebral ischaemia was greater in 
female mice than in male mice (Kelley et al., 2011).  However, certain strains of WT 
mice that are available commercially have -synuclein deficiency, which can affect 
the expression of neurodegenerative conditions and raises the possibility that 
there may be additional genetic differences, which could contribute to distinct pain 
phenotypes (Chandra et al., 2005; Specht & Schoepfer, 2001).   While it is 
important to be aware of this issue, detailed analysis is beyond the scope of this 
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discussion and this is an issue for the scientific community as a whole, rather than 
one of specific relevance to my electrophysiological and behavioural data. 
The results of my study demonstrate that the tail flick test was not suitable for 
investigating potential analgesic or anti-hyperalgesic effects of drugs such as 
neurosteroids in ob/ob mice.  However, my data indicated that 50 oC was an 
appropriate temperature to test for noxious heat and to determine the analgesic 
potential of specific drugs in WT mice.  It is arguable that the impaired 
performance of ob/ob mice on the rotarod and the prolonged tail flick latency time 
could potentially be due to a sensorimotor deficit rather than thermal hypoalgesia 
per se.  However, the exaggerated response of the ob/ob mice to topical acetone 
and von Frey filaments (discussed below) suggests that a mixed picture of altered 
sensitivity to peripheral noxious stimuli is present. 
 
7.12 Ganaxolone impairs thermal nociception in WT mice. 
 
Neurosteroids such as allopregnanolone, DHP and progesterone have analgesic 
effects in various experimental models (Poisbeau et al., 2005, Charlet et al., 2008, 
Meyer et al., 2008; 2010; 2011).  In addition, the spinal (intrathecal) 
administration of ganaxolone induces analgesia assessed using the tail flick test 
(52oC; Asiedu et al., 2012).  Also using the tail flick assay (50 oC), I discovered that 
the systemic (intraperitoneal) administration of ganaxolone induced a dose-
dependent analgesic effect in WT mice.  The route of administration is important 
because in clinical practice, spinal injections are performed within an operating 
theatre by a trained medical practitioner and carry a small risk of permanent 
paralysis (Aromaa et al., 1997).  As a result, spinal drug delivery is reserved for 
specific indications such as invasive surgical procedures in humans. In addition, 
drugs administered directly into the spinal fluid such as opioids may be more than 
100 times more efficacious than the same drug delivered systemically (Rathmell et 
al., 2005).  Therefore promising findings with intrathecal administration may not 
translate to clinically useful therapies due to systemic side effects.  During the tail 
flick experiments the highest dose of ganaxolone appeared to sedate the mice, 
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which raised the question of whether increased withdrawal latency was related to 
sensorimotor impairment.    Subsequently, the rotarod test was used to explore 
this potentially confounding issue further.  The highest dose of ganaxolone caused 
a significant impairment of rotarod performance, but the lower doses had no effect.  
These data suggest that ganaxolone exhibits an analgesic effect at a dose of 10 
mg/kg but only impairs rotarod performance in WT mice at higher doses such as 
30 mg/kg.  The dose-dependent effect on rotarod performance is consistent with 
the literature (Carter et al., 1997) and indicates that ganaxolone (10 mg/kg) may 
be effective for thermal nociceptive pain, rather than merely impairing 
sensorimotor function.   
 
7.13 ob/ob mice exhibit cold allodynia. 
 
The sensing of a wide range of environmental temperatures is a useful 
physiological process that confers survival advantages in many species. Indeed, 
adapting to a cold external environment can be as important as withdrawing from 
a burning hot stimulus. The thermal gated ion channels TRPM8 and TRPA1 are 
important in the generation of an afferent neural impulse in response to a noxious 
cold stimulus.  Increased sensitivity to cold stimuli is a common symptom 
associated with neural injury, and although the underlying mechanisms 
responsible for this phenomenon are poorly understood, it may be related to 
increased expression of TRPM8 and TRPA1 channels (Belmonte et al., 2009; 
Knowlton et al., 2010). Conversely, knockout of TRPM8 in mice with a peripheral 
neuropathic injury results in a significantly reduced response to cold stimuli such 
as topical acetone (Belmonte et al., 2009).  When neural hypersensitivity is 
present, the cold sensation associated with topical acetone may induce a 
temporary noxious response. Acetone has therefore also been used to elicit cold 
allodynia in animals with chemotherapy-induced neuropathic hypersensitivity 
(Flatters & Bennett, 2004, Gauchan et al., 2009, Meyer et al., 2011).  In my study, 
topical acetone elicited a greater response in ob/ob mice than it did in WT mice, 
which was consistent with cold allodynia in the former.  However, it became 
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apparent that after the initial baseline response to acetone, ob/ob mice appeared 
to acclimate to the stimulus. The partial loss of response with repeated measures 
meant that the test was not an appropriate way of investigating potential analgesic 
or anti-allodynic effects of drugs such as neurosteroids. Previous studies in which 
acetone was used to assess cold allodynia differed from my study in that they 
utilised WT mice with acute chemotherapy-induced neuropathic pain and were 
conducted over several weeks (Flatters & Bennett, 2004, Gauchan et al., 2009, 
Meyer et al., 2011).  This is relevant because differences in the mechanism 
responsible for inducing neuropathic pain may result in a significantly different 
neuropathic phenotype, i.e. the balance between loss of sensation and 
hypersensitivity may be altered.  Indeed, the motor and sensory nerve conduction 
velocities of the ob/ob mouse are significantly impaired (Drel et al., 2006).   While 
the prolonged tail withdrawal could be explained by a slower nerve conduction 
velocity, cold allodynia (and mechanical hypersensitivity) infers that there is a 
change in nociception rather than merely an impairment of conduction. 
 
7.14 ob/ob mice exhibit mechanical hypersensitivity in comparison to WT 
mice.  
 
Meyer et al., (2011) described a protocol for the use of vF filaments to investigate 
allodynia, hyperalgesia and nociceptive pain in relation to specific mechanical 
stimuli in rats.  I developed a modified version of their approach to investigate 
mechanical hypersensitivity and nociception in WT and ob/ob mice.  This involved 
choosing four vF filaments that would induce a response on a predictable number 
of occasions. The 0.16 g and 0.4 g vF filaments elicit withdrawal responses on 25% 
and 40% of occasions respectively in the WT mouse and are considered to be mild 
stimuli.  If the ob/ob mouse has an exaggerated response to these filaments this 
would be consistent with allodynia (Merskey & Bogduk, 1994).  The 0.6 g vF 
filament elicits a response on over 60% of occasions in the WT mouse, therefore it 
is considered a painful response and if the ob/ob mouse had an exaggerated 
response to this filament it would be consistent with hyperalgesia (Merskey & 
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Bogduk, 1994).  The 1 g vF filament elicits a withdrawal response on 
approximately 90% of occasions, therefore it is considered to be a clear test of 
mechanical nociceptive pain in the WT mouse.   
The ob/ob mice exhibited an exaggerated (but reproducible) response to the 0.16 
g, 0.4 g and 0.6 g vF filaments which was consistent with the presence of 
mechanical allodynia (0.16 g and 0.4 g) and mechanical hyperalgesia (0.6 g).  
Previous reports in the literature have used different methods or equipment for 
the characterisation of mechanical hypersensitivity, but the results of my study are 
consistent with their findings (Drel et al., 2006; Latham et al., 2009).  These data 
suggest that the vF filaments are a useful method of investigating the potential 
analgesic or anti-hyperalgesic effects of drugs such as neurosteroids in ob/ob mice.   
 
7.15 Ganaxolone reduces mechanical hypersensitivity in ob/ob mice and 
reduces mechanical nociceptive pain in both WT and ob/ob mice.  
 
In electrophysiological experiments using cortical slices from WT mice, ganaxolone 
and DHP both induced a marked prolongation of GABAAR mIPSC decay time, 
although the response to ganaxolone was approximately seven-fold greater than 
that of DHP.  Using the vF filaments, the systemic administration of ganaxolone (at 
10 mg/Kg, a dose that did not alter rotarod performance) proved to be analgesic 
for mechanical nociceptive pain in both ob/ob and WT mice.  In contrast, DHP (the 
precursor to allopregnanolone) was ineffective for mechanical nociceptive pain at 
the same dose.  It is not possible to translate electrophysiological findings directly 
into behavioural effects, but, taken as a whole, the data are consistent with the idea 
that ganaxolone incubation treatment ultimately has a more potent effect than that 
of DHP and for this reason potentially has greater anti-nociceptive effects in 
behavioural tests.   
However, the most interesting finding of the behavioural work was that 
ganaxolone significantly reduced the mechanical allodynia and hyperalgesia 
manifested by the ob/ob mice (DHP was also partially effective for mechanical 
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allodynia, but not hyperalgesia).  These findings are important because, in the 
clinical setting, effective treatments for various forms of nociceptive pain already 
exist, such as paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), 
opioids and regional anaesthesia for surgical procedures. In contrast, the current 
therapeutic options for neuropathic pain are very limited, therefore patients with 
diabetic neuropathy may suffer from intractable pain (Bouhassira et al., 2008; 
Dworkin et al., 2007).  The effectiveness of a single dose of the neuroactive steroid 
ganaxolone for diabetic neuropathic pain in ob/ob mice is a novel discovery, but it 
is also consistent with the literature.  Chronic administration of progesterone, DHP 
or allopregnanolone has been shown to prevent the development of neuropathic 
pain in animals associated with chemotherapeutic drugs (Meyer et al., 2010; 
2011).  Chemotherapy is usually a short-lived insult to the nervous system, while 
diabetes mellitus is a relentless lifelong condition for which there is currently no 
cure.  Therefore, the potential impact of a new therapeutic agent could be far 
greater for painful diabetic neuropathy than for many other neuropathic 
conditions.  My results indicate that ganaxolone should receive further 
consideration as a potential treatment for allodynia and hyperalgesia in humans 
with diabetes.  While it was not possible to establish whether or not ganaxolone 
induced sensorimotor impairment in ob/ob mice due to their existing 
sensorimotor deficits, WT mice exhibited analgesia to thermal and mechanical 
nociceptive pain at a dose that did not impair rotarod function.  The apparent 
‘therapeutic window’ suggests that sedation or sensorimotor impairment is an 
unlikely reason for the observed effects of ganaxolone at the dose of 10 mg/kg.  
ob/ob mice exhibited the same analgesic effect of ganaxolone to mechanical 
nociceptive pain but, more importantly, the drug also reduced mechanical 
allodynia and hyperalgesia.  To support the idea that ganaxolone is effective at 
reducing hypersensitivity in ob/ob mice, the drug did not affect the response of WT 
mice to non-painful stimuli. 
Humans with painful neuropathy commonly exhibit a mixed picture of sensory loss 
and hypersensitivity such as allodynia and hyperalgesia that may occur 
simultaneously in the same anatomical location (Costigan et al., 2009; Kehlet et al., 
2006; Merskey & Bogduk, 1994, Woolf & Salter, 2000).  The behavioural results for 
239 
 
the ob/ob mice are consistent with what may be observed in humans and therefore 
are clinically relevant.  However, there are significant limitations of these studies, 
which must be considered.  Humans complain of pain that may be related to a 
specific stimulus or, as is often the case with neuropathic pain, pain may occur 
spontaneously in the absence of an identifiable cause (Costigan et al., 2009; Kehlet 
et al., 2006; Merskey & Bogduk, 1994).  Mice are not able to communicate the 
presence or severity of pain directly and therefore studies have to rely on 
behavioural observations as a proxy measure of pain.  This is important because in 
humans with chronic neuropathic pain there may be no outward manifestation of 
the pain experience and the degree of pain-related behaviour may not correlate 
well with the perceived intensity of the pain (Wall et al., 2006).  Furthermore, it is 
common practice in clinical trials of analgesic compounds to use a verbal or 
written rating scale to record the severity of the pain experienced (Wall et al., 
2006).  For example, the subject is asked to assign their pain a severity score out of 
ten, with zero being no pain and ten being the worst pain imaginable (Macintyre & 
Schug, 2007).  Clearly this is an unavoidably different end-point from my study, but 
in future, it is likely to become common practice for more objective measures of 
nociception to be employed clinically, such as mechanical and thermal thresholds 
(Salengros et al., 2010). 
In addition, it must be understood that the experience of pain in humans is a highly 
subjective one that is hard to define.  It is not merely the reflex withdrawal of the 
hand from the fire, it may be considered as an emotional state analogous to 
happiness, anxiety or depression that is highly context specific (Wall et al., 2006).  
For instance, on the battlefield or sports field, participants may continue to play 
after sustaining an injury that would normally be associated with severe pain 
(Beecher, 1946; Wall et al., 2006).  In contrast, the same people may later become 
patients attending the chronic pain clinic and complain of disabling symptoms that 
occur in the absence of tissue damage or in some cases any identifiable stimuli 
whatsoever.  Attendees may often have significant emotional and psychological 
components to their symptomatology (Tunks et al., 2008; Wall et al., 2006).  For 
this reason, chronic pain management is typically carried out by a 
multidisciplinary team, which includes psychologists as well as doctors, nurses and 
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physiotherapists in order to address the multidimensional needs of an individual 
patient (Kehlet et al., 2006; Wall et al., 2006).  In order to identify and quantify 
these issues, standardised multidimensional tools such as the McGill pain 
questionnaire are used to facilitate the implementation of targeted therapeutic 
interventions (Melzack, 1987).  Modified versions of questionnaires such as this 
are also used increasingly within clinical trials, but unfortunately this type of 
analysis is not applicable to animal models.   
Another significant issue worthy of discussion is the nature of the mechanical and 
thermal stimuli employed within my studies.  For ethical reasons, the types of 
stimuli chosen were considered to induce discomfort, but not to cause harm to the 
animal.  This creates a somewhat artificial situation, i.e. in clinical trials of 
postoperative pain, human subjects have typically experienced a surgical incision 
that would be considered to be of much greater severity than the mice were 
subjected to in my studies.  This means that my study has tested the efficacy of 
ganaxolone on nociception and hypersensitivity rather than on ‘pain’ as a human 
may experience it.  While this is a significant issue, it is a problem for science as a 
whole to address via translational collaborations rather than something that is 
unique to my study (Mogil, 2009).  Given that humans are considered to be the 
most intellectually developed animals on earth and therefore also the most self-
aware, perhaps a pain experience that is truly reflective may never be replicated in 
animal models.  My study used standardised techniques that are in common 
scientific practice and therefore considered to be useful and quantifiable proxies 
for nociception.  These techniques may be considered as a pragmatic compromise 
given time, resources and technologies available currently.  Putting aside financial 
considerations, another complementary modality to examine activity of neurones 
located within the pain pathway and so-called pain matrix such as functional 
magnetic resonance imaging (fMRI) or positron emission tomography (PET) could 
also have been employed (Tracey, 2008; Wartolowska & Tracey, 2009).  Activation 
of structures including the thalamus, somatosensory cortex and cingulate cortex 
has been observed in both rodent and humans studies using PET and fMRI 
techniques (Knabl et al., 2008; Thompson & Bushnell, 2012; Tracey, 2008; 
Wartolowska & Tracey, 2009). Imaging in animal models facilitates the 
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performance of experiments that would not be possible in humans for ethical and 
practical reasons (Thompson & Bushnell, 2012; Wartolowska & Tracey, 2009).  
Specifically, the central actions of potential novel analgesic agents can be 
investigated to examine whether they may be suitable to put forward for clinical 
trials in patients with neuropathic pain (Knabl et al., 2008; Thompson & Bushnell, 
2012; Wartolowska & Tracey, 2009).   
Some of the major causes of severe neuropathic pain in humans include 
amputation, mastectomy, postherpetic neuralgia, thoracic surgery, trigeminal 
neuralgia and diabetes mellitus.  The accurate replication of these conditions in 
animals in order to facilitate the development of effective clinical treatments poses 
significant practical and ethical challenges.  It is hoped that a compound that was 
effective for painful diabetic neuropathy may also be effective for other types of 
neuropathic pain, but this is by no means certain (Dworkin et al., 2007).  This issue 
could be addressed in part by attempting to replicate the behavioural (and 
electrophysiological) results in other models of neuropathy.  It could also be 
studied in other species and perhaps through the parallel use of techniques such as 
fMRI and also mass spectroscopy of neural tissue.  Other animal models of 
neuropathy that have been used elsewhere include streptozotocin-induced T1DM, 
spared nerve injury, sciatic nerve ligation, chemotherapy-induced neuropathy and 
postherpetic neuralgia (Mogil, 2009). Clearly, replication of the data before 
attempting to translate the findings into clinical trials would require a 
considerable amount of work, which is beyond the scope of this thesis.  However, 
fMRI has already been used to characterise the changes in central processing 
associated with chronic cyclical dysmenorrhoea in women who were also more 
sensitive to thermal stimuli than healthy controls (Vincent et al., 2011).  
Dysmenorrhoea is associated with fluctuations in the circulating levels of steroid 
hormones including oestradiol, testosterone, progesterone and other 
neurosteroids (Maguire & Mody, 2009; Vincent et al., 2011). Changes in steroid 
hormone levels during the menstrual cycle are associated with changes in 
neuronal excitability, which is thought to be mediated via their impact on GABAARs 
(Lovick, 2008; Maguire & Mody, 2009). 
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The results of my studies suggest that a single dose of ganaxolone is effective at 
reducing mechanical hypersensitivity and nociceptive pain via the modulation of 
GABAARs.  However, this finding is only the first step in characterising the efficacy 
of the drug for the treatment of neuropathic pain.  Diabetes mellitus is currently an 
incurable and life-long condition in humans that is associated with progressive 
multisystem degeneration, including the nervous system (Davies et al., 2006).  
Careful optimisation of glycaemic control slows the progression of the disease, but 
is not able to prevent it entirely (Edwards et al., 2008).  Patients with diabetes may 
experience chronic neuropathic hypersensitivity and therefore any potential 
therapy would need to be administered chronically.  Analgesic drugs such as 
paracetamol and NSAIDs maintain their (limited) efficacy for prolonged periods of 
time, while opioid drugs are associated with the development of tolerance as well 
as other serious side effects (Ballantyne & Mao, 2003; Raghavan et al., 2011).  A 
single dose of ganaxolone is promising for neuropathic hypersensitivity, but it is 
uncertain if this compound would continue to be effective if administered 
indefinitely or whether tolerance would develop.  In order to explore this further, 
ganaxolone could be administered regularly to ob/ob mice over a period of weeks 
or months, with serial measurements of nociception.  Such a protocol could be the 
first step to test whether ganaxolone was able to prevent the development of 
hypersensitivity and if tolerance to its effect developed over time.  My 
electrophysiological data suggest that ganaxolone (and allopregnanolone) may 
have significantly greater potency at the GABAAR than the neurosteroid precursors 
progesterone and DHP.  In view of the fact that these compounds may potentially 
be active at other targets (especially in high concentrations) it seems rational to 
focus on the compounds with the greatest potency.  Indeed, side effects are often 
the rate-limiting factor in the clinical efficacy of commonly used analgesics 
(Dworkin et al., 2007; Wall et al., 2006).  In addition, in my behavioural work, I 
found that the neurosteroid precursor DHP was significantly less effective than 
ganaxolone for the reduction of mechanical nociception and hypersensitivity.   
The electrophysiological work that I carried out confirmed the concentration-
dependent effect of neuroactive steroids on GABAAR function by reductionist 
methodology, while the behavioural work attempted to determine whether these 
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findings could be translated into a relevant effect in live animals. In the former 
technique the GABAAR was isolated using antagonists to block other receptors, 
while in the latter technique, no such antagonists were used. (Antagonists for 
glycine and sodium channels (strychnine and TTX respectively) are lethal toxins in 
vivo). Ganaxolone was designed specifically to be a high-affinity GABAAR 
modulator and radioligand binding techniques have demonstrated that it has 
negligible affinity for a large number of non-target receptors, including: excitatory 
amino acid, inhibitory amino acid, peptide, monoamine and cytosolic steroid 
receptors (Carter et al., 1997).  This suggests that the effect of ganaxolone on 
nociception and hypersensitivity may be associated with its modulation of GABAAR 
function. It was not possible to correlate the in vitro and in vivo brain tissue 
concentrations of ganaxolone directly to determine if they were analogous, but in 
the former the drug had a concentration-dependent effect, while in the latter it had 
a dose-dependent effect.  Therefore my data identify ganaxolone and possibly 
other neurosteroidal compounds as potential therapeutic agents which could 
reduce painful hypersensitivity by the selective targeting of the GABAAR.  The 
results of my behavioural experiments are promising, but must be considered in 
the context of all the issues discussed above.  The inherent simplifications and 
limitations of my studies make it difficult to extrapolate with any certainty that 
ganaxolone could be a useful clinical agent for allodynia or hyperalgesia.  However, 
my studies are a pragmatic and promising first look at the potential effectiveness 
of neuroactive steroids for painful diabetic neuropathy. 
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Chapter 8: Conclusions  
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This study used a combination of electrophysiological and behavioural techniques 
in order to investigate the potential for neurosteroids to exert an analgesic effect 
via modulation of the GABAAR. The approach consisted of the characterisation of 
pain pathway neurones from both WT and diabetic mice followed by the in vitro 
and in vivo application of neurosteroidal compounds.  The study confirmed that the 
decay time of GABAAR mIPSCs of neurones from three levels of the pain pathway 
decreases with development; lamina II of the spinal cord, the nRT of the 
prethalamus and layer 2/3 of the cerebral cortex.  The neurodevelopmental 
process occurs in parallel but may take place earlier in the more primitive regions 
of the CNS.  In addition, GABAARs of neurones from all three levels of the pain 
pathway are sensitive to neurosteroids.  The acute application of allopregnanolone 
prolonged the decay time of GABAAR mIPSCs more effectively in spinal LII 
neurones from older mice consistent with the idea that immature mice already 
have a high endogenous neurosteroid tone.  γ-CD within the recording pipette 
significantly reduced the decay time of GABAAR mIPSCs of nRT neurones of mice 
aged P6, but not P9-10 or P17-25.  This finding was also consistent with the 
hypothesis that immature mice have a high endogenous neurosteroid tone, which 
decreases with development.   Surprisingly, γ-CD reduced the decay time of 
cortical GABAAR mIPSCs at P60-75, suggesting that the endogenous neurosteroid 
tone, which disappears around P20, re-emerges in adult mice. 
 
 
Neurosteroid tone appears to be reduced in diabetic mice.  As such, the GABAAR 
mIPSCs of cortical layer 2/3 neurones of two mouse models of T2DM (ob/ob and 
db/db) have shorter decay times than three strains of WT mice.  γ-CD reduced the 
decay time of cortical GABAAR mIPSCs to the same baseline value in T2DM and WT 
mice irrespective of strain.   In contrast, -CD and -CD had no effect.  Cortical 
GABAARs of WT and ob/ob mice were modestly sensitive to the neurosteroids 
allopregnanolone and ganaxolone, but not the precursor DHP.  Incubation 
treatment with neurosteroids and their precursors produced more dramatic 
effects on GABAAR mIPSCs than acute treatment had done.  This may have been 
partly related to long penetration times of these lipophilic agents in brain slice 
tissue.  Neurosteroids from sequential stages of the synthesis pathway induced 
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significantly different degrees of modulation of GABAAR mIPSCs; allopregnanolone 
> DHP > progesterone.  In addition, ganaxolone and DHP (but not 
allopregnanolone) had an exaggerated effect on cortical GABAARs of mice with 
T2DM in comparison to WT controls.  Of relevance, the neurosteroid synthesis 
pathway relies on the function of key enzymes including 5 -R and 3 -HSD.  
Inhibition of these enzymes prevented the effect of the precursors, progesterone 
and DHP respectively.  The 3 -HSD inhibitor indometacin had no impact on 
allopregnanolone incubation treatment itself, but was able to inhibit the 
neuroactive steroid ganaxolone and the precursor DHP.  Incubation with the 3 -
HSD inhibitor provera itself induced a modest increase in GABAAR mIPSC decay 
time, while indometacin and the 5 -R inhibitor finasteride had no effect.  These 
drugs may inhibit the endogenous production of more neurosteroids, but they are 
unable to remove neurosteroids that are already in situ.  In contrast, the 
neurosteroid scavenger -CD removed the endogenous neurosteroid tone and was 
also able to reduce the effect of ganaxolone and DHP incubation treatments. 
 
Pipette-applied neurosteroids allopregnanolone and ganaxolone (but not DHP) 
were also able to prolong the decay time of cortical GABAAR mIPSCs in a 
differential manner.  Allopregnanolone induced a greater effect than ganaxolone 
on GABAAR mIPSC decay time, but there was no difference in the response to the 
respective drugs between the WT and ob/ob mice.  These findings suggest that 
neurosteroids are able to modulate the GABAAR from the intracellular 
compartment and that the sensitivity of the GABAAR is the same for WT and ob/ob 
mice.  In addition, when indometacin was co-applied in the pipette with 
ganaxolone it had no impact on the efficacy of ganaxolone.  This observation is 
inconsistent with the notion that indometacin competes with ganaxolone for its 
binding of the GABAAR. 
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Ob/ob mice developed obesity and T2DM on a normal diet, which led to painful 
neuropathy by the age of P60-75.  At this age they exhibited sensorimotor 
impairment, thermal hypoalgesia, cold allodynia, mechanical allodynia and 
mechanical hyperalgesia. In WT mice the neuroactive steroid ganaxolone impaired 
sensorimotor function at 30 mg/kg, but the lower dose of 10 mg/kg did not, and 
was analgesic for thermal and mechanical nociceptive pain.  The effect of 
ganaxolone on thermal nociception and sensorimotor impairment could not be 
tested on ob/ob mice due to their pre-existing deficits.  However, ganaxolone 
significantly reduced mechanical allodynia and mechanical hyperalgesia in ob/ob 
mice.  These findings translate the electrophysiological results into behavioural 
effects in vivo and suggest that GABAAR-modulatory neurosteroidal drugs have 
analgesic properties for nociceptive and neuropathic pain. 
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